Novel 1,2,4-oxadiazoles compounds as fungicide

Abstract

NOVEL 1,2,4-OXADIAZOLES COMPOUNDS AS FUNGICIDE (I) wherein, A1, R1, R2, R3, R4 and R5 are as defined in detailed description. The present invention further discloses methods for their preparation and the use of the compounds of formula (I) as a fungicide.

Description

[0001]PI External Title of the Invention: NOVEL 1,2,4-OXADIAZOLES COMPOUNDS AS FUNGICIDE FIELD OF THE INVENTION The present invention relates to compounds of formula (I). More particularly, the present invention relates to novel 1,2,4-oxadiazoles compounds of formula (I) and a process for the preparation thereof. 5 The present invention further relates to compositions comprising compounds of formula (I) and to their use in agriculture or horticulture for controlling or preventing infestation of plants, harvested food crops, seeds or non-living materials by damaging pest, preferably controlling phytopathogenic microorganism such as fungi. BACKGROUND OF THE INVENTION: 10 Oxadiazole compounds have been disclosed in the literature because of their fungicidal activity. For example, WO2018117034, WO2018153730 and WO2018114393 disclose various oxadiazole compounds as fungicidal agents. WO2020027214, JP2020079269, WO2020165403 and WO2020079111 disclose methoxyacrylate compounds with fungicidal activity. 15 WO1999067209 discloses oxadiazole based compounds, wherein the said compounds exhibit fungicidal, insecticidal, acaricidal and nematicidal activities. The oxadiazole compounds reported in these documents have disadvantages in certain aspects, such as exhibiting a narrow application spectrum or not having satisfactory pesticidal and / or fungicidal activity, especially at low application rates. 20 Accordingly, it is an object of the present invention to provide compounds with improved / enhanced activity against phytopathogenic microorganisms such as fungi. This objective is achieved by 1,2,4-oxadiazole compounds and their use in agriculture or horticulture for controlling or preventing infestation of plants, harvested food crops, seeds, or non-living materials by phytopathogenic microorganisms, preferably fungi. 25 SUMMARY OF INVENTION: Accordingly, the present invention provides 1,2,4-oxadiazoles compounds or salts, stereoisomers, polymorphs or N-oxides thereof. PI External (I) wherein, A1, R1, R2, R3, R4and R5are as defined in the detailed description. In one embodiment, the present invention provides a process for preparing compounds of formula (I) 5 or salts thereof. In another embodiment, the present invention provides compositions for controlling or preventing phytopathogenic microorganisms, preferably fungi, comprising a biologically effective amount of the compound of formula (I) or salts, stereoisomers, polymorphs or N-oxides thereof and at least one additional component selected from the group consisting of surfactants and auxiliaries. 10 In yet another embodiment, the present invention provides compositions that further comprise at least one additional biologically active and compatible compound selected from fungicides, insecticides, nematicides, acaricides, biopesticides, herbicides, plant growth regulators, antibiotics, fertilizers, or nutrients. In still another embodiment, the present invention provides the use of compounds of formula (I), or 15 salts, stereoisomers, polymorphs or N-oxides thereof as a fungicide. In yet another embodiment, the present invention provides fungicidal compositions which comprise compounds of formula (I) that can be used to curatively or preventively control phytopathogenic fungi of plants or crops. In yet another embodiment, the present invention provides a method for curatively or preventively 20 controlling phytopathogenic fungi of plants or crops characterized in that a compound of formula (I) or a fungicidal composition according to the invention is applied to the seed, the plant or the fruit of the plant or the soil wherein the respective plant is growing or wherein it is desired to grow. In yet another embodiment, the present invention provides the use of compounds of formula (I) against resistant soybean rust fungi having an amino acid substitution of F129L in the mitochondrial 25 cytochrome b protein. DETAILED DESCRIPTION OF THE INVENTION: DEFINITIONS: Before describing in detail exemplary embodiments of the present invention, definitions, important for understanding the present invention, are given. As used in this specification and the appended claims, 30 the singular forms of "a" and "an" also include the respective plurals unless the context dictates otherwise. In the context of the present invention, the terms "about" and "approximately" denote an interval of accuracy that a person skilled in the art will understand to still ensure the technical effect of the feature in question. PI External As used herein, the terms "comprise", "comprising", "comprises", "contains", or any other thereof. Variables are intended to encompass exclusive inclusion subject to any expressly indicated limitation. For example, a composition, mixture, process, or method comprising a series of elements is not necessarily limited to these elements and may include other elements not expressly listed or unique to 5 such composition, mixture, process, or method. The transitional phrase “consisting of” excludes any element, step, or ingredient not specified. If in the claim, such would close the claim to the inclusion of materials other than those recited except for impurities ordinarily associated therewith. When the phrase “consisting of” appears in a clause of the body of a claim, rather than immediately following the preamble, it limits only the element outlined in 10 that clause; other elements are not excluded from the claim as a whole. The term "agriculture" refers to the production of crops such as food and fiber, including corn, soybeans, and other legumes, rice, grains (such as wheat, oats, barley, rye, rice, maize), leafy vegetables (such as lettuce, cabbage, and others) rape crops), fruit vegetables (such as tomatoes, peppers, eggplant, cruciferous wormwood), potatoes, sweet potatoes, grapes, cotton, tree fruits (such as citron, seeds, and citrus) small fruits (berries, cherries) 15 and other specialty crops (such as rapeseed), sunflower, olive). As used herein, the term "halogen" or “halo” refers to fluorine (fluoro), chlorine (chloro), bromine (bromo), or iodine (iodo), preferably fluorine, chlorine, or bromine. As used herein, cyano means a - CN group. As used herein, hydroxy means a -OH group. 20 As used herein, the term "C1-Cn-alkyl" refers to a straight or branched hydrocarbon chain radical consisting solely of carbon and hydrogen atoms, containing no unsaturation, having from one to n carbon atoms, and which is attached to the rest of the molecule by a single bond. C1-C8-alkyl, C1-C6- alkyl, C1-C4-alkyl, C1-C3-alkyl and C1-C2-alkyl are to be construed accordingly. Examples of C1-Cn- alkyl include, but are not limited to, n-pentyl1-methylbutyl, 2-methylbutyl, 3-methylbutyl, 2, 2-25 dimethylpropyl, 1-ethylpropyl, n-hexyl, 1-dimethylpropyl, 1, 2-dimethylpropyl, 1-methylpentyl, 2- methylpentyl, 3-methylpentyl, 4-methylpentyl, 1-dimethylbutyl, 1, 2-dimethylbutyl, 1, 3- dimethylbutyl, 2, 2-dimethylbutyl, 2, 3-dimethylbutyl, 3-dimethylbutyl, 1-ethylbutyl, 2-ethylbutyl, 1, 2-trimethylpropyl, 1,2,2-trimethylpropyl, 1-ethyl-1-methylpropyl or 1-ethyl-2-methylpropyl, preferably methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-dimethylethyl, n-pentyl or n-hexyl. 30 As used herein, the term "C2-Cn-alkenyl" refers to a straight or branched hydrocarbon chain radical consisting solely of carbon and hydrogen atoms, containing at least one double bond that can be of either the (E)- or (+ / -) configuration, having from two to n carbon atoms, which is attached to the rest of the molecule by a single bond. C3-C6-alkenyl is to be construed accordingly. Examples of C2-Cn- alkenyl include, but are not limited to, vinyl, 1-propenyl, 2-propenyl, 1-methylethenyl, 1-butenyl, 2-35 butenyl, 3-butenyl, 1-methyl-1-propenyl, 2-methyl-1-propenyl, 1-methyl-2-propenyl, 2-methyl-2- PI External propenyl, 1-pentenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, 1-methyl-1-butenyl, 2-methyl-1-butenyl, 3- methyl-1-butenyl, 1-methyl-2-butenyl, 2-methyl-2-butenyl, 3-methyl-2-butenyl, 2-methyl-2-butenyl, 1-methyl-2-butenyl, 2-methyl-2-butenyl, 3-methyl-2-butenyl, 1-methyl-3-butenyl, 2-methyl-3-butenyl, 3-methyl-3-butenyl, 1-dimethyl-2-propenyl, 1, 2-dimethyl-1-propenyl, 1, 2-dimethyl-2-propenyl, 1- 5 ethyl-1-propenyl, 1-ethyl-2-propenyl, 1-hexenyl, 2-hexenyl, 3-hexenyl, 4-hexenyl, 5-hexenyl, 1- methyl-1-pentenyl, 2-methyl-1-pentenyl, 3-methyl-1-pentenyl, 4-methyl-1-pentenyl, 1-methyl-2- pentenyl, 2-methyl-3-pentenyl, 1-methyl-2-pentenyl, 3-methyl-1-pentenyl, 3-methyl-pentenyl, 2- methyl-pentenyl, 3-methyl-2-pentenyl, 3, 2-methyl-2-pentenyl, 3-methyl-2-pentenyl, 4-methyl-2- pentenyl, 1-methyl-3-pentenyl, 2-methyl-3-pentenyl, 3-methyl-3-pentenyl, 4-methyl-3-pentenyl, 1-10 methyl-4-pentenyl, 2-methyl-4-pentenyl, 3-methyl-4-pentenyl, 4-methyl-4-pentenyl, 1-dimethyl-2- butenyl, 1-dimethyl-3-butenyl, 1, 2-dimethyl-1-butenyl, 1, 2-dimethyl-2-butenyl, methyl-2-pentenyl, methyl-3-pentenyl, methyl-2-butenyl, 1, 1, 2-dimethyl-3-butenyl, 1, 3-dimethyl-1-butenyl, 1, 3- dimethyl-2-butenyl, 1, 3-dimethyl-3-butenyl, 2-dimethyl-3-butenyl, 2, 3-dimethyl-1-butenyl, 2, 3- dimethyl-2-butenyl, 2, 3-dimethyl-3-butenyl, 3-dimethyl-1-butenyl, 3-dimethyl-2-butenyl, 1-ethyl-1-15 butenyl, 1-ethyl-2-butenyl, 1-ethyl-3-butenyl, 2-ethyl-1-butenyl, 2-dimethyl-3-butenyl, 2-dimethyl-2- butenyl, 2-ethyl-1-butenyl, 2-dimethyl-3-butenyl, 2-dimethyl, 2-ethyl-2-butenyl, 2-ethyl-3-butenyl, 1, 2-trimethyl-2-propenyl, 1-ethyl-1-methyl-2-propenyl, 1-ethyl-2-methyl-1-propenyl and 1-ethyl-2- methyl-2-propenyl. As used herein, the term "C2-Cn-haloalkenyl" refers to a C2-Cn-alkenyl radical, as generally defined 20 above, and substituted by one or more of the same or different halogen atoms. As used herein, the term "C2-Cn-alkynyl" refers to a straight or branched hydrocarbon chain radical group consisting solely of carbon and hydrogen atoms, containing at least one triple bond, having from two to n carbon atoms, and which is attached to the rest of the molecule by a single bond. Examples of C2-Cn-alkynyl include, but are not limited to, 1-propynyl, 2-propynyl, 1-butynyl, 2-butynyl, 3-butynyl,25 1-methyl-2-propynyl, 1-pentynyl, 2-pentynyl, 3-pentynyl, 4-pentynyl, 1-methyl-2-butynyl, 1-methyl- 3-butynyl, 2-methyl-3-butynyl, 3-methyl-1-butynyl, 1-dimethyl-2-propynyl, 1-ethyl-2-propynyl, 1- hexynyl, 2-hexynyl, 3-hexynyl, 4-hexynyl, 5-hexynyl, 1-methyl-2-pentynyl, 1-methyl-3-pentynyl, 1- methyl-4-pentynyl, 2-methyl-3-pentynyl, 2-methyl-4-pentynyl, 3-methyl-1-pentynyl, 3-methyl-4- pentynyl, 4-methyl-1-pentynyl, 4-methyl-2-pentynyl, 1-dimethyl-2-butynyl, 1-dimethyl-3-butynyl, 1,30 2-dimethyl-3-butynyl, 2-dimethyl-3-butynyl, 3-dimethyl-1-butynyl, 1-ethyl-2-butynyl, 1-ethyl-3- butynyl, 2-ethyl-3-butynyl and 1-ethyl-1-methyl-2-butynyl -a propynyl group. As used herein, the term "C2-Cn-haloalkynyl" refers to a C2-Cn-alkynyl radical, as generally defined above, and substituted by one or more of the same or different halogen atoms. As used herein, the term “cyano-C1-C6-alkyl-” refers to a C1-C6alkyl radical as generally defined above 35 substituted by one or more cyano groups. PI External As used herein, the term "C1-C6-alkoxy" refers to a straight chain or branched saturated alkyl radical having one to 6 carbon atoms which is attached via an oxygen atom. For example, it refers to the radical of the formula -ORa where Ra is a C1-C6-alkyl radical as generally defined above. C1-C3-alkoxy is to be construed accordingly. Examples of C1-C6-alkoxy include, but are not limited to, methoxy, ethoxy, 5 propoxy, 1-methylethoxy, butoxy, 1-methylpropoxy, 2-methylpropoxy and 1, 1-dimethylethoxy, pentyloxy, 1-methylbutyloxy, 2-methylbutyloxy, 3-methoxybutoxy, 1-dimethylpropyloxy, 1, 2- dimethylpropyloxy, 2,2-dimethylpropyloxy, 1-ethylpropyloxy, hexyloxy, 1-methylpentyloxy, 2- methylpentyloxy, 3-methylpentyloxy, 4-methylpentyloxy, 1-dimethylbutyloxy, 1, 2-dimethylbutyloxy, 1, 3-dimethylbutyloxy, 2, 2-dimethylbutyloxy, 2, 3-dimethylbutyloxy, 3-dimethylbutyloxy, 1- 10 ethylbutoxy, 2-ethylbutoxy, 1, 2-trimethylpropyloxy, 1,2, 2-trimethylpropyloxy, 1-dimethylpropyloxy, 2-methylpropyloxy, 2-dimethylpropyloxy, 1, 1-ethyl-1-methylpropoxy and 1-ethyl-2-methylpropoxy. As used herein, the term "C1-C6-haloalkyl" refers to a straight-chain or branched saturated C1-C6-alkyl radical, as generally defined above, substituted by one or more of the same or different halogen atoms. C1-C4-haloalkyl or C1-C3-haloalkyl are to be construed accordingly. Examples of C1-C6-haloalkyl 15 include but are not limited to chloromethyl, fluoromethyl, fluoroethyl, difluoromethyl, trifluoromethyl, and 2,2,2-trifluoroethyl 5-fluoropentyl, 5-chloropentyl, 5-bromopentyl, 5-iodopentyl, undecafluoropentyl, 6-fluorohexyl, 6-chlorohexyl, 6-bromohexyl, 6-iodohexyl and dodecafluorohexyl. As used herein, the term "C1-C6-haloalkoxy" refers to a straight-chain or branched saturated C1-C6- alkoxy group, as defined above, substituted by one or more of the same or different halogen atoms. C1- 20 C4-haloalkoxy is to be construed accordingly. Examples of C1-C6-haloalkoxy include, but are not limited to, i.e., for example, fluoromethoxy, difluoromethoxy, trifluoromethoxy, chlorodifluoromethoxy, bromodifluoromethoxy, 2-fluoroethoxy, 2-chloroethoxy, 2-bromoethoxy, 2- iodoethoxy, 2, 2-difluoroethoxy, 2,2, 2-trifluoroethoxy, 2-chloro-2-fluoroethoxy, 2-chloro-2, 2- difluoroethoxy, 2, 2-dichloro-2-fluoroethoxy, 2,2, 2-trichloroethoxy, pentafluoroethoxy, 2-25 fluoropropoxy, 3-fluoropropoxy, 2-chloropropoxy, 3-chloropropoxy, 2-bromopropoxy, 3- bromopropoxy, 2, 2-difluoropropoxy, 2, 3-difluoropropoxy, 2-bromopropoxy, 2, 3-dichloropropoxy, 3,3, 3-trifluoropropoxy, 3,3, 3-trichloropropoxy, 2,3,3, 3-pentafluoropropoxy, heptafluoropropoxy, 1- fluoromethyl-2-fluoroethoxy, 1-chloromethyl-2-chloroethoxy, 1-bromomethyl-2-bromoethoxy, 4- fluorobutoxy, 4-chlorobutoxy, 4-bromobutoxy and nonafluorobutoxy;. 30 As used herein, the term“C3-C6-cycloalkyl-C1-C4-alkoxy-” refers to a C1-C4-alkoxy radical as generally defined above substituted by one or more C3-C6-cycloalkyl groups as generally defined below. As used herein, the term "C2-C6-alkenyloxy" refers to -ORa, where Ra is the C2-C6-alkenyl group as defined above. As used herein, the term "C2-C6-alkynyloxy" refers to -ORa, where Ra is the C2-C6-alkynyl group as 35 defined above. PI External As used herein, the term " C1-C6-alkoxy-C1-C6-alkyl-" refers to the radical of the formula Ra-O-Rb- where Ra is a C1-C6-alkyl radical, as generally defined above, and Rb is a C1-C6alkylene radical as generally defined above. Examples of C1-C6-alkoxy-C1-C6-alkyl- include, but are not limited to, ethoxymethyl, ethoxypropyl and iso-propyloxymethyl. 5 As used herein, the term “C1-C6-alkylsulfanyl” or C1-C6-alkylthio refers to a radical of the formula - SRa wherein Ra is a C1-C6-alkyl radical as generally defined above. As used herein, the term C1-C6-haloalkylsulfanyl" refers to a C1-C6-alkylsulfanyl group, as defined above, substituted by one or more of the same or different halogen atoms. As used herein, the term “C1-C6-alkylcarbonyl” refers to a radical of the formula –C(O)Ra where Ra is10 a C1-C6-alkyl radical as generally defined above. As used herein, the term “C1-C3-alkoxy-C1-C6- alkylsulfanyl” refers to a C1-C6-alkylsulfanyl group as defined above substituted by one or more C1-C3- alkoxy groups. As used herein, the term “C3-C6-cycloalkyl-C1-C6-alkylsulfanyl-” refers to a C1-C6-alkylsulfanyl group, as defined above, substituted by one or more C3-C6-cycloalkyl groups as generally defined below. 15 As used herein, the term " C1-C6-alkylthio-C1-C3-alkyl-" refers to the radical of the formula Ra-S-Rb- where Ra is a C1-C3-alkyl radical as generally defined above, and Rb is a C1-C6-alkylene radical as generally defined above. As used herein, the term "C3-Cn-cycloalkyl" refers to three (3) to n membered cycloalkyl radicals. Examples include but are not limited to cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl. 20 As used herein, the term “C3-C6-cycloalkyloxy” refers to three (3) to six (6) membered cycloalkoxy radicals. Examples include but are not limited to cycloprpyloxy, cyclobutyloxy and cyclopentyloxy. As used herein, the term "C3-Cn-cycloalkenyl" refers to a stable, monocyclic ring radical that is partially unsaturated and contains 3 to n carbon atoms. C3-C4-cycloalkenyl is to be construed accordingly. Examples of C3-C6-cycloalkenyl include but are not limited to, 1-cyclopropenyl, 2-cyclopropenyl, 1-25 cyclobutenyl, 2-cyclobutenyl, 1-cyclopentenyl, 2-cyclopentenyl, 1,3-cyclopentadienyl, 1, 4- cyclopentadienyl, 2, 4-cyclopentadienyl, 1-cyclohexenyl, 2-cyclohexenyl, 3-cyclohexenyl, 1, 3- cyclohexadienyl, 1, 4-cyclohexadienyl and 2,5-cyclohexadienyl. As used herein, the term “C3-C6-cycloalkyl-C1-Cn-alkyl-” refers to a C1-Cn-alkyl radical as generally defined above substituted by one or more C3-C6-cycloalkyl groups as generally defined above. C3-C6- 30 cycloalkyl-C1-C3-alkyl is to be construed accordingly. Examples include but are not limited to, cycloprpylmethyl, cyclobutylmethyl, cyclopentylmethyl, cyclopentylethyl and cyclohexylmethyl. PI External As used herein, the term “C3-C6-cycloalkyl-C2-C6-alkenyl-” refers to a C2-C6-alkenyl, radical as generally defined above, substituted by one or more C3-C6-cycloalkyl groups as generally defined above. As used herein, the term “C3-C6-cycloalkyl-C2-C6-alkynyl-” refers to a C2-C6-alkynyl radical as 5 generally defined above substituted by one or more C3-C6-cycloalkyl groups as generally defined above. As used herein, the term "C3-C6-halocycloalkyl" refers to a C3-C6-cycloalkyl radical, as generally defined above, and substituted by one or more of the same or different halogen atoms. C3-C4- halocycloalkyl is to be construed accordingly. As used herein, the term “C3-C6-cycloalkyloxy-C1-C3-alkyl-” refers to a C1-C3-alkyl radical, as 10 generally defined above, substituted by one C3-C6-cycloalkyloxy group. Examples include but are not limited to, cycloprpyloxymethyl, cyclobutyloxymethyl and cyclopentyloxymethyl. As used herein, the term “4- to10- membered non-aromatic heterocyclyl ring” refers to a saturated or partially unsaturated non-aromatic monocyclic or bicyclic heterocycle ring. As used herein, the term “4-10 membered non-aromatic heterocyclyl-C1-C3-alkyl” refers to a C1-C3- 15 alkyl radical, as generally defined above, substituted by one 4- to 10- membered non-aromatic heterocyclyl ring. Examples include but are not limited to, azetidinylmethyl, oxetanylmethyl, imidazolidinylmethyl,azetidinylethyl, oxetanylethyl, imidazolidinylethyl, hexahydropyrimidinylmethyl, piperazinylethyl and oxadiazolidinylmethyl. As used herein, the term “9- or 10- membered bicyclic heteroaryl-C1-C3-alkyl” refers to a C1-C3-alkyl 20 radical, as generally defined above, substituted by one 9 or 10-membered bicyclic heteroaryl ring. Examples include but are not limited to, quinolinyl methyl, quinolinyl ethyl, isoquinolinyl methyl and isoquinolinyl ethyl. As used herein, the term “4-10 membered non-aromatic heterocyclyloxy-C1-C3-alkyl” refers to a C1- C3-alkyl radical, as generally defined above, substituted by one 4-10 membered non-aromatic 25 heterocyclyloxy ring. Examples include but are not limited to, azetidinyloxymethyl, oxetanyloxymethyl, imidazolidinyloxymethyl, azetidinylethyl, oxetanyloxyethyl, imidazolidinyloxyethyl, hexahydropyrimidinyloxymethyl, piperazinyloxyethyl and oxadiazolidinyloxymethyl. As used herein, the term “5- or 6- membered heteroaryl-C1-C3-alkyl” refers to a C1-C3-alkyl radical, as 30 generally defined above, substituted by one 5- or 6- membered heteroaryl ring. Examples include but are not limited to, imidazolyl methyl, oxadiazolyl methyl, thiadiazolyl methyl, pyridinyl ethyl, pyrazinyl ethyl, pyridinyl methyl, pyrazinyl methyl, pyrimidinyl methyl and pyrimidinyl ethyl. As used herein, the term “5- to 10-membered heteroaryloxy-C1-C3-alkyl” refers to a C1-C3-alkyl radical, as generally defined above, substituted by one 5- to 10-membered heteroaryloxy ring. Examples include PI External but are not limited to, imidazolyloxy methyl, oxadiazolyloxy methyl, thiadiazolyloxy methyl, pyridinyloxy ethyl, pyrazinyloxy ethyl, pyridinyloxy methyl, pyrazinyloxy methyl, pyrimidinyloxy methyl, pyrimidinyloxy ethyl and dihydrobenzofuran-5-yl-oxy methyl. As used herein, the term “phenyl-C1-C6-alkyl-” refers to a phenyl ring attached to a C1-C6-alkylene 5 radical as generally defined above. As used herein, the term “phenoxy-C1-C6-alkyl-” refers to a phenyl ring attached to a C1-C6-alkylene radical, as generally defined above, via an oxygen atom. As used herein, the term “C5-C12saturated or partially unsaturated bi- or tri- carbocyclyl rings”, refers to 5 to 12 membered saturated or partially unsaturated bi- or tri- carbocyclyl rings: 10 - a bicarbocyclic ring includes but is not limited to fused bicyclic rings such as decahydronaphthalene and octahydro-1H-indene; bridged bicyclic rings such as bicyclo[4.3.1]decane and bicyclo[4.2.1]nonane; spiro cyclic rings such as but not limited to spiro[4.5]decane, spiro[2.3]hexane, spiro[2.2]pentane, spiro[3.3]heptane and spiro[2.4]heptane; and 15 - a tricarbocyclic ring includes but is not limited fused tricyclic rings such as tetradecahydrobenzo[a]azulene; bridged tricyclic rings such as adamantanyl; spiro cyclic rings such as dispiro[2.0.44.13]nonane and dispiro[4.0.56.15]dodecane. The term “aryl” as used herein is a group that contains any carbon-based aromatic group including, but not limited to phenyl, naphthalene, biphenyl, anthracene, and the like. The aryl group can be substituted 20 or unsubstituted. In addition, the aryl group can be a single ring structure or comprises multiple ring structures that are either fused ring structures or attached via one or more bridging groups such as a carbon-carbon bond. As used herein, unless explicitly stated otherwise, the term "hetero" in connection with rings refers to a ring in which at least one ring atom is not carbon and which can contain 1 to 4 heteroatoms 25 independently selected from the group consisting of nitrogen, oxygen and sulfur, provided that each ring contains no more than 4 nitrogens, no more than 2 oxygens and no more than 2 sulfurs. The term "aromatic" indicates that the Huckel rule is satisfied and the term "non-aromatic" indicates that the Huckel rule is not satisfied. The term "heterocycle" or "heterocyclic" or "heterocyclic ring system ", unless specifically defined 30 elsewhere, includes "aromatic heterocycle" or "heteroaryl bicyclic ring system" and "nonaromatic heterocycle ring system" or polycyclic or bicyclic (spiro, fused, bridged, non-fused) ring compounds in which ring may be aromatic or non-aromatic, wherein the heterocycle ring contains at least one heteroatom selected from N, O, S(O)0-2, and or C ring member of the heterocycle may be replaced by C(=O), C(=S), C(=CR*R*) and C=NR*, * indicates integers. PI External The term "non-aromatic heterocycle" or "non-aromatic heterocyclic" means three- to fifteen-membered, preferably four- to ten-membered, saturated or partially unsaturated heterocycles containing one to four heteroatoms from the group of oxygen, nitrogen and sulphur: mono, bi- or tricyclic heterocycles which contain, in addition to carbon ring members, one to three nitrogen atoms and / or one oxygen or sulphur 5 atom or one or two oxygen and / or sulphur atoms; if the ring contains more than one oxygen atom, they are not directly adjacent; for example (but not limited to) oxetanyl, azetidinyl, thietanyl, tetrahydrofuranyl, tetrahydrothienyl, 1-pyrrolidinyl, 2-pyrrolidinyl, 3-pyrrolidinyl, isoxazolidinyl, isothiazolidinyl, 1-pyrazolidinyl, 3-pyrazolidinyl, 4-pyrazolidinyl, 5-pyrazolidinyl, oxazolidinyl, thiazolidinyl, 1-imidazolidinyl, 2-imidazolidinyl, 4-imidazolidinyl, 1,2,4-oxadiazolidinyl, l,2,4- 10 thiadiazolidinyl, l,2,4-triazolidin-1-yl, l,2,4-triazolidin-3-yl, l,2,3-triazolidinyl, l,3,4-oxadiazolidinyl, l,3,4-thiadiazolidinyl, 1,3,4-triazolidinyl, dihydrofuryl, dihydrothienyl, pyrrolinyl, isoxazolinyl, isothiazolinyl, dihydropyrazolyl, dihydrooxazolyl, dihydrothiazolyl,piperidinyl, pyrazynyl, morpholinyl, thiomorphlinyl, l,3-dioxan-5-yl, tetrahydropyranyl, tetrahydrothienyl, hexahydropyridazinyl, hexahydropyrimidinyl, piperazinyl and cycloserines. This definition also applies 15 to heterocyclyls as a part of a composite substituent, for example, heterocyclylalkyl etc., unless specifically defined elsewhere. The term “heteroaryl” or “aromatic heterocyclic” means 5 or 6-membered, fully unsaturated monocyclic ring systems containing one to four heteroatoms from the group of oxygen, nitrogen and sulphur; if the ring contains more than one oxygen atom, they are not directly adjacent; 5-membered 20 heteroaryl containing one to four nitrogen atoms or one to three nitrogen atoms and one sulphur or oxygen atom: 5-membered heteroaryl groups which, in addition to carbon atoms, may contain one to four nitrogen atoms or one to three nitrogen atoms and one sulphur or oxygen atom as ring members, for example (but not limited thereto) furyl, thienyl, pyrrolyl, isoxazolyl, isothiazolyl, pyrazolyl, oxazolyl, thiazolyl, imidazolyl, l,2,4-oxadiazolyl, l,2,4-thiadiazolyl, l,2,4-triazolyl, l,3,4-oxadiazolyl, 25 l,3,4-thiadiazolyl, l,3,4-triazolyl, tetrazolyl; nitrogen-bonded 5-membered heteroaryl containing one to four nitrogen atoms, or benzofused nitrogen-bonded 5-membered heteroaryl containing one to three nitrogen atoms: 5-membered heteroaryl groups which, in addition to carbon atoms, may contain one to four nitrogen atoms or one to three nitrogen atoms as ring members and in which two adjacent carbon ring members or one nitrogen and one adjacent carbon ring member may be bridged by a buta-l,3-diene- 30 l,4-diyl group in which one or two carbon atoms may be replaced by nitrogen atoms, where these rings are attached to the skeleton via one of the nitrogen ring members, for example (but not limited to) 1- pyrrolyl, 1-pyrazolyl, 1,2,4-triazol-l- yl, 1-imidazolyl, 1,2,3-triazol-l-yl and 1,3,4-triazol-l-yl. 6-membered heteroaryl which contains one to four nitrogen atoms: 6-membered heteroaryl groups which, in addition to carbon atoms, may contain, respectively, one to three and one to four nitrogen35 atoms as ring members, for example (but not limited thereto) 2-pyridinyl, 3-pyridinyl, 4-pyridinyl, 3- pyridazinyl, 4-pyridazinyl, 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl, 2-pyrazinyl, l,3,5-triazin-2-yl, PI External l,2,4-triazin-3-yl and l,2,4,5-tetrazin-3-yl; benzofused 5-membered heteroaryl containing one to three nitrogen atoms or one nitrogen atom and one oxygen or sulphur atom: for example (but not limited to) indol-l-yl, indol-2-yl, indol-3-yl, indol-4-yl, indol-5-yl, indol-6-yl, indol-7-yl, benzimidazol-l-yl, benzimidazol-2-yl, benzimidazol-4-yl, benzimidazol-5-yl, indazol-l-yl, indazol-3-yl, indazol-4-yl, 5 indazol-5-yl, indazol-6-yl, indazol-7-yl, indazol-2-yl, l-benzofuran-2-yl, l-benzofuran-3-yl, l- benzofuran-4-yl, l-benzofuran-5-yl, 1-benzofuran- 6-yl, l-benzofuran-7-yl, l-benzothiophen-2-yl, l- benzothiophen-3-yl, l-benzothiophen-4-yl, 1- benzothiophen-5-yl, l-benzothiophen-6-yl, l- benzothiophen-7-yl, l,3-benzothiazol-2-yl, 1,3- benzothiazol-4-yl, l,3-benzothiazol-5-yl, l,3- benzothiazol-6-yl, l,3-benzothiazol-7-yl, l,3-benzoxazol-2-yl, l,3-benzoxazol-4-yl, l,3-benzoxazol-5- 10 yl, 1,3-benzoxazol-6-yl and l,3-benzoxazol-7-yl; benzofused 6-membered heteroaryl which contains one to three nitrogen atoms: for example (but not limited to) quinolin-2-yl, quinolin-3-yl, quinolin-4- yl, quinolin-5-yl, quinolin-6-yl, quinolin-7-yl, quinolin-8-yl, isoquinolin-l-yl, isoquinolin-3-yl, isoquinolin-4-yl, isoquinolin-5-yl, isoquinolin-6-yl, isoquinolin-7-yl and isoquinolin-8-yl. As used herein, the term "heteroaryloxy-C1-C3-alkyl-" refers to a heteroaryl ring, as defined above, 15 which is attached to a C1-C3-alkylene radical as generally defined above via an oxygen atom. As used herein, unless explicitly stated otherwise, the term “heterocyclyloxy-C1-C3-alkyl” refers to heterocyclyl-O-Ra, where Rais C1-C3-alkyl and the heterocyclyl is as defined above. The term "N-oxide" includes any compound of formula (I) which has at least one tertiary nitrogen atom that is oxidized to an N-oxide moiety. 20 The term “plant” is understood here to mean all plants and plant populations, such as desired and undesired wild plants or crop plants (including naturally occurring crop plants). Crop plants may be plants that can be obtained by conventional breeding and optimization methods or by biotechnological and genetic engineering methods or combinations of these methods, including the transgenic plants and the plant cultivars which are protectable and non-protectable by plant breeders’ rights. 25 For the present disclosure, the term “plant” includes a living organism of the kind exemplified by trees, shrubs, herbs, grasses, ferns, and mosses, typically growing in a site, absorbing water and required substances through its roots, and synthesizing nutrients in its leaves by photosynthesis. Examples of “plant” for the purpose of the present invention include but are not limited to agricultural crops such as wheat, rye, barley, triticale, oats or rice; beet, e.g. sugar beet or fodder beet; fruits and 30 fruit trees, such as pomes, stone fruits or soft fruits, e.g. apples, pears, plums, peaches, almonds, cherries, strawberries, raspberries, blackberries or gooseberries; leguminous plants, such as lentils, peas, alfalfa or soybeans; oil plants, such as rape, mustard, olives, sunflowers, coconut, cocoa beans, castor oil plants, oil palms, ground nuts or soybeans; cucurbits, such as squashes, cucumber or melons; fiber plants, such as cotton, flax, hemp or jute; citrus fruit and citrus trees, such as oranges, lemons, 35 grapefruits or mandarins; any horticultural plants, vegetables, such as spinach, lettuce, asparagus, PI External cabbages, carrots, onions, tomatoes, potatoes, cucurbits or paprika; lauraceous plants, such as avocados, cinnamon or camphor; cucurbitaceae; oleaginous plants; energy and raw material plants, such as cereals, corn, soybean, other leguminous plants, rape, sugar cane or oil palm; tobacco; nuts; coffee; tea; cacao; bananas; peppers; vines (table grapes and grape juice grape vines); hop; turf; sweet leaf (also 5 called Stevia); natural rubber plants or ornamental and forestry plants, such as flowers, shrubs, broad- leaved trees or evergreens, e.g. conifers; and on the plant propagation material, such as seeds, and the crop material of these plants. Preferably, the plant for the present invention includes but is not limited to cereals, corn, rice, soybean and other leguminous plants, fruits and fruit trees, grapes, nuts and nut trees, citrus and citrus trees, any 10 horticultural plants, cucurbitaceae, oleaginous plants, tobacco, coffee, tea, cacao, sugar beet, sugar cane, cotton, potato, tomato, onions, peppers and vegetables, ornamentals, any floricultural plants, and other plants for the use by humans and animals. The term “plant parts” is understood to mean all parts and organs of plants above and below the ground. For the present disclosure, the term plant parts include but is not limited to cuttings, leaves, twigs, 15 tubers, flowers, seeds, branches, roots including taproots, lateral roots, root hairs, root apex, root cap, rhizomes, slips, shoots, fruits, fruit bodies, bark, stem, buds, Auxillary buds, meristems, nodes, and internodes. The term “locus thereof” includes soil, surroundings of plant or plant parts, and equipment or tools used before, during or after sowing / planting a plant or a plant part. The term “pest” for the purpose of the present disclosure includes but is not limited to fungi, 20 stramenopiles (oomycetes), bacteria, insects, and rodents. A pesticide is generally a chemical or biological agent (such as a pesticidal active ingredient, compound, composition, virus, bacterium, antimicrobial, or disinfectant) that through its effect deters, incapacitates, kills, or otherwise suppresses pests. Target pests can include insects, plant pathogens, weeds, and microbes that destroy property, cause nuisance, spread disease, or are vectors for disease. 25 The term pesticides includes also plant growth regulators that alter the growth, flowering, or reproduction rate of plants; defoliants that cause leaves or other foliage to drop from a plant, usually to facilitate harvest; desiccants that promote drying of living tissues, such as unwanted plant tops; plant activators that activate plant physiology for the defense against certain pests; safeners that reduce unwanted herbicidal action of pesticides on crop plants; and plant growth promoters that affect the plant 30 physiology to increase plant growth, biomass, yield or any other quality parameter of the harvestable goods of a crop plant. The term "pesticidally effective amount" denotes an amount of the composition or of the compounds of formula (I) and its mixtures, that are sufficient for controlling of harmful pests on cultivated plants or in the protection of materials, not resulting in substantial damage to the treated plants. Such an amount 35 can vary in a broad range and is dependent on various factors, such as the animal pest’s species to be PI External controlled, the treated cultivated plant or material, the climatic conditions, and the specific mixture being used. The term "fungicidally effective amount" denotes an amount of the composition or of the compounds of formula (I), which is sufficient for controlling harmful fungi on cultivated plants or in the protection 5 of harvested or stored products or materials, not resulting in substantial damage to the treated plants, the treated stored products or harvest, or to the treated materials. As used herein, “ LG ”means a Leaving Group. The compounds of the present disclosure may be present either in pure form or as mixtures of different possible isomeric forms such as stereoisomers or constitutional isomers. The various stereoisomers include enantiomers, diastereomers, chiral isomers, 10 atropisomers, conformers, rotamers, tautomers, optical isomers, polymorphs, and geometric isomers. Any desired mixtures of these isomers fall within the scope of the claims of the present disclosure. One skilled in the art will appreciate that one stereoisomer may be more active and / or may exhibit beneficial effects when enriched relative to the other isomer(s) or when separated from the other isomer(s). Additionally, the person skilled in the art knows processes or methods or technology to separate, enrich, 15 and / or to selectively prepare said isomers. The inventive compound of the present invention may, if appropriate, be present as mixtures of different possible isomeric forms, especially of stereoisomers, for example, E and Z, threo and erythro, and also optical isomers, but if appropriate also of tautomers. Both the E and the Z isomers, and also the threo and erythro isomers, and the optical isomers, any desired mixtures of these isomers and the possible 20 tautomeric forms are disclosed and claimed. The embodiments herein and the various features and advantageous details thereof are explained about the non-limiting embodiments in the description. Descriptions of well-known components and processing techniques are omitted to not unnecessarily obscure the embodiments herein. The examples used herein are intended merely to facilitate an understanding of ways in which the embodiments herein 25 may be practiced and to further enable those skilled in the art to practice the embodiments herein. Accordingly, the examples should not be construed as limiting the scope of the embodiments herein. The description of the specific embodiments will so fully reveal the general nature of the embodiments herein that others can, by applying current knowledge, readily modify and / or adapt for various applications such specific embodiments without departing from the generic concept, and, therefore, 30 such adaptations and modifications should and are intended to be comprehended within the meaning and range of equivalents of the disclosed embodiments. It is to be understood that the phraseology or terminology employed herein is for description and not of limitation. Therefore, while the embodiments herein have been described in terms of preferred embodiments, those skilled in the art will recognize that the embodiments herein can be practiced with modification within the spirit and scope of the 35 embodiments as described herein. PI External Although the present invention will be described for particular embodiments, this description is not to be construed in a limiting sense. In each case, the compounds of formula (I), according to the present invention, are including their free form, hydrated forms, any polymorphs or salts theirof, e.g., in the form of an agriculturally usable 5 product. Salts of the compounds of the formula (I) are agriculturally acceptable and applicable salts. They can be formed in a customary manner, e.g. by reacting the compound with an acid of the anion in question in case the compound of formula (I) has a basic functionality. Salts include, for example, acid addition salts such as hydrochlorides, sulfates, nitrates, phosphates, 10 sulfonates, acetates and benzoates. The presence of one or more possible asymmetric carbon atoms in a compound of formula (I) means that the compound may occur in chiral isomeric forms, i.e., enantiomeric or diastereomeric. Also, atropisomers may occur as a result of restricted rotation about a single bond. Formula (I) is intended to include all those possible isomeric forms and mixtures thereof. 15 The present invention includes all those possible isomeric forms and mixtures thereof of a compound of formula (I). Likewise, formula (I) is intended to include all possible tautomers (including lactam- lactim tautomerism and keto-enol tautomerism) where present. The present invention includes all possible tautomeric forms for a compound of formula (I). It has been found that the novel 1,2,4-oxadiazoles compounds of formula (I) have a very advantageous 20 level of biological activity for protecting plants against diseases that are caused by phytopathogenic fungi. The compounds of formula (I) are advantageous over the compounds reported in the literature in either improved pesticidal activity and / or fungicidal activity, a broader spectrum of biological efficacy, lower application rates, more favourable toxicological or environmental properties, or enhanced plant 25 compatibility. In view of the above objectives, the present invention provides a compound of formula (I), PI External wherein, A1is selected from NRA1or O; wherein RA1is selected from the group consisting of hydrogen, C1-C6- alkyl, C1-C6-haloalkyl, C1-C6-alkoxy, C3-C6-cycloalkyl and C3-C6-cycloalkyl-C1-C3-alkyl; R1is selected from the group consisting of hydrogen, halogen, C1-C3-alkyl, C1-C3-haloalkyl and C3-C6- 5 cycloalkyl; R2is selected from the group consisting of hydrogen, halogen, methyl and methoxy; R3is selected from the group consisting of hydrogen, halogen, C1-C3-alkyl and C1-C3-alkoxy; R4is selected from the group consisting of hydrogen, halogen, cyano, C1-C8-alkyl, C2-C6-alkenyl, C2- C6-alkynyl, C1-C6-haloalkyl, C2-C6-haloalkenyl, C2-C6-haloalkynyl, C3-C8-cycloalkyl, C3-C6-10 cycloalkenyl, C3-C6-cycloalkyloxy-C1-C3-alkyl, C3-C6-halocycloalkyl, C1-C6-alkoxy, C2-C6- alkenyloxy, C2-C6-alkynyloxy, C1-C6-haloalkoxy, C3-C6-cycloalkyloxy, C1-C6-alkylsulfanyl, C1-C6- haloalkylsulfanyl, cyano-C1-C6-alkyl-, C3-C6-cycloalkyl-C1-C6-alkyl-, C3-C6-cycloalkyl-C2-C6-alkenyl- , C3-C6-cycloalkyl-C2-C4-alkynyl-, C1-C6-alkoxy-C1-C6-alkyl-, -(CHR3)0-2C(R6)=NOR11, -NR8R9, - NR8COR10, -NR8CONR8R9, -NR8SO2R10, -(CHR3)0-2COR9, -(CHR3)0-2COOR6, -(CHR3)0-2NHCOR6a, -15 (CHR3)0-2CONR8R9, -(CHR3)0-2NHCOOR6, -CON=SO(R12)-R13, -CONR8SO2R10, phenyl, phenyl-C1- C6-alkyl-, phenoxy-C1-C3-alkyl-, naphthyl, C5-C12 saturated or partially unsaturated bi- or tri- carbocyclyl rings, 5- or 6- membered heteroaryl rings, 8- to 10- membered bicyclic heteroaryl rings, 4- to 10- membered non-aromatic heterocyclyl rings, 4-10 membered non-aromatic heterocyclyl-C1-C3- alkyl, 4-10 membered non-aromatic heterocyclyloxy-C1-C3-alkyl, 5- or 6- membered heteroaryl-C1-C3-20 alkyl, 5- to 10- membered heteroaryloxy-C1-C3-alkyl and 9- or 10- membered bicyclic heteroaryl-C1- C3-alkyl; wherein said 4- to 10- membered non-aromatic heterocyclyl ring, 5- or 6- membered heteroaryl ring and 8- to 10- membered bicyclic heteroaryl ring contain 1, 2 or 3 heteroatoms independently selected from N, O or S(O)0-2; wherein the aliphatic group of said R4is unsubstituted or substituted by one to four substituents 25 independently selected from R7a, and the cyclic group of said R4is unsubstituted or substituted by one to four substituents independently selected from R7b; R5is selected from H or C1-C3-alkyl; or R5and RA1together with the N atom to which they are attached form a 5-6 membered non-aromatic 30 heterocyclic ring which contain 1, 2 or 3 heteroatoms independently selected from N, O, S, S(O) or SO2 wherein one to two carbon atoms of the heterocyclic ring may be replaced with C=O or C=S; said 5-6 membered heterocyclic ring is unsubstituted or substituted with one to three substituents independently selected from halogen, C1-C6 alkyl, C1-C6-haloalkyl, C1-C6-alkoxy or C1-C6-haloalkoxy; PI External R6is selected from hydrogen or C1-C6-alkyl; R6ais selected from the group consisting of C1-C6-alkyl, C1-C6-haloalkyl, C1-C6-alkoxy, C1-C6-alkoxy- C1-C3-alkyl, C1-C6-alkylthio-C1-C3-alkyl, C3-C6-cycloalkyl and phenyl; wherein said phenyl is unsubstituted or substituted with one to three identical or different substituents selected from chloro, 5 fluoro, bromo, methyl, trifluoromethyl, methoxy or ethoxy; R7ais selected from the group consisting of halogen, cyano, NO2, -OH, -N(R8)2, C1-C6-alkyl, C2-C6- alkenyl, C2-C6-alkynyl, C1-C6-haloalkyl, C2-C6-haloalkenyl, C3-C6-cycloalkyl, C1-C6-alkoxy, C3-C6- cycloalkyloxy, C1-C6-haloalkoxy, C1-C6-alkylsulfanyl, -NH-S(O)2-C1-C6-alkyl, -S(O)2-C1-C6-alkyl, - SR9a, benzyloxy, pyrazolyl, pyridinyl, phenyl, naphthyl, indanyl, phenylthio, C1-C6-haloalkylsulfanyl 10 and C1-C6-alkylcarbonyl; wherein said C3-C6-cycloalkyl, pyrazolyl, phenyl and phenylthio groups are unsubstituted or substituted with one to three identical or different substituents selected from chloro, fluoro, bromo, methyl, ethyl, amino, trifluoromethyl, methoxy or ethoxy; R7bis selected from the group consisting of halogen, cyano, NO2, -OH, -N(R8)2, C1-C6-alkyl, C2-C6- alkenyl, C1-C6-cyanoalkyl, C1-C6-haloalkyl, C3-C6-cycloalkyl, C3-C6-cyanocycloalkyl C3-C6-15 cycloalkyl-C1-C3-alkyl, C1-C6-alkoxy, oxo, thioxo, C1-C6-haloalkoxy, C1-C6-alkylsulfanyl, C1-C6- haloalkylsulfanyl, phenyl, phenoxy, a 4-6 membered non-aromatic heterocyclyl ring which contain 1, 2 or 3 heteroatoms independently selected from N, O or S, C1-C6-alkylcarbonyl, -SCF3, -S(O)2-R9a, - (CHR3)0-2C(R6)=NOR11a, -NR8aR9a, -NR8aCOR10a, NR8aCONR8aR9a, -NR8aSO2R10a, -(CHR3)0-2COR9a, - (CHR3)0-2COOR6, -(CHR3)0-2CONR8aR9a, -CON=SO(R12a)-R13aand -CONR8aSO2R10a; wherein said 20 phenyl, phenoxy and heterocyclyl ring is unsubstituted or substituted with one to three identical or different substituents selected from chloro, fluoro, bromo, methyl, cyclopropyl, difluoromethyl, trifluoromethyl, methoxy, ethoxy or propoxy; R8is independently selected from the group consisting of hydrogen, C1-C6-alkyl, C3-C6-cycloalkyl, phenyl and C1-C6-alkoxy; 25 R9is selected from the group consisting of hydrogen, C1-C6-alkyl, C1-C6-haloalkyl, C3-C6-cycloalkyl, C3-C6-cycloalkyl-C1-C6-alkyl, phenyl and a 5-6 membered heteroaryl ring; wherein said phenyl is unsubstituted or substituted with identical or different one to three groups selected from methyl, methoxy or halogen; R10is selected from the group consisting of halogen, -OH, -N(R8)2, C1-C6-alkyl, C1-C6-haloalkyl, C3- 30 C6-cycloalkyl, C6-cycloalkyl-C1-C6-alkyl, phenyl and a 5-6 membered heteroaryl ring; R11is selected from the group consisting of C1-C6-alkyl, C1-C6-haloalkyl, C3-C6-cycloalkyl, C3-C6- cycloalkyl-C1-C6-alkyl, benzyl and phenyl; R12is selected from the group consisting of C1-C6-alkyl, C1-C6-haloalkyl, C3-C6-cycloalkyl, C3-C6- cycloalkyl-C1-C6-alkyl, phenyl and a 5-6 membered heteroaryl ring; PI External R13is selected from the group consisting of C1-C6-alkyl, C1-C6-haloalkyl, C3-C6-cycloalkyl, C3-C6- cycloalkyl-C1-C6-alkyl, phenyl and a 5-6 membered heteroaryl ring; R8ais selected from the group consisting of hydrogen, C1-C6-alkyl, C3-C6-cycloalkyl and C1-C6-alkoxy; R9ais selected from the group consisting of hydrogen, C1-C6-alkyl, C1-C6-haloalkyl, C3-C6-cycloalkyl, 5 C3-C6-cycloalkyl-C1-C6-alkyl, pyridinyl and phenyl; wherein said phenyl is unsubstituted or substituted with identical or different one to three groups selected from methyl, methoxy or halogen; R10ais selected from the group consisting of halogen, OH, C1-C6-alkyl, C1-C6-haloalkyl, C3-C6- cycloalkyl and C6-cycloalkyl-C1-C6-alkyl; R11ais selected from the group consisting of C1-C6-alkyl, C1-C6-haloalkyl, C3-C6-cycloalkyl and C3-C6- 10 cycloalkyl-C1-C6-alkyl; R12ais selected from the group consisting of C1-C6-alkyl, C1-C6-haloalkyl, C3-C6-cycloalkyl and C3-C6- cycloalkyl-C1-C6-alkyl; R13ais selected from the group consisting of C1-C6-alkyl, C1-C6-haloalkyl, C3-C6-cycloalkyl and C3-C6- cycloalkyl-C1-C6-alkyl; 15 or salts, stereoisomers, polymorphs or N-oxides thereof. In one embodiment of the present invention, the compound of formula (I) is represented as a compound of formula (I-A), 20 wherein R1, R2, R3, R4and R5are as defined for the compounds of formula (I) according to the present invention. In another embodiment, the present invention provides the compound of formula (I-A), wherein R1, R2, R3and R4are as defined for the compounds of formula (I) according to the present invention, and R5is methyl. 25 In yet another embodiment, the present invention provides the compound of formula (I-A), wherein R1is selected from hydrogen, halogen or C1-C3-alkyl; R2is selected from hydrogen or methyl; R3is PI External selected from hydrogen or C1-C3-alkyl; R5is methyl, and R4is as defined for the compounds of formula (I) according to the present invention. In a preferred embodiment, the present invention provides the compounds of formula (I-A), wherein R1is selected from hydrogen, halogen or C1-C3-alkyl, preferably R1is selected from hydrogen, methyl, 5 chloro or fluoro; R2is selected from hydrogen or methyl, preferably R2is hydrogen; R3is hydrogen and R4is selected from the group consisting of hydrogen, halogen, cyano, C1-C8-alkyl, C2-C6-alkenyl, C2- C6-alkynyl, C1-C6-haloalkyl, C2-C6-haloalkenyl, C2-C6-haloalkynyl, C3-C8-cycloalkyl, C3-C6- cycloalkenyl, C3-C6-cycloalkyloxy-C1-C3-alkyl, C3-C6-halocycloalkyl, C1-C6-alkoxy, C2-C6- alkenyloxy, C2-C6-alkynyloxy, C1-C6-haloalkoxy, C3-C6-cycloalkyloxy, C1-C6-alkylsulfanyl, C1-C6-10 haloalkylsulfanyl, cyano-C1-C6-alkyl-,C3-C6-cycloalkyl-C1-C4-alkyl-, C3-C6-cycloalkyl-C2-C6-alkenyl- , C3-C6-cycloalkyl-C2-C4-alkynyl-, C1-C6-alkoxy-C1-C3-alkyl-, -(CHR3)0-2C(R6)=NOR11, -NR8R9, - NR8COR10, -NR8CONR8R9, -NR8SO2R10, -(CHR3)0-2COR9, -(CHR3)0-2COOR6, -(CHR3)0-2NHCOR6a, - (CHR3)0-2CONR8R9, -(CHR3)0-2NHCOOR6, -CON=SO(R12)-R13, -CONR8SO2R10, phenyl, phenyl-C1- C6-alkyl-, phenoxy-C1-C3-alkyl-, naphthyl, a C5-C12 saturated or partially unsaturated bi- or tri- 15 carbocyclyl ring, a 5- or 6- membered heteroaryl ring, a 8-10- membered bicyclic heteroaryl ring, a 4- to 10-membered non-aromatic heterocyclyl ring, a 4-10 membered non-aromatic heterocyclyl-C1-C3- alkyl, a 4-10 membered heterocyclyloxy-C1-C3-alkyl, a 5- or 6- membered heteroaryl-C1-C3-alkyl, a 5- to 10- membered heteroaryloxy-C1-C3-alkyl and a 9- or 10- membered bicyclic heteroaryl-C1-C3-alkyl; wherein said 4- to 10- membered non-aromatic heterocyclyl ring, the 5- or 6- membered heteroaryl ring 20 and 8 to 10 membered bicyclic heteroaryl ring contain 1, 2 or 3 heteroatoms independently selected from N, O or S; wherein the aliphatic group of said R4is unsubstituted or substituted by one to four substituents independently selected from R7a, and the cyclic group of said R4is unsubstituted or substituted by one to four substituents independently selected from R7b. 25 In another preferred embodiment, the present invention provides the compound of formula (I-A), wherein R1is selected from hydrogen, halogen or C1-C3-alkyl, preferably R1is selected from hydrogen, methyl, chloro or fluoro; R2is selected from hydrogen or methyl, preferably R2is hydrogen; R3is hydrogen and R4is selected from the group consisting of hydrogen, halogen, cyano, C1-C8-alkyl, C2- C6-alkenyl, C2-C6-alkynyl, C1-C6-haloalkyl, C2-C6-haloalkenyl, C2-C6-haloalkynyl, C3-C8-cycloalkyl,30 C3-C6-cycloalkenyl, C3-C6-cycloalkyloxy-C1-C3-alkyl, C1-C6-alkoxy, C1-C6-alkoxy-C1-C3-alkyl-, C1- C6-haloalkoxy, C3-C6-cycloalkyl-C1-C4-alkyl-, -(CHR3)0-2C(R6)=NOR11, -NR8COR10, -(CHR3)0-2COR9, -(CHR3)0-2COOR6, -(CHR3)0-2NHCOR6a, -(CHR3)0-2CONR8R9, -(CHR3)0-2NHCOOR6, phenyl, phenyl-C1-C6-alkyl-, phenoxy-C1-C3-alkyl-, naphthyl, a C5-C12 saturated or partially unsaturated bi- or tri- carbocyclyl ring, a 5- or 6- membered heteroaryl ring, a 8 to 10 membered bicyclic heteroaryl ring,35 a 4-to 10- membered non-aromatic heterocyclyl ring, 4-10 membered non-aromatic heterocyclyl-C1- C3-alkyl, 4-10 membered non-aromatic heterocyclyloxy-C1-C3-alkyl, 5- or 6- membered heteroaryl- PI External C1-C3-alkyl, a 5- to 10- membered heteroaryloxy-C1-C3-alkyl and 9- or 10- membered bicyclic heteroaryl-C1-C3-alkyl; wherein said 4- to 10- membered non-aromatic heterocyclyl ring, the 5- or 6- membered heteroaryl ring and 8 to 10 membered bicyclic heteroaryl ring contain 1, 2 or 3 heteroatoms independently selected from N, O or S(O)0-2; 5 wherein the aliphatic group of said R4is unsubstituted or substituted by one to four substituents independently selected from R7a, and the cyclic group of said R4is unsubstituted or substituted by one to four substituents independently selected from R7b. In another preferred embodiment, the present invention provides the compound of formula (I-A), wherein R7ais selected from the group consisting of halogen, cyano, NO2, -OH, -N(R8)2, C1-C6-alkyl,10 C2-C6-alkenyl, C2-C6-alkynyl, C1-C6-haloalkyl, C2-C6-haloalkenyl, C3-C6-cycloalkyl, C1-C6-alkoxy, C3- C6-cycloalkyloxy, C1-C6-haloalkoxy, C1-C6-alkylsulfanyl, -NH-S(O)2-C1-C6-alkyl, -S(O)2-C1-C6-alkyl, -SR9a, benzyloxy, pyrazolyl, pyridinyl, phenyl, naphthyl, phenylthio, - C1-C6-haloalkylsulfanyl,C1-C6- alkylcarbonyl, and 4-6 membered non-aromatic heterocyclyl; wherein said C3-C6-cycloalkyl, pyrazolyl, phenyl and phenylthio groups are unsubstituted or substituted with one to three identical or different 15 substituents selected from chloro, fluoro, bromo, methyl, ethyl, amino, trifluoromethyl, methoxy or ethoxy; R7bis selected from the group consisting of halogen, cyano, NO2, -OH, -N(R8)2, C1-C6-alkyl, C2-C6- alkenyl, C1-C6-cyanoalkyl, C1-C6-haloalkyl, C3-C6-cycloalkyl, C3-C6-cyanocycloalkyl C3-C6- cycloalkyl-C1-C3-alkyl, C1-C6-alkoxy, oxo, thioxo, C1-C6-haloalkoxy, C1-C6-alkylsulfanyl, C1-C6- 20 haloalkylsulfanyl, phenyl, phenoxy, 4-6 membered non-aromatic heterocyclyl ring contain 1, 2 or 3 heteroatoms independently selected from N, O or S(O)0-2, C1-C6-alkylcarbonyl, -SCF3, -S(O)2-R9a, - phenyl, phenoxy and heterocyclyl ring is unsubstituted or substituted with one to three identical or 25 different substituents selected from chloro, fluoro, bromo, methyl, cyclopropyl, difluoromethyl, trifluoromethyl, methoxy, ethoxy or propoxy. In yet another preferred embodiment, the present invention provides the compound of formula (I-A), wherein R7ais selected from the group consisting of halogen, cyano, NO2, -OH, -N(R8)2, C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C1-C6-haloalkyl, C2-C6-haloalkenyl, C3-C6-cycloalkyl, C1-C6-alkoxy, C3- 30 C6-cycloalkyloxy, C1-C6-haloalkoxy, C1-C6-alkylsulfanyl, -NH-S(O)2-C1-C6-alkyl, -S(O)2-C1-C6-alkyl, -SR9a, benzyloxy, pyrazolyl, pyridinyl, phenyl, naphthyl, phenylthio, -C1-C6-haloalkylsulfanyl and C1- C6-alkylcarbonyl; wherein said C3-C6-cycloalkyl preferably cyclopropyl, pyrazolyl, phenyl and phenylthio groups are unsubstituted or substituted with one to three identical or different substituents selected from chloro, fluoro, bromo, methyl, amino, trifluoromethyl, methoxy or ethoxy; 35 R7bis selected from the group consisting of halogen, cyano, NO2, -OH, -N(R8)2, C1-C6-alkyl, C2-C6- alkenyl, C1-C6-cyanoalkyl, C1-C6-haloalkyl, C3-C6-cycloalkyl, C3-C6-cyanocycloalkyl C3-C6- PI External cycloalkyl-C1-C3-alkyl, C1-C6-alkoxy, oxo, thioxo, C1-C6-haloalkoxy, C1-C6-alkylsulfanyl, C1-C6- haloalkylsulfanyl, phenyl, phenoxy, a 4-6 membered non-aromatic heterocyclyl ring which contain 1, 2 or 3 heteroatoms independently selected from N, O or S, C1-C6-alkylcarbonyl, -SCF3, -S(O)2-R9a, - 5 phenyl, phenoxy and heterocyclyl ring is unsubstituted or substituted with one to three identical or different substituents selected from chloro, fluoro, bromo, methyl, cyclopropyl, difluoromethyl, trifluoromethyl, methoxy, ethoxy or propoxy. In one embodiment of the present invention, the compound of formula (I) is represented as a compound 10 of formula (I-B), (I-B) wherein, RA1is selected from the group consisting of hydrogen, C1-C6-alkyl, C1-C6-haloalkyl, C1-C6- alkoxy, C3-C6-cycloalkyl and C3-C6-cycloalkyl-C1-C3-alkyl; and R1, R2, R3, R4and R5are as defined 15 for the compounds of formula (I). In another embodiment of the present invention, the compound of formula (I-B) is represented as a compound of formula (I-B1), 20 wherein, R1, R2, R3, R4and R5are as defined for the compounds of formula (I). The following list provides definitions, including preferred definitions, for the substituents A1, R1, R2, R3, R4, R5, R6, R6a, R7a, R7bR8, R8a, R9, R9a, R10, R10a, R11R11a, R12, R12a, R13and R13awith reference to the compounds of formula (I) of the present invention. For any one of these substituents, any of the PI External definitions given below may be combined with any definition of any other substituent given below or elsewhere in this document. In one embodiment of the present invention, A1is selected from the group consisting NRA1or O. In another embodiment of the present invention, A1is NRA1wherein RA1is selected from the group 5 consisting of hydrogen, C1-C3-alkyl, C1-C3-haloalkyl, C1-C3-alkoxy, C3-C6-cycloalkyl and C3-C6- cycloalkyl-C1-C3-alkyl. In a preferred embodiment of the present invention, A1is O. In one embodiment of the present invention, R1is selected from the group consisting of hydrogen, halogen, C1-C3-alkyl, C1-C3-haloalkyl and C3-C6-cycloalkyl. 10 In another embodiment of the present invention, R1is selected from the group consisting of hydrogen, halogen and C1-C3-alkyl. In yet another embodiment of the present invention, R1is selected from the group consisting of hydrogen, halogen, methyl, ethyl and propyl. In a preferred embodiment of the present invention, R1is selected from the group consisting of 15 hydrogen, fluoro, chloro, methyl, ethyl and propyl. In a more preferred embodiment of the present invention, R1is selected from the group consisting of hydrogen, fluoro, chloro, methyl and ethyl. In a most preferred embodiment of the present invention, R1is methyl. In one embodiment of the present invention, R2is selected from the group consisting of hydrogen, 20 halogen, methyl and methoxy. In another embodiment of the present invention, R2is selected from the group consisting of hydrogen, halogen and methyl. In a preferred embodiment of the present invention, R2is selected from hydrogen, fluoro, chloro or methyl. 25 In a more preferred embodiment of the present invention, R2is hydrogen. In one embodiment of the present invention, R3is selected from the group consisting of hydrogen, halogen, C1-C3-alkyl and C1-C3-alkoxy. In a preferred embodiment of the present invention, R3is selected from hydrogen, halogen or C1-C3- alkyl. 30 In a more preferred embodiment of the present invention, R3is hydrogen. In one embodiment of the present invention, R4is selected from the group consisting of hydrogen, halogen, cyano, C1-C8-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C1-C6-haloalkyl, C2-C6-haloalkenyl, C2-C6- PI External haloalkynyl, C3-C8-cycloalkyl, C3-C6-cycloalkenyl, C3-C6-cycloalkyloxy-C1-C3-alkyl, C3-C6- halocycloalkyl, C1-C6-alkoxy, C2-C6-alkenyloxy, C2-C6-alkynyloxy, C1-C6-haloalkoxy, C3-C6- cycloalkyloxy, C1-C6-alkylsulfanyl, C1-C6-haloalkylsulfanyl, cyano-C1-C6-alkyl-,C3-C6-cycloalkyl-C1- C6-alkyl-, C3-C6-cycloalkyl-C2-C6-alkenyl-, C3-C6-cycloalkyl-C2-C4-alkynyl-, C1-C6-alkoxy-C1-C6- 5 alkyl-, - CON=SO(R12)-R13, -CONR8SO2R10, phenyl, phenyl-C1-C6-alkyl-, phenoxy-C1-C3-alkyl, naphthyl, a C5-C12saturated or partially unsaturated bi- or tri- carbocyclyl ring, a 5- or 6- membered heteroaryl ring, a 8 to 10 membered bicyclic heteroaryl ring, a 4- to 10- membered non-aromatic heterocyclyl ring,10 4-10 membered non-aromatic heterocyclyl-C1-C3-alkyl, 4-10 membered non-aromatic heterocyclyloxy- C1-C3-alkyl, 5- or 6- membered heteroaryl-C1-C3-alkyl, 5- to 10- membered heteroaryloxy-C1-C3-alkyl and 9- or 10- membered bicyclic heteroaryl-C1-C3-alkyl; wherein said 4- to 10- membered non-aromatic heterocyclyl ring, 5- or 6- membered heteroaryl ring and 8 to 10 membered bicyclic heteroaryl ring contain 1, 2 or 3 heteroatoms independently selected from N, O or S(O)0-2; 15 wherein the aliphatic group of said R4is unsubstituted or substituted by one to four substituents independently selected from R7a, and the cyclic group of said R4is unsubstituted or substituted by one to four substituents independently selected from R7b; In another embodiment of the present invention, R4is selected from the group consisting of hydrogen, halogen, cyano, C1-C8-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C1-C6-haloalkyl, C2-C6-haloalkenyl, C2-C6- 20 haloalkynyl, C3-C8-cycloalkyl, C3-C6-cycloalkenyl, C3-C6-cycloalkyloxy-C1-C3-alkyl, C1-C6-alkoxy, C1-C6-haloalkoxy, C3-C6-cycloalkyloxy, C1-C6-alkylsulfanyl, cyano-C1-C6-alkyl-,C3-C6-cycloalkyl-C1- C4-alkyl-, C1-C6-alkoxy-C1-C3-alkyl- -NR8SO2R10, -(CHR3)0-2COR9, - (CHR3)0-2NHCOOR6, phenyl, phenyl-C1-C6-alkyl-, phenoxy-C1-C3-alkyl, naphthyl, a C5-C12 saturated 25 or partially unsaturated bi- or tri- carbocyclyl ring, a 5- or 6- membered heteroaryl ring, a 8 to 10 membered bicyclic heteroaryl ring, a 4- to 10- membered non-aromatic heterocyclyl ring, 4-10 membered non-aromatic heterocyclyl-C1-C3-alkyl, 4-10 membered non-aromatic heterocyclyloxy-C1- C3-alkyl, 5- or 6- membered heteroaryl-C1-C3-alkyl, 5- to 10- membered heteroaryloxy-C1-C3-alkyl and 9- or 10- membered bicyclic heteroaryl-C1-C3-alkyl; wherein said 4- to 10- membered non-aromatic 30 heterocyclyl ring, 5- or 6- membered heteroaryl ring and 8 to 10 membered bicyclic heteroaryl ring contain 1, 2 or 3 heteroatoms independently selected from N, O or S(O)0-2; wherein the aliphatic group of said R4is unsubstituted or substituted by one to four substituents independently selected from R7a, and the cyclic group of said R4is unsubstituted or substituted by one to four substituents independently selected from R7b. 35 In a preferred embodiment of the present invention, R4is selected from the group consisting of hydrogen, halogen, cyano, C1-C8-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C1-C6-haloalkyl, C2-C6- PI External haloalkenyl, C2-C6-haloalkynyl, C3-C8-cycloalkyl, C3-C6-cycloalkenyl, C3-C6-cycloalkyloxy-C1-C3- alkyl, C1-C6-alkoxy, C1-C6-haloalkoxy, C3-C6-cycloalkyloxy, C1-C6-alkylsulfanyl, C3-C6-cycloalkyl- C1-C4-alkyl-, C1-C6-alkoxy-C1-C3-alkyl-, -(CHR3)0-2C(R6)=NOR11, -NR8R9, -NR8COR10, -(CHR3)0-2COR9, -(CHR3)0-2COOR6, -(CHR3)0-2NHCOR6a, -(CHR3)0-2CONR8R9, -(CHR3)0-2NHCOOR6, phenyl, 5 phenyl-C1-C6-alkyl-, phenoxy-C1-C3-alkyl, naphthyl, a C5-C12saturated or partially unsaturated bi- or tri- carbocyclyl ring, a 5- or 6- membered heteroaryl ring, a 8 to 10 membered bicyclic heteroaryl ring, a 4- to 10- membered non-aromatic heterocyclyl ring, 4-10 membered non-aromatic heterocyclyl-C1- C3-alkyl, 4-10 membered non-aromatic heterocyclyloxy-C1-C3-alkyl, 5- or 6- membered heteroaryl-C1- C3-alkyl, 5- to 10- membered heteroaryloxy-C1-C3-alkyl and 9- or 10- membered bicyclic heteroaryl- 10 C1-C3-alkyl; wherein said 4- to 10- membered non-aromatic heterocyclyl ring, 5- or 6- membered heteroaryl ring and 8 to 10 membered bicyclic heteroaryl ring contain 1, 2 or 3 heteroatoms independently selected from N, O or S(O)0-2; wherein the aliphatic group of said R4is unsubstituted or substituted by one to four substituents independently selected from R7a, and the cyclic group of said R4is unsubstituted or substituted by one 15 to four substituents independently selected from R7b. In another preferred embodiment of the present invention, R4is selected from phenyl or phenyl-C1-C6- alkyl-; wherein the aliphatic group of said R4is unsubstituted or substituted by one to four substituents independently selected from R7a, and the cyclic group of said R4is unsubstituted or substituted by one to four substituents independently selected from R7b. 20 In yet another preferred embodiment of the present invention, R4is selected from a 5- or 6- membered heteroaryl ring, 5- or 6- membered heteroaryl-C1-C3-alkyl, a 8 to 10 membered bicyclic heteroaryl ring, 9- or 10- membered bicyclic heteroaryl-C1-C3-alkyl, 4-10 membered non-aromatic heterocyclyl-C1-C3- alkyl or a 4- to 10- membered non-aromatic heterocyclyl ring; wherein said rings contain 1, 2 or 3 heteroatoms independently selected from N, O or S(O)0-2 preferably N, O or S; wherein the aliphatic 25 group of said R4is unsubstituted or substituted by one to three substituents independently selected from R7a, and the cyclic group of said R4is unsubstituted or substituted by one to four substituents independently selected from R7b. In yet another preferred embodiment of the present invention, R4is selected from a 5- or 6- membered heteroaryl ring, a 9- or 10-membered bicyclic heteroaryl ring or a 4- to 10- membered non-aromatic 30 heterocyclyl ring; wherein said R4is unsubstituted or substituted by one to three substituents independently selected from R7b. In yet another preferred embodiment of the present invention, R4is selected from C1-C6-alkyl or C1-C6- haloalkyl; wherein said C1-C6-alkyl or C1-C6-haloalkyl is unsubstituted or substituted by one to three substituents independently selected from R7a; PI External In yet another preferred embodiment of the present invention, R4is C3-C6-cycloalkyl; wherein said C3- C6-cycloalkyl is unsubstituted or substituted by one to three substituents independently selected from R7b. In one embodiment of the present invention, R7ais selected from the group consisting of halogen, cyano, 5 NO2, -OH, -N(R8)2, C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C1-C6-haloalkyl, C2-C6-haloalkenyl, C3- C6-cycloalkyl, C1-C6-alkoxy, C3-C6-cycloalkyloxy, C1-C6-haloalkoxy, C1-C6-alkylsulfanyl, -NH-S(O)2- C1-C6-alkyl, -S(O)2-C1-C6-alkyl, -SR9a, benzyloxy, pyrazolyl, pyridinyl, phenyl, naphthyl, phenylthio, - C1-C6-haloalkylsulfanyl,C1-C6-alkylcarbonyl, and 4-6 membered heterocyclyl; wherein said C3-C6- cycloalkyl, pyrazolyl, phenyl and phenylthio groups are unsubstituted or substituted with one to three 10 identical or different substituents selected from chloro, fluoro, bromo, methyl, ethyl, amino, trifluoromethyl, methoxy or ethoxy. In another embodiment of the present invention, R7ais selected from the group consisting of halogen, cyano, -OH, -N(R8)2, C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C1-C6-haloalkyl, C2-C6-haloalkenyl, C3-C6-cycloalkyl, C1-C6-alkoxy, C1-C6-haloalkoxy, C1-C6-alkylsulfanyl, -NH-S(O)2-C1-C6-alkyl, - 15 S(O)2-C1-C6-alkyl, -SR9a, benzyloxy, pyrazolyl, pyridinyl, phenyl, naphthyl, -C1-C6-haloalkylsulfanyl, C1-C6-alkylcarbonyl, and 4-6 membered heterocyclyl; wherein said C3-C6-cycloalkyl, pyrazolyl, phenyl and phenylthio groups are unsubstituted or substituted with one to three identical or different substituents selected from chloro, fluoro, bromo, methyl, amino, trifluoromethyl, methoxy or ethoxy. In a preferred embodiment of the present invention, R7ais selected from the group consisting of halogen, 20 cyano, -OH, -N(R8)2, C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C1-C6-haloalkyl, C2-C6-haloalkenyl, C3-C6-cycloalkyl, C1-C6-alkoxy, C1-C6-haloalkoxy, C1-C6-alkylsulfanyl, -NH-S(O)2-C1-C6-alkyl, - S(O)2-C1-C6-alkyl, -SR9a, benzyloxy, pyrazolyl, pyridinyl, phenyl, naphthyl and 4-6 membered heterocyclyl; wherein said C3-C6-cycloalkyl preferably cyclopropyl, pyrazolyl, phenyl and phenylthio groups are unsubstituted or substituted with one to three identical or different substituents selected from 25 chloro, fluoro, bromo, methyl, amino, trifluoromethyl, methoxy or ethoxy. In one embodiment of the present invention, R7bis selected from the group consisting of halogen, cyano, NO2, -OH, -N(R8)2, C1-C6-alkyl, C2-C6-alkenyl, C1-C6-cyanoalkyl, C1-C6-haloalkyl, C3-C6-cycloalkyl, C3-C6-cyanocycloalkyl C3-C6-cycloalkyl-C1-C3-alkyl, C1-C6-alkoxy, oxo, thioxo, C1-C6-haloalkoxy, C1-C6-alkylsulfanyl, C1-C6-haloalkylsulfanyl, phenyl, phenoxy, 4-6 membered heterocyclyl ring30 contain 1, 2 or 3 heteroatoms independently selected from N, O or S, C1-C6-alkylcarbonyl, -SCF3, - S(O)2-R9a, -(CHR3)0-2C(R6)=NOR11a, -NR8aR9a, -NR8aCOR10a, NR8aCONR8aR9a, -NR8aSO2R10a, - (CHR3)0-2COR9a, -(CHR3)0-2COOR6, -(CHR3)0-2CONR8aR9a, -CON=SO(R12a)-R13aand - CONR8aSO2R10a; wherein said phenyl, phenoxy and heterocyclyl ring is unsubstituted or substituted with one to three identical or different substituents selected from chloro, fluoro, bromo, methyl, 35 cyclopropyl, difluoromethyl, trifluoromethyl, methoxy, ethoxy or propoxy. PI External In another embodiment of the present invention, R7bis selected from the group consisting of halogen, cyano, NO2, -OH, -N(R8)2, C1-C6-alkyl, C2-C6-alkenyl, C1-C6-cyanoalkyl, C1-C6-haloalkyl, C3-C6- cycloalkyl, C3-C6-cyanocycloalkyl C3-C6-cycloalkyl-C1-C3-alkyl, C1-C6-alkoxy, oxo, thioxo, C1-C6- haloalkoxy, C1-C6-alkylsulfanyl, C1-C6-haloalkylsulfanyl, phenyl, phenoxy, a 4-6 membered 5 heterocyclyl ring which contain 1, 2 or 3 heteroatoms independently selected from N, O or S, C1-C6- alkylcarbonyl, -SCF3, -S(O)2-R9a, -(CHR3)0-2C(R6)=NOR11a, -NR8aR9a, -NR8aCOR10a, NR8aCONR8aR9a, -NR8aSO2R10aand -(CHR3)0-2COR9a; wherein said phenyl, phenoxy and heterocyclyl ring is unsubstituted or substituted with one to three identical or different substituents selected from chloro, fluoro, bromo, methyl, cyclopropyl, difluoromethyl, trifluoromethyl, methoxy, ethoxy or propoxy. 10 In a preferred embodiment of the present invention, R7bis selected from the group consisting of halogen, cyano, NO2, -OH, -N(R8)2, C1-C6-alkyl, C2-C6-alkenyl, C1-C6-cyanoalkyl, C1-C6-haloalkyl, C3-C6- cycloalkyl, C3-C6-cyanocycloalkyl C3-C6-cycloalkyl-C1-C3-alkyl, C1-C6-alkoxy, oxo, thioxo, C1-C6- haloalkoxy, C1-C6-alkylsulfanyl, phenyl, phenoxy, a 4-6 membered heterocyclyl ring which contain 1, 2 or 3 heteroatoms independently selected from N, O or S, -SCF3, -S(O)2-R9a, -(CHR3)0-2C(R6)=NOR11a15 and -(CHR3)0-2COR9a; wherein said phenyl, phenoxy and heterocyclyl ring is unsubstituted or substituted with one to three identical or different substituents selected from chloro, fluoro, bromo, methyl, cyclopropyl, difluoromethyl, trifluoromethyl or methoxy. In one embodiment of the present invention, R5is selected from H or C1-C3-alkyl. In another embodiment of the present invention, R5is C1-C3-alkyl. 20 In a preferred embodiment of the present invention, R5is C1-C3-alkyl selected from methyl, ethyl, propyl or isopropyl. In a more preferred embodiment of the present invention, R5is methyl. In one embodiment of the present invention, R6is selected from H or C1-C6-alkyl. In another embodiment of the present invention, R6is H. 25 In yet another embodiment of the present invention, R6is C1-C6-alkyl. In a preferred embodiment of the present invention, R6is C1-C4-alkyl. In one embodiment of the present invention, R6ais selected from the group consisting of C1-C6-alkyl, C1-C6-haloalkyl, C1-C6-alkoxy, C1-C6-alkoxy-C1-C3-alkyl, C1-C6-alkylthio-C1-C3-alkyl, C3-C6- cycloalkyl and phenyl; wherein said phenyl is unsubstituted or substituted with one to three identical or 30 different substituents selected from chloro, fluoro, bromo, methyl, trifluoromethyl, methoxy or ethoxy. In another embodiment of the present invention, R6ais selected from the group consisting of C1-C6- alkyl, C1-C6-haloalkyl, C1-C6-alkoxy-C1-C3-alkyl, C1-C6-alkylthio-C1-C3-alkyl, C3-C6-cycloalkyl and PI External phenyl; wherein said phenyl is unsubstituted or substituted with one to three identical or different substituents selected from chloro, fluoro, bromo, methyl, trifluoromethyl, methoxy or ethoxy. In a preferred embodiment of the present invention, R6ais selected from the group consisting of C1-C4- alkyl, C1-C4-haloalkyl, C1-C4-alkoxy-C1-C3-alkyl, C1-C4-alkylthio-C1-C3-alkyl, C3-C6-cycloalkyl and 5 phenyl; wherein said phenyl is unsubstituted or substituted with one to three identical or different substituents selected from chloro, fluoro, bromo, methyl, trifluoromethyl, methoxy or ethoxy. In one embodiment of the present invention, R8is independently selected from the group consisting of hydrogen, C1-C6-alkyl, C3-C6-cycloalkyl, phenyl and C1-C6-alkoxy; In another embodiment of the present invention, R8is independently selected from the group consisting 10 of hydrogen, C1-C4-alkyl, C3-C6-cycloalkyl, phenyl and C1-C4-alkoxy; In a preferred embodiment of the present invention, R8is independently selected from the group consisting of hydrogen, C1-C4-alkyl and phenyl. In one embodiment of the present invention, R9is selected from the group consisting of hydrogen, C1- C6-alkyl, C1-C6-haloalkyl, C3-C6-cycloalkyl, C3-C6-cycloalkyl-C1-C6-alkyl, phenyl and a 5-6 membered 15 heteroaryl; wherein said phenyl is unsubstituted or substituted with identical or different one to three substituents selected from methyl, methoxy or halogen. In another embodiment of the present invention, R9is selected from the group consisting of hydrogen, C1-C4-alkyl, C1-C4-haloalkyl, C3-C6-cycloalkyl, C3-C6-cycloalkyl-C1-C3-alkyl, phenyl and 5-6 membered heteroaryl; wherein said phenyl is unsubstituted or substituted with identical or different one 20 to three substituents selected from methyl, methoxy or halogen. In a preferred embodiment of the present invention, R9is selected from the group consisting of hydrogen, C1-C4-alkyl, C1-C4-haloalkyl, C3-C6-cycloalkyl and phenyl; wherein said phenyl is unsubstituted or substituted with identical or different one to three groups selected from methyl, methoxy or halogen. 25 In one embodiment of the present invention, R10is selected from the group consisting of halogen, -OH, -N(R8)2, C1-C6-alkyl, C1-C6-haloalkyl, C3-C6-cycloalkyl, C6-cycloalkyl-C1-C6-alkyl, phenyl and 5-6 membered heteroaryl In another embodiment of the present invention, R10is selected from the group consisting of halogen, - OH, -N(R8)2, C1-C4-alkyl, C1-C4-haloalkyl, C3-C6-cycloalkyl, C6-cycloalkyl-C1-C3-alkyl, phenyl and 5- 30 6 membered heteroaryl In one embodiment of the present invention, R11is selected from the group consisting of C1-C6-alkyl, C1-C6-haloalkyl, C3-C6-cycloalkyl, C3-C6-cycloalkyl-C1-C6-alkyl, benzyl and phenyl. PI External In another embodiment of the present invention, R11is selected from the group consisting of C1-C6- alkyl, C1-C6-haloalkyl, C3-C6-cycloalkyl, benzyl and phenyl. In yet another embodiment of the present invention, R11is selected from the group consisting of C1-C6- alkyl, C1-C6-haloalkyl, benzyl and phenyl. 5 In one embodiment of the present invention, R12is selected from the group consisting of C1-C6-alkyl, C1-C6-haloalkyl, C3-C6-cycloalkyl, C3-C6-cycloalkyl-C1-C6-alkyl, phenyl and 5-6 membered heteroaryl. In another embodiment of the present invention, R12is selected from the group consisting of C1-C6- alkyl, C1-C6-haloalkyl, C3-C6-cycloalkyl and C3-C6-cycloalkyl-C1-C6-alkyl. In yet another embodiment of the present invention, R12is selected from the group consisting of C1-C6- 10 alkyl, C1-C6-haloalkyl and C3-C6-cycloalkyl. In one embodiment of the present invention, R13is selected from the group consisting of C1-C6-alkyl, C1-C6-haloalkyl, C3-C6-cycloalkyl, C3-C6-cycloalkyl-C1-C6-alkyl, phenyl and 5-6 membered heteroaryl. In another embodiment of the present invention, R13is selected from the group consisting of C1-C6- alkyl, C1-C6-haloalkyl, C3-C6-cycloalkyl and C3-C6-cycloalkyl-C1-C6-alkyl. 15 In yet another embodiment of the present invention, R13is selected from the group consisting of C1-C6- alkyl, C1-C6-haloalkyl and C3-C6-cycloalkyl. In one embodiment of the present invention, R8ais selected from the group consisting of hydrogen, C1- C6-alkyl, C3-C6-cycloalkyl, and C1-C6-alkoxy. In another embodiment of the present invention, R8ais selected from the group consisting of hydrogen, 20 C1-C3-alkyl, C3-C6-cycloalkyl, and C1-C3-alkoxy. In yet another embodiment of the present invention, R8ais selected from the group consisting of hydrogen, C1-C3-alkyl and C1-C3-alkoxy. In one embodiment of the present invention, R9ais selected from the group consisting of hydrogen, C1- C6-alkyl, C1-C6-haloalkyl, C3-C6-cycloalkyl, C3-C6-cycloalkyl-C1-C6-alkyl, pyridinyl, phenyl; wherein 25 said phenyl is unsubstituted or substituted with identical or different one to three substituents selected from methyl, methoxy or halogen. In another embodiment of the present invention, R9ais selected from the group consisting of hydrogen, C1-C4-alkyl, C1-C4-haloalkyl, C3-C6-cycloalkyl, C3-C6-cycloalkyl-C1-C3-alkyl, pyridinyl, phenyl; wherein said phenyl is unsubstituted or substituted with identical or different one to three groups 30 selected from methyl, methoxy or halogen. In yet another embodiment of the present invention, R9ais selected from the group consisting of C1-C4- alkyl, C1-C4-haloalkyl, C3-C6-cycloalkyl-C1-C3-alkyl, pyridinyl, phenyl; wherein said phenyl is PI External unsubstituted or substituted with identical or different one to three substituents selected from methyl, methoxy or halogen. In one embodiment of the present invention, R10ais selected from the group consisting of halogen, -OH, C1-C6-alkyl, C1-C6-haloalkyl, C3-C6-cycloalkyl and C6-cycloalkyl-C1-C6-alkyl. 5 In another embodiment of the present invention, R10ais selected from the group consisting of halogen, -OH, C1-C4-alkyl, C1-C4-haloalkyl, C3-C6-cycloalkyl and C6-cycloalkyl-C1-C3-alkyl. In yet another embodiment of the present invention, R10ais selected from the group consisting of halogen, -OH, C1-C4-alkyl and C1-C4-haloalkyl. In one embodiment of the present invention, R11ais selected from the group consisting of C1-C6-alkyl, 10 C1-C6-haloalkyl, C3-C6-cycloalkyl and C3-C6-cycloalkyl-C1-C6-alkyl. In another embodiment of the present invention, R11ais selected from the group consisting of C1-C4- alkyl, C1-C4-haloalkyl, C3-C6-cycloalkyl and C3-C6-cycloalkyl-C1-C4-alkyl. In a preferred embodiment of the present invention, R11ais C1-C4-alkyl which is selected from methyl, ethyl, propyl, isopropyl or butyl. 15 In one embodiment of the present invention, R12ais selected from the group consisting of C1-C6-alkyl, C1-C6-haloalkyl, C3-C6-cycloalkyl and C3-C6-cycloalkyl-C1-C6-alkyl. In another embodiment of the present invention, R12ais selected from the group consisting of C1-C4- alkyl, C1-C4-haloalkyl, C3-C6-cycloalkyl and C3-C6-cycloalkyl-C1-C3-alkyl. In yet another embodiment of the present invention, R12ais selected from the group consisting of C1- 20 C4-alkyl and C1-C4-haloalkyl. In one embodiment of the present invention, R13ais selected from the group consisting of C1-C6-alkyl, C1-C6-haloalkyl, C3-C6-cycloalkyl and C3-C6-cycloalkyl-C1-C6-alkyl. In another embodiment of the present invention, R13ais selected from the group consisting of C1-C4- alkyl, C1-C4-haloalkyl, C3-C6-cycloalkyl and C3-C6-cycloalkyl-C1-C3-alkyl. 25 In yet another embodiment of the present invention, R13ais selected from the group consisting of C1- C4-alkyl and C1-C4-haloalkyl. In one embodiment of the present invention, R5and RA1together with the N atom to which they are attached form a 5-6 membered non-aromatic heterocyclic ring which may contain optional additional heteroatoms selected from N, O, S, S(O) or SO2, wherein one to two carbon atoms may be replaced 30 with C=O or C=S; said 5-6 membered heterocyclic ring is unsubstituted or substituted with one to three substituents independently selected from halogen, C1-C6alkyl, C1-C6-haloalkyl, C1-C6-alkoxy or C1-C6- haloalkoxy. PI External In another embodiment of the present invention, R5and RA1together, with the N atom to which they are attached, form a 5-6 membered non-aromatic heterocyclic ring which may contain optional additional heteroatoms selected from N, O, S, S(O) or SO2; said 5-6 membered heterocyclic ring is unsubstituted or substituted with one to three substituents independently selected from halogen, C1-C45 alkyl, C1-C4-haloalkyl, C1-C4-alkoxy or C1-C4-haloalkoxy. In a preferred embodiment of the present invention, R5and RA1together with the N atom to which they are attached form a 6- membered non-aromatic heterocyclic ring which may contain optional additional heteroatoms selected from N, O or S; said 6- membered heterocyclic ring is unsubstituted or substituted with one to two substituents independently selected from halogen, C1-C4 alkyl, C1-C4-haloalkyl, C1-C4- 10 alkoxy or C1-C4-haloalkoxy. In a more preferred embodiment of the present invention, R5and RA1together with the N atom to which they are attached form a 6-membered non-aromatic heterocyclic ring which may contain optional additional heteroatoms selected from N or O; said 6-membered heterocyclic ring is unsubstituted or substituted with one to two substituents independently selected from halogen or C1-C4 alkyl. 15 In one embodiment of the present invention, wherein the aliphatic group of said R4is unsubstituted or substituted by one to four substituents independently selected from R7a, and the cyclic group of said R4is unsubstituted or substituted by one to four substituents independently selected from R7bis represented as: for example, when R4is C1-C8-alkyl (aliphatic group) then the C1-C8-alkyl group is unsubstituted or substituted by one to four substituents independently selected from R7a. Similarly, when R4is phenyl 20 (cyclic group) then the phenyl group is unsubstituted or substituted by one to four substituents independently selected from R7b. Similarly, when R4is phenyl-C1-C6-alkyl then the C1-C6-alkyl group (aliphatic group) of phenyl-C1-C6-alkyl is unsubstituted or substituted by one to four substituents independently selected from R7a; and the phenyl group (cyclic group) of phenyl-C1-C6-alkyl is unsubstituted or substituted by one to four substituents independently selected from R7b. Examples 25 provided here are just for illustrative purposes only. This substitution pattern will be applicable for all groups of R4unless defined specifically elsewhere. In one embodiment, the present invention provides a process for preparing the compound of formula(I). In one embodiment the compound of formula (I) can be a mixture of E and Z isomers. In another embodiment, the compound of formula (I) is a Z isomer. 30 The compounds of formula (I), (including all stereoisomers, N-oxides, and salts thereof), typically exist in more than one form, and formula (I) thus includes all crystalline and non-crystalline forms of the compounds that formula (I) represents. The term "polymorph" refers to a particular crystalline form of a chemical compound that can crystallize in different crystalline forms, these forms having different arrangements and / or conformations of the molecules in the crystal lattice. Although polymorphs can PI External have the same chemical composition, they can also differ in composition due to the presence or absence of co-crystallized water or other molecules, which can be weakly or strongly bound in the lattice. Polymorphs can differ in such chemical, physical and biological properties as crystal shape, density, hardness, color, chemical stability, melting point, hygroscopicity, suspensibility, dissolution rate and 5 biological availability. One skilled in the art will appreciate that a polymorph of a compound represented by formula (I) can exhibit beneficial effects (e.g., suitability for preparation of useful formulations, improved biological performance) relative to another polymorph or a mixture of polymorphs of the same compound represented by formula (I). The preparation and isolation of a particular polymorph of a compound represented by formula (I) can be achieved by methods known to 10 those skilled in the art including, for example, crystallization using selected solvents and temperatures. In one embodiment, the present invention provides a compound of formula (Z); wherein, R1, R2, R3, A1and R5are as defined herein above and indicate the point of attachment to the rest of molecule. 15 In one embodiment, the present invention provides a method for preparing a compound of formula (I) wherein A1is oxygen, wherein said method comprises the steps of: a) reacting a compound of formula (II) with a compound of formula (VIII) in the presence of a suitable solvent to obtain a compound of formula (I) as shown in the below scheme: ; 20 reacting a compound of formula (II) with a compound of formula (IX) in the presence of a PI External suitable coupling agent, a suitable base and a suitable solvent to obtain a compound of formula (I) as shown in the below scheme: ; 5 reacting a compound of formula (II) with a compound of formula (X) in the presence of a suitable base and a suitable solvent to obtain a compound of formula (I) as shown in the below scheme: ; b) reacting a compound of formula (III) with aqueous hydroxylamine or hydroxylamine 10 hydrochloride optionally in the presence of a suitable base and a suitable solvent to obtain a compound of formula (II) as shown in the below scheme: c) reacting a compound of formula (IV) with cyanide salts via a metal catalysed reaction in the presence of a suitable base, a suitable metal catalyst and a suitable solvent to obtain a compound 15 of formula (III) as shown in the below scheme: . In one embodiment, the present invention provides a method for preparing a compound of formula PI External (IV) wherein A1is oxygen, wherein said method comprises the steps of: a) reacting a compound of formula (V) in the presence of a suitable base, a suitable formylating agent and a suitable solvent to obtain a compound of formula (V-A), followed by methylation in the presence of a suitable base, a suitable reagent and a suitable solvent to obtain a compound 5 of formula (IV) reacting a compound of formula (V) with an orthoester, in the presence of an acid and a suitable solvent to obtain a compound of formula (IV) 10 b) reacting a compound of formula (VI) with a compound of formula (VII) in the presence of a suitable base and a suitable solvent to obtain a compound of formula (V) wherein, LG is halogen, A1is oxygen and R1, R2, R3, R4and R5are as defined herein above. 15 In one embodiment, the present invention provides a method for preparing a compound of formula (I- B) wherein said method comprises the step of: a) reacting a compound of formula (I) with a compound of formula (XI-A) in the presence of a suitable solvent and at a suitable temperature to obtain a compound of formula (I-B): PI External wherein, R1, R2, R3, R4, RA1and R5are as defined herein above. In one embodiment, the present invention provides a method for preparing a compound of formula (I- B1) wherein said method comprises the step of: 5 a) reacting a compound of formula (I) with a compound of formula (XI) in the presence of a suitable solvent and at a suitable temperature to obtain a compound of formula (I-B1): wherein, R1, R2, R3, R4and R5are as defined herein above. The compounds of the present invention as defined by formula (I) and / or in table 1 may be prepared, in 10 a known manner, in a variety of ways as described in the schemes. Compounds of the present invention can be made as shown in the following schemes, in which, unless otherwise stated, the definition of each variable is as defined above for compounds of formula (I). General Synthetic Schemes Scheme 1 15 The compounds of formula (I) can be obtained from a compound of formula (II) in the presence of acetic anhydride or acetyl chloride. The preferred solvents for the transformation are tetrahydrofuran, acetonitrile and the like. Preferred reaction temperatures for the said conversion are between 20 °C – PI External 50 °C. Such transformation is known in the literature, for example, see Tetrahedron Lett. 2001, 42, 1441-1443 and Synthesis 2001, 16, 2427-2430 and is shown in scheme 1. Scheme 2 5 Alternatively, compounds of formula (I) can be obtained from compounds of formula (II), in the presence of substituted carboxylic acids. The following synthetic route involves the coupling of amidoximes (formula II) with carboxylic acids (IX) in the presence of coupling agents such as O- benzotriazol-1-yl-N,N,N′,N′-tetramethyluronium tetrafluoroborate (TBTU), 1-hydroxybenzotriazole hydrate (HOBt), propylphosphonic anhydride followed by in-situ thermal cyclization as shown in 10 scheme 2. The bases used in the above conversion are such as disopropyl ethyl amine, triethyl amine or alike. Preferred solvents for the reaction are toluene, dichloromethane, dimethyl formamide, ethyl acetate, tetrahydrofuran and the like. Such transformation is known in the literature, for example, see Org. Biomol. Chem.2021, 19, 10611-10616. 15 Scheme 3 Further, compounds of formula (I) can be obtained from compounds of formula (II), in the presence of substituted acid chlorides of formula (X). The following synthetic route involves the coupling of amidoximes (formula II) with acid chlorides in the presence of organic or inorganic bases such as 20 pyridine triethyl amine, potassium carbonate and the like; followed by an in situ thermal cyclization as shown in scheme 3. Appropriate solvents used in the reaction are such as toluene, xylene, dichloroethane or dioxane. Such transformation is known in the literature, for example, see Org. Lett. 2017, 19, 2885-2888. Scheme 4 PI External Amidoxime compounds of the formula (II) can be obtained by reacting nitrile compounds of the formula (III), with aqueous hydroxylamine or hydroxylamine hydrochloride, optionally in the presence of a base, such as organic base e.g. triethylamine or diisopropyl ethyl amine, at a temperature between 0oC 5 to 25oC as shown in the scheme 4. Scheme 5 The nitrile compounds of formula (III) can be prepared from compounds of formula (IV) wherein LG is halogen, such as fluoride or chloride, in the presence of cyanide salts, such as copper cyanide, 10 potassium ferrocyanide optionally in the presence of an organic or inorganic base, such as potassium carbonate, pyridine, sodium carbonate and the like. Compounds of formula (III) can also be made from compounds of formula (IV) wherein LG is a halogen such as Br or I, in the presence of cyanide salts, such as copper cyanide, zinc cyanide and the like via a metal catalyzed reaction such as palladium catalyst as shown in scheme 5. Such transformation is known in the literature, for example, see Synth. 15 Commun. 1994, 24, 887-890. Furthermore, such transformation can also be achieved by the metal- catalyzed cyanation using a non-toxic cyanide source e.g., potassium ferrocyanide (K₄[Fe(CN)₆), as described in the literature, J. Org. Chem.2018, 83, 4922-4931. Scheme 6 20 Compounds of formula (IV) can be obtained from compounds of formula (V) by treatment with a base, such as sodium methoxide, sodium hydride and a formylating agent such as methyl formate to generate PI External compounds of formula (V-A), followed by methylation with a reagent such as dimethyl sulfate in the presence of a base such as potassium carbonate. Alternatively, compounds of formula (IV) can also be obtained directly from compounds of formula (V) via treatment with an orthoester, such as HC(OMe)3, optionally in the presence of an acid, such as sulphuric acid or hydrochloric acid, in a suitable solvent 5 such as methanol, as shown in the scheme 6. Such transformation is known in the literature, for examples, see J. Agric. Food Chem. 2007, 55, 5697-5700, Molecules 2010, 15, 9024-9034 and Org. Process Res. Dev.2015, 19, 639-645. Scheme 7 10 Compounds of formula (V), can be obtained from compounds of formula (VI) by treatment with an organic or inorganic base and a compound of formula (VII), in organic solvents, such as N,N- dimethylformamide or N-methyl pyrrolidone as shown in scheme 7. Such transformations are known in the literature, for example, see: Eur.JOC, 2015, 2197-2204. Compounds of formula (VII) are commercially available or can be readily prepared from commercially available compounds by standard 15 functional group transformations. Scheme 8 Compounds of formula (l-B1), can be obtained from compounds of formula (I) by reacting with amine of formula (XI) in suitable solvents such as water, tetrahydrofuran, dioxane and the like, at a temperature 20 between 0oC to 25oC as shown in scheme 8. Such transformations are known in the literature, for examples, see Synth. Commun.1982, 12 , 989-993; Nat. Commun.2021, 12, 5964 and WO9907665A1 In one embodiment, compounds of formula (I) of the present invention may possess a number of benefits including, inter alia, advantageous levels of biological activity for protecting plants against pest and phytogenic fungi or superior properties for use as an agrochemical active ingredient (for example, PI External greater biological activity, an advantageous spectrum of activity, an increased safety profile (including improved crop tolerance), improved physicochemical properties, or increased biodegradability). In one embodiment, the present invention relates to an agrochemical composition comprising the compound of formula (I), salts, stereoisomers, polymorphs or N-oxides thereof, optionally with one or 5 more additional active ingredients with the auxiliary such as an inert carrier or any other essential ingredient such as surfactants, additives, solid diluents, and liquid diluents. In another embodiment, the present invention relates to an agrochemical composition which comprises a fungicidally effective amount of a compound of formula (I) in such an amount that can vary in a broad range and is dependent on various factors, such as the fungal species to be controlled, the treated 10 cultivated plant, stored product, harvest or material, the climatic conditions and the specific compounds of formula (I) used. The invention also relates to agrochemical compositions comprising an auxiliary and at least one compound of formula (I). The compounds of formula (I) may be used in unmodified form or, preferably, together with the 15 adjuvants conventionally employed in the art of formulation. To this end they may be conveniently formulated in the known manner of a twin pack, a powder for dry seed treatment (DS), an emulsion for seed treatment (ES), a flowable concentrate for seed treatment (FS), a solution for seed treatment (LS), a water dispersible powder for seed treatment (WS), a capsule suspension for seed treatment (CF), a gel for seed treatment (GF), an emulsion concentrate (EC), a suspension concentrate (SC), a suspo- 20 emulsion (SE), a capsule suspension (CS), a water dispersible granule (WG), an emulsifiable granule (EG), an emulsion, water in oil (EO), an emulsion, oil in water (EW), a micro-emulsion (ME), an oil dispersion (OD), an oil miscible flowable (OF), an oil miscible liquid (OL), a soluble concentrate (SL), an ultra-low volume suspension (SU), an ultra-low volume liquid (UL), a technical concentrate (TK), a dispersible concentrate (DC), a wettable powder (WP) or any technically feasible formulation in 25 combination with agriculturally acceptable adjuvants. As with the type of the compositions, the methods of application, such as spraying, atomising, dusting, scattering, coating or pouring, are chosen in accordance with the intended objectives and the prevailing circumstances. The compositions may also contain further adjuvants such as stabilizers, antifoams, viscosity regulators, binders or tackifiers as well as fertilizers, micronutrient donors or other formulations for obtaining special effects. 30 Such compositions may be produced in a conventional manner, e.g. by mixing the active ingredients with appropriate formulation inerts (diluents, solvents, fillers and optionally other formulating ingredients such as surfactants, biocides, anti-freeze, stickers, thickeners, and compounds that provide adjuvant effects). Also, conventional slow-release formulations may be employed where long-lasting efficacy is intended. Particularly formulations to be applied in spraying forms, such as water-dispersible 35 concentrates (e.g. EC, SC, DC, OD, SE, EW, EO, and the like), wettable powders and granules, may PI External contain surfactants such as wetting and dispersing agents and other compounds that provide adjuvant effects, e.g. the condensation product of formaldehyde with naphthalene sulphonate, an alkylarylsulphonate, a lignin sulphonate, a fatty alkyl sulphate, and ethoxylated alkylphenol and an ethoxylated fatty alcohol. 5 The compound or composition of formula (I) of the present invention is usually mixed with an inert carrier such as a solid carrier, a liquid carrier, or a gaseous carrier, and if necessary, a surfactant or other auxiliary agent is added to form an emulsion. Formulated into oils, powders, granules, wettable powders, granule wettable powders, flowable agents, dry flowable agents, microcapsules, aerosol agents, poison bait agents, resin preparations, paste-like preparations, foaming agents, carbon dioxide 10 gas preparations, etc. is used. These preparations may be processed and used as mosquito coils, electric mosquito repellent mats, liquid mosquito repellent preparations, fumigants, fumigants, and sheet preparations. These formulations usually contain 0.01 to 95% by weight of the compound or composition of formula (I) of the present invention. Suitable agricultural adjuvants and carriers that are useful in formulating the compositions of the 15 invention in the formulation types described above are well known to those skilled in the art. Pesticidal agents are referred to herein using their common name and are known, for example, from "The Pesticide Manual", 15th Ed., British Crop Protection Council 2009. In addition, the compositions of the invention may also be applied with one or more systemically acquired resistance inducers (“SAR” inducer). SAR inducers are known and described in, for example, 20 United States Patent No. US 6,919,298 and include, for example, salicylates and the commercial SAR inducer acibenzolar-S-methyl. The compounds of formula (I) are normally used in the form of agrochemical compositions and can be applied to the crop area or plant to be treated, simultaneously or in succession with further compounds. These further compounds can be e.g. fertilizers or micronutrient donors or other preparations, which influence the growth of plants. They can also be selective herbicides 25 or non-selective herbicides as well as insecticides, fungicides, bactericides, nematicides, molluscicides, or mixtures of several of these preparations, if desired together with further carriers, surfactants or application promoting adjuvants customarily employed in the art of formulation. The application can be carried out before or during sowing. Methods for applying the compound of formula (I), the combination, and the composition thereof, 30 respectively, are applied onto plant propagation material, especially seeds, including dressing, coating, pelleting, dusting, and soaking as well as in-furrow application methods. Preferably, the compound of formula (I), the combination, and the composition thereof, respectively, are applied to the plant propagation material by a method such that germination is not induced, e. g. by seed dressing, pelleting, coating, and dusting. PI External When employed in plant protection, the amounts of active substances applied are, depending on the kind of effect desired, from 0.001 to 5 kg per ha, preferably from 0.005 to 3 kg per ha, more preferably from 0.05 to 1.0 kg per ha, and in particular from 0.1 to 1.0 kg per ha. In the treatment of plant propagation materials such as seeds, e. g. by dusting, coating or drenching 5 seeds, amounts of the active substance from 0.1 to 5000 g, preferably from 1 to 1000 g, more preferably from 1 to 100 g per 100 kg of plant propagation material (preferably seeds) are generally required. When used in the protection of materials or stored products, the amount of active substance applied depends on the kind of application area and on the desired effect. Amounts customarily applied in the protection of materials are 0.001 g to 5 kg, preferably 0.005 g to 1 kg, of active substance per cubic 10 meter of the treated material. Various types of oils, wetters, adjuvants, fertilizer, or micronutrients, and further pesticides (e. g. herbicides, insecticides, fungicides, growth regulators, safeners, biopesticides) may be added to the active substances or the compositions comprising them as premix or, if appropriate, not until immediately prior to use (tank mix). These agents can be mixed with the composition according to the 15 invention in a weight ratio of 1:100 to 100:1. The compounds of formula (I) may be used in the form of compositions for controlling or protecting against damaging pest and / or phytopathogenic microorganisms, comprising as active ingredient at least one compound of formula (I) or at least one preferred individual compound as defined herein, in free form or agrochemically usable salt form, and at least one of the above-mentioned adjuvants. 20 The invention, therefore, provides a composition, comprising at least one compound formula (I) an agriculturally acceptable carrier, and optionally an adjuvant. An agriculturally acceptable carrier is for example a carrier that is suitable for agricultural use. Agricultural carriers are well known in the art. Preferably said composition may comprise at least one or more pesticidally-active compounds, for example, an additional fungicidal active ingredient in addition to the compound of formula (I). 25 The compound of formula (I) may be the sole active ingredient of a composition or it may be admixed with one or more additional active ingredients such as a pesticide, fungicide, insecticide, herbicide, or plant growth regulator where appropriate. Examples of suitable additional active ingredients include the following: acycloamino acid fungicides, aliphatic nitrogen fungicides, amide fungicides, anilide fungicides, antibiotic fungicides, aromatic 30 fungicides, arsenical fungicides, aryl phenyl ketone fungicides, benzamide fungicides, benzanilide fungicides, benzimidazole fungicides, benzothiazole fungicides, botanical fungicides, bridged diphenyl fungicides, carbamate fungicides, carbanilate fungicides, conazole fungicides, copper fungicides, dicarboximide fungicides, dinitrophenol fungicides, dithiocarbamate fungicides, dithiolane fungicides, furamide fungicides, furanilide fungicides, hydrazide fungicides, imidazole fungicides, mercury PI External fungicides, morpholine fungicides, organophosphorous fungicides, organotin fungicides, oxathiin fungicides, oxazole fungicides, phenylsulfamide fungicides, polysulfide fungicides, pyrazole fungicides, pyridine fungicides, pyrimidine fungicides, pyrrole fungicides, quaternary ammonium fungicides, quinoline fungicides, quinone fungicides, quinoxaline fungicides, strobilurin fungicides, 5 sulfonanilide fungicides, thiadiazole fungicides, thiazole fungicides, thiazolidine fungicides, thiocarbamate fungicides, thiophene fungicides, triazine fungicides, triazole fungicides, triazolopyrimidine fungicides, urea fungicides, valinamide fungicides, and zinc fungicides. The active ingredient mixture of the compounds of formula (I) and an active ingredient as described above are preferably in a mixing ratio of from 1000:1 to 1:5000, especially from 500:1 to 1:500, more 10 especially in a ratio of from 100:1 to 1:100. Those mixing ratios are by weight. The mixtures as described above can be used in a method for controlling pests, which comprises applying a composition comprising a mixture as described above to the pests or their environment. The mixtures comprising a compound of formula (I) and one or more active ingredients as described above can be applied, for example, in a single “ready-mix” form, in a combined spray mixture composed 15 of separate formulations of the single active ingredient components, such as a “tank-mix”, and in the combined use of the single active ingredients when applied sequentially, i.e. one after the other with a reasonably short period, such as a few hours or days. The order of applying the compounds of formula (I) and the active ingredient(s) as described above is not essential for working the present invention. When applying the compound of formula (I) and a pesticidally active substance sequentially the time 20 between both applications may vary e. g. between 2 hours to 7 days. Also, a broader range is possible ranging from 0.25 hours to 30 days, preferably from 0.5 hours to 14 days, particularly from 1 hour to 7 days or from 1.5 hours to 5 days, even more, preferred from 2 hours to 1 day. In the binary mixtures and the composition according to the invention the weight ratio of component 1) and the component 2) generally depends on the properties of the active components used, usually, it is in the range of 1:1000 25 to 1000:1, often in the range of 1:100 to 100:1, regularly in the range of 1:50 to 50:1, preferably in the range of 1:20 to 20:1, more preferably in the range of 1:10 to 10:1, even more preferably in the range of 1:4 to 4:1 and in particular in the range of 1:2 to 2:1. The compositions according to the invention are prepared in a manner known per se, in the absence of auxiliaries for example by grinding, screening and / or compressing a solid active ingredient, and in the 30 presence of at least one auxiliary for example by intimately mixing and / or grinding the active ingredient with the auxiliary (auxiliaries). These processes for the preparation of the compositions and the use of the compounds of formula (I) for the preparation of these compositions are also a subject of the invention. The compounds and compositions of the present invention are thus useful agronomically for protecting 35 field crops from phytophagous invertebrate pests, and also nonagronomically for protecting other PI External horticultural crops and plants from phytophagous invertebrate pests. This utility includes protecting crops and other plants (i.e. both agronomic and nonagronomic) that contain genetic material introduced by genetic engineering (i.e. transgenic) or modified by mutagenesis to provide advantageous traits. Compounds of the present invention are characterized by favorable metabolic and / or soil residual 5 patterns and exhibit activity controlling a spectrum of agronomic and non-agronomic invertebrate pests. The compounds of the present invention are preventively and / or curatively valuable active ingredients in the field of pest control, even at low rates of application, which can be used against pesticide-resistant pests such as insects and fungi, and / or have a very favorable biocidal spectrum and are well tolerated by warm-blooded species, fish and plants. 10 In another embodiment, the compound of formula (I) and the composition according to the invention, are suitable as fungicides. They are distinguished by their effectiveness against a broad spectrum of phytopathogenic fungi, including soi1-borne fungi, which derive especially from the classes of the Plasmodiophoromycetes, Peronosporomycetes (syn. Oomycetes), Chytridiomycetes, Zygomycetes, Ascomycetes, Basidiomycetes, and Deuteromycetes (syn. Fungi imperfecti). Some are systemically 15 effective and can be used in crop protection as foliar fungicides, fungicides for seed dressing, and soil fungicides. Moreover, they are suitable for controlling harmful fungi, which inter alia occur in wood or roots of plants. The compounds of formula (I) and the compositions thereof are preferably useful in the control of phytopathogenic fungi and insects on various cultivated plants, such as cereals, e. g. wheat, rye, barley, 20 triticale, oats, or rice; beet, fruits, leguminous plants such as soybean, oil plants, cucurbits, fiber plants, citrus fruits, vegetables, lauraceous plants, energy and raw material plants, corn; tobacco; nuts; coffee; tea; bananas; vines (table grapes and grape juice grapevines); natural rubber plants; or ornamental and forestry plants; on the plant propagation material, such as seeds; and on the crop material of these plants. 25 According to the invention, all of the above-cultivated plants are understood to comprise all species, subspecies, variants, varieties, and / or hybrids which belong to the respective cultivated plants, including but not limited to winter and spring varieties, in particular in cereals such as wheat and barley, as well as oilseed rape, e.g. winter wheat, spring wheat, winter barley etc. Corn is also known as Indian corn or maize (Zea mays) which comprises all kinds of corn such as field 30 corn and sweet corn. According to the invention all soybean cultivars or varieties are comprised, in particular indeterminate and determinate cultivars or varieties. The term "cultivated plants" is to be understood as including plants that have been modified by mutagenesis or genetic engineering to provide a new trait to a plant or to modify an already present trait. PI External The compound of formula (I), the combination or the composition thereof may be used to treat several fungal pathogens. Non-limiting examples of pathogens of fungal diseases that can be treated in accordance with the invention include: Ustilaginales such as Ustilaginoidea virens, Ustilago nuda, Ustilago tritici, Ustilago zeae, rusts for 5 example those caused by Pucciniales such as Cerotelium fici, Chrysomyxa arctostaphyli, Coleosporium ipomoeae, Hemileia vastatrix, Puccinia arachidis, Puccinia cacabata, Puccinia graminis, Puccinia recondita, Puccinia sorghi, Puccinia hordei, Puccinia striiformis f.sp. Hordei, Puccinia striiformis f.sp. Secalis, Pucciniastrum coryli, or Uredinales such as Cronartium ribicola, Gymnosporangium juniperi-viginianae, Melampsora medusae, Phakopsora pachyrhizi, Phragmidium 10 mucronatum, Physopella ampelosidis, Tranzschelia discolor and Uromyces viciae-fabae; and other rots and diseases such as those caused by Cryptococcus spp., Exobasidium vexans, Marasmiellus inoderma, Mycena spp., Sphacelotheca reiliana, Typhula ishikariensis, Urocystis agropyri, ltersonilia perplexans, Corticium invisum, Laetisaria fuciformis, Waitea circinata, Rhizoctonia solani, Thanetephorus cucurmeris, Entyloma dahliae, Entylomella microspora, Neovossia moliniae and Tilletia caries. 15 Blastocladiomycetes, such as Physoderma maydis. Mucoromycetes, such as Choanephora cucurbitarum; Mucor spp.; and Rhizopus arrhizus. In another embodiment diseases caused by rust disease pathogens, for example, Gymnosporangium species, for example, Gymnosporangium sabinae; Hemileia species, for example, Hemileia vastatrix; Phakopsora species, for example, Phakopsora pachyrhizi or Phakopsora meibomiae; Puccinia species, 20 for example, Puccinia recondita, Puccinia graminis oder Puccinia striiformis; Uromyces species, for example, Uromyces appendiculatus; In particular, Cronartium ribicola (White pine blister rust); Gymnosporangium juniperi-virginianae (Cedar-apple rust); Hemileia vastatrix (Coffee rust); Phakopsora meibomiae and P. pachyrhizi (Soybean rust); Puccinia coronata (Crown Rust of Oats and Ryegrass); Puccinia graminis (Stem rust 25 of wheat and Kentucky bluegrass, or black rust of cereals); Puccinia hemerocallidis (Daylily rust); Puccinia persistens subsp. triticina (wheat rust or 'brown or red rust'); Puccinia sorghi (rust in corn); Puccinia striiformis ('Yellow rust' in cereals); Uromyces appendiculatus (rust of beans); Uromyces phaseoli (Bean rust); Puccinia melanocephala ('Brown rust' in sugarcane); Puccinia kuehnii ('Orange rust' in sugarcane). 30 Plants which can be treated in accordance with the invention include the following: cotton, flax, grapevine, fruits, vegetables, such as Rosaceae sp (for example pome fruits such as apples, pears, apricots, cherries, almonds and peaches), Ribesioidae sp., Juglandaceae sp., Betulaceae sp., Anacardiaceae sp., Fagaceae sp., Moraceae sp., Oleaceae sp., Actinidaceae sp., Lauraceae sp., Musaceae sp. (for example banana trees and plantations), Rubiaceae sp. (for example coffee), Theaceae 35 sp., Sterculiceae sp., Rutaceae sp. (for example lemons, oranges and grapefruit); Vitaceae sp. (for PI External example grapes); Solanaceae sp. (for example tomatoes, peppers), Liliaceae sp., Asteraceae sp. (for example lettuce), Umbelliferae sp., Cruciferae sp., Chenopodiaceae sp., Cucurbitaceae sp. (for example cucumber), Alliaceae sp. (for example leek, onion), Papilionaceae sp. (for example peas); major crop plants, such as Poaceae / Gramineae sp. (for example maize, turf, cereals such as wheat, rye, 5 rice, barley, oats, millet and triticale), Asteraceae sp. (for example sunflower), Brassicaceae sp. (for example white cabbage, red cabbage, broccoli, cauliflower, Brussels sprouts, pak choi, kohlrabi, radishes, and oilseed rape, mustard, horseradish and cress), Fabacae sp. (for example bean, peanuts), Papilionaceae sp. (for example soya bean), Solanaceae sp. (for example potatoes), Chenopodiaceae sp. (for example sugar beet, fodder beet, swiss chard, beetroot); Malvaceae (for example cotton); useful 10 plants and ornamental plants for gardens and wooded areas; and genetically modified varieties of each of these plants. More preference is given to controlling the following diseases of soya beans: Fungal diseases on leaves, stems, pods, and seeds caused, for example, by Altemaria leaf spot (Altemaria spec. atrans tenuissima), Anthracnose (Colletotrichum gloeosporoides dematium var. truncatum), brown spot (Septoria glycines 15 ), cercospora leaf spot and blight ( Cercospora kikuchii), choanephora leaf blight (Choanephora infundibulifera trispora (Syn.)), dactuliophora leaf spot (Dactuliophora glycines), downy mildew (Peronospora manshurica), drechslera blight (Drechslera glycini), frogeye leaf spot (Cercospora sojina), leptosphaerulina leaf spot (Leptosphaerulina trifolii), phyllostica leaf spot (Phyllosticta sojaecola), pod and stem blight (Phomopsis sojae), powdery mildew (Microsphaera diffusa), 20 pyrenochaeta leaf spot (Pyrenochaeta glycines), rhizoctonia aerial, foliage, and web blight (Rhizoctonia solani), rust (Phakopsora pachyrhizi, Phakopsora meibomiae), scab (Sphaceloma glycines), stemphylium leaf blight (Stemphylium botryosum), target spot (Corynespora cassiicola). Fungal diseases on roots and the stem base caused, for example, by black root rot (Calonectiia crotalariae), charcoal rot (Macrophomina phaseolina), fusarium blight or wilt, root rot, and pod and collar rot 25 (Fusarium oxysporum, Fusarium orthoceras, Fusarium semitectum, Fusarium equiseti), mycoleptodiscus root rot (Mycoleptodiscus terrestris), neocosmospora (Neocosmospora vasinfecta), pod and stem blight (Diaporthe phaseolorum), stem canker (Diaporthe phaseolorum var. caulivora), phytophthora rot (Phytophthora megasperma), brown stem rot (Phialophora gregata), pythium rot (Pythium aphanidennatum, Pythium irregulare, Pythium debaryanum, Pythium myriotylum, Pythium 30 ultimum), rhizoctonia root rot, stem decay, and damping-off (Rhizoctonia solani), sclerotinia stem decay (Sclerotinia sclerotiorum), sclerotinia southern blight (Sclerotinia rolfsii), thielaviopsis root rot (Thielaviopsis basicola). The present invention also relates to the use of the compound of formula (I), the combination or the composition thereof for combating the following plant diseases: Puccinia spp. (rusts) on various plants, 35 for example, but not limited to P. triticina (brown or leaf rust), P. striiformis (stripe or yellow rust), P. hordei (dwarf rust), P. graminis (stem or black rust), or P. recondita (brown or leaf rust) on cereals, PI External such as e. g. wheat, barley or rye and Phakopsoraceae spp. on various plants, in particular Phakopsora pachyrhizi and P. meibomiae (soybean rust) on soybeans, Hemileia vastatrix (Coffee rust), Uromyces appendiculatus, Uromyces fabae and Uromyces phaseoli (rust of beans). The compounds of formula (I) and compositions thereof, respectively, are particularly suitable for 5 controlling the following causal agents of plant diseases: rusts on soybean and cereals (e.g. Phakopsora pachyrhizi and P. meibomiae on soybean; Puccinia tritici and P. striiformis on wheat); molds on specialty crops, soybean, oil seed rape and sunflowers (e.g. Botrytis cinerea on strawberries and vines, Sclerotinia sc / erotiorum, S. minor and S. rolfsii on oil seed rape, sunflowers, and soybean); Fusarium diseases on cereals (e.g. Fusarium cu / morum and F. graminearum on wheat); 10 downy mildews on specialty crops (e.g. Plasmopara vitico / a on vines, Phytophthora infestans on potatoes); powdery mildews on specialty crops and cereals (e.g. Uncinula necator on vines, Erysiphe spp. on various specialty crops, 8 / umeria graminis on cereals); and leaf spots on cereals, soybean, and corn (e.g. Septoria tritici and S. nodorum on cereals, S. glycines on soybean, Cercospora spp. on corn and soybean). 15 In one aspect, the present invention relates to the method of protecting plants susceptible to and / or under attack by phytopathogenic fungi containing an amino acid substitution of F129L in the mitochondrial cytochrome b protein conferring resistance to Qo inhibitors, which method comprises applying to said plants, treating plant propagation material of said plants with, and / or applying to said phytopathogenic fungi, at least one compound of formula (I) or a composition thereof. 20 According to another embodiment, the method for combating phytopathogenic fungi comprises: a) identifying the phytopathogenic fungi containing an amino acid substitution F129L in the mitochondrial cytochrome b protein conferring resistance to Qo inhibitors, or the materials, plants, the soil, or seeds that are at risk of being diseased from phytopathogenic fungi as defined herein, and b) treating said fungi or the materials, plants, the soil or plant propagation material with an effective amount of at least 25 one compound of formula (I), or a composition comprising it thereof. The term "phytopathogenic fungi an amino acid substitution F129L in the mitochondrial cytochrome b protein conferring resistance to Qo inhibitors" is to be understood that at least 10% of the fungal isolates to be controlled contain such F129L substitution in the mitochon-drial cytochrome b protein conferring resistance to Qo inhibitors, preferably at least 30%, more preferably at least 50%, even more preferably 30 at least 75% of the fungi, most preferably between 90 and 100%; in particular between 95 and 100% . Furthermore, the present invention relates to the use of compounds of formula (I) as defined herein for combating phytopathogenic fungi containing an amino acid substitution F129L in the mitochondrial cytochrome b protein conferring resistance to Qo inhibitors. "Qo inhibitor," as used herein, includes any substance that is capable of diminishing and / or PI External inhibiting respiration by binding to a ubihydroquinone oxidation center of a cytochrome bc1 complex in mitochondria. The oxidation center is typically located on the outer side of the inner mitochondrial membrane. The mutation F129L in the cytochrome b (cytb, also referred to as cob) gene shall mean any substitution 5 of nucleotides of codon 129 encoding "F" (phenylalanine; e.g. TTT or TTC) that leads to a codon encoding "L" (leucine; e.g. TTA, TTG, TTG, CTT, CTC, CTA or CTG), for example, the substitution of the first nucleotide of codon 129 'T' to 'C' (TTT to CTT), in the cytochrome b gene resulting in a single amino acid substitution in the position 129 from F (phenylalanine) to L (leucine) (F129L) in the cytochrome b protein (Cytb). In the present invention, the mutation F129L in the cytochrome b gene 10 shall be understood to be a single amino acid substitution in position 129 from F (phenylalanine) to L (leucine) (F129L) in the cytochrome b protein. Many other phytopathogenic fungi acquired the F129L mutation in the cytochrome b gene conferring resistance to Qo inhibitors, such as rusts, in particular soybean rust (Phakopsora pachyrhizi and Phakopsora meibromiae) as well as fungi from the genera Alternaria, Pyrenophora and Rhizoctonia. 15 Preferred fungal species are Alternaria solani, Phakopsora pachyrhizi, Phakopsora meibromiae, Pyrenophora teres, Pyrenophora tritici-repentis, Zymoseptoria tritici, Corynespora spp. Cercospora spp. and Rhizoctonia solani; in particular, Phakopsora pachyrhizi. In one aspect, the present invention relates to the method of protecting plants susceptible to and / or under attack by phytopathogenic fungi containing an amino acid substitution of G143A in the mitochondrial 20 cytochrome b protein conferring resistance to Qo inhibitors, which method comprises applying to said plants, treating plant propagation material of said plants with, and / or applying to said phytopathogenic fungi, at least one compound of formula (I) or a composition comprising it thereof. The compounds of fomula (I) and composition comprising it thereof, respectively, are also suitable for controlling harmful pest and / or microorganisms in the protection of stored products or harvest, and in 25 the protection of materials. The compounds of formula (I) are employed as such or in form of compositions by treating the fungi, the plants, and plant propagation materials, such as seeds; soil, surfaces, materials, or rooms to be protected from fungal attack with a fungicidally effective amount of the active substances. The application can be carried out both before and after the infection of the plants, plant propagation 30 materials, such as seeds; soil, surfaces, materials or rooms by the fungi. These young plants may also be protected before transplantation by a total or partial treatment by immersion or pouring. PI External Preferably, a treatment of plant propagation materials with the compound of formula (I), the combination and or the composition thereof, respectively, is used for controlling a multitude of fungi on cereals, such as wheat, rye, barley, and oats; rice, corn, cotton, and soybeans. Furthermore, plants capable of synthesizing one or more proteins to increase the resistance or tolerance 5 of those plants to bacterial, viral, or fungal pathogens by the use of recombinant DNA techniques are also within the scope of the present invention. Examples of such proteins are the so-called "pathogenesis-related proteins" (PR proteins, see, e. g. EP392225), plant disease resistance genes (e. g. potato cultivars, which express resistance genes acting against Phytophthora infestans derived from the Mexican wild potato Solanum bulbocastanum) or T4-lysozym (e. g. potato cultivars capable of 10 synthesizing these proteins with increased resistance against bacteria such as Erwinia amylvora). The methods for producing such genetically modified plants are generally known to the person skilled in the art and are described, e. g. in the publications mentioned above. Furthermore, plants are capable of synthesizing one or more proteins, by the use of recombinant DNA techniques, to increase productivity (e. g. biomass production, grain yield, starch content, oil content, 15 or protein content), tolerance to drought, salinity, or other growth-limiting environmental factors or tolerance to pests and fungal, bacterial or viral pathogens of those plants are within the scope of the present invention. Furthermore, plants that contain a modified amount of substances of content or new substances of content, by the use of recombinant DNA techniques, to improve human or animal nutrition, e. g. oil 20 crops that produce health-promoting long-chain omega-3 fatty acids or unsaturated omega-9 fatty acids (e. g. Nexera® rape, DOW Agro Sciences, Canada) are also within the scope of the present invention. Furthermore, plants that contain a modified amount of substances of content or new substances of content, by the use of recombinant DNA techniques, to improve raw material production, e. g. potatoes that produce increased amounts of amylopectin (e. g. Amflora® potato, BASF SE, Germany) are also 25 within the scope of the present invention. The present invention also relates to a method for combating infestation of plants by phytopathogenic micro-organisms in agricultural crops and or horticultural crops wherein an effective amount of at least one compound of formula (I) or the combination of the present invention or the composition of the present invention, is applied to the seeds of plants. The compound, the combination, and the 30 composition of the present invention can be used for combating plant diseases. The compound of formula (I), the combinations, and the composition thereof, respectively, are also suitable for controlling harmful fungi in the protection of stored products or harvest and the protection of materials. The term "protection of materials" is to be understood to denote the protection of technical and non-living materials, such as adhesives, glues, wood, paper and paperboard, textiles, leather, paint PI External dispersions, plastics, cooling lubricants, fiber or fabrics, against the infestation and destruction by harmful microorganisms, such as fungi and pest such as insect. As to the protection of wood and other materials, particular attention is paid to the following harmful fungi : Ascomycetes such as Ophiostoma spp., Ceratocystis spp., Aureobasidium pullulans, 5 Sclerophoma spp., Chaetomium spp., Humicola spp., Petriella spp., Trichurus spp.; Basidiomycetes such as Coniophora spp., Coriolus spp., Gloeophyllum spp., Lentinus spp., Pleurotus spp., Pora spp., Serpula spp. and Tyromyces spp., Deuteromycetes such as Aspergillus spp., Cladosporium spp., Penicillium spp., Trichoderma spp., Altemaria spp., Paecilomyces spp. and Zygomycetes such as Mucor spp., and in addition in the protection of stored products and harvest the following yeast fungi are worthy 10 of note: Candida spp. and Saccharomyces cerevisae. In one embodiment the compound of formula (I), the combination, and the composition thereof, respectively, are particularly suitable for controlling the following plant diseases: Phakopsora pachyrhizi and P. meibomiae (soybean rust) on soybeans as well as the leaf spot diseases Cercospora spp. and Corynespora spp. 15 The present invention further relates to a method for combating phytopathogenic fungi. The method comprises treating the fungi or the materials, plants, plant parts, locus thereof, soil or seeds to be protected against fungal attack, with an effective amount of at least one compound of formula (I) or the combination or the composition comprising at least one compound of formula (I). The compound of formula (I), the combination, and the composition thereof, respectively, may be used 20 for improving the health of a plant. The invention also relates to a method for improving plant health by treating a plant, its propagation material and / or the locus where the plant is growing or is to grow with an effective amount of compound I and the composition thereof, respectively. The term "plant health" is to be understood to denote a condition of the plant and / or its products which is determined by several indicators alone or in combination with each other such as yield (e. g. increased 25 biomass and / or increased content of valuable ingredients), plant vigor (e. g. improved plant growth and / or greener leaves ("greening effect")), quality (e. g. improved content or composition of certain ingredients) and tolerance to abiotic and / or biotic stress. The above-identified indicators for the health condition of a plant may be interdependent or may result from each other. Another aspect of the invention is related to the use of a compound of formula (I) as such or in the form 30 of a composition for treating the fungi or the plants, plant propagation materials, such as seeds, soil, surfaces, materials or rooms to be protected from fungal attack with a fungicidally effective amount of the active ingredients. The application can be carried out both before and after the infection of the plants, plant propagation materials, such as seeds, soil, surfaces, materials, or rooms by the fungi. PI External Plant propagation materials may be treated with a compound of formula (I), the combination and the composition thereof protectively either at or before planting or transplanting. Chemistry Examples: The following examples set forth the manner and process of making compounds of the present invention 5 without being a limitation thereof and include the best mode contemplated by the inventors for carrying out the invention. Example 1 Preparation of methyl (Z)-3-methoxy-2-(2-methyl-5-(5-(trifluoromethyl)-1,2,4-oxadiazol-3- yl)phenoxy)acrylate 10 Step-1: Preparation of methyl 2-(5-bromo-2-methylphenoxy) acetate To a stirred solution of 5-bromo-2-methylphenol (10 g, 53.5 mmol) and methyl 2-bromoacetate (7.59 mL, 80 mmol) in tetrahydrofuran (100 mL) at 25 ℃, potassium carbonate (14.78 g, 107 mmol) was 15 added. The reaction mixture was stirred at 65 °C for 12 h. After completion of the reaction, the reaction mixture was cooled to 25 ℃, diluted with water (100 mL) and extracted with ethyl acetate (2 x 100 mL). The combined organic layers were dried over anhydrous sodium sulfate and concentrated under reduced pressure to obtain an oily residue, which was purified by flash column chromatography to obtain methyl 2-(5-bromo-2-methylphenoxy)acetate (11.77 g, 45.4 mmol, 85% yield) as a brown 20 viscous liquid. 1H-NMR (400 MHz, DMSO-d6) δ 7.11 (dd, J = 7.8, 0.5 Hz, 1H), 7.07-7.04 (m, 2H), 4.88 (d, J = 9.3 Hz, 2H), 3.69 (d, J = 4.9 Hz, 3H), 2.15 (d, J = 14.7 Hz, 3H); MS: m / z = 259.26. [M+1]. Step-2: Preparation of methyl 2-(5-bromo-2-methylphenoxy)-3-hydroxyacrylate PI External To a stirred solution of methyl 2-(5-bromo-2-methylphenoxy)acetate (8 g, 30.9 mmol) and methyl formate (11.53 mL, 185 mmol) in tetrahydrofuran (30 mL) at 25 ℃, sodium methoxide (3.34 g, 61.8 mmol) was added in portions under nitrogen atmosphere. The reaction mixture was stirred at 25 ℃ for 1 h. After completion of the reaction, the reaction mixture was poured into ice-water (100 mL), 5 neutralized with 1N HCl (pH~ 5-6) and extracted with ethyl acetate (2 x 100 mL). The combined organic layers were dried over anhydrous sodium sulfate and concentrated under reduced pressure to obtain methyl 2-(5-bromo-2-methylphenoxy)-3-hydroxyacrylate (6.21 g, 21.61 mmol, 70 % yield), as a viscous gum, which was taken directly to the next step without further purification. 1H-NMR (400 MHz, CDCl3) δ 7.05-7.00 (m, 2H), 6.82 (d, J = 1.5 Hz, 1H), 4.63 (d, J = 5.4 Hz, 2H), 10 3.81 (s, 3H), 2.25 (d, J = 16.6 Hz, 3H); MS: m / z = 288.3. [M+1]. Step-3: Preparation of methyl (Z)-2-(5-bromo-2-methylphenoxy)-3-methoxyacrylate To a stirred solution of methyl 2-(5-bromo-2-methylphenoxy)-3-hydroxyacrylate (10 g, 34.8 mmol) in N,N-dimethylformamide (30 mL) at 25oC under nitrogen atmosphere, potassium carbonate (7.22 g, 15 52.2 mmol) and iodomethane (2.2 ml, 34.8 mmol) were added in sequence. The reaction mixture was stirred at 25 ℃ for 6 h. After completion of the reaction, the reaction mixture was diluted with water (100 mL) and extracted with ethyl acetate (2 x 100 mL). The combined organic layers were dried over anhydrous sodium sulfate and concentrated under reduced pressure to obtain an oily residue, which was purified by flash column chromatography to obtain methyl (Z)-2-(5-bromo-2-methylphenoxy)-3- 20 methoxyacrylate (6.29 g, 20.90 mmol, 60 % yield) as an off-white solid. 1H-NMR (400 MHz, DMSO-d6) δ 7.57 (s, 1H), 7.14 (dd, J = 7.9, 0.6 Hz, 1H), 7.08 (dd, J = 8.1, 2.0 Hz, 1H), 6.78 (d, J = 1.8 Hz, 1H), 3.86 (s, 3H), 3.65 (d, J = 7.0 Hz, 3H), 2.07 (t, J = 2.9 Hz, 3H). MS: m / z = 302.58. [M+1]. Step-4: Preparation of methyl (Z)-2-(5-cyano-2-methylphenoxy)-3-methoxyacrylate 25 To a stirred solution of methyl (Z)-2-(5-bromo-2-methylphenoxy)-3-methoxyacrylate (1 g, 3.32 mmol) in dioxane (10 mL) and water (3.3 mL), [XantPhos Pd(allyl)]Cl (0.12 g, 0.16 mmol), potassium acetate (0.16 g, 1.66 mmol) and potassium hexacyanoferrate (II) trihydrate (0.77 g, 1.82 mmol) were added under nitrogen atmosphere. The reaction mixture was freed from oxygen by application of nitrogen gas PI External for 10 minutes and allowed to stir for further 12 h at 100 °C. After completion of the reaction, the reaction mixture was cooled to 25 ℃, diluted with water (50 mL) and extracted with ethyl acetate (2 x 50 mL). The combined organic layers were dried over anhydrous sodium sulfate and concentrated under reduced pressure to obtain a solid, which was purified by flash column chromatography to obtain methyl 5 (Z)-2-(5-cyano-2-methylphenoxy)-3-methoxyacrylate (0.49 g, 1.99 mmol, 60 % yield) as an off-white solid. 1H-NMR (400 MHz, DMSO-d6) δ 7.58 (s, 1H), 7.41-7.36 (m, 2H), 7.11 (d, J = 1.5 Hz, 1H), 3.87 (d, J = 4.9 Hz, 3H), 3.65 (s, 3H), 2.29 (s, 3H); GCMS: m / z = 247.1 [M.]. Step-5: Preparation of methyl (2Z)-2-(5-(N'-hydroxycarbamimidoyl)-2-methylphenoxy)-3- 10 methoxyacrylate To a stirred solution of methyl (Z)-2-(5-cyano-2-methylphenoxy)-3-methoxyacrylate (1 g, 4.04 mmol) in ethanol (15 mL), 50% aqueous hydroxylamine (0.78 mL, 6.07 mmol) was added dropwise at 0 °C over 5 minutes. The reaction mixture was then stirred at 25 ℃ for 12 h. After completion of the reaction, 15 the solid obtained was filtered and dried to get a white solid as the desired product. 1H-NMR (400 MHz, DMSO-d6) δ 9.56 (s, 1H), 7.55 (s, 1H), 7.20-7.14 (m, 2H), 7.01 (d, J = 1.5 Hz, 1H), 5.72 (s, 2H), 3.85 (d, J = 11.5 Hz, 3H), 3.64 (d, J = 9.3 Hz, 3H), 2.21 (d, J = 8.1 Hz, 3H); MS: m / z = 280.95. [M+1]. Step-6: Preparation of methyl (Z)-3-methoxy-2-(2-methyl-5-(5-(trifluoromethyl)-1,2,4- 20 oxadiazol-3-yl)phenoxy)acrylate To a stirred solution of methyl (2Z)-2-(5-(N'-hydroxycarbamimidoyl)-2-methylphenoxy)-3- methoxyacrylate (1.3 g, 4.64 mmol) in tetrahydrofuran (30 mL), trifluoroacetic anhydride (1.31 mL, 9.28 mmol) was added dropwise at 0oC. The reaction mixture was stirred at 25oC for 12 h. After 25 completion of the reaction, the reaction mixture was diluted with water (50 mL) and extracted with ethyl acetate (2 x 50 mL). The combined organic layers were dried over anhydrous sodium sulfate and concentrated under reduced pressure to obtain an oily residue, which was purified by flash column PI External chromatography to obtain methyl (Z)-3-methoxy-2-(2-methyl-5-(5-(trifluoromethyl)-1,2,4-oxadiazol- 3-yl)phenoxy)acrylate (1.25 g, 3.50 mmol, 75 % yield) as a off-white solid. 1H-NMR (400 MHz, DMSO-d6) δ 7.68 (s, 1H), 7.62 (dd, J = 7.7, 1.6 Hz, 1H), 7.44 (d, J = 7.6 Hz, 1H), 7.26 (d, J = 1.7 Hz, 1H), 3.87 (s, 3H), 3.67 (d, J = 15.6 Hz, 3H), 2.32 (s, 3H); GCMS: m / z = 5 358.1 [M.] Example 2: Alternative method for the preparation of methyl (Z)-2-(5-cyano-2-methylphenoxy)- 3-methoxyacrylate Step-1: Preparation of methyl 2-(5-cyano-2-methylphenoxy)acetate 10 To a stirred solution of 3-hydroxy-4-methylbenzonitrile (9.5 g, 71.3 mmol) and methyl 2-bromoacetate (13.6 ml, 143 mmol) in tetrahydrofuran (100 mL), K2CO3 (19.72 g, 143 mmol) was added at 25 °C, and the resulting reaction mixture was stirred at 65 °C for 12 h. After completion of the reaction, the reaction mixture was allowed to cool down to 25 °C, diluted with ethyl acetate (200 mL) and passed through a celite®pad. The ethyl acetate layer was washed with water (100 mL) and brine (80 mL), dried over15 anhydrous sodium sulphate and concentrated under reduced pressure to obtain methyl 2-(5-cyano-2- methylphenoxy)acetate (13.2 g, 64.2 mmol, 90 % yield) as a brown liquid. 1H-NMR (400 MHz, DMSO-D6) δ 7.38 (s, 1H), 7.36-7.33 (m, 2H), 4.93 (s, 2H), 3.73-3.68 (m, 3H), 2.25 (s, 3H); GCMS: m / z = 205.1 [M]. Step 2: Preparation of methyl 2-(5-cyano-2-methylphenoxy)-3-hydroxyacrylate 20 To a stirred solution of methyl 2-(5-bromo-2-methylphenoxy)acetate (9 g, 43.9 mmol) and methyl formate (16.38 mL, 263 mmol) in tetrahydrofuran (100 mL) at 25 °C under argon, sodium methoxide (4.74 g, 88 mmol) was added portion wise. The reaction mixture was stirred at 25 °C for 2 h and poured into an ice-water solution and then extracted with ethyl acetae (2 x 100 mL). The combined organic layers were washed with brine (80 mL), dried over anhydrous sodium sulphate, filtered and 25 concentrated under reduced pressure to obtain methyl 2-(5-cyano-2-methylphenoxy)-3-hydroxyacrylate (7.16 g, 30.7 mmol, 70 % yield) as a crude product, which was taken directly to the next step without further purification. GCMS: m / z = 233.1 [M]. Step 3: Preparation of methyl (Z)-2-(5-cyano-2-methylphenoxy)-3-methoxyacrylate To an ice cold solution of methyl 2-(5-cyano-2-methylphenoxy)-3-hydroxyacrylate (8 g, 34.3 mmol) in 30 N,N-dimethylformamide (100 mL), K2CO3(7.11 g, 51.5 mmol) was added and the reaction mixture was PI External stirred for 5 min. Iodomethane (3.22 mL, 51.5 mmol) was added dropwise and the resulting mixture was stirred at 25 °C for 16 h. After completion of the reaction, the reaction mixture was diluted with ethyl acetate (100 mL) and passed through a celite®pad. The filtrate was diluted with water (100 mL) and extracted. The organic layer was separated and the aqueous layer was again extracted with ethyl 5 acetate (100 mL). The combined organic layers were washed with water (80 mL), brine (80 mL), dried over anhydrous sodium sulphate and concentrated under reduced pressure to obtain a crude product which was purified by flash column chromatography to obtain methyl (Z)-2-(5-cyano-2- methylphenoxy)-3-methoxyacrylate (3.82 g, 15.44 mmol, 45 % yield) as a solid. 1H-NMR (400 MHz, DMSO-d6) δ 7.58 (s, 1H), 7.41-7.36 (m, 2H), 7.11 (d, J = 1.5 Hz, 1H), 3.87 (d, J 10 = 4.9 Hz, 3H), 3.65 (s, 3H), 2.29 (s, 3H); GCMS: m / z = 247.1 [M.]. Example 3: Preparation of methyl (Z)-2-(5-(5-(4-bromophenyl)-1,2,4-oxadiazol-3-yl)-2- methylphenoxy)-3-methoxyacrylate To a stirred solution of methyl (2Z)-2-(5-(N'-hydroxycarbamimidoyl)-2-methylphenoxy)-3- 15 methoxyacrylate (0.3 g, 1.07 mmol), triethyl amine (0.45 mL, 3.21 mmol), 4-bromobenzoic acid (0.22 g, 1.07 mmol) and 1-propanephosphonic acid cyclic anhydride (1.593 mL, 2.68 mmol) were added sequentially at 0 °C. The reaction mixture was stirred at 90 °C for 12 h. After completion of the reaction, the reaction mixture was cooled to 25oC, quenched by saturated sodium bicarbonate solution (10 mL) and extracted with ethyl acetate (2 x 20 mL). The combined organic layers were dried over anhydrous 20 sodium sulfate and concentrated under reduced pressure to obtain a solid which was purified by flash column chromatography to obtain methyl (Z)-2-(5-(5-(4-bromophenyl)-1,2,4-oxadiazol-3-yl)-2- methylphenoxy)-3-methoxyacrylate (216 mg, 0.48 mmol, 45 % yield) as a white solid. 1H-NMR (400 MHz, DMSO-d6) δ 8.09 (dd, J = 6.6, 2.0 Hz, 2H), 7.87 (dd, J = 6.6, 2.0 Hz, 2H), 7.67 (s, 1H), 7.65 (dd, J = 7.6, 1.7 Hz, 1H), 7.42 (d, J = 7.8 Hz, 1H), 7.31 (d, J = 1.5 Hz, 1H), 3.89 (s, 3H), 25 3.66 (s, 3H), 2.32 (s, 3H); MS: m / z = 446.45 [M+1]. Example 4: Preparation of methyl (Z)-2-(5-(5-(2-chlorophenyl)-1,2,4-oxadiazol-3-yl)-2- methylphenoxy)-3-methoxyacrylate PI External To a stirred solution of methyl (2Z)-2-(5-(N'-hydroxycarbamimidoyl)-2-methylphenoxy)-3- methoxyacrylate (500 mg, 1.78 mmol) in toluene (10 mL), pyridine (0.173 mL, 2.14 mmol) was added at 0 °C followed by dropwise addition of 2-chlorobenzoyl chloride (0.27 mL, 2.14 mmol). The resulting reaction mixture was stirred at 100 °C for 16 h. After completion of the reaction, the reaction 5 mixture was cooled to 25oC, quenched by saturated sodium bicarbonate solution (20 mL) and extracted with ethyl acetate (2 x 20 mL). The combined organic layers were dried over anhydrous sodium sulfate and concentrated under reduced pressure to obtain an oily residue which was purified by flash column chromatography to obtain methyl (Z)-2-(5-(5-(2-chlorophenyl)-1,2,4-oxadiazol-3-yl)-2- methylphenoxy)-3-methoxyacrylate (450 mg, 1.1 mmol, 62.9 % yield) as a white solid. 101H-NMR (400 MHz, DMSO-d6) δ 8.13 (dd, J = 7.7, 1.3 Hz, 1H), 7.77-7.70 (m, 2H), 7.67-7.64 (m, 2H), 7.63-7.59 (m, 1H), 7.43 (d, J = 8.1 Hz, 1H), 7.33 (d, J = 1.7 Hz, 1H), 3.88 (s, 3H), 3.66 (s, 3H), 2.32 (s, 3H); MS: m / z = 401.00 [M+1]. Example 5: Preparation of ethyl (Z)-3-(3-((1,3-dimethoxy-3-oxoprop-1-en-2-yl)oxy)-4- methylphenyl)-1,2,4-oxadiazole-5-carboxylate 15 To a stirred solution of methyl (2Z)-2-(5-(N'-hydroxycarbamimidoyl)-2-methylphenoxy)-3- methoxyacrylate (900 mg, 3.21 mmol) in toluene (10 mL), pyridine (2.60 mL, 32.1 mmol) was added followed by addition of ethyl 2-chloro-2-oxoacetate (0.43 mL, 4.17 mmol) dropwise at 0 °C. The resulting mixture was stirred at 90 °C for 16 h. After completion of the reaction, the reaction mixture 20 was cooled to 25oC, quenched by saturated sodium bicarbonate solution (20 mL) and extracted with ethyl acetate (2 x 20 mL). The combined organic layers were dried over anhydrous sodium sulfate and concentrated under reduced pressure to obtain an oily residue which was purified by flash column chromatography to obtain ethyl (Z)-3-(3-((1,3-dimethoxy-3-oxoprop-1-en-2-yl)oxy)-4-methylphenyl)- 1,2,4-oxadiazole-5-carboxylate (600 mg, 1.656 mmol, 51.6 % yield) as an off white solid. 251H-NMR (400 MHz, CDCl3) δ 7.72 (dd, J = 7.8, 1.7 Hz, 1H), 7.45 (d, J = 1.5 Hz, 1H), 7.37 (s, 1H), 7.29 (d, J = 7.3 Hz, 1H), 4.56 (qt, J = 7.1 Hz, 2H), 3.89 (s, 3H), 3.71 (s, 3H), 2.41 (s, 3H), 1.49 (t, J = 7.2 Hz, 3H); GCMS: m / z = 362.3 [M.] Example-6: Preparation of (Z)-2-(5-(5-(4-bromophenyl)-1,2,4-oxadiazol-3-yl)-2-methylphenoxy)- 3-methoxy-N-methylacrylamide PI External To a stirred solution of methyl (2Z)-2-(5-(N'-hydroxycarbamimidoyl)-2-methylphenoxy)-3- methoxyacrylate (0.3 g, 0.67 mmol) in tetrahydrofuran (6 mL), methylamine in 40% water (0.07 mL, 0.81 mmol) was added drop-wise and the reaction mixture was stirred for 12 hours at 25 °C. After 5 completion of the reaction, the reaction mixture was diluted with water (10 mL) and extracted with ethyl acetate (2 x 20 mL). The combined organic layers were washed with brine (10 mL) and dried over anhydrous sodium sulfate and concentrated under reduced pressure to get an oily residue which was purified by flash column chromatography to obtain (Z)-2-(5-(5-(4-bromophenyl)-1,2,4-oxadiazol-3-yl)- 2-methylphenoxy)-3-methoxy-N-methylacrylamide (160 mg, 0.36 mmol, 53.5 % yield) as a white solid. 101H-NMR (400 MHz, DMSO-d6) δ 8.09-8.07 (m, 2H), 7.87 (d, J = 8.6 Hz, 2H), 7.60 (dd, J = 7.7, 1.6 Hz, 1H), 7.43 (d, J = 13.4 Hz, 1H), 7.38 (d, J = 8.1 Hz, 1H), 7.31 (s, 1H), 6.60 (d, J = 18.3 Hz, 1H), 3.53 (s, 3H), 2.84 (d, J = 4.6 Hz, 3H), 2.34 (s, 3H). LCMS (M+1) : 445.85. Example 7: methyl (Z)-2-(5-(5-benzyl-1,2,4-oxadiazol-3-yl)-2-methylphenoxy)-3- methoxyacrylate 15 Methyl (Z)-2-(5-(5-benzyl-1,2,4-oxadiazol-3-yl)-2-methylphenoxy)-3-methoxyacrylate was synthesized by following the same procedure as described in example-3, using (2Z)-2-(5-(N'- hydroxycarbamimidoyl)-2-methylphenoxy)-3-methoxyacrylate and 2-phenylacetyl chloride as a starting material. 201H-NMR (400 MHz, CHLOROFORM-D) δ 7.63 (dd, J = 7.6, 1.5 Hz, 1H), 7.40 (d, J = 1.5 Hz, 1H), 7.37-7.32 (m, 5H), 7.31-7.28 (m, 1H), 7.24 (s, 1H), 4.27 (s, 2H), 3.86 (d, J = 7.6 Hz, 3H), 3.69 (d, J = 4.6 Hz, 3H), 2.40 (s, 3H); LCMS (M+1) : 380.9. Example 8: methyl (Z)-3-methoxy-2-(2-methyl-5-(5-(2-phenylpropan-2-yl)-1,2,4-oxadiazol-3- yl)phenoxy)acrylate 25 PI External Methyl (Z)-3-methoxy-2-(2-methyl-5-(5-(2-phenylpropan-2-yl)-1,2,4-oxadiazol-3- yl)phenoxy)acrylate was synthesized by following the same procedure as described in example-3, using methyl (2Z)-2-(5-(N'-hydroxycarbamimidoyl)-2-methylphenoxy)-3-methoxyacrylate and 2-methyl-2- phenylpropanoyl chloride as starting material. 51H-NMR (400 MHz, CHLOROFORM-D) δ 7.63 (dd, J = 7.6, 1.5 Hz, 1H), 7.40 (d, J = 1.5 Hz, 1H), 7.37-7.32 (m, 5H), 7.31-7.28 (m, 1H), 7.24 (s, 1H), 4.27 (s, 2H), 3.86 (d, J = 7.6 Hz, 3H), 3.69 (d, J = 4.6 Hz, 3H), 2.40 (s, 3H); LCMS (M+1) : 408.9 Example 9: methyl (Z)-2-(5-(5-(4-fluorophenethyl)-1,2,4-oxadiazol-3-yl)-2-methylphenoxy)-3- methoxyacrylate 10 Methyl (Z)-2-(5-(5-(4-fluorophenethyl)-1,2,4-oxadiazol-3-yl)-2-methylphenoxy)-3-methoxyacrylate was synthesized by following the same procedure as described in example-2, using methyl (2Z)-2-(5- (N'-hydroxycarbamimidoyl)-2-methylphenoxy)-3-methoxyacrylate and 3-(4-fluorophenyl)propanoic acid as a starting material.1H-NMR (400 MHz, DMSO-d6) δ 7.65 (s, 1H), 7.54 (dd, J = 7.7, 1.3 Hz, 15 1H), 7.36 (d, J = 8.1 Hz, 1H), 7.32 (dd, J = 8.4, 5.7 Hz, 2H), 7.21 (d, J = 1.5 Hz, 1H), 7.10 (t, J = 8.9 Hz, 2H), 3.87 (s, 3H), 3.65 (s, 3H), 3.28 (d, J = 7.8 Hz, 2H), 3.09 (t, J = 7.6 Hz, 2H), 2.29 (s, 3H); LCMS (M+1) : 413.05. Example 10: Preparation of methyl (Z)-3-methoxy-2-(5-(5-(4-methoxy-3-(prop-1-en-2- yl)phenethyl)-1,2,4-oxadiazol-3-yl)-2-methylphenoxy)acrylate 20 Step 1: Preparation of methyl 3-(4-methoxyphenyl)propanoate To a stirred solution of 3-(4-methoxyphenyl)propanoic acid (4 g, 22.20 mmol) in N,N- dimethylformamide (40 mL), K2CO3(9.20 g, 66.6 mmol) and methyl iodide (1.7 ml, 26.6 mmol) were 25 added respectively. The resulting reaction mixture was stirred at 40 °C for 4 h. After completion of the reaction, the reaction mixture was diluted with ethyl acetate (100 mL) and filtered through a celite®pad, PI External then the organic layer was washed with water (30 mL) followed by brine (20 mL). The organic layer was dried over anhydrous sodium sulphate and concentrated under reduced pressure to obtain an oily residue which was purified by flash column chromatography to obtain methyl 3-(4- methoxyphenyl)propanoate (4 g, 20.59 mmol, 93 % yield) as pale yellow solid. GCMS (M+: 194.1). 5 Step 2: Preparation of methyl 3-(3-bromo-4-methoxyphenyl)propanoate. To a stirred solution of methyl 3-(4-methoxyphenyl)propanoate (4 g, 20.60 mmol) in dichloromethane (50 mL), aluminium chloride (2.75 g, 20.60 mmol) was slowly added at 0 °C. The reaction mixture was stirred for 10 min and bromine (1.06 mL, 20.60 mmol) was added portionwise. The reaction was stirred 10 for 1 h at 25 °C. After completion of the reaction, the reaction mixture was slowly poured into a saturated aqueous NH4Cl (100 mL) solution and then extracted with ethyl acetate (2 x 80 mL). The combined organic layers were washed with brine solution (20 mL), dried over anhydrous sodium sulphate and evaporated under reduced pressure to obtain an oily residue, which was purified by flash column chromatography to obtain methyl 3-(3-bromo-4-methoxyphenyl)propanoate (5.2 g, 19.04 15 mmol, 92 % yield).1H-NMR (400 MHz, CHLOROFORM-D) δ 7.38 (d, J = 2.2 Hz, 1H), 7.10 (dd, J = 8.3, 2.2 Hz, 1H), 6.82 (t, J = 4.2 Hz, 1H), 3.89-3.85 (m, 3H), 3.68 (t, J = 6.2 Hz, 3H), 2.87 (t, J = 7.7 Hz, 2H), 2.61-2.57 (m, 2H). Step 3: Preparation of methyl 3-(4-methoxy-3-(prop-1-en-2-yl)phenyl)propanoate 20 To a stirred solution of methyl 3-(3-bromo-4-methoxyphenyl)propanoate (1.8 g, 6.59 mmol) in 1,4- dioxane (20 mL) and water (5 mL), potassium phosphate tribasic (2.80 g, 13.2 mmol) and isopropenylboronicacidpinacolester (1.85 ml, 9.89 mmol) were added. The solution was degassed with nitrogen for 10 min, then PdCl2(dppf) (1.1 g, 1.32 mmol) was added. The resulting reaction mixture was stirred at 100 °C for 3 h. After completion of the reaction, the reaction mixture was diluted with 25 ethyl acetate (50 mL) and water (30 mL), then filtered through a celite®pad. The organic layer was separated and the aqueous layer was extracted with ethyl acetate (2 x 30 mL), the combined organic layers were washed with brine (20 mL), dried over anhydrous sodium sulphate and concentrated under reduced pressure to obtain an oily residue, which was purified by flash column chromatography to obtain methyl 3-(4-methoxy-3-(prop-1-en-2-yl)phenyl)propanoate (1.1 g, 4.69 mmol, 71.2 % yield) was 30 obtained as off white solid.1H-NMR (400 MHz, CHLOROFORM-D) δ 7.06 (dd, J = 8.3, 2.2 Hz, 1H), PI External 7.02-7.00 (m, 1H), 6.83-6.89 (0H), 6.80 (d, J = 8.3 Hz, 1H), 5.14 (td, J = 2.6, 1.2 Hz, 1H), 5.04 (q, J = 1.0 Hz, 1H), 3.85-3.78 (m, 3H), 3.67 (s, 3H), 2.89 (t, J = 7.8 Hz, 2H), 2.63-2.58 (m, 2H), 2.17-2.05 (m, 3H). GCMS (M+ : 234.1). Step 4: Preparation of obtain 3-(4-methoxy-3-(prop-1-en-2-yl)phenyl)propanoic acid 5 To a stirred solution of methyl 3-(4-methoxy-3-(prop-1-en-2-yl)phenyl)propanoate (900 mg, 3.84 mmol) in a mixture of tetrahydrofuran (10 mL), methanol (2.00 mL) and water (5.00 mL), lithium hydroxide monohydrate (322 mg, 7.68 mmol) was added and the resulting mixture was stirred at 25 °C for 2 hour. After completion of the reaction, the reaction mixture was acidified with 1N HCl (pH~5) 10 and the aqueous layer was extracted with ethyl acetate (2 x 20 mL). The combined organic layer were dried over anhydrous sodium sulphate, filtered and evaporated under reduced pressure to obtain 3-(4- methoxy-3-(prop-1-en-2-yl)phenyl)propanoic acid (0.8 g, 3.63 mmol, 95 % yield).1H-NMR (400 MHz, CHLOROFORM-D) δ 7.08 (dd, J = 8.3, 2.4 Hz, 1H), 7.03 (d, J = 2.2 Hz, 1H), 6.81 (d, J = 8.3 Hz, 1H), 5.14 (td, J = 2.6, 1.2 Hz, 1H), 5.04 (q, J = 1.0 Hz, 1H), 3.80 (d, J = 9.5 Hz, 3H), 2.90 (t, J = 7.8 Hz, 2H), 15 2.68-2.64 (m, 2H), 2.11 (q, J = 0.7 Hz, 3H); LCMS (M+1) : 220.95. Step 5: Preparation of methyl (Z)-3-methoxy-2-(5-(5-(4-methoxy-3-(prop-1-en-2-yl)phenethyl)- 1,2,4-oxadiazol-3-yl)-2-methylphenoxy)acrylate Methyl (Z)-3-methoxy-2-(5-(5-(4-methoxy-3-(prop-1-en-2-yl)phenethyl)-1,2,4-oxadiazol-3-yl)-2- methylphenoxy)acrylate was synthesized by following the same procedure as described in example-2,20 using methyl (2Z)-2-(5-(N'-hydroxycarbamimidoyl)-2-methylphenoxy)-3-methoxyacrylate and 3-(4- methoxy-3-(prop-1-en-2-yl)phenyl)propanoic acid as a starting material.1H-NMR (400 MHz, CHLOROFORM-D) δ 7.64 (dd, J = 7.6, 1.5 Hz, 1H), 7.41 (d, J = 1.5 Hz, 1H), 7.36 (s, 1H), 7.28 (s, 1H), 7.10 (dd, J = 8.3, 2.4 Hz, 1H), 7.06 (d, J = 2.4 Hz, 1H), 6.81 (d, J = 8.3 Hz, 1H), 5.13 (dt, J = 3.7, 1.6 Hz, 1H), 5.03 (q, J = 1.0 Hz, 1H), 3.88 (s, 3H), 3.81 (s, 3H), 3.71 (d, J = 3.7 Hz, 3H), 3.23-3.18 (m, 25 2H), 3.14-3.09 (m, 2H), 2.41 (s, 3H), 2.09 (q, J = 0.7 Hz, 3H); LCMS (M+1): 465.2. Example 11: Preparation of methyl (Z)-2-(5-(5-(1-(4-bromophenoxy)cyclopropyl)-1,2,4- oxadiazol-3-yl)-2-methylphenoxy)-3-methoxyacrylate. Step 1: Preparation of ethyl 4-bromo-2-(4-bromophenoxy)butanoate PI External To a stirred solution of 4-bromophenol (0.8 g, 4.56 mmol) in N,N-dimethylformamide (10 mL) and ethyl 2,4-dibromobutanoate (1.13 mL, 5.48 mmol), potassium carbonate (1.26 g, 9.13 mmol) was added. The resulting reaction mixture was stirred at 25 °C for 12 h. After completion of the reaction, 5 water was added to the reaction mixture and extracted with ethyl acetate (2 x 20 mL). The combined organic layers were dried over anhydrous sodium sulphate and evaporated under reduced pressure to obtain an oily residue, which was purified by flash column chromatography to obtain ethyl 4-bromo-2- (4-bromophenoxy)butanoate (1 g, 2.73 mmol, 59.9 % yield) as a colourless liquid.1H-NMR (400 MHz, CHLOROFORM-D) δ 7.39-7.36 (m, 2H), 6.82-6.78 (m, 2H), 4.80 (dd, J = 8.9, 4.0 Hz, 1H), 4.22 (q, J 10 = 7.1 Hz, 2H), 3.63-3.57 (m, 2H), 2.52-2.39 (m, 2H), 1.26 (td, J = 7.1, 3.4 Hz, 3H). Step 2: Preparation of ethyl 1-(4-bromophenoxy)cyclopropane-1-carboxylate To a stirred solution of ethyl 4-bromo-2-(4-bromophenoxy)butanoate (1g, 2.73 mmol) in tetrahydrofuran (10 mL), lithium bis(trimethylsilyl)amide (6.01 mL, 6.01 mmol) was added dropwise 15 under nitrogen atmosphere at -78 °C and the resulting reaction mixture was stirred at -78 °C for 2 h. After completion of the reaction, the reaction mixture was poured into ice-cold saturated ammonium chloride solution. The aqueous layer was extracted with ethyl acetate (2 x 20 mL), dried over anhydrous sodium sulphate, filtered and evaporated under reduced pressure to obtain an oily residue, which was purified by flash column chromatography to obtain ethyl 1-(4-bromophenoxy)cyclopropane-1- 20 carboxylate (650 mg, 2.28 mmol, 83 % yield) as a colourless liquid.1H-NMR (400 MHz, CHLOROFORM-D) δ 7.38-7.32 (m, 2H), 6.82-6.78 (m, 2H), 4.19 (q, J = 7.2 Hz, 2H), 1.60 (dd, J = 8.3, 5.1 Hz, 2H), 1.35-1.28 (m, 2H), 1.19 (t, J = 7.2 Hz, 3H); LCMS (M-1): 285. Step 3: Preparation of 1-(4-bromophenoxy)cyclopropane-1-carboxylic acid 25 To a stirred solution of ethyl 1-(4-bromophenoxy)cyclopropane-1-carboxylate (900 mg, 3.16 mmol) in 1,4-dioxane (10 mL), lithium hydroxide (302 mg, 12.63 mmol) and 2 mL of water were added. The resulting reaction mixture was stirred at 25 °C for 6 h. The reaction mixture was evaporated and diluted with water (5 mL), and washed with ethyl acetate (20 mL), and the aqueous layer was further acidified PI External with 10% HCl followed by an extraction with ethyl acetate (2 x 20 mL). The combined organic layers were evaporated under reduced pressure to obtain 1-(4-bromophenoxy)cyclopropane-1-carboxylic acid (500 mg, 1.95 mmol, 61.6 % yield) as a light brown solid.1H-NMR (400 MHz, CHLOROFORM-D) δ 7.40-7.32 (m, 2H), 6.85-6.81 (m, 2H), 1.69 (dd, J = 8.4, 5.3 Hz, 2H), 1.38 (dd, J = 8.6, 5.1 Hz, 2H); 5 LCMS (M-1) : 257.9. Step 4: Preparation of methyl (Z)-2-(5-(5-(1-(4-bromophenoxy)cyclopropyl)-1,2,4-oxadiazol-3- yl)-2-methylphenoxy)-3-methoxyacrylate (Z)-2-(5-(5-(1-(4-bromophenoxy)cyclopropyl)-1,2,4-oxadiazol-3-yl)-2-methylphenoxy)-3- methoxyacrylate was synthesized by following the same procedure as described in example-2, using10 methyl (2Z)-2-(5-(N'-hydroxycarbamimidoyl)-2-methylphenoxy)-3-methoxyacrylate and 4- bromophenoxycyclopropane-1-carboxylic acid as a starting material.1H-NMR (400 MHz, CHLOROFORM-D) δ 7.58 (dd, J = 7.6, 1.5 Hz, 1H), 7.38-7.33 (m, 4H), 7.24 (d, J = 7.8 Hz, 1H), 6.88- 6.84 (m, 2H), 3.85 (s, 3H), 3.74 (d, J = 9.3 Hz, 1H), 3.69 (s, 4H), 2.39 (s, 3H), 1.82 (dd, J = 8.7, 5.5 Hz, 2H). 15 Example 12: Preparation of methyl (Z)-2-(5-(5-((3-bromophenoxy)difluoromethyl)-1,2,4- oxadiazol-3-yl)-2-methylphenoxy)-3-methoxyacrylate Step 1: Preparation of 2-(3-bromophenoxy)-2,2-difluoroacetic acid 20 To a stirred suspension of 3-bromophenol (1.0 g, 5.8 mmol) in 1,4-dioxane (20 mL), sodium hydride (0.25 g, 6.36 mmol) was added portionwise at 0 °C under nitrogen atmosphere. Subsequently, the resulting brown reaction mixture was stirred at 25 °C for 0.5 h, followed by the addition of sodium 2- bromo-2,2-difluoroacetate (1.25 g, 6.36 mmol) in 1,4-dioxane (10.00 mL). The resulting reaction 25 mixture was stirred at 70 °C for 1 h. The reaction mixture was cooled down to 25 °C and poured into ice-cooled water (30 mL), acidified with 3M HCl, and extracted with ethyl acetate (3 x 20 mL). The combined organic layers were washed with brine solution (20 mL), dried over anhydrous sodium sulphate, filtered and evaporated under reduced pressure to obtain an oily residue, which was purified PI External by flash column chromatography to obtain 2-(3-bromophenoxy)-2,2-difluoroacetic acid (0.8 g, 3.00 mmol, 52 % yield). LCMS (M-1): 266.75. Step 2: Preparation of methyl (Z)-2-(5-(5-((3-bromophenoxy)difluoromethyl)-1,2,4-oxadiazol-3- yl)-2-methylphenoxy)-3-methoxyacrylate 5 Methyl (Z)-2-(5-(5-((3-bromophenoxy)difluoromethyl)-1,2,4-oxadiazol-3-yl)-2-methylphenoxy)-3- methoxyacrylate was synthesized by following the same procedure as described in example-2, using methyl (2Z)-2-(5-(N'-hydroxycarbamimidoyl)-2-methylphenoxy)-3-methoxyacrylate and 2-(3- bromophenoxy)-2,2-difluoroacetic acid as a starting material.1H-NMR (400 MHz, CHLOROFORM- D) δ 7.70 (dd, J = 7.7, 1.6 Hz, 1H), 7.51 (s, 1H), 7.47-7.45 (m, 1H), 7.43 (d, J = 1.7 Hz, 1H), 7.38 (s, 10 1H), 7.31-7.28 (m, 3H), 3.90 (s, 3H), 3.72 (s, 3H), 2.43 (s, 3H); LCMS (M+1): 512.95. Example 13: methyl (Z)-2-(5-(5-(1-cyclopropyl-5-methyl-1H-pyrazol-4-yl)-1,2,4-oxadiazol-3-yl)- 2-methylphenoxy)-3-methoxyacrylate Step-1: Preparation of ethyl 1-cyclopropyl-5-methyl-1H-pyrazole-4-carboxylate 15 To a stirred solution of ethyl 2-(ethoxymethylene)-3-oxobutanoate (15 g, 81 mmol) in ethanol (80 mL), 1-cyclopropylhydrazine HCl (7.95 g, 73.2 mmol) was added and the resulting reaction mixture was stirred at 73 °C for 16 h. After completion of the reaction, the reaction mixture was evaporated under reduced pressure, diluted with water (50 mL) and extracted with ethyl acetate (2 x 100 mL). The 20 combined organic layers were washed with brine solution (20 mL) and dried over anhydrous sodium sulphate, filtered and evaporated under reduced pressure to obtain ethyl 1-cyclopropyl-5-methyl-1H- pyrazole-4-carboxylate (11.8 g, 60.8 mmol, 83 % yield) as a brown oil.1H-NMR (400 MHz, CHLOROFORM-D) δ 7.78 (s, 1H), 4.30-4.25 (m, 2H), 3.37-3.32 (m, 1H), 2.63 (d, J = 4.3 Hz, 3H), 1.34 (td, J = 7.3, 5.0 Hz, 3H), 1.20-1.15 (m, 2H), 1.13-1.06 (m, 2H); LCMS (M+1) : 194.3 25 Step-2: 1-cyclopropyl-5-methyl-1H-pyrazole-4-carboxylic acid To a stirred solution of ethyl 1-cyclopropyl-5-methyl-1H-pyrazole-4-carboxylate (11.8 g, 60.8 mmol) in 1,4-dioxane (25 mL) and ethanol (25 mL), NaOH (4.86 g, 122 mmol) solution in water (25.00 ml) PI External was added, and the resulting reaction mixture was stirred for 16 h at 25 °C. After completion of the reaction, the reaction mixture was evaporated under reduced pressure to obtain an oily residue which was diluted with water (10 mL) and acidified using 1N HCl till pH 4-5. The precipitate formed was filtered and dried to afford the desired product 1-cyclopropyl-5-methyl-1H-pyrazole-4-carboxylic acid 5 (6.8 g, 40.9 mmol, 67.4 % yield) as an off-white solid.1H-NMR (400 MHz, DMSO-d6) δ 12.19 (s, 1H), 7.64 (s, 1H), 3.56-3.51 (m, 1H), 2.54 (s, 3H), 1.06-0.96 (m, 4H); LCMS (M+1) : 166.18. Step-3: methyl (Z)-2-(5-(5-(1-cyclopropyl-5-methyl-1H-pyrazol-4-yl)-1,2,4-oxadiazol-3-yl)-2- methylphenoxy)-3-methoxyacrylate Oxalyl chloride (0.66 mL, 6 mmol) was slowly added to the stirred solution of 1-cyclopropyl-5-methyl- 10 1H-pyrazole-4-carboxylic acid (215 mg, 1.2 mmol) in dichloromethane (4 mL) at 0oC, then a catalytic amount of N,N-dimethylformamide ( 2-3 drops) was added. The resulting reaction mixture was stirred at 25 °C for 4 h. After completion of the reaction, the reaction mixture was concentrated under reduced pressure to obtain 1-cyclopropyl-5-methyl-1H-pyrazole-4-carbonyl chloride. To a stirred solution of methyl (2Z)-2-(5-(N'-hydroxycarbamimidoyl)-2-methylphenoxy)-3- 15 methoxyacrylate (300 mg, 1.07 mmol) in toluene (10 mL), was added pyridine (0.260 mL, 3.21 mmol) at 0 °C followed by the dropwise addition of a solution of 1-cyclopropyl-5-methyl-1H-pyrazole-4- carbonyl chloride (237 mg, 1.28 mmol) in toluene (15 mL) and the resulting reaction mixture was stirred at 100 °C for 16 h. After completion of reaction, the reaction mixture was quenched with water (10 mL) and extracted with ethyl acetate (2 x 20 mL). The combined organic layers were washed with brine (20 20 mL) and dried over anhydrous sodium sulphate, filtered and evaporated under reduced pressure to obtain an oily residue, which was purified by flash column chromatography to obtain methyl (Z)-2-(5- (5-(1-cyclopropyl-5-methyl-1H-pyrazol-4-yl)-1,2,4-oxadiazol-3-yl)-2-methylphenoxy)-3- methoxyacrylate (140 mg, 0.341 mmol, 31.9 % yield) as a pale yellow solid.1H-NMR (400 MHz, CHLOROFORM-D) δ 8.00 (s, 1H), 7.71 (dd, J = 7.6, 1.5 Hz, 1H), 7.47 (d, J = 1.5 Hz, 1H), 7.37 (s, 25 1H), 7.28 (d, J = 8.3 Hz, 1H), 3.88 (s, J = 7.5 Hz, 3H), 3.70 (s, J = 15.0 Hz, 3H), 3.46-3.40 (m, 1H), 2.77 (s, J = 14.7 Hz, 3H), 2.33 (s, J = 15.0 Hz, 3H), 1.28-1.21 (m, 2H), 1.20-1.12 (m, 2H); LCMS (M+1) : 411.10. Example 14: Preparation of methyl (Z)-3-methoxy-2-(2-methyl-5-(5-((5-methyl-3- (trifluoromethyl)-1H-pyrazol-1-yl)methyl)-1,2,4-oxadiazol-3-yl)phenoxy)acrylate 30 Methyl (Z)-3-methoxy-2-(2-methyl-5-(5-((5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl)methyl)- 1,2,4-oxadiazol-3-yl)phenoxy)acrylate was synthesized by following the same procedure as described PI External in example-2, using methyl (2Z)-2-(5-(N'-hydroxycarbamimidoyl)-2-methylphenoxy)-3- methoxyacrylate and 2-(5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl)acetic acid as a starting material.1H-NMR (400 MHz, DMSO-d6) δ 7.65 (s, 1H), 7.52 (dd, J = 7.6, 1.5 Hz, 1H), 7.38 (d, J = 7.8 Hz, 1H), 7.21 (d, J = 1.5 Hz, 1H), 6.64 (s, 1H), 5.94 (s, 2H), 3.86 (s, 3H), 3.64 (s, 3H), 2.38 (s, 3H), 5 2.29 (s, 3H); LCMS (M-1) : 450.95. Example 15: Preparation of methyl (Z)-3-methoxy-2-(2-methyl-5-(5-((2-oxo-3- (trifluoromethyl)pyridin-1(2H)-yl)methyl)-1,2,4-oxadiazol-3-yl)phenoxy)acrylate Methyl (Z)-3-methoxy-2-(2-methyl-5-(5-((2-oxo-3-(trifluoromethyl)pyridin-1(2H)-yl)methyl)-1,2,4- 10 oxadiazol-3-yl)phenoxy)acrylate was synthesized by following the same procedure as described in example-2, using methyl (2Z)-2-(5-(N'-hydroxycarbamimidoyl)-2-methylphenoxy)-3-methoxyacrylate and 2-(2-oxo-3-(trifluoromethyl)pyridin-1(2H)-yl)acetic acid as a starting material. 1H-NMR (400 MHz, DMSO-D6) δ 8.22 (dd, J = 6.8, 1.7 Hz, 1H), 8.09-8.07 (m, 1H), 7.63 (s, 1H), 7.50 (dd, J = 7.7, 1.6 Hz, 1H), 7.37 (d, J = 8.1 Hz, 1H), 7.19 (d, J = 1.5 Hz, 1H), 6.53 (t, J = 7.0 Hz, 1H), 15 5.57 (s, 2H), 3.85 (s, 3H), 3.63 (s, 3H), 2.29 (s, 3H); LCMS (M+1) : 465.9. Accordingly, the compounds of the current invention have been illustrated in the following Table-1, in a non-limiting manner. In the following examples, M+1 (or M-1) means the molecular ion peak, plus or minus 1 a.m.u. (atomic mass unit) respectively, as observed in the mass spectrometry. All1H NMR experiments were reported in units, parts per million (ppm), and were measured relative 20 to the signals for residual deuterated solvents as the internal standard unless otherwise stated. The following compounds (Table 1) of the present invention were obtained using analogous procedures as described in the schemes or the examples. Table: 1 Compd No. Compound Name Analytical Data methyl (Z)-3-methoxy-2-(2-1H-NMR (400 MHz, DMSO-d6) δ 7.67 (s, 1H), 7.62 (dd, J 1 methyl-5-(5-(trifluoromethyl)- = 7.7, 1.6 Hz, 1H), 7.44 (d, J = 7.8 Hz, 1H), 7.26 (d, J = 1.7 1,2,4-oxadiazol-3- Hz, 1H), 3.87 (s, 3H), 3.67 (d, J = 15.9 Hz, 3H), 2.31 (d, J yl)phenoxy)acrylate = 12.7 Hz, 3H); GCMS(M.) : 358.1 1 methyl (Z)-3-methoxy-2-(2- H-NMR (400 MHz, DMSO-d6) δ 7.65 (s, 1H), 7.54 (dd, J 2 methyl-5-(5-methyl-1,2,4- = 7.6, 1.5 Hz, 1H), 7.36 (d, J = 8.1 Hz, 1H), 7.23 (d, J = 1.5 oxadiazol-3-yl)phenoxy)acrylate Hz, 1H), 3.87 (s, 3H), 3.65 (s, 3H), 2.63 (s, 3H), 2.29 (s, 3H); LCMS(M+1) : 304.9 PI External 1 methyl (Z)-3-methoxy-2-(2- H-NMR (400 MHz, CDCl3) δ 8.70 (s, 1H), 7.68 (dd, J = 3 methyl-5-(1,2,4-oxadiazol-3- 7.7, 1.6 Hz, 1H), 7.45 (d, J = 1.2 Hz, 1H), 7.37 (s, 1H), 7.29 yl)phenoxy)acrylate (d, J = 7.6 Hz, 1H), 3.88 (d, J = 2.7 Hz, 3H), 3.71 (d, J = 2.2 Hz, 3H), 2.41 (d, J = 5.6 Hz, 3H); LCMS(M+1) : 290.5 1 methyl (Z)-2-(5-(5-(4- H-NMR (400 MHz, DMSO-d6) δ 8.09 (dd, J = 6.6, 2.0 Hz, bromophenyl)-1,2,4-ox 2H), 7.87 (dd, J = 6.6, 2.0 Hz, 2H), 7.67 (s, 1H), 7.65 (dd, 4 adiazol-3- yl)-2-methylphenoxy)-3- J = 7.6, 1.7 Hz, 1H), 7.42 (d, J = 7.8 Hz, 1H), 7.31 (d, J = methoxyacrylate 1.5 Hz, 1H), 3.89 (s, 3H), 3.66 (s, 3H), 2.32 (s, 3H); LCMS(M+1) : 446.4 1 methyl (Z)-2-(5-(5-isobutyl-1,2,4- H-NMR (400 MHz, DMSO-d6) δ 7.65 (s, 1H), 7.55 (d, J = ox 6.4 Hz, 1H), 7.37 (d, J = 7.8 Hz, 1H), 7.23 (s, 1H), 3.87 (s, 5 adiazol-3-yl)-2- methylphenoxy)-3- 3H), 3.66 (d, J = 10.3 Hz, 3H), 2.87 (d, J = 7.1 Hz, 2H), methoxyacrylate 2.29 (s, 3H), 2.18-2.11 (m, 1H), 0.96 (d, J = 6.6 Hz, 6H); LCMS(M+1) : 346.9 methyl (Z)-2-(5-(5-(4-1H-NMR (400 MHz, DMSO-d6) δ 8.29 (d, J = 8.3 Hz, 2H), 6 acetylphenyl)-1,2,4-oxadiazol-3- 8.18 (d, J = 8.6 Hz, 2H), 7.67 (d, J = 7.6 Hz, 2H), 7.43 (d, yl)-2-methylphenoxy)-3- J = 7.8 Hz, 1H), 7.33 (s, 1H), 3.89 (s, 3H), 3.67 (s, 3H), methoxyacrylate 2.66 (s, 3H), 2.32 (s, 3H); LCMS(M+1) : 408.8 methyl (Z)-2-(5-(5-1H-NMR (400 MHz, DMSO-d6) δ 7.67 (s, 1H), 7.61 (dd, J (chlorodifluoromethyl)-1,2,4- = 7.7, 1.6 Hz, 1H), 7.44 (d, J = 8.1 Hz, 1H), 7.25 (d, J = 1.7 7 oxadiazol-3-yl)-2- Hz, 1H), 3.87 (d, J = 4.2 Hz, 3H), 3.65 (s, 3H), 2.32 (s, 3H); methylphenoxy)-3- LCMS(M+1) : 374.5 methoxyacrylate methyl (Z)-2-(5-(5-1H-NMR (400 MHz, DMSO-d6) δ 7.67 (s, 1H), 7.64-7.38 8 (difluoromethyl)-1,2,4-oxadiazol- (m, 3H), 7.26 (d, J = 1.5 Hz, 1H), 3.87 (s, 3H), 3.65 (s, 3H), 3-yl)-2-methylphenoxy)-3- 2.31 (s, 3H); LCMS(M+1) : 340.6 methoxyacrylate 1 methyl (Z)-3-methoxy-2-(3-(5- H-NMR (400 MHz, DMSO-d6): δ 7.70 (dt, J = 7.9, 1.3 Hz, 9 (trifluoromethyl)-1,2,4-oxadiazol- 1H), 7.65 (s, 1H), 7.55 (t, J = 8.1 Hz, 1H), 7.44 (q, J = 1.3 3-yl)phenoxy)acrylate Hz, 1H), 7.22 (ddd, J = 8.3, 2.7, 0.9 Hz, 1H), 3.87 (s, 3H), 3.66 (s, 3H); LCMS(M+1) : 344.5 1H-NMR (400 MHz, DMSO-d6): δ 9.74-9.70 (m, 1H), 7.68 methyl (Z)-2- (dt, J = 7.7, 1.2 Hz, 1H), 7.64 (d, J = 6.8 Hz, 1H), 7.50 (t, J10(3-(1,2,4-oxadiazol- 3-yl)phenoxy)-3-methoxyacrylate = 7.9 Hz, 1H), 7.45 (q, J = 1.3 Hz, 1H), 7.15 (dq, J = 8.3, 1.2 Hz, 1H), 3.86-3.84 (m, 3H), 3.68-3.65 (m, 3H); LCMS(M+1) : 276.5 1 methyl (Z)-2-(3-(5- H-NMR (400 MHz, DMSO-d6): δ 7.70-7.41 (m, 4H), 7.20 11 (difluoromethyl)-1,2,4-oxadiazol- (ddd, J = 8.3, 2.6, 0.9 Hz, 1H), 6.28 (t, J = 53.1 Hz, 1H), 3-yl)phenoxy)-3-methoxyacrylate 3.86 (d, J = 3.4 Hz, 3H), 3.65 (d, J = 2.4 Hz, 3H); GCMS (M.) : 326.1 methyl (Z)-2-(3-(5-1H-NMR (400 MHz, DMSO-d6) δ 7.69 (dt, J = 8.0, 1.2 Hz, 12 (chlorodifluoromethyl)-1,2,4- 1H), 7.65 (s, 1H), 7.54 (t, J = 8.1 Hz, 1H), 7.43 (q, J = 1.3 oxadiazol-3-yl)phenoxy)-3- Hz, 1H), 7.22 (dq, J = 8.3, 1.2 Hz, 1H), 3.87 (s, 3H), 3.66 methoxyacrylate (s, 3H); GCMS (M.) : 360.4 1 methyl (Z)-3-methoxy-2-(3-(5- H-NMR (400 MHz, DMSO-d6) δ 7.63-7.61 (m, 2H), 7.48 13 methyl-1,2,4-oxadiazol-3- (t, J = 8.1 Hz, 1H), 7.39 (q, J = 1.3 Hz, 1H), 7.13 (dq, J = yl)phenoxy)acrylate 8.3, 1.2 Hz, 1H), 3.86 (s, 3H), 3.65 (s, 3H), 2.65 (s, 3H); LCMS(M+1) : 290.5 methyl (Z)-2-(2-chloro-5-(5-1H-NMR (400 MHz, DMSO-d6) δ 7.76-7.74 (m, 2H), 7.71 14 (trifluoromethyl)-1,2,4-oxadiazol- (dd, J = 8.3, 1.8 Hz, 1H), 7.39 (d, J = 1.5 Hz, 1H), 3.89 (s, 3-yl)phenoxy)-3-methoxyacrylate 3H), 3.67 (s, 3H); LCMS(M+1) : 378.85 PI External methyl (Z)-2-(2-chloro-5-(5-1H-NMR (400 MHz, DMSO-d6) δ 5.90-5.88 (m, 2H), 5.84 15 (chlorodifluoromethyl)-1,2,4- (dd, J = 8.3, 1.8 Hz, 1H), 5.53 (d, J = 1.5 Hz, 1H), 2.04 (s, oxadiazol-3-yl)phenoxy)-3- 3H), 1.82 (s, 3H); GCMS(M.) : 394.1 methoxyacrylate methyl (Z)-2-(2-chloro-5-(5-1H-NMR (400 MHz, DMSO-d6) δ 7.74-7.68 (m, 3H), 7.66- 16 (difluoromethyl)-1,2,4-oxadiazol- 7.40 (m, 1H), 7.39 (d, J = 1.7 Hz, 1H), 3.87 (d, J = 15.9 Hz, 3-yl)phenoxy)-3-methoxyacrylate 3H), 3.69 (d, J = 14.2 Hz, 3H); GCMS(M.) : 360.1 methyl (Z)-2-(2-chloro-5-(5-1H-NMR (400 MHz, DMSO-d6) δ 7.76 (d, J = 7.6 Hz, 2H), 17 (perfluoroethyl)-1,2,4-oxadiazol- 7.71 (dd, J = 8.3, 2.0 Hz, 1H), 7.39 (d, J = 1.7 Hz, 1H), 3.89 3-yl)phenoxy)-3-methoxyacrylate (s, 3H), 3.67 (s, 3H); GCMS(M.) : 428.1 methyl (Z)-2-(5-(5-(4-1H-NMR (400 MHz, DMSO-d6) δ 8.30 (dd, J = 6.8, 2.0 Hz, 18 acetylphenyl)-1,2,4-oxadiazol-3- 2H), 8.22-8.18 (m, 2H), 7.78-7.72 (m, 3H), 7.46 (d, J = 1.2 yl)-2-chlorophenoxy)-3- Hz, 1H), 3.91 (s, 3H), 3.69 (s, 3H), 2.67 (d, J = 2.9 Hz, 3H); methoxyacrylate LCMS(M+1) : 428.9 1H-NMR (400 MHz, DMSO-d6) δ 7.73 (s, 1H), 7.68 (d, J = methyl (Z)-2-(2-chloro-5-(5- 8.1 Hz, 1H), 7.64 (dd, J = 8.2, 1.8 Hz, 1H), 7.36 (d, J = 1.5 19 isobutyl-1,2,4-oxadiazol-3- Hz, 1H), 3.89 (s, 3H), 3.67 (s, 3H), 2.89 (d, J = 7.1 Hz, 2H), yl)phenoxy)-3-methoxyacrylate 2.18-2.11 (m, 1H), 0.96 (d, J = 6.6 Hz, 6H); LCMS(M+1) : 366.9 1 methyl (Z)-2-(2-chloro-5-(5-ethyl- H-NMR (400 MHz, DMSO-d6) δ 7.73 (s, 1H), 7.68 (d, J = 20 1,2,4-oxadiazol-3-yl)phenoxy)-3- 8.3 Hz, 1H), 7.65 (d, J = 1.5 Hz, 1H), 7.36 (d, J = 1.5 Hz, methoxyacrylate 1H), 3.89 (s, 3H), 3.67 (s, 3H), 3.00 (q, J = 7.5 Hz, 2H), 1.31 (t, J = 7.5 Hz, 3H); LCMS(M+1) : 338.8 1 methyl (Z)-2-(2-chloro-5-(5- H-NMR (400 MHz, DMSO-d6) δ 7.73 (s, 1H), 7.68 (d, J = 21 isopropyl-1,2,4-oxadiazol-3- 8.3 Hz, 1H), 7.64 (dd, J = 8.3, 1.8 Hz, 1H), 7.35 (d, J = 1.5 yl)phenoxy)-3-methoxyacrylate Hz, 1H), 3.89 (s, 3H), 3.67 (s, 3H), 3.35 (q, J = 6.9 Hz, 1H), 1.36-1.34 (m, 6H); LCMS(M+1) : 352.9 methyl (Z)-2-(2-chloro-5-(1,2,4-1H-NMR (400 MHz, DMSO-d6) δ 9.72 (s, 1H), 7.73-7.69 22 oxadiazol-3-yl)phenoxy)-3- (m, 3H), 7.41 (t, J = 0.8 Hz, 1H), 3.89 (s, 3H), 3.67 (s, 3H); methoxyacrylate LCMS(M+1) : 310.8 (Z)-N,3-dimethoxy-2-(2-methyl-1H-NMR (400 MHz, DMSO-d6) δ 11.20 (s, 1H), 7.62 (dd, 23 5-(5-(trifluoromethyl)-1,2,4- J = 7.6, 1.5 Hz, 1H), 7.43 (d, J = 7.8 Hz, 1H), 7.31-7.29 (m, oxadiazol-3- 2H), 3.74 (s, 3H), 3.57 (s, 3H), 2.33 (d, J = 10.8 Hz, 3H); yl)phenoxy)acrylamide LCMS(M+1) : 373.5 (Z)-3-methoxy-2-(2-methyl-5-(5-1H-NMR (400 MHz, DMSO-d6) δ 12.60 (s, 1H), 7.63-7.60 24 (trifluoromethyl)-1,2,4-oxadiazol- (m, 2H), 7.44 (d, J = 7.8 Hz, 1H), 7.29 (d, J = 1.5 Hz, 1H), 3-yl)phenoxy)acrylic acid 3.86 (s, 3H), 2.33 (s, 3H); LCMS(M-1) : 343 1 methyl (Z)-2-(5-(5-isopropyl- H-NMR (400 MHz, DMSO-d6) δ 7.65 (s, 1H), 7.55 (dd, J 1,2,4- = 7.6, 1.5 Hz, 1H), 7.36 (d, J = 7.6 Hz, 1H), 7.22 (d, J = 1.5 25 oxadiazol-3-yl)-2- methylphenoxy)-3- Hz, 1H), 3.87 (s, 3H), 3.65 (s, 3H), 3.34 (t, J = 7.0 Hz, 1H), methoxyacrylate 2.32-2.29 (m, 3H), 1.35 (d, J = 6.8 Hz, 6H); LCMS(M+1) : 333.05 1 methyl (Z)-2-(5-(5-ethyl-1,2,4- H-NMR (400 MHz, DMSO-d6) δ 7.67-7.63 (m, 1H), 7.55 oxa (dd, J = 7.6, 1.5 Hz, 1H), 7.37-7.35 (m, 1H), 7.23 (d, J = 26 diazol-3-yl)-2- methylphenoxy)-3- 1.7 Hz, 1H), 3.85 (d, J = 16.4 Hz, 3H), 3.66 (d, J = 14.7 Hz, methoxyacrylate 3H), 2.98 (q, J = 7.6 Hz, 2H), 2.30 (d, J = 8.1 Hz, 3H), 1.31 (t, J = 7.6 Hz, 3H); LCMS(M+1) : 318.55 (Z)-3-methoxy-2-(2-methyl-5-(5-1H-NMR (400 MHz, DMSO-d6) δ 7.63 (dd, J = 7.8, 1.7 Hz, 27 (trifluoromethyl)-1,2,4-oxadiazol- 1H), 7.45 (d, J = 7.6 Hz, 1H), 7.39 (d, J = 1.5 Hz, 1H), 7.06 3-yl)phenoxy)-1-morpholinoprop- (s, 1H), 3.77 (s, 3H), 3.51-3.45 (m, 8H), 2.31 (s, 3H), 2.11- 2-en-1-one 2.07 (m, 2H); LCMS(M+1) : 414.05 PI External 1 (Z)-3-methoxy-2-(2-methyl-5-(5- H-NMR (400 MHz, DMSO-d6) δ 7.62 (dd, J = 7.8, 1.7 Hz, (trifluo 1H), 7.44 (d, J = 8.3 Hz, 1H), 7.40 (d, J = 1.5 Hz, 1H), 6.98 28 romethyl)-1,2,4-oxadiazol- 3-yl)phenoxy)-1-(piperidin-1- (s, 1H), 3.75 (s, 3H), 3.44 (t, J = 5.2 Hz, 4H), 2.32 (s, 3H), yl)prop-2-en-1-one 1.50-1.47 (m, 2H), 1.37-1.34 (m, 4H); LCMS(M+1) : 412.05 (Z)-3-methoxy-2-(2-methyl-5-(5-1H-NMR (400 MHz, DMSO-d6) δ 7.62 (dd, J = 7.7, 1.6 Hz, (trifluoromethyl)-1,2,4-oxadiazol- 1H), 7.44 (d, J = 8.3 Hz, 1H), 7.38 (d, J = 1.5 Hz, 1H), 7.02 29 3-yl)phenoxy)-1-(4- (s, 1H), 3.76 (s, 3H), 3.48 (s, 4H), 2.32 (s, 3H), 2.16 (t, J = methylpiperazin-1-yl)prop-2-en- 4.6 Hz, 4H), 2.08 (s, 3H); GCMS(M.) : 426.3 1-one (Z)-3-methoxy-2-(2-methyl-5-(5-1H-NMR (400 MHz, DMSO-d6) δ 7.63 (dd, J = 7.7, 1.6 Hz, 30 (trifluoromethyl)-1,2,4-oxadiazol- 1H), 7.45 (d, J = 8.1 Hz, 1H), 7.39 (d, J = 1.7 Hz, 1H), 7.05 3-yl)phenoxy)-1- (s, 1H), 3.76-3.72 (m, 7H), 2.46 (s, 4H), 2.33 (s, 3H); thiomorpholinoprop-2-en-1-one LCMS(M+1) : 429.45 methyl (Z)-2-(2-fluoro-5-(5-1H-NMR (400 MHz, DMSO-d6) δ 7.74 (qd, J = 4.3, 2.1 Hz, 31 (trifluoromethyl)-1,2,4-oxadiazol- 2H), 7.55 (dd, J = 10.9, 8.4 Hz, 1H), 7.44 (dd, J = 8.1, 2.0 3-yl)phenoxy)-3-methoxyacrylate Hz, 1H), 3.89 (s, 3H), 3.67 (s, 3H); GCMS(M.) : 362.1 methyl (Z)-2-(5-(5-1H-NMR (400 MHz, DMSO-d6) δ 7.74-7.40 (m, 5H), 3.89 32 (difluoromethyl)-1,2,4-oxadiazol- (s, 3H), 3.67 (s, 3H); GCMS(M.) : 344.1 3-yl)-2-fluorophenoxy)-3- methoxyacrylate methyl (Z)-2-(5-(5-1H-NMR (400 MHz, DMSO-d6) δ 7.75-7.71 (m, 2H), 7.55 (chlorodifluoromethyl)-1,2,4- (dd, J = 10.9, 8.4 Hz, 1H), 7.44 (dd, J = 8.1, 2.0 Hz, 1H), 33 oxadiazol-3-yl)-2- 3.89 (s, 3H), 3.67 (s, 3H); GCMS(M.) : 378.1 fluorophenoxy)-3- methoxyacrylate methyl (Z)-2-(2-fluoro-5-(5-1H-NMR (400 MHz, DMSO-d6) δ 7.75-7.72 (m, 2H), 7.56 34 (perfluoroethyl)-1,2,4-oxadiazol- (dd, J = 10.9, 8.4 Hz, 1H), 7.45 (dd, J = 7.9, 2.1 Hz, 1H), 3-yl)phenoxy)-3-methoxyacrylate 3.89 (s, 3H), 3.67 (s, 3H); GCMS(M.) : 412.1 1H-NMR (400 MHz, DMSO-d6) δ 7.71 (s, 1H), 7.65 (s, methyl (Z)-2-(2-fluoro-5-(5- 1H), 7.47 (dd, J = 11.0, 8.6 Hz, 1H), 7.40 (dd, J = 8.1, 2.0 35 isopropyl-1,2,4-oxadiazol-3- Hz, 1H), 3.88 (d, J = 3.4 Hz, 3H), 3.67 (s, 3H), 3.34 (d, J = yl)phenoxy)-3-methoxyacrylate 7.0 Hz, 1H), 1.35 (d, J = 7.0 Hz, 6H); LCMS(M+1) : 412.05 1 methyl (Z)-2-(5-(5-ethyl-1,2,4- H-NMR (400 MHz, DMSO-d6) δ 7.71 (s, 1H), 7.66 (qd, J ox = 4.3, 2.0 Hz, 1H), 7.47 (dd, J = 11.0, 8.6 Hz, 1H), 7.40 (dd, 36 adiazol-3-yl)-2- fluorophenoxy)-3- J = 8.3, 1.8 Hz, 1H), 3.87 (d, J = 14.1 Hz, 3H), 3.71-3.67 methoxyacrylate (m, 3H), 2.99 (q, J = 7.5 Hz, 2H), 1.34-1.27 (m, 3H); LCMS(M+1) : 323.05 (Z)-1-(3-methoxy-2-(2-methyl-5-1H-NMR (400 MHz, DMSO-d6) δ 7.62 (dd, J = 7.7, 1.6 Hz, (5-(trifluoromethyl)-1,2,4- 1H), 7.46-7.42 (m, 2H), 7.13 (s, 1H), 3.80-3.76 (m, 7H), 37 oxadiazol-3- 2.32 (t, J = 5.7 Hz, 7H); LCMS(M+1) : 425.45 yl)phenoxy)acryloyl)piperidin-4- one 1H-NMR (400 MHz, CDCl3) δ 7.67 (dd, J = 7.7, 1.6 Hz, (Z)-N-(1-cyclopropylethyl)-3- 1H), 7.50-7.47 (m, 2H), 7.32 (dd, J = 7.8, 0.5 Hz, 1H), 4.56 38 methoxy-2-(2-methyl-5-(5- (q, J = 6.6 Hz, 1H), 3.64 (d, J = 10.0 Hz, 3H), 2.71-2.62 (m, (trifluoromethyl)-1,2,4-oxadiazol- 1H), 2.47-2.44 (m, 3H), 1.29-1.25 (m, 3H), 0.88-0.79 (m, 3-yl)phenoxy)acrylamide 1H), 0.60-0.49 (m, 2H), 0.33-0.17 (m, 2H); LCMS(M+1) : 412.30 1H-NMR (400 MHz, DMSO-d6) δ 7.68 (q, J = 4.5 Hz, 1H),39(Z)-3-methoxy-N-methyl-2-(2- 7.61 (dd, J = 7.6, 1.5 Hz, 1H), 7.44 (d, J = 7.6 Hz, 1H), 7.28 methyl-5-(5-(trifluoromethyl)- PI External 1,2,4-oxadiazol-3- (d, J = 2.4 Hz, 2H), 3.71 (s, 3H), 2.64-2.57 (m, 3H), 2.39 yl)phenoxy)acrylamide (d, J = 18.0 Hz, 3H); LCMS(M+1) : 357.9 1 (Z)-N-ethyl-3-methoxy-2-(2- H-NMR (400 MHz, DMSO-d6) δ 7.79 (t, J = 5.8 Hz, 1H), methyl-5-(5-(trifluorom 7.61 (dd, J = 7.6, 1.8 Hz, 1H), 7.43 (d, J = 7.9 Hz, 1H), 7.29 40 ethyl)- 1,2,4-oxadiazol-3- (d, J = 1.8 Hz, 1H), 7.27 (s, 1H), 3.71 (s, 3H), 3.12 (dt, J = yl)phenoxy)acrylamide 13.8, 6.6 Hz, 2H), 2.37 (s, 3H), 0.97 (t, J = 7.2 Hz, 3H); LCMS(M+1) : 372.25 1 (Z)-N-ethyl-3-methoxy-2-(2- H-NMR (400 MHz, DMSO-d6) δ 7.80 (t, J = 5.9 Hz, 1H), methyl-5-(5-(perfl 7.61 (dd, J = 7.7, 1.6 Hz, 1H), 7.44 (d, J = 7.8 Hz, 1H), 7.29 41 uoroethyl)- 1,2,4-oxadiazol-3- (d, J = 1.7 Hz, 1H), 7.27 (s, 1H), 3.71 (s, 3H), 3.15-3.08 (m, yl)phenoxy)acrylamide 2H), 2.38 (d, J = 7.1 Hz, 3H), 0.97 (t, J = 7.1 Hz, 3H); LCMS(M+1) : 422.0 (Z)-3-methoxy-N-methyl-2-(2-1H-NMR (400 MHz, DMSO-d6) δ 7.57 (dd, J = 7.6, 1.7 Hz, 42 methyl-5-(5-(perfluoroethyl)- 1H), 7.45-7.40 (m, 2H), 7.26 (d, J = 1.5 Hz, 1H), 6.62 (dd, 1,2,4-oxadiazol-3- J = 13.1, 4.8 Hz, 1H), 3.52 (s, 3H), 2.83 (d, J = 4.4 Hz, 3H), yl)phenoxy)acrylamide 2.35 (s, 3H); LCMS(M+1) : 408.1 1 (Z)-2-(5-(5-isopropyl-1,2,4- H-NMR (400 MHz, DMSO-d6) δ 7.66 (q, J = 4.5 Hz, 1H), oxadiazol 7.54 (dd, J = 7.6, 1.5 Hz, 1H), 7.37-7.35 (m, 1H), 7.26 (s, 43 -3-yl)-2- methylphenoxy)-3-methoxy-N- 1H), 7.25 (d, J = 1.5 Hz, 1H), 3.71 (s, 3H), 3.38-3.32 (m, methylacrylamide 1H), 2.64-2.59 (m, 3H), 2.34-2.30 (m, 3H), 1.37-1.31 (m, 6H); LCMS(M+1) : 332.0 1H-NMR (400 MHz, DMSO-d6) δ 7.65 (d, J = 4.6 Hz, 1H), (Z)-2-(5-(5-ethyl-1,2,4-oxadiazol- 7.54 (dd, J = 7.8, 1.5 Hz, 1H), 7.36 (d, J = 7.8 Hz, 1H), 7.26 44 3-yl)-2-methylphenoxy)-3- (s, 2H), 3.70 (s, 3H), 2.98 (q, J = 7.6 Hz, 2H), 2.61 (d, J = methoxy-N-methylacrylamide 4.6 Hz, 3H), 2.33 (d, J = 5.6 Hz, 3H), 1.31 (t, J = 7.6 Hz, 3H); LCMS(M+1) : 318.05 methyl (Z)-3-methoxy-2-(2-1H-NMR (400 MHz, DMSO-d6) δ 7.68 (s, 1H), 7.62 (dd, J 45 methyl-5-(5-(perfluoroethyl)- = 7.7, 1.6 Hz, 1H), 7.45 (d, J = 8.1 Hz, 1H), 7.26 (d, J = 1.5 1,2,4-oxadiazol-3- Hz, 1H), 3.87 (s, 3H), 3.65 (s, 3H), 2.32 (s, 3H); GCMS yl)phenoxy)acrylate (M.) : 408.1 1 methyl (Z)-2-(5-(5-cyclobutyl- H-NMR (400 MHz, DMSO-d6) δ 7.65 (s, 1H), 7.56 (dd, J 1,2, = 7.7, 1.6 Hz, 1H), 7.37 (d, J = 8.1 Hz, 1H), 7.23 (d, J = 1.5 46 4-oxadiazol-3-yl)-2- methylphenoxy)-3- Hz, 1H), 3.93-3.84 (m, 4H), 3.65 (s, 3H), 2.43-2.35 (m, methoxyacrylate 4H), 2.29 (s, 3H), 2.16-2.03 (m, 2H); LCMS (M+1) : 345.05 methyl (Z)-2-(5-(5-1H-NMR (400 MHz, DMSO-d6) δ 8.00 (s, 1H), 7.67 (s, 47 (dichloromethyl)-1,2,4-oxadiazol- 1H), 7.59 (dd, J = 7.6, 1.5 Hz, 1H), 7.42 (d, J = 8.3 Hz, 1H), 3-yl)-2-methylphenoxy)-3- 7.24 (d, J = 1.8 Hz, 1H), 3.87 (s, 3H), 3.65 (s, 3H), 2.31 (s, methoxyacrylate 3H); LCMS (M-1) : 371.00 methyl (Z)-2-(5-(5-1H-NMR (400 MHz, DMSO-d6) δ 7.66 (s, 1H), 7.57 (dd, J 48 (chloromethyl)-1,2,4-oxadiazol-3- = 7.6, 1.5 Hz, 1H), 7.40 (d, J = 7.6 Hz, 1H), 7.24 (d, J = 1.5 yl)-2-methylphenoxy)-3- Hz, 1H), 5.15 (s, 2H), 3.87 (s, 3H), 3.65 (s, 3H), 2.30 (s, methoxyacrylate 3H); GCMS (M.) : 337.9 methyl (Z)-3-methoxy-2-(5-(5-1H-NMR (400 MHz, DMSO-d6) δ 7.66 (d, J = 2.8 Hz, 1H), 49 (methoxymethyl)-1,2,4- 7.59-7.56 (m, 1H), 7.40-7.36 (m, 1H), 7.25 (d, J = 1.5 Hz, oxadiazol-3-yl)-2- 1H), 4.80 (t, J = 6.4 Hz, 2H), 3.87 (s, 3H), 3.65 (s, 3H), 3.39 methylphenoxy)acrylate (s, 3H), 2.29 (s, 3H); LCMS (M+1) : 335.05 1H-NMR (400 MHz, DMSO-d6) δ 7.65 (s, 1H), 7.56 (dd, J methyl (Z)-3-methoxy-2-(2- = 7.6, 1.5 Hz, 1H), 7.37 (d, J = 7.8 Hz, 1H), 7.23 (d, J = 1.5 50 methyl-5-(5-(pentan-3-yl)-1,2,4- Hz, 1H), 3.87 (s, 3H), 3.65 (s, 3H), 3.04-2.97 (m, 1H), 2.29 oxadiazol-3-yl)phenoxy)acrylate (s, 3H), 1.79-1.69 (m, 4H), 0.85-0.79 (m, 6H); LCMS (M+1) : 361.10 PI External 1 methyl (Z)-2-(5-(5-(2- H-NMR (400 MHz, DMSO-d6) δ 8.13 (dd, J = 7.7, 1.3 Hz, chlorophenyl)-1,2,4-oxadi 1H), 7.77-7.70 (m, 2H), 7.67-7.64 (m, 2H), 7.63-7.59 (m, 51 azol-3- yl)-2-methylphenoxy)-3- 1H), 7.43 (d, J = 8.1 Hz, 1H), 7.33 (d, J = 1.7 Hz, 1H), 3.88 methoxyacrylate (s, 3H), 3.66 (s, 3H), 2.32 (s, 3H); LCMS(M+1) : 401.00 1 methyl (Z)-2-(5-(5-(3- H-NMR (400 MHz, DMSO-d6) δ 8.02-8.00 (m, 1H), 7.96- fluorophenyl)-1,2,4 7.93 (m, 1H), 7.72 (td, J = 8.1, 5.9 Hz, 1H), 7.67-7.65 (m, 52 -oxadiazol-3- yl)-2-methylphenoxy)-3- 2H), 7.63-7.58 (m, 1H), 7.42 (d, J = 8.3 Hz, 1H), 7.32 (d, J methoxyacrylate = 1.5 Hz, 1H), 3.89 (s, 3H), 3.66 (s, 3H), 2.32 (s, 3H); LCMS(M+1) : 385.05 1 methyl (Z)-2-(5-(5-(3- H-NMR (400 MHz, DMSO-d6) δ 8.28 (t, J = 1.7 Hz, 1H), bromophenyl)-1,2,4-oxad 8.16 (dt, J = 7.9, 1.2 Hz, 1H), 7.94 (dq, J = 8.1, 1.0 Hz, 1H), 53 iazol-3- yl)-2-methylphenoxy)-3- 7.68-7.65 (m, 2H), 7.62 (t, J = 7.9 Hz, 1H), 7.42 (d, J = 8.3 methoxyacrylate Hz, 1H), 7.32 (d, J = 1.5 Hz, 1H), 3.89 (s, 3H), 3.66 (s, 3H), 2.32 (s, 3H); LCMS(M+1) : 445.0 1 methyl (Z)-2-(5-(5-(2- H-NMR (400 MHz, DMSO-d6) δ 8.19 (td, J = 7.6, 1.7 Hz, fluorophenyl) 1H), 7.80-7.78 (m, 1H), 7.67 (s, 1H), 7.66 (dd, J = 7.6, 1.5 54 -1,2,4-oxadiazol-3- yl)-2-methylphenoxy)-3- Hz, 1H), 7.56-7.47 (m, 2H), 7.42 (d, J = 8.1 Hz, 1H), 7.33 methoxyacrylate (d, J = 1.7 Hz, 1H), 3.89 (s, 3H), 3.66 (s, 3H), 2.32 (s, 3H); LCMS(M+1) : 385.30 1 methyl (Z)-2-(5-(5-(3- H-NMR (400 MHz, DMSO-d6) δ 8.13 (tt, J = 7.5, 1.4 Hz, chlorophenyl) 2H), 7.81 (dq, J = 8.1, 1.1 Hz, 1H), 7.71-7.65 (m, 3H), 7.42 55 -1,2,4-oxadiazol-3- yl)-2-methylphenoxy)-3- (d, J = 7.9 Hz, 1H), 7.32 (d, J = 1.5 Hz, 1H), 3.88 (d, J = methoxyacrylate 9.5 Hz, 3H), 3.66 (d, J = 6.4 Hz, 3H), 2.32 (s, 3H); LCMS(M+1) : 401.05 1 methyl (Z)-2-(5-(5-(2- H-NMR (400 MHz, DMSO-d6) δ 8.07-8.05 (m, 1H), 7.94- b 7.91 (m, 1H), 7.67 (s, 1H), 7.64 (ddd, J = 9.5, 4.5, 2.4 Hz, 56 romophenyl)-1,2,4-oxadiazol-3- yl)-2-methylphenoxy)-3- 3H), 7.43 (d, J = 7.8 Hz, 1H), 7.33 (d, J = 1.5 Hz, 1H), 3.88 methoxyacrylate (s, 3H), 3.66 (s, 3H), 2.32 (s, 3H); LCMS(M+1) : 445.90 1 methyl (Z)-3-methoxy-2-(2- H-NMR (400 MHz, DMSO-d6) δ 8.17-8.15 (m, 2H), 7.68- 57 methyl-5-(5-phenyl-1,2,4- 7.60 (m, 5H), 7.42 (d, J = 7.6 Hz, 1H), 7.33 (d, J = 1.5 Hz, oxadiazol-3-yl)phenoxy)acrylate 1H), 3.89 (s, 3H), 3.66 (s, 3H), 2.32 (s, 3H); LCMS(M+1) : 367.05 1 methyl (Z)-2-(5-(5-(2,3- H-NMR (400 MHz, DMSO-d6) δ 7.80 (d, J = 7.3 Hz, 1H), dimethylphenyl)- 7.67-7.64 (m, 2H), 7.49 (d, J = 7.6 Hz, 1H), 7.42 (d, J = 8.3 58 1,2,4-oxadiazol- 3-yl)-2-methylphenoxy)-3- Hz, 1H), 7.35-7.31 (m, 2H), 3.88 (s, 3H), 3.66 (s, 3H), 2.53 methoxyacrylate (s, 3H), 2.36 (s, 3H), 2.32 (s, 3H); LCMS(M+1) : 395.10 1H-NMR (400 MHz, DMSO-d6) δ 7.65 (s, 1H), 7.55 (dd, J methyl (Z)-3-methoxy-2-(2- = 7.6, 1.5 Hz, 1H), 7.37 (d, J = 7.8 Hz, 1H), 7.23 (d, J = 1.7 59 methyl-5-(5-propyl-1,2,4- Hz, 1H), 3.87 (s, 3H), 3.65 (s, 3H), 2.94 (t, J = 7.5 Hz, 2H), oxadiazol-3-yl)phenoxy)acrylate 2.29 (s, 3H), 1.78 (td, J = 14.8, 7.4 Hz, 2H), 0.96 (t, J = 7.3 Hz, 3H); LCMS (M+1) : 333.35 1H-NMR (400 MHz, DMSO-d6) δ 7.65 (s, 1H), 7.54 (dd, J methyl (Z)-2-(5-(5-cyclohexyl- = 7.6, 1.5 Hz, 1H), 7.36 (d, J = 8.1 Hz, 1H), 7.22 (d, J = 1.5 60 1,2,4-oxadiazol-3-yl)-2- Hz, 1H), 3.87 (s, 3H), 3.65 (s, 3H), 3.08 (tt, J = 11.1, 3.7 methylphenoxy)-3- Hz, 1H), 2.29 (s, 3H), 2.04 (dd, J = 13.0, 3.2 Hz, 2H), 1.80- methoxyacrylate 1.72 (m, 2H), 1.66-1.62 (m, 2H), 1.59-1.53 (m, 2H), 1.44- 1.34 (m, 2H); LCMS (M+1) : 373.10 methyl (Z)-2-(5-(5-cyclopropyl-1H-NMR (400 MHz, DMSO-d6) δ 7.62-7.66 (1H), 7.47- 61 1,2,4-oxadiazol-3-yl)-2- 7.53 (1H), 7.32-7.37 (1H), 7.17-7.21 (1H), 3.82-3.90 (3H), methylphenoxy)-3- 3.60-3.68 (3H), 2.34-2.42 (1H), 2.26-2.30 (3H), 1.22-1.29 methoxyacrylate (2H), 1.12-1.18 (2H); LCMS(M+1) : 331.3 PI External methyl (Z)-3-methoxy-2-(2-1H-NMR (400 MHz, DMSO-d6) δ 8.28 (dd, J = 6.7, 1.8 Hz, methyl-5-(5-(4- 2H), 7.98 (d, J = 8.3 Hz, 2H), 7.68-7.65 (m, 2H), 7.43 (d, J 62 ((trifluoromethyl)thio)phenyl)- = 8.3 Hz, 1H), 7.33 (d, J = 1.2 Hz, 1H), 3.89 (s, 3H), 3.66 1,2,4-oxadiazol-3- (s, 3H), 2.32 (s, 3H); LCMS(M+1) : 467 yl)phenoxy)acrylate 1H-NMR (400 MHz, CDCl3) δ 8.01 (dd, J = 8.2, 6.5 Hz, methyl (Z)-3-methoxy-2-(2- 2H), 7.75 (dd, J = 7.6, 1.5 Hz, 1H), 7.50 (d, J = 1.5 Hz, 1H), 63 methyl-5-(5-(m-tolyl)-1,2,4- 7.45-7.42 (m, 2H), 7.40-7.38 (m, 1H), 7.30 (d, J = 8.1 Hz, oxadiazol-3-yl)phenoxy)acrylate 1H), 3.90 (d, J = 5.6 Hz, 3H), 3.73 (s, 3H), 2.47 (s, 3H), 2.42 (d, J = 2.9 Hz, 3H); LCMS(M+1) : 381.2 1 methyl (Z)-2-(5-(5-(2-fluoro-6- H-NMR (400 MHz, CDCl3) δ 7.86 (dd, J = 9.2, 2.8 Hz, methylphenyl)- 1H), 7.74 (dd, J = 7.6, 1.5 Hz, 1H), 7.50 (d, J = 1.5 Hz, 1H), 64 1,2,4-oxadiazol-3- yl)-2-methylphenoxy)-3- 7.38 (s, 1H), 7.35-7.30 (m, 2H), 7.18 (td, J = 8.3, 2.9 Hz, methoxyacrylate 1H), 3.90 (s, 3H), 3.72 (s, 3H), 2.72 (s, 3H), 2.43 (s, 3H); LCMS(M+1) : 399.35 1H-NMR (400 MHz, CDCl3) δ 8.15-8.13 (m, 1H), 7.76 (dd, methyl (Z)-3-methoxy-2-(2- J = 7.9, 1.5 Hz, 1H), 7.51 (d, J = 1.5 Hz, 1H), 7.47 (td, J = 65 methyl-5-(5-(o-tolyl)-1,2,4- 7.5, 1.5 Hz, 1H), 7.38-7.34 (m, 3H), 7.31-7.29 (m, 1H), oxadiazol-3-yl)phenoxy)acrylate 3.89 (d, J = 8.3 Hz, 3H), 3.73 (d, J = 4.0 Hz, 3H), 2.77 (d, J = 11.3 Hz, 3H), 2.43 (s, 3H); LCMS(M+1) : 381.05 methyl (Z)-2-(5-(5-(4-fluoro-3-1H-NMR (400 MHz, CDCl3) δ 8.49 (dd, J = 6.5, 1.8 Hz, (trifluoromethyl)phenyl)-1,2,4- 1H), 8.41 (dq, J = 8.6, 2.2 Hz, 1H), 7.74 (dd, J = 7.8, 1.5 66 oxadiazol-3-yl)-2- Hz, 1H), 7.47 (d, J = 1.7 Hz, 1H), 7.43-7.39 (m, 2H), 7.31 methylphenoxy)-3- (d, J = 7.8 Hz, 1H), 3.91 (s, 3H), 3.73 (s, 3H), 2.43 (s, 3H); methoxyacrylate LCMS(M+1) : 453.15 1 methyl (Z)-2-(5-(5-(4- H-NMR (400 MHz, CDCl3) δ 8.15 (dt, J = 9.0, 2.1 Hz, chlorophenyl)-1,2, 2H), 7.73 (dd, J = 7.7, 1.6 Hz, 1H), 7.53 (qd, J = 4.4, 2.1 67 4-oxadiazol-3- yl)-2-methylphenoxy)-3- Hz, 2H), 7.48 (d, J = 1.5 Hz, 1H), 7.39 (s, 1H), 7.30 (d, J = methoxyacrylate 7.6 Hz, 1H), 3.89 (d, J = 9.3 Hz, 3H), 3.72 (s, 3H), 2.43 (s, 3H); LCMS(M+1) : 401.1 1 methyl (Z)-3-methoxy-2-(2- H-NMR (400 MHz, CDCl3) δ 8.09-8.07 (m, 1H), 7.94- methyl-5- 7.89 (m, 1H), 7.79-7.71 (m, 3H), 7.51 (d, J = 1.5 Hz, 1H), 68 (5-(2- (trifluoromethyl)phenyl)-1,2,4- 7.37 (s, 1H), 7.31 (d, J = 7.6 Hz, 1H), 3.89 (d, J = 6.1 Hz, oxadiazol-3-yl)phenoxy)acrylate 3H), 3.72 (s, 3H), 2.41 (d, J = 19.9 Hz, 3H); LCMS(M+1) : 435.25 methyl (Z)-2-(5-(5-benzyl-1,2,4-1H-NMR (400 MHz, CDCl3) δ 7.63 (dd, J = 7.7, 1.6 Hz, 69 oxadiazol-3-yl)-2- 1H), 7.40 (d, J = 1.7 Hz, 1H), 7.37-7.33 (m, 5H), 7.31-7.29 methylphenoxy)-3- (m, 1H), 7.24 (s, 1H), 4.27 (s, 2H), 3.87 (s, 3H), 3.70 (s, methoxyacrylate 3H), 2.40 (s, 3H); LCMS (M+1) : 381.35 methyl (Z)-2-(5-(5-(tert-butyl)-1H-NMR (400 MHz, CDCl3) δ 7.65 (dd, J = 7.6, 1.5 Hz, 70 1,2,4-oxadiazol-3-yl)-2- 1H), 7.40 (d, J = 1.5 Hz, 1H), 7.36 (s, 1H), 7.25 (s, 1H), methylphenoxy)-3- 3.88 (s, 3H), 3.70 (s, 3H), 2.40 (s, 3H), 1.47 (s, 9H); LCMS methoxyacrylate (M+1) : 347.05 methyl (Z)-2-(5-(5-(4-1H-NMR (400 MHz, CDCl3) δ 8.24-8.20 (m, 2H), 7.73 (dd, 71 fluorophenyl)-1,2,4-oxadiazol-3- J = 7.7, 1.6 Hz, 1H), 7.48 (d, J = 1.5 Hz, 1H), 7.39 (s, 1H), yl)-2-methylphenoxy)-3- 7.30 (d, J = 8.1 Hz, 1H), 7.24-7.22 (m, 2H), 3.90 (s, 3H), methoxyacrylate 3.72 (s, 3H), 2.43 (s, 3H); LCMS(M+1) : 385.1 methyl (Z)-3-methoxy-2-(2-1H-NMR (400 MHz, CDCl3) δ 7.68 (dd, J = 7.6, 1.5 Hz, 72 methyl-5-(5-(trichloromethyl)- 1H), 7.41 (d, J = 1.7 Hz, 1H), 7.38 (s, 1H), 7.31-7.29 (m, 1,2,4-oxadiazol-3- 1H), 3.90 (s, 3H), 3.72 (s, 3H), 2.42 (s, 3H); LCMS(M+1) yl)phenoxy)acrylate : 407.9 PI External 1H-NMR (400 MHz, CDCl3) δ 7.80 (dt, J = 7.7, 1.2 Hz, methyl (Z)-3-methoxy-2-(5-(5-(3- 1H), 7.75 (dd, J = 7.8, 1.7 Hz, 1H), 7.71 (q, J = 1.3 Hz, 1H), 73 methoxyphenyl)-1,2,4-oxadiazol- 7.52-7.49 (m, 1H), 7.48-7.42 (m, 1H), 7.40-7.38 (m, 1H), 3-yl)-2-methylphenoxy)acrylate 7.30 (d, J = 7.9 Hz, 1H), 7.14 (dq, J = 8.3, 1.2 Hz, 1H), 3.92-3.91 (m, 6H), 3.73 (d, J = 6.1 Hz, 3H), 2.43 (s, 3H); 1 methyl (Z)-2-(5-(5-(2,4- H-NMR (400 MHz, DMSO-d6) δ 8.17 (d, J = 8.6 Hz, 1H), dichlorophenyl 7.98 (d, J = 2.1 Hz, 1H), 7.72 (dd, J = 8.6, 2.1 Hz, 1H), 74 )-1,2,4-oxadiazol- 3-yl)-2-methylphenoxy)-3- 7.67-7.64 (m, 2H), 7.42 (d, J = 7.9 Hz, 1H), 7.32 (d, J = 1.5 methoxyacrylate Hz, 1H), 3.88 (s, 3H), 3.66 (s, 3H), 2.32 (s, 4H); LCMS(M+1) : 435 1 methyl (Z)-2-(5-(5-(4-chloro-2- H-NMR (400 MHz, DMSO-d6) δ 8.20 (t, J = 8.3 Hz, 1H), fluorophenyl)-1,2,4-oxa 7.83 (dd, J = 10.7, 2.1 Hz, 1H), 7.68 (s, 1H), 7.64 (dd, J = 75 diazol-3- yl)-2-methylphenoxy)-3- 7.6, 1.5 Hz, 1H), 7.60-7.57 (m, 1H), 7.42 (d, J = 8.3 Hz, methoxyacrylate 1H), 7.32 (d, J = 1.5 Hz, 1H), 3.89 (s, 3H), 3.66 (s, 3H), 2.32 (s, 3H); LCMS(M+1) : 419.25 1H-NMR (400 MHz, DMSO-d6) δ 8.11-8.08 (m, 2H), 7.67 methyl (Z)-3-methoxy-2-(5-(5-(4- (s, 1H), 7.64 (dd, J = 7.6, 1.5 Hz, 1H), 7.40 (d, J = 7.6 Hz, 76 methoxyphenyl)-1,2,4-oxadiazol- 1H), 7.31 (d, J = 1.7 Hz, 1H), 7.18 (dd, J = 6.8, 2.0 Hz, 2H), 3-yl)-2-methylphenoxy)acrylate 3.89 (s, 3H), 3.87 (s, 3H), 3.66 (s, 3H), 2.32 (s, 3H); LCMS(M+1) : 397 methyl (Z)-2-(5-(5-(2-chloro-6-1H-NMR (400 MHz, DMSO-d6) δ 7.81 (td, J = 8.3, 6.1 Hz, 77 fluorophenyl)-1,2,4-oxadiazol-3- 1H), 7.67-7.64 (m, 3H), 7.60-7.55 (m, 1H), 7.44 (d, J = 7.8 yl)-2-methylphenoxy)-3- Hz, 1H), 7.32 (d, J = 1.5 Hz, 1H), 3.88 (s, 3H), 3.65 (s, 3H), methoxyacrylate 2.33 (s, 3H); LCMS(M+1) : 418.95 1 methyl (Z)-2-(5-(5-(3- H-NMR (400 MHz, DMSO-d6) δ 8.58 (t, J = 1.5 Hz, 1H), cyanophenyl)-1,2,4-oxad 8.47-8.45 (m, 1H), 8.19 (dd, J = 7.9, 1.3 Hz, 1H), 7.87 (t, J 78 iazol-3- yl)-2-methylphenoxy)-3- = 8.1 Hz, 1H), 7.68-7.66 (m, 2H), 7.43 (d, J = 8.1 Hz, 1H), methoxyacrylate 7.33 (d, J = 1.5 Hz, 1H), 3.89 (s, 3H), 3.66 (s, 3H), 2.32 (s, 3H); LCMS(M+1) : 392.2 1H-NMR (400 MHz, DMSO-d6) δ 8.05 (d, J = 8.3 Hz, 2H), methyl (Z)-3-methoxy-2-(2- 7.67 (s, 1H), 7.64 (dd, J = 7.8, 1.4 Hz, 1H), 7.46 (d, J = 7.9 79 methyl-5-(5-(p-tolyl)-1,2,4- Hz, 2H), 7.41 (d, J = 7.6 Hz, 1H), 7.31 (d, J = 1.5 Hz, 1H), oxadiazol-3-yl)phenoxy)acrylate 3.89 (s, 3H), 3.66 (s, 3H), 2.42 (s, 3H), 2.32 (s, 3H); LCMS(M+1) : 381.05 1 methyl (Z)-3-methoxy-2-(2- H-NMR (400 MHz, DMSO-d6) δ 7.65 (s, 1H), 7.55 (dd, J methyl-5 = 7.8, 1.5 Hz, 1H), 7.37 (d, J = 7.8 Hz, 1H), 7.23 (d, J = 1.5 80 -(5-(2- (methylthio)ethyl)-1,2,4- Hz, 1H), 3.87 (s, 3H), 3.65 (s, 3H), 3.28 (d, J = 7.1 Hz, 2H), oxadiazol-3-yl)phenoxy)acrylate 2.95-2.90 (m, 2H), 2.29 (s, 3H), 2.10 (s, 3H); LCMS (M+1) : 365.30 methyl (Z)-3-methoxy-2-(2-1H-NMR (400 MHz, DMSO-d6) δ 8.37 (d, J = 8.3 Hz, 2H), 81 methyl-5-(5-(4- 8.03 (d, J = 8.3 Hz, 2H), 7.69-7.66 (m, 2H), 7.43 (d, J = 7.9 (trifluoromethyl)phenyl)-1,2,4- Hz, 1H), 7.33 (d, J = 1.2 Hz, 1H), 3.89 (s, 3H), 3.66 (s, 3H), oxadiazol-3-yl)phenoxy)acrylate 2.32 (s, 3H); LCMS(M+1) : 435.05 1 methyl (Z)-2-(5-(5-cyclopentyl- H-NMR (400 MHz, DMSO-d6) δ 7.64 (s, 1H), 7.54 (dd, J 1,2,4-oxadia = 7.6, 1.5 Hz, 1H), 7.36 (d, J = 7.9 Hz, 1H), 7.21 (d, J = 1.5 82 zol-3-yl)-2- methylphenoxy)-3- Hz, 1H), 3.86 (s, 3H), 3.64 (s, 3H), 3.45 (t, J = 7.9 Hz, 1H), methoxyacrylate 2.29 (s, 3H), 2.12-2.06 (m, 2H), 1.87-1.81 (m, 2H), 1.77- 1.61 (m, 4H); LCMS (M+1) : 359.05 1 methyl (Z)-3-methoxy-2-(2- H-NMR (400 MHz, DMSO-d6) δ 8.10 (dd, J = 4.9, 1.2 Hz, methyl-5-(5-(thiop 1H), 8.06 (dd, J = 3.7, 1.2 Hz, 1H), 7.67 (s, 1H), 7.62 (dd, 83 hen-2-yl)- 1,2,4-oxadiazol-3- J = 7.8, 1.5 Hz, 1H), 7.41 (d, J = 8.1 Hz, 1H), 7.35 (dd, J = yl)phenoxy)acrylate 5.0, 3.8 Hz, 1H), 7.28 (d, J = 1.5 Hz, 1H), 3.89 (s, 3H), 3.66 (s, 3H), 2.31 (s, 3H); LCMS (M+1) : 372.95 PI External 1 methyl (Z)-3-methoxy-2-(2- H-NMR (400 MHz, DMSO-d6) δ 9.31 (d, J = 1.5 Hz, 1H), 84 methyl-5-(5-(pyridin-3-yl)-1,2,4- 8.88 (dd, J = 4.8, 1.6 Hz, 1H), 8.52 (dt, J = 8.2, 2.0 Hz, 1H), oxadiazol-3-yl)phenoxy)acrylate 7.71-7.66 (m, 3H), 7.43 (d, J = 7.8 Hz, 1H), 7.34 (d, J = 1.5 Hz, 1H), 3.89 (s, 3H), 3.66 (s, 3H), 2.32 (s, 3H) methyl (Z)-3-methoxy-2-(2-1H-NMR (400 MHz, DMSO-d6) δ 9.05 (dd, J = 4.7, 1.1 Hz, methyl-5-(5-(2- 1H), 8.62 (d, J = 7.0 Hz, 1H), 8.02 (dd, J = 8.1, 4.7 Hz, 1H), 85 (trifluoromethyl)pyridin-3-yl)- 7.67-7.64 (m, 2H), 7.44 (d, J = 8.3 Hz, 1H), 7.33 (d, J = 1.5 1,2,4-oxadiazol-3- Hz, 1H), 3.87 (s, 3H), 3.65 (s, 3H), 2.33 (s, 3H); LCMS yl)phenoxy)acrylate (M+1) : 436.05 1 methyl (Z)-3-methoxy-2-(2- H-NMR (400 MHz, DMSO-d6) δ 8.87 (s, 1H), 8.36 (s, 86 methyl-5-(5-(oxazol-5-yl)-1,2,4- 1H), 7.68 (s, 1H), 7.63 (dd, J = 7.6, 1.5 Hz, 1H), 7.42 (d, J oxadiazol-3-yl)phenoxy)acrylate = 8.3 Hz, 1H), 7.29 (d, J = 1.5 Hz, 1H), 3.88 (s, 3H), 3.65 (s, 3H), 2.32 (s, 3H); LCMS (M+1) : 357.95 1 methyl (Z)-3-methoxy-2-(2- H-NMR (400 MHz, DMSO-d6) δ 9.18 (d, J = 2.1 Hz, 1H), methyl-5-( 8.40 (dd, J = 8.1, 2.3 Hz, 1H), 7.67-7.65 (m, 2H), 7.55 (d, J 87 5-(6-methylpyridin-3- yl)-1,2,4-oxadiazol-3- = 8.3 Hz, 1H), 7.42 (d, J = 8.3 Hz, 1H), 7.32 (d, J = 1.5 Hz, yl)phenoxy)acrylate 1H), 3.89 (s, 3H), 3.66 (s, 3H), 2.60 (s, 3H), 2.32 (s, 3H); LCMS (M+1) : 382.00 1 methyl (Z)-3-methoxy-2-(2- H-NMR (400 MHz, DMSO-d6) δ 7.70 (d, J = 2.0 Hz, 1H), meth 7.67 (s, 1H), 7.65 (d, J = 1.7 Hz, 1H), 7.43 (d, J = 7.6 Hz, 88 yl-5-(5-(1-methyl-1H- pyrazol-5-yl)-1,2,4-oxadiazol-3- 1H), 7.32 (d, J = 1.7 Hz, 1H), 7.20 (d, J = 2.2 Hz, 1H), 4.27 yl)phenoxy)acrylate (s, 3H), 3.88 (s, 3H), 3.66 (s, 3H), 2.32 (s, 3H); LCMS (M+1) : 371.10 methyl (Z)-3-methoxy-2-(2-1H-NMR (400 MHz, DMSO-d6) δ 8.57 (s, 1H), 7.67 (s, 89 methyl-5-(5-(2-methylthiazol-5- 1H), 7.61 (dd, J = 7.6, 1.5 Hz, 1H), 7.41 (d, J = 8.3 Hz, 1H), yl)-1,2,4-oxadiazol-3- 7.27 (d, J = 1.7 Hz, 1H), 3.88 (s, 3H), 3.65 (s, 3H), 2.80 (s, yl)phenoxy)acrylate 3H), 2.31 (s, 3H); LCMS (M+1) : 387.90 1 methyl (Z)-3-methoxy-2-(2- H-NMR (400 MHz, DMSO-d6) δ 7.96 (d, J = 4.9 Hz, 1H), methyl-5-(5-(3-methylt 7.61 (dd, J = 7.6, 1.5 Hz, 1H), 7.40 (d, J = 7.9 Hz, 1H), 7.29 90 hiophen-2- yl)-1,2,4-oxadiazol-3- (d, J = 1.2 Hz, 1H), 7.21 (d, J = 4.9 Hz, 1H), 3.89 (s, 3H), yl)phenoxy)acrylate 3.66 (s, 3H), 2.63 (s, 3H), 2.31 (s, 3H); LCMS (M+1) : 387.10 1H-NMR (400 MHz, DMSO-d6) δ 7.67 (s, 1H), 7.63 (d, J = methyl (Z)-2-(5-(5-(3- 7.6 Hz, 1H), 7.42 (d, J = 7.8 Hz, 1H), 7.31 (s, 1H), 6.89 (s, cyclopropyl-1-ethyl-1H-pyrazol- 91 1H), 4.58 (d, J = 7.1 Hz, 2H), 3.88 (s, 3H), 3.65 (s, 3H), 5-yl)-1,2,4-oxadiazol-3-yl)-2- 2.32 (s, 3H), 1.39 (t, J = 7.1 Hz, 3H), 1.16 (t, J = 7.1 Hz, methylphenoxy)-3- 1H), 0.91 (dd, J = 8.4, 2.3 Hz, 2H), 0.73 (t, J = 2.4 Hz, 2H); methoxyacrylate LCMS(M+1) : 425.5 methyl (Z)-3-methoxy-2-(2-1H-NMR (400 MHz, DMSO-d6) δ 8.47-8.45 (m, 2H), 8.43- 92 methyl-5-(5-(4-nitrophenyl)- 8.40 (m, 2H), 7.68-7.66 (m, 2H), 7.43 (d, J = 8.3 Hz, 1H), 1,2,4-oxadiazol-3- 7.34 (d, J = 1.7 Hz, 1H), 3.89 (s, 3H), 3.67 (s, 3H), 2.33 (s, yl)phenoxy)acrylate 3H); LCMS(M+1) : 412.05 methyl (Z)-2-(5-(5-(4-(tert-1H-NMR (400 MHz, DMSO-d6) δ 8.09-8.07 (m, 2H), 7.69- 93 butyl)phenyl)-1,2,4-oxadiazol-3- 7.64 (m, 4H), 7.41 (d, J = 7.6 Hz, 1H), 7.32 (d, J = 1.5 Hz, yl)-2-methylphenoxy)-3- 1H), 3.89 (s, 3H), 3.66 (s, 3H), 2.32 (s, 3H), 1.33 (s, 9H); methoxyacrylate LCMS(M+1) : 423.4 methyl (Z)-2-(5-(5-(4-1H-NMR (400 MHz, DMSO-d6) δ 7.67-7.64 (m, 2H), 7.42 (dimethylamino)phenyl)-1,2,4- (t, J = 6.9 Hz, 3H), 7.36-7.31 (m, 2H), 7.06 (s, 1H), 3.89 (s, 94 oxadiazol-3-yl)-2- 3H), 3.66 (s, 3H), 3.00 (s, 6H), 2.32 (s, 3H); LCMS(M+1) methylphenoxy)-3- : 410.05 methoxyacrylate PI External methyl (Z)-2-(5-(5-(4-1H-NMR (400 MHz, DMSO-d6) δ 8.33-8.31 (m, 2H), 8.12 95 cyanophenyl)-1,2,4-oxadiazol-3- (d, J = 8.6 Hz, 2H), 7.68-7.65 (m, 2H), 7.43 (d, J = 7.8 Hz, yl)-2-methylphenoxy)-3- 1H), 7.33 (d, J = 1.5 Hz, 1H), 3.89 (s, 3H), 3.66 (s, 3H), methoxyacrylate 2.32 (s, 3H); LCMS(M+1) : 392.1 1 methyl (Z)-2-(5-(5-(2- H-NMR (400 MHz, DMSO-d6) δ 7.65 (s, 1H), 7.56 (dd, J chloroethyl)-1,2,4-ox = 7.6, 1.5 Hz, 1H), 7.38 (d, J = 7.8 Hz, 1H), 7.24 (d, J = 1.5 96 adiazol-3- yl)-2-methylphenoxy)-3- Hz, 1H), 4.06 (t, J = 6.4 Hz, 2H), 3.87 (s, 3H), 3.65 (s, 3H), methoxyacrylate 3.51 (t, J = 6.4 Hz, 2H), 2.29 (s, 3H); LCMS (M+1) : 352.90 methyl (Z)-2-(5-(5-(4-1H-NMR (400 MHz, DMSO-d6) δ 7.68 (s, 1H), 7.66-7.63 (difluoromethyl)-2-methylthiazol- (m, 1H), 7.53 (s, 1H), 7.44-7.40 (m, 1H), 7.29 (d, J = 1.5 97 5-yl)-1,2,4-oxadiazol-3-yl)-2- Hz, 1H), 3.88 (s, 3H), 3.65 (s, 3H), 2.82 (s, 3H), 2.31 (s, methylphenoxy)-3- 3H); LCMS (M+1) : 438.30 methoxyacrylate methyl (Z)-2-(5-(5-(2-chloro-5-1H-NMR (400 MHz, DMSO-d6) δ 9.18 (dd, J = 2.4, 0.7 Hz, (trifluoromethyl)pyridin-3-yl)- 1H), 8.91 (d, J = 2.0 Hz, 1H), 7.70 (d, J = 1.5 Hz, 1H), 7.68 98 1,2,4-oxadiazol-3-yl)-2- (s, 1H), 7.44 (d, J = 8.1 Hz, 1H), 7.34 (d, J = 1.7 Hz, 1H), methylphenoxy)-3- 3.88 (s, 3H), 3.66 (s, 3H), 2.32 (s, 3H); LCMS (M+1) : methoxyacrylate 470.15 methyl (Z)-2-(5-(5-(2,4-1H-NMR (400 MHz, DMSO-d6) δ 7.67 (s, 1H), 7.60 (dd, J dimethylthiazol-5-yl)-1,2,4- = 7.7, 1.6 Hz, 1H), 7.40 (d, J = 7.6 Hz, 1H), 7.28 (d, J = 1.7 99 oxadiazol-3-yl)-2- Hz, 1H), 3.88 (s, 3H), 3.66 (s, 3H), 2.73 (d, J = 6.4 Hz, 6H), methylphenoxy)-3- 2.31 (s, 3H); LCMS (M+1) : 402.10 methoxyacrylate 1 methyl (Z)-3-methoxy-2-(2- H-NMR (400 MHz, DMSO-d6) δ 7.65 (d, J = 6.4 Hz, 1H), 7.55 (dd, J = 7.6, 1.5 Hz, 1H), 7.3 0 meth 6 (t, J = 7.2 Hz, 1H), 7.23 10 yl-5-(5-(tetrahydro-2H- pyran-4-yl)-1,2,4-oxadiazol-3- (d, J = 1.5 Hz, 1H), 3.92-3.89 (m, 1H), 3.87 (s, 3H), 3.65 yl)phenoxy)acrylate (s, 3H), 3.50-3.34 (m, 4H), 2.32-2.29 (m, 3H), 2.06-1.97 (m, 2H), 1.84-1.74 (m, 2H); LCMS(M+1) : 375.1 1H-NMR (400 MHz, DMSO-d6) δ 7.65 (s, 1H), 7.55 (dd, J methyl (Z)-3-methoxy-2-(2- = 7.6, 1.5 Hz, 1H), 7.37 (d, J = 7.9 Hz, 1H), 7.22 (d, J = 1.5 101 methyl-5-(5-(tetrahydrofuran-3- Hz, 1H), 4.05 (t, J = 8.1 Hz, 1H), 3.96-3.90 (m, 2H), 3.88- yl)-1,2,4-oxadiazol-3- 3.86 (m, 4H), 3.80-3.78 (m, 1H), 3.65 (s, 3H), 2.32-2.43 yl)phenoxy)acrylate (1H), 2.29 (s, 3H), 2.23 (d, J = 2.1 Hz, 2H); LCMS(M+1) : 361 methyl (Z)-2-(5-(5-(4,4-1H-NMR (400 MHz, DMSO-d6) δ 7.65 (s, 1H), 7.55 (dd, J difluorocyclohexyl)-1,2,4- = 7.6, 1.5 Hz, 1H), 7.37 (d, J = 7.9 Hz, 1H), 7.23 (d, J = 1.5 102 oxadiazol-3-yl)-2- Hz, 1H), 3.87 (s, 3H), 3.64 (s, 3H), 3.32-3.39 (1H), 2.29 (s, methylphenoxy)-3- 3H), 2.19-1.84 (m, 8H); LCMS(M+1) : 409.05 methoxyacrylate 1 methyl (Z)-2-(5-(5-(4- H-NMR (400 MHz, DMSO-d6) δ 8.08 (d, J = 8.6 Hz, 2H), 03 isopropyl 7.68 (s, 1H), 7.65 (dd, J = 7.6, 1.5 Hz, 1H), 7.53 (d, J = 8.3 1 phenyl)-1,2,4-oxadiazol- 3-yl)-2-methylphenoxy)-3- Hz, 2H), 7.41 (d, J = 7.9 Hz, 1H), 7.31 (d, J = 1.5 Hz, 1H), methoxyacrylate 3.89 (s, 3H), 3.66 (s, 3H), 2.32 (s, 4H), 1.25 (d, J = 7.0 Hz, 6H); LCMS(M+1) : 409.05 methyl (Z)-2-(5-(5-(5,6-1H-NMR (400 MHz, DMSO-d6) δ 9.12 (d, J = 2.1 Hz, 1H), dichloropyridin-3-yl)-1,2,4- 8.82 (d, J = 2.1 Hz, 1H), 7.67 (dd, J = 7.3, 1.8 Hz, 2H), 7.43 104 oxadiazol-3-yl)-2- (d, J = 8.3 Hz, 1H), 7.32 (d, J = 1.5 Hz, 1H), 3.89 (s, 3H), methylphenoxy)-3- 3.66 (s, 3H), 2.32 (s, 3H); LCMS (M+1) : 436.00 methoxyacrylate methyl (Z)-3-methoxy-2-(2-1H-NMR (400 MHz, DMSO-d6) δ 9.12 (d, J = 4.9 Hz, 2H), 105 methyl-5-(5-(pyrimidin-2-yl)- 7.82 (t, J = 5.0 Hz, 1H), 7.69-7.67 (m, 2H), 7.43 (d, J = 8.1 1,2,4-oxadiazol-3- Hz, 1H), 7.35 (d, J = 1.7 Hz, 1H), 3.89 (s, 3H), 3.66 (s, 3H), yl)phenoxy)acrylate 2.33 (s, 3H); LCMS (M+1) : 369.20 PI External methyl (Z)-2-(5-(5-(3,3-1H-NMR (400 MHz, DMSO-d6) δ 7.66 (s, 1H), 7.56 (dd, J difluorocyclobutyl)-1,2,4- = 7.6, 1.5 Hz, 1H), 7.38 (d, J = 7.6 Hz, 1H), 7.23 (d, J = 1.5 106 oxadiazol-3-yl)-2- Hz, 1H), 3.87-3.82 (m, 4H), 3.64 (s, 3H), 3.19-3.13 (m, methylphenoxy)-3- 2H), 3.11-3.00 (m, 2H), 2.30 (s, 3H); LCMS(M+1) : 381.1 methoxyacrylate 1H-NMR (400 MHz, DMSO-d6) δ 7.66 (d, J = 6.4 Hz, 1H), methyl (Z)-3-methoxy-2-(2- 7.55 (dd, J = 7.7, 1.6 Hz, 1H), 7.37 (d, J = 8.1 Hz, 1H), 7.23 107 methyl-5-(5-(tetrahydro-2H- (d, J = 1.5 Hz, 1H), 3.87 (s, 3H), 3.65 (s, 3H), 3.27-3.22 (m, thiopyran-4-yl)-1,2,4-oxadiazol- 1H), 2.81-2.61 (m, 4H), 2.36-2.31 (m, 2H), 2.29 (s, 3H), 3-yl)phenoxy)acrylate 1.87 (ddd, J = 24.6, 11.2, 3.2 Hz, 2H); LCMS(M+1) : 391.05 methyl (Z)-2-(5-(5-(3-fluoro-4-1H-NMR (400 MHz, DMSO-d6) δ 8.27 (d, J = 10.7 Hz, 1H), (trifluoromethyl)phenyl)-1,2,4- 8.18 (d, J = 7.9 Hz, 1H), 8.09 (t, J = 7.6 Hz, 1H), 7.67 (dd, 108 oxadiazol-3-yl)-2- J = 8.1, 2.0 Hz, 2H), 7.43 (d, J = 8.3 Hz, 1H), 7.33 (d, J = methylphenoxy)-3- 1.5 Hz, 1H), 3.89 (s, 3H), 3.66 (s, 3H), 2.32 (s, 3H); methoxyacrylate LCMS(M+1) : 452.95 1 methyl (Z)-2-(5-(5-(5-fluoro-2- H-NMR (400 MHz, DMSO-d6) δ 7.85 (dd, J = 9.3, 2.9 Hz, methylphenyl)-1,2,4-oxadiazol-3- 1H), 7.68-7.64 (m, 2H), 7.54 (dd, J = 8.6, 5.5 Hz, 1H), 7.47 109 yl)-2-methylphenoxy)-3- (td, J = 8.6, 2.8 Hz, 1H), 7.42 (d, J = 7.6 Hz, 1H), 7.34 (d, methoxyacrylate J = 1.5 Hz, 1H), 3.88 (s, 3H), 3.66 (s, 3H), 2.66-2.65 (m, 3H), 2.32 (s, 3H); LCMS(M+1) : 399 1 methyl (Z)-2-(5-(5-(4-chloro-3- H-NMR (400 MHz, DMSO-d6) δ 8.16 (dd, J = 9.5, 1.8 Hz, fluo 1H), 8.01 (dd, J = 8.4, 1.4 Hz, 1H), 7.90 (t, J = 7.9 Hz, 1H), 110 rophenyl)-1,2,4-oxadiazol-3- yl)-2-methylphenoxy)-3- 7.68-7.64 (m, 2H), 7.42 (d, J = 7.6 Hz, 1H), 7.31 (d, J = 0.9 methoxyacrylate Hz, 1H), 3.89 (s, 3H), 3.66 (s, 3H), 2.32 (s, 3H); LCMS(M+1) : 419 1 methyl (Z)-2-(5-(5-(3-chloro-4- H-NMR (400 MHz, DMSO-d6) δ 8.34 (dd, J = 6.8, 2.2 Hz, fluorophenyl)-1,2,4-o 1H), 8.19 (qd, J = 4.5, 2.2 Hz, 1H), 7.71 (t, J = 8.9 Hz, 1H), 111 xadiazol-3- yl)-2-methylphenoxy)-3- 7.67 (s, 1H), 7.65 (dd, J = 7.7, 1.6 Hz, 1H), 7.42 (d, J = 8.3 methoxyacrylate Hz, 1H), 7.31 (d, J = 1.7 Hz, 1H), 3.89 (s, 3H), 3.66 (s, 3H), 2.32 (s, 3H); LCMS (M+1) : 419 1 methyl (Z)-2-(5-(5-(3,4- H-NMR (400 MHz, DMSO-d6) δ 8.25-8.20 (m, 1H), 8.05 difluorophenyl)-1,2,4-oxa (qd, J = 4.3, 1.8 Hz, 1H), 7.77-7.71 (m, 1H), 7.68 (s, 1H), 112 diazol- 3-yl)-2-methylphenoxy)-3- 7.65 (dd, J = 7.6, 1.5 Hz, 1H), 7.42 (d, J = 7.9 Hz, 1H), 7.31 methoxyacrylate (d, J = 1.5 Hz, 1H), 3.89 (s, 3H), 3.66 (s, 3H), 2.32 (s, 3H); LCMS (M+1) : 403.05 1 methyl (Z)-2-(5-(5-(3,5- H-NMR (400 MHz, DMSO-d6) δ 7.88-7.85 (m, 2H), 7.73- difluorophe 7.68 (m, 1H), 7.68 (s, 1H), 7.65 (dd, J = 7.6, 1.5 Hz, 1H), 113 nyl)-1,2,4-oxadiazol- 3-yl)-2-methylphenoxy)-3- 7.43 (d, J = 8.3 Hz, 1H), 7.32 (d, J = 1.5 Hz, 1H), 3.89 (s, methoxyacrylate 3H), 3.66 (s, 3H), 2.32 (s, 3H); LCMS (M+18) :419.95 methyl (Z)-2-(5-(5-(4-1H-NMR (400 MHz, DMSO-d6) δ 7.69-7.57 (m, 2H), 7.40 fluorotetrahydro-2H-pyran-4-yl)- (d, J = 7.6 Hz, 1H), 7.25 (s, 1H), 3.87 (d, J = 1.5 Hz, 3H), 114 1,2,4-oxadiazol-3-yl)-2- 3.82 (d, J = 11.6 Hz, 2H), 3.72 (t, J = 10.1 Hz, 2H), 3.65 (d, methylphenoxy)-3- J = 1.2 Hz, 3H), 2.37 (dd, J = 14.4, 4.3 Hz, 1H), 2.30 (s, methoxyacrylate 3H), 2.27-2.17 (m, 3H); LCMS (M+1) : 392.95 ethyl (Z)-3-(3-((1,3-dimethoxy-3-1H-NMR (400 MHz, CDCl3) δ 7.72 (dd, J = 7.8, 1.7 Hz, 115 oxoprop-1-en-2-yl)oxy)-4- 1H), 7.45 (d, J = 1.5 Hz, 1H), 7.37 (s, 1H), 7.29 (d, J = 7.3 methylphenyl)-1,2,4-oxadiazole- Hz, 1H), 4.56 (q, J = 7.1 Hz, 2H), 3.89 (s, 3H), 3.71 (s, 3H), 5-carboxylate 2.41 (s, 3H), 1.49 (t, J = 7.2 Hz, 3H); LCMS(M+1) :363 PI External 1 methyl (Z)-3-methoxy-2-(2- H-NMR (400 MHz, CHLOROFORM-D) δ 7.65-7.61 (m, methyl-5-(5-(methylcarbamoyl) 1H), 7.40 (d, J = 1.5 Hz, 1H), 7.37 (s, 1H), 7.28 (d, J = 7.8 116 - 1,2,4-oxadiazol-3- Hz, 1H), 7.21 (d, J = 4.2 Hz, 1H), 3.88 (d, J = 3.9 Hz, 3H), yl)phenoxy)acrylate 3.72 (d, J = 5.1 Hz, 3H), 3.08 (d, J = 5.1 Hz, 3H), 2.41-2.36 (m, 3H); LCMS (M+1) : 347.2 methyl (2Z)-3-methoxy-2-(5-(5-1H-NMR (400 MHz, DMSO-d6) δ 8.18 (dd, J = 6.8, 2.0 Hz, (4-(1- 2H), 7.94-7.92 (m, 2H), 7.68 (s, 1H), 7.66 (dd, J = 7.7, 1.6 117 (methoxyimino)ethyl)phenyl)- Hz, 1H), 7.42 (d, J = 7.6 Hz, 1H), 7.32 (d, J = 1.5 Hz, 1H), 1,2,4-oxadiazol-3-yl)-2- 3.97 (s, 3H), 3.89 (s, 3H), 3.67 (s, 3H), 2.32 (s, 3H), 2.23 methylphenoxy)acrylate (s, 3H); LCMS (M+1) : 438.20 1 methyl (Z)-2-(5-(5-(4- H-NMR (400 MHz, DMSO-d6) δ 7.64 (s, 1H), 7.52 (dd, J chlorobenzyl)-1,2,4- = 7.6, 1.5 Hz, 1H), 7.44-7.39 (m, 4H), 7.38-7.26 (m, 2H), 118 oxadiazol-3- yl)-2-methylphenoxy)-3- 7.21 (d, J = 1.5 Hz, 1H), 4.42 (d, J = 7.9 Hz, 2H), 3.86 (s, methoxyacrylate 3H), 3.63 (d, J = 4.3 Hz, 3H), 3.57 (s, 1H), 2.29 (s, 3H); LCMS (M+1) : 414.90 methyl (Z)-2-(5-(5-(2-1H-NMR (400 MHz, DMSO-d6) δ 7.64 (s, 1H), 7.52-7.45 119 fluorobenzyl)-1,2,4-oxadiazol-3- (m, 2H), 7.42-7.38 (m, 1H), 7.35 (d, J = 7.6 Hz, 1H), 7.27- yl)-2-methylphenoxy)-3- 7.20 (m, 3H), 4.45 (d, J = 7.9 Hz, 2H), 3.86 (s, 3H), 3.64- methoxyacrylate 3.61 (m, 3H), 2.29 (s, 3H); LCMS (M+1) : 399.10 1 methyl (Z)-3-methoxy-2-(2- H-NMR (400 MHz, DMSO-d6) δ 7.79 (d, J = 7.9 Hz, 1H), methyl-5-(5-( 7.71 (q, J = 7.5 Hz, 2H), 7.64-7.61 (m, 2H), 7.57 (t, J = 7.5 120 2- (trifluoromethyl)benzyl)-1,2,4- Hz, 1H), 7.49 (dd, J = 7.6, 1.5 Hz, 1H), 4.58 (s, 2H), 3.85 oxadiazol-3-yl)phenoxy)acrylate (s, 3H), 3.77 (d, J = 1.2 Hz, 1H), 3.63 (s, 3H), 2.28 (s, 3H); LCMS (M+1) : 449.15 methyl (Z)-2-(5-(5-(2,4-1H-NMR (400 MHz, DMSO-d6) δ 7.70 (d, J = 2.1 Hz, 1H), 121 dichlorobenzyl)-1,2,4-oxadiazol- 7.64 (s, 1H), 7.60-7.57 (m, 1H), 7.51-7.47 (m, 2H), 7.35 (d, 3-yl)-2-methylphenoxy)-3- J = 8.3 Hz, 1H), 7.19 (d, J = 1.8 Hz, 1H), 4.53 (s, 2H), 3.85 methoxyacrylate (s, 3H), 3.64 (s, 3H), 2.28 (s, 3H); LCMS (M+1) : 448.90 methyl (Z)-2-(5-(5-(3,5-1H-NMR (400 MHz, DMSO-d6) δ 7.64 (s, 1H), 7.58 (t, J = 122 dichlorobenzyl)-1,2,4-oxadiazol- 2.0 Hz, 1H), 7.53-7.51 (m, 3H), 7.35 (t, J = 1.8 Hz, 1H), 3-yl)-2-methylphenoxy)-3- 7.21 (d, J = 1.5 Hz, 1H), 4.48 (s, 2H), 3.86 (s, 3H), 3.64 (s, methoxyacrylate 3H), 2.29 (s, 3H); LCMS (M+1) : 448.90 1 methyl (Z)-2-(5-(5-(5-bromo-2- H-NMR (400 MHz, DMSO-d6) δ 7.64 (s, 1H), 7.54 (d, J = methylbenzyl)-1,2 2.2 Hz, 1H), 7.51 (dd, J = 7.8, 1.5 Hz, 1H), 7.42 (dd, J = 123 ,4-oxadiazol-3- yl)-2-methylphenoxy)-3- 8.1, 2.2 Hz, 1H), 7.35 (d, J = 8.3 Hz, 1H), 7.19 (d, J = 8.3 methoxyacrylate Hz, 2H), 4.43 (s, 2H), 3.86 (s, 3H), 3.64 (s, 3H), 2.29 (s, 3H), 2.23 (s, 3H); LCMS (M+1) :474.75 methyl (Z)-3-methoxy-2-(2-1H-NMR (400 MHz, DMSO-d6) δ 7.64 (s, 1H), 7.57 (dd, J 124 methyl-5-(5-(2-phenylpropan-2- = 7.6, 1.5 Hz, 1H), 7.38-7.31 (m, 5H), 7.30-7.23 (m, 3H), yl)-1,2,4-oxadiazol-3- 3.86 (s, 3H), 3.64 (s, 3H), 2.30 (s, 3H), 1.81 (s, 6H); LCMS yl)phenoxy)acrylate (M+1) : 409.10 1 methyl (Z)-3-methoxy-2-(2- H-NMR (400 MHz, DMSO-d6) δ 7.64 (s, 1H), 7.55 (dd, J methyl-5-(5- = 7.6, 1.5 Hz, 1H), 7.38-7.34 (m, 5H), 7.31-7.27 (m, 1H), 125 (1-phenylethyl)- 1,2,4-oxadiazol-3- 7.22 (d, J = 1.5 Hz, 1H), 4.64 (q, J = 7.2 Hz, 1H), 3.86 (s, yl)phenoxy)acrylate 3H), 3.64 (s, 3H), 2.29 (s, 3H), 1.69 (d, J = 7.3 Hz, 3H); LCMS (M+1) : 395.20 1H-NMR (400 MHz, DMSO-d6) δ 7.64 (s, 1H), 7.53 (dd, J methyl (Z)-2-(5-(5-(4- = 7.6, 1.5 Hz, 1H), 7.36 (d, J = 7.6 Hz, 1H), 7.27 (d, J = 8.3 126 isopropylbenzyl)-1,2,4-oxadiazol- Hz, 2H), 7.22 (dd, J = 6.0, 1.7 Hz, 1H), 7.16 (d, J = 1.2 Hz, 3-yl)-2-methylphenoxy)-3- 1H), 4.35 (s, 2H), 3.86 (s, 3H), 3.64 (d, J = 3.7 Hz, 3H), methoxyacrylate 2.86 (t, J = 6.9 Hz, 1H), 2.29 (s, 3H), 1.17 (d, J = 6.7 Hz, 7H); LCMS (M+1) : 424.50 PI External 1H-NMR (400 MHz, DMSO-d6) δ 7.64 (s, 1H), 7.51 (dd, J methyl (Z)-2-(5-(5-(2,3- = 7.6, 1.5 Hz, 1H), 7.36-7.34 (m, 1H), 7.20 (d, J = 1.5 Hz, 127 dimethylbenzyl)-1,2,4-oxadiazol- 1H), 7.12-7.10 (m, 2H), 7.06 (dd, J = 8.9, 6.1 Hz, 1H), 4.41 3-yl)-2-methylphenoxy)-3- (s, 2H), 3.84 (d, J = 15.0 Hz, 3H), 3.64 (s, 3H), 2.30 (d, J = methoxyacrylate 13.1 Hz, 3H), 2.23 (d, J = 6.4 Hz, 3H), 2.16 (s, 3H); LCMS (M+1) : 409.15 1 methyl (Z)-2-(5-(5-(3,5- H-NMR (400 MHz, DMSO-d6) δ 7.65 (s, 1H), 7.53 (dd, J difluorobenzyl)-1,2,4 = 7.6, 1.5 Hz, 1H), 7.36 (d, J = 8.1 Hz, 1H), 7.23-7.15 (m, 128 -oxadiazol- 3-yl)-2-methylphenoxy)-3- 2H), 7.13-7.08 (m, 1H), 7.01 (dd, J = 8.8, 2.2 Hz, 1H), 4.48 methoxyacrylate (s, 2H), 3.86 (s, 3H), 3.64 (s, 3H), 2.29 (s, 3H); LCMS (M+1) : 417.00 1 methyl (Z)-2-(5-(5-(2,4- H-NMR (400 MHz, DMSO-d6) δ 7.64 (s, 1H), 7.55 (dd, J difluorobenzyl)-1,2 = 15.3, 8.7 Hz, 1H), 7.50 (dd, J = 7.6, 1.5 Hz, 1H), 7.35 (d, 129 ,4-oxadiazol- 3-yl)-2-methylphenoxy)-3- J = 8.1 Hz, 1H), 7.34-7.28 (m, 1H), 7.20 (d, J = 1.5 Hz, 1H), methoxyacrylate 4.45 (s, 2H), 3.86 (s, 3H), 3.64 (s, 3H), 3.60 (s, 1H), 2.28 (s, 3H); LCMS (M+1) : 417.00 1 methyl (Z)-3-methoxy-2-(2- H-NMR (400 MHz, DMSO-d6) δ 7.63 (s, 1H), 7.59 (dd, J = 7.8, 1.7 Hz, 1H), 7.51-7.47 (m, 2H), 7.45-7.32 (m, 2H), 130 methyl-5-(5-(2- (trifluoromethoxy)benzyl)-1,2,4- 7.20 (d, J = 1.5 Hz, 1H), 4.47 (s, 2H), 3.86 (d, J = 6.7 Hz, oxadiazol-3-yl)phenoxy)acrylate 3H), 3.65-3.61 (m, 4H), 2.28 (s, 3H); LCMS (M+1) : 465.00 1 methyl (Z)-2-(5-(5-(2-chloro-4- H-NMR (400 MHz, DMSO-d6) δ 9.42 (s, 1H), 8.28 (d, J = fluorobenzyl)-1,2,4-ox 7.8 Hz, 1H), 7.48 (td, J = 7.8, 1.7 Hz, 1H), 7.36-7.32 (m, 131 adiazol-3- yl)-2-methylphenoxy)-3- 2H), 7.26 (t, J = 7.8 Hz, 2H), 4.47 (s, 2H), 3.77-3.68 (m, methoxyacrylate 3H),3.65-3.61 (m, 4H), , 1.72-1.68 (m, 2H); LCMS (M+1) : 432.90 1 methyl (Z)-3-methoxy-2-(2- H-NMR (400 MHz, DMSO-d6) δ 7.65 (s, 1H), 7.56 (dd, J 132 methyl-5-(5-neopentyl-1,2,4- = 7.6, 1.5 Hz, 1H), 7.37 (d, J = 8.3 Hz, 1H), 7.24 (d, J = 1.5 oxadiazol-3-yl)phenoxy)acrylate Hz, 1H), 3.87 (s, 3H), 3.64 (s, 3H), 2.88 (s, 2H), 2.30 (s, 3H), 1.01 (s, 9H); LCMS (M+1) : 361.05 1 methyl (Z)-2-(5-(5-(4- H-NMR (400 MHz, DMSO-d6) δ 7.65 (s, 1H), 7.52 (dd, J fluorobenzyl)-1,2, = 7.7, 1.6 Hz, 1H), 7.42 (ddd, J = 12.0, 5.4, 3.2 Hz, 2H), 133 4-oxadiazol-3- yl)-2-methylphenoxy)-3- 7.36 (d, J = 8.1 Hz, 1H), 7.22-7.17 (m, 3H), 4.42 (s, 2H), methoxyacrylate 3.86 (s, 3H), 3.64 (s, 4H), 2.29 (s, 2H); LCMS (M+1) : 398.90 1H-NMR (400 MHz, DMSO-d6) δ 7.64 (s, 1H), 7.53 (dd, J methyl (Z)-3-methoxy-2-(2- = 7.8, 1.7 Hz, 1H), 7.36 (d, J = 8.6 Hz, 1H), 7.25-7.21 (m, 134 methyl-5-(5-(4-methylbenzyl)- 1H), 7.16 (d, J = 7.9 Hz, 2H), 7.11 (d, J = 3.1 Hz, 1H), 4.35 1,2,4-oxadiazol-3- (s, 2H), 3.84 (s, J = 15.0 Hz, 3H), 3.67-3.60 (s, 3H), 3.47 yl)phenoxy)acrylate (d, J = 13.4 Hz, 1H), 2.31-2.26 (m, 6H); LCMS (M+1) : 395.15 1 methyl (Z)-2-(5-(5-(4-(tert- H-NMR (400 MHz, DMSO-d6) δ 7.64 (s, 1H), 7.53 (dd, J butyl)benzyl)-1 = 7.7, 1.6 Hz, 1H), 7.38-7.35 (m, 2H), 7.28 (d, J = 8.3 Hz, 135 ,2,4-oxadiazol-3- yl)-2-methylphenoxy)-3- 2H), 7.21 (d, J = 1.5 Hz, 1H), 4.35 (s, 2H), 3.86 (s, 3H), methoxyacrylate 3.64 (s, 3H), 2.29 (s, 3H), 1.25 (s, 10H); LCMS (M+1) : 437 1 methyl (Z)-2-(5-(5-(3- H-NMR (400 MHz, DMSO-d6) δ 7.64 (s, 1H), 7.53 (dd, J fluorobenzyl)-1,2,4-oxadiazo = 7.7, 1.6 Hz, 1H), 7.41 (td, J = 8.0, 6.2 Hz, 1H), 7.36 (d, J 136 l-3- yl)-2-methylphenoxy)-3- = 8.3 Hz, 1H), 7.27-7.21 (m, 2H), 7.17-7.12 (m, 1H), 4.46 methoxyacrylate (s, 2H), 3.86 (s, 3H), 3.63 (s, J = 5.1 Hz, 4H), 2.29 (s, 3H); LCMS (M+1): 398.95137methyl (Z)-3-methoxy-2-(2- 1H-NMR (400 MHz, DMSO-d6) δ 7.62 (s, 1H), 7.48-7.45 methyl-5-(5-(1- (m, 3H), 7.41-7.33 (m, 4H), 3.85 (s, 3H), 3.63 (s, 3H), 2.28 PI External phenylcyclopropyl)-1,2,4- (s, 4H), 1.78-1.75 (dd, 2H), 1.59 (dd, J = 7.5, 4.5 Hz, 2H); oxadiazol-3-yl)phenoxy)acrylate LCMS (M+1) : 407.00 1 methyl (Z)-2-(5-(5-(2- H-NMR (400 MHz, DMSO-d6) δ 7.64 (d, J = 2.7 Hz, 1H), chlorobenzyl)-1,2,4-oxa 7.55-7.49 (m, 3H), 7.38 (dd, J = 5.7, 3.5 Hz, 2H), 7.35 (d, J 138 diazol-3- yl)-2-methylphenoxy)-3- = 8.1 Hz, 1H), 7.29 (dd, J = 5.9, 3.4 Hz, 1H), 4.52 (s, 2H), methoxyacrylate 3.85 (s, 3H), 3.64 (s, 3H), 2.29 (s, 3H); LCMS (M+1): 414.85 1 methyl (Z)-3-methoxy-2-(2- H-NMR (400 MHz, DMSO-d6) δ 7.65 (s, 1H), 7.53 (dd, J methy = 7.6, 1.5 Hz, 1H), 7.36 (d, J = 8.3 Hz, 1H), 7.26-7.22 (d, 139 l-5-(5-(3-methylbenzyl)- 1,2,4-oxadiazol-3- 2H), 7.16-7.13 (d, 1H), 7.11 (d, J = 7.6 Hz, 1H), 4.36 (s, yl)phenoxy)acrylate 2H), 3.84 (d, J = 15.3 Hz, 3H), 3.64 (s, 4H), 2.32-2.25 (m, 6H); LCMS (M+1): 395.20 1H-NMR (400 MHz, DMSO-d6) δ 7.64 (s, 1H), 7.52 (dd, J methyl (Z)-3-methoxy-2-(5-(5-(4- = 7.6, 1.5 Hz, 1H), 7.36 (d, J = 8.3 Hz, 2H), 7.28 (d, J = 8.8 140 methoxybenzyl)-1,2,4-oxadiazol- Hz, 2H), 7.21 (d, J = 1.7 Hz, 1H), 6.93-6.90 (m, 2H), 4.32 3-yl)-2-methylphenoxy)acrylate (s, 2H), 3.86 (s, 3H), 3.73 (s, 3H), 3.64 (s, 3H), 2.29 (s, 3H); LCMS (M+1):410.90 methyl (Z)-3-methoxy-2-(2-1H-NMR (400 MHz, DMSO-d6) δ 7.93-7.88 (m, 4H), 7.64 141 methyl-5-(5-(naphthalen-2- (s, 1H), 7.54-7.49 (m, 4H), 7.35 (d, J = 8.1 Hz, 1H), 4.59 ylmethyl)-1,2,4-oxadiazol-3- (s, 2H), 3.85 (s, 3H), 3.63 (s, 4H), 2.28 (s, 3H); LCMS yl)phenoxy)acrylate (M+1):430.95 1 methyl (Z)-2-(5-(5-(2,3- H-NMR (400 MHz, DMSO-d6) δ 7.64 (s, 1H), 7.51 (dd, J difluorobenzyl)-1,2,4-oxadiazol- = 7.6, 1.5 Hz, 1H), 7.46-7.39 (d, 1H), 7.36 (d, J = 7.6 Hz, 142 3-yl)-2-methylphenoxy)-3- 1H), 7.32-7.29 (d, 1H), 7.20 (d, J = 1.5 Hz, 1H), 4.52 (s, J methoxyacrylate = 11.7 Hz, 2H), 3.86 (s, 3H), 3.64 (s, 3H), 2.29 (s, 3H), 1.98 (s, 1H); LCMS (M+1): 416.95 methyl (Z)-2-(5-(5-(2-1H-NMR (400 MHz, DMSO-d6) δ 7.64 (s, 1H), 7.51-7.48 (difluoromethoxy)benzyl)-1,2,4- (m, 2H), 7.42 (td, J = 7.9, 1.7 Hz, 1H), 7.36-6.99 (m, 4H), 143 oxadiazol-3-yl)-2- 4.40 (s, 2H), 3.85 (s, 3H), 3.64 (s, 4H), 2.28 (s, 3H); LCMS methylphenoxy)-3- (M+1): 446.90 methoxyacrylate 1 methyl (Z)-2-(5-(5-(3-chloro-2- H-NMR (400 MHz, DMSO-d6) δ 7.64 (s, 1H), 7.60-7.56 fluorobenzyl)-1, (m, 1H), 7.52-7.45 (m, 1H), 7.36 (d, J = 7.8 Hz, 1H), 7.25 144 2,4-oxadiazol-3- yl)-2-methylphenoxy)-3- (td, J = 7.8, 1.0 Hz, 1H), 7.20 (d, J = 1.5 Hz, 1H), 4.53 (s, methoxyacrylate 2H), 3.86 (s, 3H), 3.64 (s, 3H), 2.29 (s, 3H), 1.98 (s, 1H); LCMS (M+1): 432.95 1H-NMR (400 MHz, DMSO-d6) δ 7.64 (s, 1H), 7.53 (dd, J = 7.6, 1.5 Hz, 1H), 7.36 (d, J = 8.3 Hz, 1H), 7.27 (d, J = 7.9 methyl (Z)-3-methoxy-2-(5-(5-(3- 145 Hz, 1H), 7.22 (d, J = 1.5 Hz, 1H), 6.96 (t, J = 2.0 Hz, 1H), methoxybenzyl)-1,2,4-oxadiazol- 6.91 (d, J = 7.6 Hz, 1H), 4.38 (s, 2H), 3.84 (s, J = 15.4 Hz, 3-yl)-2-methylphenoxy)acrylate 3H), 3.72 (s, J = 10.0 Hz, 3H), 3.66 (s, J = 13.7 Hz, 4H), 2.29 (s, 3H); LCMS (M+1): 411.10 1 methyl (Z)-3-methoxy-2-(2- H-NMR (400 MHz, DMSO-d6) δ 7.69 (d, J = 0.9 Hz, 1H), methyl-5-(5-((4-methy 7.65 (s, 1H), 7.53 (dd, J = 7.7, 1.6 Hz, 1H), 7.37 (d, J = 8.3 146 l-1H- pyrazol-1-yl)methyl)-1,2,4- Hz, 1H),7.21 (d, J = 1.5 Hz, 1H), 5.75 (s, J = 8.3 Hz, 2H), oxadiazol-3-yl)phenoxy)acrylate 3.84 (s, J = 15.4 Hz, 3H), 3.64 (s, 4H), 2.29 (s, 3H), 2.02 (s, 3H); LCMS (M+1): 385.95 1H-NMR (400 MHz, DMSO-d6) δ 7.64 (s, 1H), 7.51 (dd, J methyl (Z)-3-methoxy-2-(5-(5-(2- = 7.7, 1.6 Hz, 1H), 7.35 (d, J = 8.3 Hz, 1H), 7.31 (t, J = 7.5 147 methoxybenzyl)-1,2,4-oxadiazol- Hz, 2H), 7.20 (d, J = 1.7 Hz, 1H), 7.03 (d, J = 7.8 Hz, 1H), 3-yl)-2-methylphenoxy)acrylate 4.29 (s, 2H), 3.86 (s, 3H), 3.73 (s, 4H), 3.64 (s, 3H), 2.28 (s, 3H); LCMS (M+1): 410.95 PI External 1 methyl (Z)-2-(5-(5-(2- H-NMR (400 MHz, DMSO-d6) δ 7.64 (s, 1H), 7.51 (dd, J cyanoben = 7.7, 1.6 Hz, 1H), 7.35 (d, J = 8.3 Hz, 1H), 7.31 (t, J = 7.5 148 zyl)-1,2,4-oxadiazol-3- yl)-2-methylphenoxy)-3- Hz, 2H), 7.20 (d, J = 1.7 Hz, 1H), 7.03 (d, J = 7.8 Hz, 1H), methoxyacrylate 4.29 (s, 2H), 3.86 (s, 3H), 3.73 (s, 4H), 2.28 (s, 3H); LCMS (M+1): 404.00 1H-NMR (400 MHz, DMSO-d6) δ 9.39-9.37 (m, 1H), 8.91 methyl (Z)-3-methoxy-2-(2- (d, J = 1.7 Hz, 1H), 7.68 (s, 1H), 7.65 (dd, J = 7.6, 1.5 Hz, 149 methyl-5-(5-(thiazol-4-yl)-1,2,4- 1H), 7.42 (d, J = 7.8 Hz, 1H), 7.32 (d, J = 1.7 Hz, 1H), 3.89 oxadiazol-3-yl)phenoxy)acrylate (s, 3H), 3.66 (s, 3H), 2.32 (s, 3H); LCMS (M+1): 374.05 1 methyl (Z)-2-(5-(5-(2-chloro-5- H-NMR (400 MHz, DMSO-d6) δ 7.95 (d, J = 2.1 Hz, 1H), methylphen 7.67 (d, J = 2.8 Hz, 1H), 7.64 (d, J = 1.8 Hz, 1H), 7.54 (t, J 150 yl)-1,2,4-oxadiazol-3- yl)-2-methylphenoxy)-3- = 1.1 Hz, 1H), 7.41 (s, 1H), 7.33 (dd, J = 4.6, 1.8 Hz, 1H), methoxyacrylate 3.88 (s, 3H), 3.66 (s, 3H), 2.40 (s, 3H), 2.32 (s, 3H), 2.31 (s, 1H); LCMS (M+1): 415.15 methyl (Z)-2-(5-(5-(3-chloro-5-1H-NMR (400 MHz, DMSO-d6) δ 7.95 (d, J = 0.8 Hz, 2H), 151 methylphenyl)-1,2,4-oxadiazol-3- 7.68-7.65 (s, 2H), 7.42 (d, J = 8.3 Hz, 1H), 7.31 (s, J = 1.5 yl)-2-methylphenoxy)-3- Hz, 1H), 3.89 (s, 3H), 3.66 (s, 3H), 2.44 (d, J = 0.6 Hz, 3H), methoxyacrylate 2.32 (s, 3H); LCMS (M+1):414.90 1 methyl (Z)-2-(5-(5-(5-bromo-2- H-NMR (400 MHz, DMSO-d6) δ 8.15 (d, J = 2.4 Hz, 1H), methylphenyl)-1,2,4-oxadiazol-3- 7.76 (dd, J = 8.3, 2.1 Hz, 1H), 7.63 (dd, J = 8.1, 1.7 Hz, 152 yl)-2-methylphenoxy)-3- 2H), 7.43 (d, J = 8.6 Hz, 1H), 7.39 (d, J = 7.6 Hz, 1H), 7.30 methoxyacrylate (d, J = 1.5 Hz, 1H), 3.85 (s, 3H), 3.65 (d, J = 15.0 Hz, 3H), 2.60 (s, 3H), 2.29 (s, 3H); LCMS (M+1): 460.80 methyl (Z)-2-(5-(5-(3-chloro-4-1H-NMR (400 MHz, DMSO-d6) δ 8.64 (q, J = 1.3 Hz, 1H), (trifluoromethyl)phenyl)-1,2,4- 8.24 (q, J = 1.3 Hz, 1H), 7.86 (q, J = 2.6 Hz, 1H), 7.72 (dd, 153 oxadiazol-3-yl)-2- J = 5.2, 1.2 Hz, 1H), 7.67 (s, 1H), 7.42-7.40 (m, 1H), 7.30 methylphenoxy)-3- (d, J = 1.5 Hz, 1H), 3.89 (s, 3H), 3.65 (d, J = 5.8 Hz, 3H), methoxyacrylate 2.31 (s, 3H) : LCMS (M+1) : 373.38 methyl (Z)-2-(5-(5-((4-1H-NMR (400 MHz, DMSO-d6) δ 8.10 (d, J = 8.9 Hz, 2H), cyanophenyl)difluoromethyl)- 7.99 (d, J = 8.6 Hz, 1H), 7.65 (s, 1H), 7.55 (d, J = 7.6, 1.5 154 1,2,4-oxadiazol-3-yl)-2- Hz, 1H), 7.40 (d, J = 7.9 Hz, 1H), 7.22 (d, J = 1.5 Hz, 1H), methylphenoxy)-3- 3.86 (s, J = 3.4 Hz, 3H), 3.64 (s, J = 4.0 Hz, 3H), 3.16 (d, J methoxyacrylate = 5.5 Hz, 1H), 2.30 (s, 3H); LCMS (M+1): 441.4 methyl (Z)-2-(5-(5-(2-(4-1H-NMR (400 MHz, DMSO-d6) δ 7.64 (s, 1H), 7.58-7.49 bromophenyl)propan-2-yl)-1,2,4- (d, 2H), 7.37 (d, J = 7.9 Hz, 1H), 7.30-7.27 (d, 2H), 7.22 (d, 155 oxadiazol-3-yl)-2- J = 1.5 Hz, 1H), 3.86 (s, 3H), 3.66 (s, J = 14.7 Hz, 3H), 3.16 methylphenoxy)-3- (d, J = 5.2 Hz, 1H), 2.30 (s, 3H), 1.83-1.76 (m, 6H); LCMS methoxyacrylate (M+1): 489.00 1 methyl (Z)-2-(5-(5-(4-fluoro-3- H-NMR (400 MHz, DMSO-d6) δ 7.65 (s, 1H), 7.55 (dd, J = 7.6, 1.5 Hz, 1H), 7.40 (d, J = 7.6 Hz, 1H), 7.23 (d, J = 1.5 156 methylphenyl)-1,2,4-oxadiazol-3- yl)-2-methylphenoxy)-3- Hz, 1H), 5.34 (s, 2H), 3.87 (s, 3H), 3.73 (q, J = 7.4 Hz, 4H), methoxyacrylate 3.64 (s, 3H), 2.31 (d, J = 5.2 Hz, 3H), 1.36 (t, J = 7.3 Hz, 6H) : LCMS (M+1) : 412.56 methyl (Z)-3-methoxy-2-(2-1H-NMR (400 MHz, DMSO-d6) δ 8.20 (dt, J = 7.6, 1.3 Hz, 157 methyl-5-(5-(3- 1H), 8.06 (s, 1H), 7.84-7.75 (m, 2H), 7.68-7.65 (m, 2H), (trifluoromethoxy)phenyl)-1,2,4- 7.43 (d, J = 8.3 Hz, 1H), 7.32 (d, J = 1.5 Hz, 1H), 3.89 (s, oxadiazol-3-yl)phenoxy)acrylate 3H), 3.66 (s, 3H), 2.32 (s, 3H); LCMS (M+1) : 450.90 methyl (Z)-2-(5-(5-(2-chloro-5-1H-NMR (400 MHz, DMSO-d6) δ 7.87 (d, J = 7.3 Hz, 1H), (trifluoromethyl)phenyl)-1,2,4- 7.81-7.77 (m, 1H), 7.58 (s, 1H), 7.35 (dd, J = 8.1, 2.0 Hz, 158 oxadiazol-3-yl)-2- 1H), 7.28-7.22 (m, 2H), 7.10 (d, J = 8.3 Hz, 1H), 3.86 (s, methylphenoxy)-3- 3H), 3.64 (s, 3H), 2.32-2.27 (m, 3H), 2.18 (s, 3H) : LCMS methoxyacrylate (M+1) : 399.35 PI External methyl (Z)-2-(5-(5-(2-1H-NMR (400 MHz, DMSO-d6) δ 8.66 (s, 1H), 7.67 (s, chlorothiazol-5-yl)-1,2,4- 1H), 7.61 (dd, J = 7.6, 1.5 Hz, 1H), 7.41 (d, J = 8.3 Hz, 1H), 159 oxadiazol-3-yl)-2- 3.87 (s, J = 6.1 Hz, 4H), 3.65 (s, J = 4.0 Hz, 3H), 2.31 (s, methylphenoxy)-3- 3H); LCMS (M+1): 407.95 methoxyacrylate methyl (Z)-2-(5-(5-(1-(4-1H-NMR (400 MHz, DMSO-d6) δ 7.64 (s, 1H), 7.54 (dd, J chlorophenyl)ethyl)-1,2,4- = 7.8, 1.5 Hz, 1H), 7.44-7.40 (d, 3H), 7.39-7.36 (d, 1H), 160 oxadiazol-3-yl)-2- 7.21 (d, J = 1.5 Hz, 1H), 4.68 (q, J = 7.2 Hz, 1H), 3.86 (s, methylphenoxy)-3- 3H), 3.64 (s, 3H), 2.29 (s, 3H), 2.06 (s, 1H), 1.68 (d, J = 7.1 methoxyacrylate Hz, 3H); LCMS (M+1): 428.95 1H-NMR (400 MHz, DMSO-d6) δ 7.65 (s, 1H), 7.53 (dd, J methyl (Z)-2-(5-(5-((2,3- = 7.6, 1.5 Hz, 1H), 7.36 (d, J = 7.8 Hz, 1H), 7.21 (d, J = 1.7 dihydrobenzofuran-5-yl)methyl)- 161 Hz, 2H), 7.07 (d, J = 8.1 Hz, 1H), 6.72 (s, J = 8.1 Hz, 1H), 1,2,4-oxadiazol-3-yl)-2- 4.49 (t, J = 8.7 Hz, 2H), 4.29 (t, 2H), 3.84 (s, J = 15.6 Hz, methylphenoxy)-3- 3H), 3.64 (s, 3H), 3.14 (t, J = 8.7 Hz, 2H), 2.32-2.29 (s, methoxyacrylate 3H); LCMS (M+1): 423.05 1H-NMR (400 MHz, DMSO-d6) δ 7.64 (s, 1H), 7.53 (dd, J methyl (Z)-3-methoxy-2-(2- = 7.7, 1.6 Hz, 1H), 7.36 (d, J = 8.3 Hz, 1H), 7.22 (d, J = 1.5 methyl- Hz, 1H), 7.18 (d, J = 1.2 Hz, 2H), 7.13-7.09 (d, 1H), 4.70 162 5-(5-(1,2,3,4- tetrahydronaphthalen-1-yl)-1,2,4- (t, J = 6.2 Hz, 1H), 3.86 (s, J = 2.4 Hz, 3H), 3.64 (s, J = 3.2 oxadiazol-3-yl)phenoxy)acrylate Hz, 3H), 2.29 (s, 3H), 2.20-2.14 (m, 2H), 1.98 (s, 1H), 1.94- 1.82 (m, 3H), 1.23 (s, 1H), 1.16 (t, J = 7.2 Hz, 1H); LCMS (M+1): 423.05 1 methyl (Z)-2-(5-(5-(4-bromo-3- H-NMR (400 MHz, DMSO-d6) δ 8.11 (dd, J = 9.0, 2.0 Hz, fluorophenyl)-1,2,4-oxadiazol-3- 1H), 8.02 (dd, J = 8.3, 7.0 Hz, 1H), 7.93 (s, J = 8.3, 1.8 Hz, 163 yl)-2-methylphenoxy)-3- 1H), 7.67 (s, 1H), 7.65 (dd, J = 7.6, 1.5 Hz, 1H), 7.42 (d, J methoxyacrylate = 7.6 Hz, 1H), 3.88 (s, J = 8.6 Hz, 3H), 3.65 (s, J = 5.2 Hz, 3H), 2.32 (s, 3H); LCMS (M+1): 463.00 methyl (Z)-2-(5-(5-(3-bromo-5-1H-NMR (400 MHz, DMSO-d6) δ 8.58 (s, 1H), 8.39 (t, J = (trifluoromethyl)phenyl)-1,2,4- 1.7 Hz, 2H), 7.69 (dd, J = 7.2, 2.1 Hz, 1H), 7.43 (s, J = 8.3 164 oxadiazol-3-yl)-2- Hz, 1H), 7.32 (s, J = 1.5 Hz, 1H), 3.89 (s, 3H), 3.66 (s, 3H), methylphenoxy)-3- 2.32 (s, 3H); LCMS (M+1): 514.65 methoxyacrylate methyl (Z)-2-(5-(5-(2,2-1H-NMR (400 MHz, DMSO-d6) δ 8.19 (d, J = 1.5 Hz, 1H), difluorobenzo[d][1,3]dioxol-5- 8.07 (dd, J = 8.4, 1.7 Hz, 1H), 7.69 (d, J = 8.6 Hz, 1H), 7.67 165 yl)-1,2,4-oxadiazol-3-yl)-2- (s, 1H), 7.65 (dd, J = 7.6, 1.5 Hz, 1H), 7.42 (d, J = 8.3 Hz, methylphenoxy)-3- 1H), 7.31 (d, J = 1.5 Hz, 1H), 3.89 (s, 3H), 3.66 (s, 3H), methoxyacrylate 2.32 (s, 3H); LCMS (M+1): 447.05 methyl (Z)-2-(5-(5-(3,5-1H-NMR (400 MHz, DMSO-d6) δ 8.14 (s, J = 1.8 Hz, 1H), 166 dichlorophenyl)-1,2,4-oxadiazol- 8.03 (s, J = 2.0 Hz, 1H), 7.68-7.65 (d, 2H), 7.43 (s, J = 8.3 3-yl)-2-methylphenoxy)-3- Hz, 1H), 7.32 (s, J = 1.5 Hz, 1H), 3.89 (s, 3H), 3.66 (s, 3H), methoxyacrylate 2.32 (s, 3H); LCMS (M+1): 434.85 1 methyl (Z)-3-methoxy-2-(2- H-NMR (400 MHz, DMSO-d6) δ 7.74 (s, 1H), 7.65 (s, methyl-5-(5-(1 1H), 7.53 (dd, J = 7.9, 1.5 Hz, 1H), 7.38 (d, J = 7.6 Hz, 1H), 167 -(4-methyl-1H- pyrazol-1-yl)ethyl)-1,2,4- 7.30 (s, 1H), 6.05 (q, J = 7.0 Hz, 1H), 4.02 (q, J = 7.0 Hz, oxadiazol-3-yl)phenoxy)acrylate 1H), 3.86 (s, 3H), 3.64 (s, 3H), 2.29 (s, 3H), 2.01 (s, 3H), 1.88 (d, J = 7.0 Hz, 3H); LCMS (M+1): 399.20 methyl (Z)-2-(5-(5-(3-cyano-5-1H-NMR (400 MHz, DMSO-d6) δ 8.91 (s, 1H), 8.74 (s, (trifluoromethyl)phenyl)-1,2,4- 1H), 8.67 (s, 1H), 7.71-7.69 (d, 1H), 7.68 (s, 1H), 7.44 (d, 168 oxadiazol-3-yl)-2- J = 8.3 Hz, 1H), 7.33 (s, J = 1.5 Hz, 1H), 3.90 (s, J = 9.2 methylphenoxy)-3- Hz, 3H), 3.66 (s, 3H), 2.33 (s, 3H); LCMS (M+1): 460.95 methoxyacrylate169methyl (Z)-3-methoxy-2-(2- 1H-NMR (400 MHz, DMSO-d6) δ 8.41 (dd, J = 8.1, 1.7 Hz, methyl-5-(5-(3-oxo-2,3-dihydro- 1H), 8.28 (d, J = 1.2 Hz, 1H), 7.88 (d, J = 7.9 Hz, 1H), 7.69 PI External 1H-inden-5-yl)-1,2,4-oxadiazol-3- (s, 1H), 7.67 (dd, J = 7.8, 1.7 Hz, 1H), 7.42 (s, J = 8.3 Hz, yl)phenoxy)acrylate 1H), 7.33 (s, J = 1.5 Hz, 1H), 3.89 (s, 3H), 3.67 (s, 3H), 3.24 (t, J = 5.8 Hz, 2H), 2.76-2.73 (m, 2H), 2.32 (s, 3H); LCMS (M+1): 420.95 methyl (Z)-2-(5-(5-(3-bromo-4-1H-NMR (400 MHz, DMSO-d6) δ 8.44 (dd, J = 6.6, 2.3 Hz, 170 fluorophenyl)-1,2,4-oxadiazol-3- 1H), 8.22 (d, J = 4.4, 2.1 Hz, 1H), 7.69-7.64 (m, 3H), 7.42 yl)-2-methylphenoxy)-3- (s, J = 8.3 Hz, 1H), 7.31 (s, J = 1.5 Hz, 1H), 3.89 (s, 3H), methoxyacrylate 3.66 (s, 3H), 2.32 (s, 3H); LCMS (M+1): 462.85 1H-NMR (400 MHz, DMSO-d6) δ 7.95 (t, J = 1.5 Hz, 1H), methyl (Z)-2-(5-(5-(3-bromo-5- 7.77 (q, J = 1.2 Hz, 1H), 7.72 (t, J = 2.0 Hz, 1H), 7.67 (dd, (2,2,2-trifluoroethoxy)phenyl)- 171 J = 7.5, 1.7 Hz, 1H), 7.42 (d, J = 8.3 Hz, 1H), 7.32 (s, J = 1,2,4-oxadiazol-3-yl)-2- 1.5 Hz, 1H), 4.99 (m, J = 8.8 Hz, 2H), 3.87 (s, J = 18.3 Hz, methylphenoxy)-3- 3H), 3.68 (sd, J = 16.8 Hz, 3H), 2.32 (s, 3H); LCMS (M+1): methoxyacrylate 544.85 methyl (Z)-2-(5-(5-(2-fluoro-6-1H-NMR (400 MHz, DMSO-d6) δ 7.80 (dd, J = 7.7, 5.7 Hz, (trifluoromethyl)phenyl)-1,2,4- 1H), 7.75-7.71 (m, 2H), 7.54 (s, 1H), 7.23 (s, 2H), 6.87 (d, 172 oxadiazol-3-yl)-2- J = 28.1 Hz, 1H), 3.84 (s, 3H), 3.64 (s, 3H), 2.23 (s, 3H); methylphenoxy)-3- LCMS (M+1): 453.01 methoxyacrylate 1 methyl (Z)-3-methoxy-2-(5-(5-(3- H-NMR (400 MHz, DMSO-d6) δ 8.30 (d, J = 8.9 Hz, 1H), methoxy-5-methylphenyl) 8.14 (d, J = 8.3 Hz, 1H), 8.03 (d, J = 10.4 Hz, 1H), 7.69- 173 -1,2,4- oxadiazol-3-yl)-2- 7.67 (m, 2H), 7.44 (d, J = 7.9 Hz, 1H), 7.33 (d, J = 1.5 Hz, methylphenoxy)acrylate 1H), 3.89 (s, 3H), 3.66 (s, 3H), 2.32 (s, 3H) : LCMS (M+1) : 469.48 1 methyl (Z)-3-methoxy-2-(2- H-NMR (400 MHz, DMSO-d6) δ 8.72 (dd, J = 4.9, 1.7 Hz, methyl-5-(5 1H), 8.43 (dd, J = 8.1, 1.7 Hz, 1H), 7.67-7.65 (m, 2H), 7.51 174 -(2-methylpyridin-3- yl)-1,2,4-oxadiazol-3- (dd, J = 7.9, 5.3 Hz, 1H), 7.43 (d, J = 8.3 Hz, 1H), 7.35 (d, yl)phenoxy)acrylate J = 1.5 Hz, 1H), 3.89 (s, 3H), 3.66 (s, 3H), 2.88 (s, 3H), 2.32 (s, 3H); LCMS (M+1) : 382.10 methyl (Z)-3-methoxy-2-(2-1H-NMR (400 MHz, DMSO-d6) δ 7.97 (t, J = 2.6 Hz, 1H), 175 methyl-5-(5-(2,3,6- 7.67 (dd, J = 7.3, 1.8 Hz, 2H), 7.45 (d, J = 8.3 Hz, 1H), 7.33 trifluoropyridin-4-yl)-1,2,4- (d, J = 1.5 Hz, 1H), 3.89 (s, 3H), 3.66 (s, 3H), 2.32 (s, 3H); oxadiazol-3-yl)phenoxy)acrylate LCMS (M+1) : 422.10 1 methyl (Z)-3-methoxy-2-(2- H-NMR (400 MHz, DMSO-d6) δ 9.03 (m, J = 1.7 Hz, 1H), methyl-5-(5-(3-ni 8.82-8.81 (m, 1H), 7.72 (dd, J = 7.6, 1.5 Hz, 1H), 7.69 (s, 176 tro-5- (trifluoromethyl)phenyl)-1,2,4- 1H), 7.45 (d, J = 8.6 Hz, 1H), 7.35 (s, J = 1.5 Hz, 1H), 3.90 oxadiazol-3-yl)phenoxy)acrylate (s, 3H), 3.67 (s, 3H), 2.33-2.31 (s, 3H); LCMS (M+1): 480.10 1 methyl (Z)-2-(5-(5-(2-chloro-4- H-NMR (400 MHz, DMSO-d6) δ 8.22 (dd, J = 8.9, 6.1 Hz, fluorophenyl) 1H), 7.81 (d, J = 8.9, 2.4 Hz, 1H), 7.67 (s, 1H), 7.65 (dd, J 177 -1,2,4-oxadiazol-3- yl)-2-methylphenoxy)-3- = 7.6, 1.5 Hz, 1H), 7.54-7.50 (m, 1H), 7.42 (s, J = 8.3 Hz, methoxyacrylate 1H), 7.32 (s, J = 1.8 Hz, 1H), 3.88 (s, 3H), 3.65 (s, J = 3.4 Hz, 3H), 2.32 (s, 3H); LCMS (M+1): 418.85 methyl (Z)-2-(5-(5-(1-(4-1H-NMR (400 MHz, DMSO-d6) δ 7.62 (s, 1H), 7.51 (dd, J chlorophenyl)cyclopropyl)-1,2,4- = 6.6, 2.0 Hz, 1H), 7.47-7.43 (m, 2H), 7.34 (d, J = 7.0 Hz, 178 oxadiazol-3-yl)-2- 3H), 7.15 (d, J = 1.2 Hz, 1H), 3.86 (s, J = 6.4 Hz, 3H), 3.63 methylphenoxy)-3- (s, 3H), 2.28 (s, 3H), 1.77 (dd, J = 7.3, 4.6 Hz, 2H), 1.60 methoxyacrylate (dd, J = 7.3, 4.6 Hz, 2H); LCMS (M+1): 440.95 methyl (Z)-2-(5-(5-1H-NMR (400 MHz, DMSO-d6) δ 7.66 (s, 1H), 7.56 (dd, J (isopropoxymethyl)-1,2,4- = 7.7, 1.6 Hz, 1H), 7.38 (d, J = 8.3 Hz, 1H), 7.24 (d, J = 1.7 179 oxadiazol-3-yl)-2- Hz, 1H), 4.82 (s, 2H), 3.87 (s, 3H), 3.79-3.73 (m, 1H), 3.65 methylphenoxy)-3- (s, 3H), 2.30 (s, 3H), 1.15 (d, J = 6.1 Hz, 6H); LCMS (M+1) methoxyacrylate : 363.00 PI External methyl (Z)-2-(5-(5-(tert-1H-NMR (400 MHz, DMSO-d6) δ 7.66 (s, 1H), 7.56 (dd, J 180 butoxymethyl)-1,2,4-oxadiazol-3- = 7.6, 1.5 Hz, 1H), 7.38 (d, J = 7.8 Hz, 1H), 7.23 (d, J = 1.2 yl)-2-methylphenoxy)-3- Hz, 1H), 4.76 (s, 2H), 3.87 (s, 3H), 3.65 (s, 3H), 2.30 (s, methoxyacrylate 3H), 1.21 (s, 9H); LCMS (M+1) : 377.15 methyl (Z)-3-methoxy-2-(5-(5-(2-1H-NMR (400 MHz, DMSO-d6) δ 7.66 (s, 1H), 7.57 (dd, J 181 methoxypropan-2-yl)-1,2,4- = 7.6, 1.5 Hz, 1H), 7.38 (d, J = 8.3 Hz, 1H), 7.24 (d, J = 1.7 oxadiazol-3-yl)-2- Hz, 1H), 3.87 (s, 3H), 3.65 (s, 3H), 3.14 (s, 3H), 2.30 (s, methylphenoxy)acrylate 3H), 1.61 (s, 6H); LCMS (M+1) : 363.20 methyl (Z)-3-methoxy-2-(2-1H-NMR (400 MHz, DMSO-d6) δ 7.66 (s, 1H), 7.58 (dd, J 182 methyl-5-(5-((2,2,2- = 7.8, 1.5 Hz, 1H), 7.39 (d, J = 7.8 Hz, 1H), 7.25 (d, J = 1.5 trifluoroethoxy)methyl)-1,2,4- Hz, 1H), 5.08 (s, 2H), 4.31 (q, J = 9.2 Hz, 2H), 3.87 (s, 3H), oxadiazol-3-yl)phenoxy)acrylate 3.65 (s, 3H), 2.30 (s, 3H); LCMS (M+1) : 403.05 1H-NMR (400 MHz, DMSO-d6) δ 7.66 (s, 1H), 7.56 (dd, J methyl (Z)-2-(5-(5- = 7.6, 1.5 Hz, 1H), 7.38 (d, J = 7.8 Hz, 1H), 7.24 (d, J = 1.5 ((cyclohexyloxy)methyl)-1,2,4- 183 Hz, 1H), 4.85 (s, 2H), 3.87 (s, 3H), 3.65 (s, 3H), 3.48-3.43 oxadiazol-3-yl)-2- (m, 1H), 2.30 (s, 3H), 1.87 (d, J = 9.8 Hz, 2H), 1.66 (d, J = methylphenoxy)-3- 5.4 Hz, 2H), 1.47 (d, J = 5.4 Hz, 1H), 1.28-1.14 (m, 5H); methoxyacrylate LCMS (M+1) : 403.20 methyl (Z)-2-(5-(5-((4-1H-NMR (400 MHz, DMSO-d6) δ 7.66 (s, 1H), 7.56 (dd, J fluorophenoxy)methyl)-1,2,4- = 7.7, 1.6 Hz, 1H), 7.39 (d, J = 8.3 Hz, 1H), 7.24 (d, J = 1.7 184 oxadiazol-3-yl)-2- Hz, 1H), 7.19-7.13 (m, 2H), 7.12-7.08 (m, 2H), 5.55 (s, methylphenoxy)-3- 2H), 3.86 (s, 3H), 3.64 (s, 3H), 2.30 (s, 3H); LCMS (M+1) methoxyacrylate : 414.90 methyl (Z)-3-methoxy-2-(2-1H-NMR (400 MHz, DMSO-d6) δ 8.22 (dd, J = 6.8, 1.7 Hz, methyl-5-(5-((2-oxo-3- 1H), 8.09-8.07 (m, 1H), 7.63 (s, 1H), 7.50 (dd, J = 7.7, 1.6 185 (trifluoromethyl)pyridin-1(2H)- Hz, 1H), 7.37 (d, J = 8.1 Hz, 1H), 7.19 (d, J = 1.5 Hz, 1H), yl)methyl)-1,2,4-oxadiazol-3- 6.53 (t, J = 7.0 Hz, 1H), 5.57 (s, 2H), 3.85 (s, 3H), 3.63 (s, yl)phenoxy)acrylate 3H), 2.29 (s, 3H); LCMS (M+1) : 465.90 1 methyl (Z)-3-methoxy-2-(2- H-NMR (400 MHz, DMSO-d6) δ 7.65 (s, 1H), 7.54 (dd, J methyl-5-(5- = 7.7, 1.6 Hz, 1H), 7.38 (d, J = 8.3 Hz, 1H), 7.22 (d, J = 1.5 186 ((2-oxopiperidin-1- yl)methyl)-1,2,4-oxadiazol-3- Hz, 1H), 4.81 (s, 2H), 3.86 (s, 3H), 3.64 (s, 3H), 3.45 (t, J yl)phenoxy)acrylate = 5.9 Hz, 2H), 2.31-2.28 (m, 5H), 1.76 (dt, J = 16.9, 5.8 Hz, 4H); LCMS (M+1) : 402.10 1 methyl (Z)-3-methoxy-2-(2- H-NMR (400 MHz, DMSO-d6) δ 9.17 (s, 1H), 8.68 (d, J = methyl-5-(5 5.1 Hz, 1H), 7.67 (d, J = 7.6 Hz, 2H), 7.54 (d, J = 5.1 Hz, 187 -(4-methylpyridin-3- yl)-1,2,4-oxadiazol-3- 1H), 7.43 (d, J = 7.8 Hz, 1H), 7.35 (d, J = 1.2 Hz, 1H), 3.89 yl)phenoxy)acrylate (s, 3H), 3.66 (s, 3H), 2.70 (s, 3H), 2.32 (s, 3H); LCMS (M+1) : 381.95 methyl (Z)-2-(5-(5-(2-1H-NMR (400 MHz, DMSO-d6) δ 8.68 (q, J = 2.2 Hz, 1H), bromopyridin-3-yl)-1,2,4- 8.47 (dd, J = 7.8, 2.0 Hz, 1H), 7.73 (dd, J = 7.8, 4.6 Hz, 188 oxadiazol-3-yl)-2- 1H), 7.67-7.65 (m, 2H), 7.43 (d, J = 8.1 Hz, 1H), 7.33 (s, methylphenoxy)-3- 1H), 3.88 (s, 3H), 3.66 (s, 3H), 2.32 (s, 3H); LCMS (M+1) methoxyacrylate : 447.85 methyl (Z)-2-(5-(5-(3-chloro-5-1H-NMR (400 MHz, DMSO-d6) δ 8.47 (s, 1H), 8.35 (s, (trifluoromethyl)phenyl)-1,2,4- 1H), 8.30 (s, 1H), 7.69 (d, J = 7.5 Hz, 2H), 7.43 (d, J = 7.9 189 oxadiazol-3-yl)-2- Hz, 1H), 7.33 (d, J = 1.2 Hz, 1H), 3.89 (s, 3H), 3.66 (s, 3H), methylphenoxy)-3- 2.32 (s, 3H); LCMS (M+1) : 468.90 methoxyacrylate 1 methyl (Z)-2-(5-(5-(6- H-NMR (400 MHz, DMSO-d6) δ 9.52 (d, J = 2.2 Hz, 1H), fluoroquinolin-3-yl)-1,2,4- 9.26 (d, J = 2.0 Hz, 1H), 8.23 (dd, J = 9.3, 5.6 Hz, 1H), 8.13 190 oxadiazol-3-yl)-2- (dd, J = 9.2, 2.8 Hz, 1H), 7.91-7.87 (m, 1H), 7.71 (d, J = methylphenoxy)-3- 9.8 Hz, 2H), 7.45 (d, J = 7.6 Hz, 1H), 7.36 (d, J = 1.2 Hz, methoxyacrylate 1H), 3.90 (s, 3H), 3.68 (s, 3H), 2.33 (s, 3H); LCMS (M+1) : 436.10 PI External methyl (Z)-2-(5-(5-(6-fluoro-5-1H-NMR (400 MHz, DMSO-d6) δ 8.84 (s, 1H), 8.61-8.59 methylpyridin-3-yl)-1,2,4- (m, 1H), 7.68-7.65 (m, 2H), 7.43 (d, J = 7.6 Hz, 1H), 7.32 191 oxadiazol-3-yl)-2- (s, 1H), 3.89 (s, 3H), 3.66 (s, 3H), 2.38 (s, 3H), 2.32 (s, 3H); methylphenoxy)-3- LCMS (M+1) : 400.15 methoxyacrylate 1 methyl (Z)-3-methoxy-2-(2- H-NMR (400 MHz, DMSO-d6) δ 8.32 (s, 1H), 7.97 (d, J = methyl-5-(5-(2- 8.3 Hz, 1H), 7.75 (d, J = 7.9 Hz, 1H), 7.69-7.67 (m, 2H), 192 methyl-5- (trifluoromethyl)phenyl)-1,2,4- 7.43 (d, J = 7.9 Hz, 1H), 7.34 (d, J = 1.5 Hz, 1H), 3.89 (s, oxadiazol-3-yl)phenoxy)acrylate 3H), 3.66 (s, 3H), 2.76 (s, 3H), 2.33 (s, 3H); LCMS (M+1) : 449.05 1 methyl (Z)-2-(5-(5-(3,5- H-NMR (400 MHz, DMSO-d6) δ 7.77 (s, 2H), 7.68 (s, dimethylphenyl)-1,2 1H), 7.65 (dd, J = 7.6, 1.5 Hz, 1H), 7.41 (d, J = 8.3 Hz, 1H), 193 ,4-oxadiazol- 3-yl)-2-methylphenoxy)-3- 7.36 (s, 1H), 7.31 (d, J = 1.7 Hz, 1H), 3.89 (s, 3H), 3.66 (s, methoxyacrylate 3H), 2.39 (s, 6H), 2.32 (s, 3H); LCMS (M+1) : 395.05 methyl (Z)-2-(5-(5-(1,1-1H-NMR (400 MHz, DMSO-d6) δ 7.67 (s, 1H), 7.60 (dd, J 194 difluoroethyl)-1,2,4-oxadiazol-3- = 7.6, 1.5 Hz, 1H), 7.42 (d, J = 7.9 Hz, 1H), 7.25 (s, J = 1.5 yl)-2-methylphenoxy)-3- Hz, 1H), 3.87 (s, 3H), 3.65 (s, 3H), 2.31 (s, 3H), 2.26-2.16 methoxyacrylate (s, 3H); LCMS (M+1): 355.05 1 methyl (Z)-3-methoxy-2-(2- H-NMR (400 MHz, DMSO-d6) δ 7.66 (s, 1H), 7.56 (dd, J methyl-5-(5 = 7.7, 1.6 Hz, 1H), 7.37 (d, J = 7.8 Hz, 1H), 7.24 (d, J = 1.2 195 -((1- methylcyclopropyl)methyl)-1,2,4- Hz, 1H), 3.87 (s, 3H), 3.65 (s, 3H), 2.93 (s, 2H), 2.30 (s, oxadiazol-3-yl)phenoxy)acrylate 3H), 1.08 (s, 3H), 0.57-0.55 (m, 2H), 0.39 (dd, J = 5.7, 4.3 Hz, 2H); LCMS (M+1) : 359.15 methyl (Z)-3-methoxy-2-(2-1H-NMR (400 MHz, DMSO-d6) δ 7.67 (s, 1H), 7.59 (dd, J methyl-5-(5-(1- = 7.7, 1.3 Hz, 1H), 7.40 (d, J = 7.6 Hz, 1H), 7.25 (d, J = 1.2 196 (trifluoromethyl)cyclobutyl)- Hz, 1H), 3.87 (s, 3H), 3.65 (s, 3H), 2.84-2.72 (m, 4H), 2.31 1,2,4-oxadiazol-3- (s, 3H), 2.12 (t, J = 8.3 Hz, 2H); LCMS (M+1) : 413.05 yl)phenoxy)acrylate methyl (Z)-2-(5-(5-(4-1H-NMR (400 MHz, DMSO-d6) δ 8.30 (d, J = 8.3 Hz, 2H), (difluoromethyl)phenyl)-1,2,4- 7.85 (d, J = 8.3 Hz, 2H), 7.68-7.65 (m, 2H), 7.43 (d, J = 7.9 197 oxadiazol-3-yl)-2- Hz, 1H), 7.33-7.05 (m, 2H), 3.89 (s, 3H), 3.67 (s, 3H), 2.32 methylphenoxy)-3- (s, 3H); LCMS (M+1): 417.05 methoxyacrylate methyl (Z)-2-(5-(5-(2,4-1H-NMR (400 MHz, DMSO-d6) δ 8.26 (td, J = 8.5, 6.5 Hz, 198 difluorophenyl)-1,2,4-oxadiazol- 1H), 7.67-7.61 (m, 3H), 7.43-7.37 (d, 2H), 7.32 (d, J = 1.2 3-yl)-2-methylphenoxy)-3- Hz, 1H), 3.89 (s, 3H), 3.66 (s, 3H), 2.32 (s, 3H); LCMS methoxyacrylate (M+1) : 403.00 methyl (Z)-2-(5-(5-(3-(1-1H-NMR (400 MHz, DMSO-d6) δ 8.19 (s, 1H), 8.14 (d, J = cyanoethyl)phenyl)-1,2,4- 7.6 Hz, 1H), 7.79 (d, J = 7.6 Hz, 1H), 7.71 (d, J = 7.6 Hz, 199 oxadiazol-3-yl)-2- 1H), 7.68-7.66 (d, 2H), 7.32 (s, J = 1.5 Hz, 2), 4.54 (q, J = methylphenoxy)-3- 7.1 Hz, 1H), 3.89 (s, J = 4.9 Hz, 3H), 3.67 (s, 3H), 2.32 (s, methoxyacrylate 3H), 1.61 (d, J = 7.3 Hz, 3H); LCMS (M+1) : 420.05 1 methyl (Z)-2-(2-chloro-5-(5- H-NMR (400 MHz, DMSO-d6) δ 7.72 (s, 1H), 7.66 (d, J = 200 cyclopropyl-1,2,4-oxadiazol-3- 8.3 Hz, 1H), 7.59 (dd, J = 8.3, 1.8 Hz, 1H), 3.89 (s, 3H), yl)phenoxy)-3-methoxyacrylate 3.67 (s, 3H), 2.42-2.38 (m, 1H), 1.29-1.22 (d, 2H), 1.21- 1.14 (d, 2H); LCMS (M+1) : 350.95 methyl (Z)-2-(2-chloro-5-(5-1H-NMR (400 MHz, DMSO-d6) δ 7.73 (s, 1H), 7.70 (d, J = 201 (methoxymethyl)-1,2,4- 8.3 Hz, 1H), 7.66 (dd, J = 8.3, 1.8 Hz, 1H), 7.38 (d, J = 1.5 oxadiazol-3-yl)phenoxy)-3- Hz, 1H), 4.81 (s, 2H), 3.89 (s, 3H), 3.67 (s, 3H), 3.40 (s, methoxyacrylate 3H); LCMS (M+1) : 354.95 methyl (Z)-2-(2-chloro-5-(5-1H-NMR (400 MHz, DMSO-d6) δ 7.73 (s, 1H), 7.70 (d, J = 202 (ethoxymethyl)-1,2,4-oxadiazol- 8.3 Hz, 1H), 7.66 (dd, J = 8.3, 1.5 Hz, 1H), 7.37 (d, J = 1.8 3-yl)phenoxy)-3-methoxyacrylate PI External Hz, 1H), 4.84 (s, 2H), 3.89 (s, 3H), 3.67 (s, 3H), 3.61 (q, J = 7.0 Hz, 2H), 1.19-1.14 (m, 3H); LCMS (M+1) : 369.10 1 methyl (Z)-2-(2-chloro-5-(5- H-NMR (400 MHz, DMSO-d6) δ 7.72 (d, J = 6.1 Hz, 1H), 203 (pentan-3-yl)-1,2,4-oxadiazol-3- 7.69-7.64 (m, 2H), 7.36 (d, J = 1.5 Hz, 1H), 3.89 (s, 3H), yl)phenoxy)-3-methoxyacrylate 3.67 (s, 3H), 3.06-2.99 (m, 1H), 1.79-1.70 (m, 4H), 0.84 (q, J = 7.2 Hz, 7H); LCMS (M+1) : 380.95 1 methyl (Z)-2-(2-chloro-5-(5- H-NMR (400 MHz, DMSO-d6) δ 7.73 (d, J = 4.6 Hz, 1H), (cyclopropylmeth 7.69-7.63 (m, 2H), 7.36 (d, J = 1.7 Hz, 1H), 3.89 (s, 3H), 204 yl)-1,2,4- oxadiazol-3-yl)phenoxy)-3- 3.67 (s, 3H), 2.95 (dd, J = 12.1, 7.0 Hz, 2H), 2.66 (dd, 2H), methoxyacrylate 2.56-2.52 (m, 2H), 1.17-1.13 (m, 1H), ; LCMS (M+1) : 364.95 methyl (Z)-2-(5-(5-1H-NMR (400 MHz, DMSO-d6) δ 7.65 (s, 1H), 7.54 (dd, J (cyclohexylmethyl)-1,2,4- = 7.6, 1.5 Hz, 1H), 7.37-7.35 (m, 1H), 7.22 (d, J = 1.5 Hz, 205 oxadiazol-3-yl)-2- 1H), 3.87 (s, 3H), 3.65 (s, 3H), 2.87 (d, J = 7.0 Hz, 2H), methylphenoxy)-3- 2.29 (s, 3H), 1.81 (s, 1H), 1.68-1.58 (m, 5H), 1.24-1.01 (m, methoxyacrylate 5H); LCMS (M+1) : 387.25 methyl (Z)-2-(2-chloro-5-(5-(3-1H-NMR (400 MHz, DMSO-d6) δ 8.47 (d, J = 8.1 Hz, 1H), 206 (trifluoromethyl)phenyl)-1,2,4- 8.40 (d, 1H), 8.13 (d, J = 7.8 Hz, 1H), 7.92 (d, J = 7.8 Hz, oxadiazol-3-yl)phenoxy)-3- 1H), 7.79-7.72 (m, 3H), 7.46 (d, J = 1.7 Hz, 1H), 3.91 (s, methoxyacrylate 3H), 3.69 (s, 3H); LCMS (M+1) : 455.05 1 methyl (Z)-2-(5-(5-(cyclopent-1- H-NMR (400 MHz, DMSO-d6) δ 7.65 (s, 1H), 7.57 (dd, J en-1-yl)-1 = 7.6, 1.5 Hz, 1H), 7.38 (d, J = 8.3 Hz, 1H), 7.24 (d, J = 1.5 207 ,2,4-oxadiazol-3-yl)-2- methylphenoxy)-3- Hz, 1H), 7.03 (t, J = 2.0 Hz, 1H), 3.87 (s, 3H), 3.65 (s, 3H), methoxyacrylate 2.81-2.77 (m, 2H), 2.66-2.53 (m, 2H), 2.30 (s, 3H), 2.03 (q, J = 7.6 Hz, 2H); LCMS (M+1) : 357.20 1 methyl (Z)-2-(2-chloro-5-(5-(3- H-NMR (400 MHz, DMSO-d6) δ 8.02 (d, J = 7.6 Hz, 1H), 208 fluorophenyl)-1,2,4-oxadiazol-3- 7.96 (dd, J = 9.3, 2.3 Hz, 1H), 7.76-7.70 (m, 4H), 7.61 (dd, yl)phenoxy)-3-methoxyacrylate J = 8.4, 2.3 Hz, 1H), 7.45 (d, J = 0.9 Hz, 1H), 3.91 (s, 3H), 3.69 (s, 3H); LCMS (M+1) : 405.10 1 methyl (Z)-2-(2-chloro-5-(5-(2- H-NMR (400 MHz, DMSO-d6) δ 8.20 (dd, J = 7.6, 1.6 Hz, 209 fluorophenyl)-1,2,4-oxadiazol-3- 1H), 7.82-7.72 (m, 4H), 7.54 (dd, J = 11.0, 8.6 Hz, 1H), yl)phenoxy)-3-methoxyacrylate 7.51-7.47 (m, 1H), 3.89 (s, J = 14.7 Hz, 3H), 3.68 (s, 3H); LCMS (M+1) : 404.95 methyl (Z)-2-(2-chloro-5-(5-(2,4-1H-NMR (400 MHz, DMSO-d6) δ 8.18 (d, J = 8.6 Hz, 1H), 210 dichlorophenyl)-1,2,4-oxadiazol- 7.99 (d, J = 2.1 Hz, 1H), 7.74-7.74 (m, 4H), 7.45 (s, 1H), 3-yl)phenoxy)-3-methoxyacrylate 3.90 (s, 3H), 3.68 (s, 3H); LCMS (M+1) : 456.35 methyl (Z)-3-methoxy-2-(2-1H-NMR (400 MHz, DMSO-d6) δ 8.69 (s, 1H), 7.68 (s, 211 methyl-5-(5-(2-methylthiazol-4- 1H), 7.64 (dd, J = 7.7, 1.6 Hz, 1H), 7.41 (d, J = 7.8 Hz, 1H), yl)-1,2,4-oxadiazol-3- 7.30 (d, J = 1.5 Hz, 1H), 3.89 (s, 3H), 3.66 (s, 3H), 2.78 (s, yl)phenoxy)acrylate 3H), 2.31 (s, 3H); LCMS (M+1): 388.05 1H-NMR (400 MHz, DMSO-d6) δ 7.65 (s, 1H), 7.55 (dd, J methyl (Z)-3-methoxy-2-(5-(5-(2- = 7.6, 1.5 Hz, 1H), 7.37 (d, J = 7.8 Hz, 1H), 7.22 (d, J = 1.5 212 methoxyethyl)-1,2,4-oxadiazol-3- Hz, 1H), 3.87 (s, 3H), 3.75 (t, J = 6.1 Hz, 2H), 3.65 (s, 3H), yl)-2-methylphenoxy)acrylate 3.26-3.21 (m, 5H), 2.29 (s, 3H); LCMS (M+1) : 349.05 1 methyl (Z)-3-methoxy-2-(2- H-NMR (400 MHz, DMSO-d6) δ 7.66 (s, 1H), 7.57 (dd, J methy = 7.7, 1.6 Hz, 1H), 7.39 (d, J = 8.1 Hz, 1H), 7.35-7.30 (m, 213 l-5-(5-(phenoxymethyl)- 1,2,4-oxadiazol-3- 2H), 7.24 (d, J = 1.7 Hz, 1H), 7.08-7.05 (m, 2H), 7.03-6.99 yl)phenoxy)acrylate (m, 1H), 5.56 (s, 2H), 3.86 (s, 3H), 3.64 (s, 3H), 2.30 (s, 3H); LCMS (M+1) : 397.10 methyl (Z)-2-(5-(5-((2-1H-NMR (400 MHz, DMSO-d6) δ 7.66 (s, 1H), 7.56 (dd, J 214 fluorophenoxy)methyl)-1,2,4- = 7.7, 1.6 Hz, 1H), 7.39 (d, J = 8.1 Hz, 1H), 7.32-7.24 (m, oxadiazol-3-yl)-2- 3H), 7.17-7.13 (m, 1H), 7.03 (tdd, J = 7.8, 4.6, 1.5 Hz, 1H), PI External methylphenoxy)-3- 5.64 (s, 2H), 3.86 (s, 3H), 3.64 (s, 3H), 2.30 (s, 3H); LCMS methoxyacrylate (M+1) : 414.95 1 methyl (Z)-3-methoxy-2-(2- H-NMR (400 MHz, DMSO-d6) δ 7.66 (s, 1H), 7.55 (dd, J methyl-5-(5-((2-oxothiazolidin- = 7.6, 1.5 Hz, 1H), 7.39 (d, J = 8.1 Hz, 1H), 7.23 (d, J = 1.5 215 3- yl)methyl)-1,2,4-oxadiazol-3- Hz, 1H), 4.85 (s, 2H), 3.87 (s, 3H), 3.78 (t, J = 7.3 Hz, 2H), yl)phenoxy)acrylate 3.65 (s, 3H), 3.39 (t, J = 7.3 Hz, 2H), 2.30 (s, 3H); LCMS (M+1) : 406.00 1 methyl (Z)-3-methoxy-2-(2- H-NMR (400 MHz, DMSO-d6) δ 7.66 (s, 1H), 7.58-7.53 methyl-5-(5-((2-oxopyrroli (m, 1H), 7.38 (d, J = 8.1 Hz, 1H), 7.22 (d, J = 1.5 Hz, 1H), 216 din-1- yl)methyl)-1,2,4-oxadiazol-3- 4.77 (s, 2H), 3.86 (s, 3H), 3.64 (s, 3H), 3.46 (t, J = 7.0 Hz, yl)phenoxy)acrylate 2H), 2.32-2.25 (m, 5H), 2.03-1.95 (m, 2H); LCMS (M+1) : 388.15 1H-NMR (400 MHz, DMSO-d6) δ 7.66 (d, J = 4.2 Hz, 1H), methyl (Z)-2-(5-(5- 7.57 (dd, J = 7.7, 1.6 Hz, 1H), 7.38 (d, J = 8.3 Hz, 1H), 7.24 (cyclobutoxymethyl)-1,2,4- 217 (d, J = 1.7 Hz, 1H), 4.73 (s, 2H), 4.12-4.05 (m, 1H), 3.87 oxadiazol-3-yl)-2- (s, 3H), 3.65 (s, 3H), 2.29 (s, 3H), 2.18-2.10 (m, 2H), 1.93- methylphenoxy)-3- 1.83 (m, 2H), 1.66-1.58 (m, 1H), 1.50-1.38 (m, 1H); LCMS methoxyacrylate (M+1) : 375.25 methyl (Z)-2-(2-chloro-5-(5-(4-1H-NMR (400 MHz, DMSO-d6) δ 8.25-8.22 (m, 2H), 7.75- 218 fluorophenyl)-1,2,4-oxadiazol-3- 7.73 (d, 3H), 7.53-7.49 (m, 2H) , 3.91 (s, 3H), 3.69 (s, 3H); yl)phenoxy)-3-methoxyacrylate LCMS (M+1) : 405.05 methyl (Z)-2-(5-(5-(3-1H-NMR (400 MHz, DMSO-d6) δ 8.28 (m, J = 1.7 Hz, 1H), 219 bromophenyl)-1,2,4-oxadiazol-3- 8.18-8.15 (m, 1H), 7.96-7.91 (m, 2H), 7.77-7.72 (m, 3H), yl)-2-chlorophenoxy)-3- 3.91 (s, 3H), 3.69 (s, 3H); LCMS (M+1) : 466.90 methoxyacrylate methyl (Z)-2-(2-chloro-5-(5-(2-1H-NMR (400 MHz, DMSO-d6) δ 8.18-8.16 (m, 1H), 8.08- 220 (trifluoromethyl)phenyl)-1,2,4- 8.06 (m, 1H), 7.98-7.95 (d, 2H), 7.74 (dd, 3H), 6.01 (s, J = oxadiazol-3-yl)phenoxy)-3- 1.1 Hz, 1H), 3.90 (s, 3H), 3.68 (s, 3H),2.96 (s, 3H); LCMS methoxyacrylate (M+1) : 436.00 1 methyl (Z)-2-(2-chloro-5-(5-(p- H-NMR (400 MHz, DMSO-d6) δ 8.05 (dd, J = 6.6, 1.7 Hz, 221 tolyl)-1,2,4-oxadiazol-3- 2H), 7.75 (s, 1H), 7.73 (q, J = 1.0 Hz, 2H), 7.48-7.44 (m, yl)phenoxy)-3-methoxyacrylate 3H), 3.91 (s, 3H), 3.69 (s, 3H), 2.43 (s, 3H); LCMS (M+1) : 401.05 methyl (Z)-2-(5-(5-(6-1H-NMR (400 MHz, DMSO-d6) δ 8.55 (d, J = 9.2 Hz, 1H), chloropyridazin-3-yl)-1,2,4- 8.24 (d, J = 9.2 Hz, 1H), 7.70-7.68 (m, 2H), 7.46-7.44 (m, 222 oxadiazol-3-yl)-2- 1H), 7.36 (d, J = 1.5 Hz, 1H), 3.89 (s, 3H), 3.66 (s, 3H), methylphenoxy)-3- 2.33 (s, 3H); LCMS (M+1) : 403.00 methoxyacrylate 1 methyl (Z)-3-methoxy-2-(2- H-NMR (400 MHz, DMSO-d6) δ 7.68-7.64 (m, 3H), 7.55 methyl-5-(5-((tetrahydro (dd, J = 7.7, 1.6 Hz, 1H), 7.39 (q, J = 4.0 Hz, 2H), 7.24 (d, 223 -2H- pyran-4-yl)methyl)-1,2,4- J = 1.5 Hz, 1H), 7.19 (t, J = 7.7 Hz, 1H), 5.76 (s, 2H), 3.86 oxadiazol-3-yl)phenoxy)acrylate (s, 3H), 3.64 (s, 3H), 2.32-2.30 (m, 3H) : LCMS (M+1) : 465.71 methyl (Z)-3-methoxy-2-(2-1H-NMR (400 MHz, DMSO-d6) δ 9.22 (s, 1H), 7.68-7.65 methyl-5-(5-(2- (m, 2H), 7.43 (d, J = 8.1 Hz, 1H), 7.32 (d, J = 1.5 Hz, 1H), 224 (trifluoromethyl)thiazol-4-yl)- 3.89 (s, 3H), 3.66 (s, 3H), 2.32 (s, 3H); LCMS (M+1): 1,2,4-oxadiazol-3- 442.10 yl)phenoxy)acrylate methyl (Z)-3-methoxy-2-(2-1H-NMR (400 MHz, DMSO-d6) δ 7.68 (s, 1H), 7.64 (dd, J 225 methyl-5-(5-(3-methylisoxazol-5- = 7.7, 1.6 Hz, 1H), 7.54 (s, 1H), 7.43 (d, J = 8.3 Hz, 1H), yl)-1,2,4-oxadiazol-3- 7.30 (d, J = 1.7 Hz, 1H), 3.88 (s, 3H), 3.66 (s, 3H), 2.39 (s, yl)phenoxy)acrylate 3H), 2.32 (s, 3H); LCMS (M+1): 372.10226methyl (Z)-2-(5-(5-((3,5- 1H-NMR (400 MHz, CDCl3) δ 7.60 (dd, J = 7.7, 1.6 Hz, dimethylisoxazol-4-yl)methyl)- 1H), 7.37 (d, J = 1.7 Hz, 1H), 7.35 (s, 1H), 7.27 (s, 1H), PI External 1,2,4-oxadiazol-3-yl)-2- 3.94 (s, 2H), 3.88 (s, 3H), 3.70 (s, 3H), 2.41 (s, 3H), 2.40 methylphenoxy)-3- (s, 3H), 2.29 (s, 3H); LCMS (M+1) : 400.15 methoxyacrylate methyl (Z)-2-(5-(5-((2-1H-NMR (400 MHz, DMSO-d6) δ 7.70 (s, 1H), 7.65 (s, chlorothiazol-4-yl)methyl)-1,2,4- 1H), 7.54 (dd, J = 7.7, 1.6 Hz, 1H), 7.37 (d, J = 8.3 Hz, 1H), 227 oxadiazol-3-yl)-2- 7.22 (d, J = 1.5 Hz, 1H), 4.54 (d, J = 0.7 Hz, 2H), 3.86 (s, methylphenoxy)-3- 3H), 3.64 (s, 3H), 2.29 (s, 3H); LCMS (M+1): 422.05 methoxyacrylate 1 methyl (Z)-2-(2-chloro-5-(5-((2- H-NMR (400 MHz, DMSO-d6) δ 7.73 (s, 1H), 7.70 (d, J = fluorophenoxy)met 8.3 Hz, 1H), 7.65 (dd, J = 8.3, 2.0 Hz, 1H), 7.37 (d, J = 1.7 228 hyl)-1,2,4- oxadiazol-3-yl)phenoxy)-3- Hz, 1H), 7.32-7.25 (m, 2H), 7.17-7.13 (m, 1H), 7.03 (tdd, J methoxyacrylate = 7.8, 4.6, 1.5 Hz, 1H), 5.66 (s, 2H), 3.88 (s, 3H), 3.66 (s, 3H); LCMS (M+1): 435.05 1H-NMR (400 MHz, CHLOROFORM-D) δ 7.89-7.84 (m, 1H), 7.70 (dd, J = 7.8, 1.5 Hz, 1H), 7.62 (dd, J = 7.2, 2.1 methyl (Z)-3-methoxy-2-(2- 229 Hz, 2H), 7.46-7.40 (m, 4H), 7.37 (d, J = 6.8 Hz, 1H), 7.29 methyl-5-(5-((E)-styryl)-1,2,4- (d, J = 8.3 Hz, 1H), 7.06 (d, J = 16.4 Hz, 1H), 3.86 (d, J = oxadiazol-3-yl)phenoxy)acrylate 27.1 Hz, 3H), 3.73 (t, J = 4.4 Hz, 3H), 2.41 (d, J = 8.3 Hz, 3H); LCMS (M+1) : 392.48 methyl (Z)-2-(5-(5-(3-chloro-1-1H-NMR (400 MHz, DMSO-d6) δ 7.67 (s, 1H), 7.66-7.64 methyl-1H-pyrazol-5-yl)-1,2,4- (m, 1H), 7.43 (d, J = 7.9 Hz, 1H), 7.33 (s, 1H), 7.31 (d, J = 230 oxadiazol-3-yl)-2- 1.5 Hz, 1H), 4.23 (s, 3H), 3.88 (s, 3H), 3.66 (s, 3H), 2.32 methylphenoxy)-3- (s, 3H);LCMS (M+1) : 405.7 methoxyacrylate methyl (Z)-2-(5-(5-(4-chloro-1-1H-NMR (400 MHz, DMSO-d6) δ 8.31 (s, 1H), 7.67 (s, methyl-1H-pyrazol-3-yl)-1,2,4- 1H), 7.63 (dd, J = 7.6, 1.5 Hz, 1H), 7.41 (d, J = 7.6 Hz, 1H), 231 oxadiazol-3-yl)-2- 7.32 (d, J = 1.5 Hz, 1H), 3.99 (s, 3H), 3.88 (s, 3H), 3.66 (s, methylphenoxy)-3- 3H), 2.32 (s, 3H);LCMS (M+1) : 405.6 methoxyacrylate methyl (Z)-2-(5-(5-(2-1H-NMR (400 MHz, DMSO-d6) δ 8.14 (dd, J = 7.9, 1.3 Hz, 232 chlorophenyl)-1,2,4-oxadiazol-3- 1H), 7.78-7.70 (m, 4H), 7.62 (td, J = 7.4, 1.5 Hz, 1H), 7.56- yl)-2-fluorophenoxy)-3- 7.50 (m, 2H), 3.90 (s, 3H), 3.68 (s, 3H);LCMS (M+1) : methoxyacrylate 405.6 methyl (Z)-2-(5-(5-(3,5-1H-NMR (400 MHz, DMSO-d6) δ 7.89-7.87 (m, 2H), 7.78- 233 difluorophenyl)-1,2,4-oxadiazol- 7.69 (m, 3H), 7.57-7.48 (m, 2H), 3.91 (s, 3H), 3.68 (s, 3-yl)-2-fluorophenoxy)-3- 3H);LCMS (M+1) : 407 methoxyacrylate methyl (Z)-2-(5-(5-(4-chloro-2-1H-NMR (400 MHz, DMSO-d6) δ 8.21 (t, J = 8.2 Hz, 1H), 234 fluorophenyl)-1,2,4-oxadiazol-3- 7.84 (dd, J = 10.6, 2.1 Hz, 1H), 7.77-7.74 (m, 1H), 7.73 (s, yl)-2-fluorophenoxy)-3- 1H), 7.59 (dd, J = 8.6, 2.2 Hz, 1H), 7.56-7.48 (m, 2H), 3.90 methoxyacrylate (s, 3H), 3.68 (s, 3H);LCMS (M+1) : 423.1 methyl (Z)-2-(5-(5-(3-1H-NMR (400 MHz, DMSO-d6) δ 8.72 (d, J = 8.1 Hz, 1H), 235 bromophenyl)-1,2,4-oxadiazol-3- 8.01 (d, J = 8.1 Hz, 1H), 7.68-7.67 (m, 2H), 7.44 (d, J = 7.8 yl)-2-fluorophenoxy)-3- Hz, 1H), 7.35 (d, J = 1.5 Hz, 1H), 3.89 (s, 3H), 3.66 (s, 3H), methoxyacrylate 2.96 (s, 3H), 2.33 (s, 3H) : LCMS (M+1) : 450.45 methyl (Z)-2-(5-(5-(3-chloro-4-1H-NMR (400 MHz, DMSO-d6) δ 8.35 (dd, J = 7.1, 2.2 Hz, 236 fluorophenyl)-1,2,4-oxadiazol-3- 1H), 8.19 (qd, J = 4.4, 2.2 Hz, 1H), 7.78-7.70 (m, 3H), 7.56- yl)-2-fluorophenoxy)-3- 7.48 (m, 2H), 3.91 (s, 3H), 3.68 (s, 3H);LCMS (M+1) : methoxyacrylate 423.6 methyl (Z)-2-(5-(5-((3,3-1H-NMR (400 MHz, DMSO-d6) δ 7.65 (s, 1H), 7.54 (dd, J difluorocyclobutyl)methyl)-1,2,4- = 7.6, 1.5 Hz, 1H), 7.37 (d, J = 8.3 Hz, 1H), 7.23 (d, J = 1.5 237 oxadiazol-3-yl)-2- Hz, 1H), 3.87 (s, 3H), 3.64 (s, 3H), 3.23 (d, J = 7.3 Hz, 2H), methylphenoxy)-3- 2.82-2.71 (m, 2H), 2.66-2.57 (m, 1H), 2.47-2.39 (m, 2H), methoxyacrylate 2.29 (s, 3H); LCMS (M+1) : 400.15 PI External methyl (Z)-2-(2-chloro-5-(5-(m-1H-NMR (400 MHz, DMSO-d6) δ 7.97 (d, J = 9.2 Hz, 2H), 238 tolyl)-1,2,4-oxadiazol-3- 7.77-7.73 (m, 3H), 7.57-7.54 (m, 2H), 3.91 (s, 3H), 3.69 (s, yl)phenoxy)-3-methoxyacrylate 3H), 2.45 (s, J = 3.4 Hz, 3H); LCMS (M+1) : 401.10 methyl (Z)-2-(2-chloro-5-(5-(4-1H-NMR (400 MHz, DMSO-d6) δ 8.31-8.27 (m, 2H), 7.99 239 ((trifluoromethyl)thio)phenyl)- (d, J = 8.3 Hz, 2H), 7.78-7.72 (m, 3H), 7.62-7.60 1,2,4-oxadiazol-3-yl)phenoxy)-3- (s,1H),3.91 (s, 3H), 3.69 (s, 3H); LCMS (M+1) : 486.95 methoxyacrylate methyl (Z)-2-(2-chloro-5-(5-(2-1H-NMR (400 MHz, DMSO-d6) δ 7.82 (d, J = 8.4, 6.1 Hz, 240 chloro-6-fluorophenyl)-1,2,4- 1H), 7.74-7.73 (m, 3H), 7.68-7.65 (m, 1H), 7.61-7.56 (m, oxadiazol-3-yl)phenoxy)-3- 1H), 7.54-7.51(s,1H), 3.90 (s, 3H), 3.67 (s, 3H); LCMS methoxyacrylate (M+1) : 438.85 methyl (Z)-2-(2-chloro-5-(5-(5-1H-NMR (400 MHz, DMSO-d6) δ 7.86 (dd, J = 9.4, 2.8 Hz, 241 fluoro-2-methylphenyl)-1,2,4- 1H), 7.77-7.72 (m, 3H), 7.55 (dd, J = 8.6, 5.6 Hz, 1H), 7.49 oxadiazol-3-yl)phenoxy)-3- (dd, J = 8.4, 2.8 Hz, 1H), 7.47-7.46 (m, 1H), 3.90 (s, 3H), methoxyacrylate 3.68 (s, 3H), 2.65 (s, 3H); LCMS (M+1) : 418.85 methyl (Z)-2-(5-(5-(4-1H-NMR (400 MHz, DMSO-d6) δ 8.11-8.07 (m, 2H), 7.88 242 bromophenyl)-1,2,4-oxadiazol-3- (dt, J = 9.0, 2.1 Hz, 2H), 7.75-7.71 (m, 3H), 7.45 (t, J = 0.6 yl)-2-chlorophenoxy)-3- Hz, 1H), 3.91 (s, 3H), 3.68 (s, 3H); LCMS (M+18) : 466.80 methoxyacrylate 1 methyl (Z)-2-(2-chloro-5-(5- H-NMR (400 MHz, DMSO-d6) δ 7.82 (td, J = 8.4, 6.1 Hz, 243 phenyl-1,2,4-oxadiazol-3- 1H), 7.74-7.73 (m, 3H), 7.68-7.65 (d, 2H), 7.61-7.56 (d, yl)phenoxy)-3-methoxyacrylate 2H), 7.45 (s, J = 1.1 Hz, 1H), 3.90 (s, 3H), 3.67 (s, 3H); LCMS (M+1) : 386.90 1 methyl (Z)-2-(2-chloro-5-(5-(3- H-NMR (400 MHz, DMSO-d6) δ 7.76-7.71 (m, 4H), 7.63 244 methoxyphenyl)-1,2,4-oxadiazol- (d, J = 1.4 Hz, 1H), 7.58 (s, J = 8.1 Hz, 1H), 7.45 (d, J = 1.5 3-yl)phenoxy)-3-methoxyacrylate Hz, 1H), 7.31 (d, J = 8.4, 2.6, 0.8 Hz, 1H), 3.91 (s, 3H), 3.88 (s, 3H), 3.69 (s, 3H); LCMS (M+1) : 416.95 1 methyl (Z)-2-(2-chloro-5-(5-(4- H-NMR (400 MHz, DMSO-d6) δ 8.07 (d, J = 7.6, 1.2 Hz, 245 chlorophenyl)-1,2,4-oxadiazol-3- 1H), 7.76-7.71 (m, 3H), 7.60 (d, J = 7.5, 1.2 Hz, 1H), 7.50- yl)phenoxy)-3-methoxyacrylate 7.44 (m, 3H), 3.91 (s, 3H), 3.68 (s, 3H); LCMS (M+1) : 422.45 1 methyl (Z)-2-(2-chloro-5-(5-(2- H-NMR (400 MHz, DMSO-d6) δ 8.24 (d, J = 10.6, 7.6, 2.2 246 chlorophenyl)-1,2,4-oxadiazol-3- Hz, 1H), 8.06 (d, J = 4.2, 1.7 Hz, 1H), 7.78-7.72 (m, 4H), yl)phenoxy)-3-methoxyacrylate 7.44 (dd, J = 1.1 Hz, 2H), 3.91 (s, 3H), 3.68 (s, 3H); LCMS (M+1) : 423.10 methyl (Z)-2-(2-chloro-5-(5-(3,4-1H-NMR (400 MHz, DMSO-d6) δ 8.15 (d, J = 7.8, 1.5 Hz, 247 dichlorophenyl)-1,2,4-oxadiazol- 1H), 7.78-7.70 (m, 5H), 7.62 (d, J = 7.5, 1.5 Hz, 1H), 3.90 3-yl)phenoxy)-3-methoxyacrylate (s, 3H), 3.68 (s, 3H); LCMS (M+1) : 424.45 methyl (Z)-2-(2-chloro-5-(5-(o-1H-NMR (400 MHz, DMSO-d6) δ 8.17 (dd, J = 6.7, 2.1 Hz, 248 tolyl)-1,2,4-oxadiazol-3- 2H), 7.75-7.73 (m, 5H), 7.45 (d, J = 0.7 Hz, 1H), 3.91 (s, yl)phenoxy)-3-methoxyacrylate 3H), 3.68 (s, 3H), 2.06 (s, 3H); LCMS (M+1) : 402.00 methyl (Z)-2-(5-(5-(3,4-1H-NMR (400 MHz, DMSO-d6) δ 8.26-8.21 (m, 1H), 8.07- 249 difluorophenyl)-1,2,4-oxadiazol- 8.04 (m, 1H), 7.78-7.71 (m, 3H), 7.56-7.48 (m, 2H), 3.91 3-yl)-2-fluorophenoxy)-3- (s, 3H), 3.68 (s, 3H);LCMS (M+1) : 407.1 methoxyacrylate methyl (Z)-2-(5-(5-(4,6-1H-NMR (400 MHz, DMSO-d6) δ 9.05 (s, 1H), 7.66 (d, J = dimethylpyridin-3-yl)-1,2,4- 9.0 Hz, 2H), 7.42 (d, J = 8.1 Hz, 2H), 7.34 (s, 1H), 3.88 (s, 250 oxadiazol-3-yl)-2- 3H), 3.66 (s, 3H), 2.66 (s, 3H), 2.54 (s, 3H), 2.32 (s, 3H); methylphenoxy)-3- LCMS (M+1) : 396.25 methoxyacrylate251methyl (Z)-2-(5-(5-(5- 1H-NMR (400 MHz, DMSO-d6) δ 9.19 (s, 1H), 8.93 (d, J = fluoropyridin-3-yl)-1,2,4- 2.9 Hz, 1H), 8.49-8.46 (m, 1H), 7.68-7.66 (m, 2H), 7.44 (d, PI External oxadiazol-3-yl)-2- J = 8.1 Hz, 1H), 7.33 (d, J = 1.5 Hz, 1H), 3.89 (s, 3H), 3.66 methylphenoxy)-3- (s, 3H), 2.32 (s, 3H); LCMS (M+1) : 386.10 methoxyacrylate methyl (Z)-2-(5-(5-(5-1H-NMR (400 MHz, DMSO-d6) δ 9.25 (d, J = 1.8 Hz, 1H), chloropyridin-3-yl)-1,2,4- 8.97 (d, J = 2.4 Hz, 1H), 8.63 (t, J = 2.1 Hz, 1H), 7.69-7.66 252 oxadiazol-3-yl)-2- (m, 2H), 7.44 (d, J = 7.9 Hz, 1H), 7.33 (d, J = 1.5 Hz, 1H), methylphenoxy)-3- 3.89 (s, 3H), 3.66 (s, 3H), 2.32 (s, 3H); LCMS (M+1) : methoxyacrylate 401.95 methyl (Z)-2-(5-(5-(2-chloro-5-1H-NMR (400 MHz, DMSO-d6) δ 8.82 (d, J = 2.9 Hz, 1H), fluoropyridin-3-yl)-1,2,4- 8.59 (dd, J = 8.1, 2.9 Hz, 1H), 7.67-7.65 (m, 2H), 7.44 (d, J 253 oxadiazol-3-yl)-2- = 7.8 Hz, 1H), 7.33 (d, J = 1.5 Hz, 1H), 3.88 (s, 3H), 3.66 methylphenoxy)-3- (s, 3H), 2.32 (s, 3H); LCMS (M+1) : 420.00 methoxyacrylate methyl (Z)-2-(5-(5-(2-1H-NMR (400 MHz, DMSO-d6) δ 9.32 (s, 1H), 8.31 (dd, J chloroquinolin-3-yl)-1,2,4- = 8.6, 0.6 Hz, 1H), 8.09 (d, J = 7.9 Hz, 1H), 8.04-8.00 (m, 254 oxadiazol-3-yl)-2- 1H), 7.83-7.79 (m, 1H), 7.71-7.68 (m, 2H), 7.46-7.44 (m, methylphenoxy)-3- 1H), 7.37 (d, J = 1.5 Hz, 1H), 3.90 (s, 3H), 3.67 (s, 3H), methoxyacrylate 2.33 (s, 3H); LCMS (M+1) : 451.95 1 methyl (Z)-3-methoxy-2-(2- H-NMR (400 MHz, DMSO-d6) δ 8.22 (q, J = 1.1 Hz, 1H), methyl-5-(5-((3- 7.65 (s, 1H), 7.53 (dd, J = 7.6, 1.5 Hz, 1H), 7.38 (d, J = 8.3 255 (trifluoromethyl)- 1H-pyrazol-1-yl)methyl)-1,2,4- Hz, 1H), 7.21 (d, J = 1.5 Hz, 1H), 6.85 (d, J = 2.0 Hz, 1H), oxadiazol-3-yl)phenoxy)acrylate 6.01 (s, 2H), 3.86 (s, 3H), 3.64 (s, 3H), 2.29 (s, 3H); LCMS (M-1) : 437.00 methyl (Z)-2-(5-(5-((1H-1H-NMR (400 MHz, DMSO-d6) δ 8.13-8.11 (m, 1H), 7.93 benzo[d][1,2,3]triazol-1- (dd, J = 7.6, 1.0 Hz, 1H), 7.64-7.60 (m, 2H), 7.49-7.45 (m, 256 yl)methyl)-1,2,4-oxadiazol-3-yl)- 2H), 7.34 (d, J = 8.1 Hz, 1H), 7.16 (d, J = 1.7 Hz, 1H), 6.57 2-methylphenoxy)-3- (s, 2H), 3.82 (s, 3H), 3.62 (s, 3H), 2.27 (s, 3H); LCMS methoxyacrylate (M+1) : 422.10 methyl (Z)-2-(5-(5-((3,5-1H-NMR (400 MHz, DMSO-d6) δ 7.78 (s, 1H), 7.64 (s, bis(trifluoromethyl)-1H-pyrazol- 1H), 7.50 (dd, J = 7.6, 1.5 Hz, 1H), 7.38 (d, J = 7.8 Hz, 1H), 257 1-yl)methyl)-1,2,4-oxadiazol-3- 7.20 (d, J = 1.5 Hz, 1H), 6.21 (s, 2H), 3.85 (s, 3H), 3.64 (s, yl)-2-methylphenoxy)-3- 3H), 2.29 (s, 3H); LCMS (M+1) : 506.85 methoxyacrylate methyl (Z)-2-(5-(5-((2,4-1H-NMR (400 MHz, DMSO-d6) δ 7.66 (s, 1H), 7.56 (dd, J dimethylphenoxy)methyl)-1,2,4- = 7.7, 1.6 Hz, 1H), 7.39 (d, J = 8.3 Hz, 1H), 7.24 (d, J = 1.7 258 oxadiazol-3-yl)-2- Hz, 1H), 6.99 (s, 1H), 6.93 (d, J = 0.7 Hz, 2H), 5.52 (s, 2H), methylphenoxy)-3- 3.86 (s, 3H), 3.64 (s, 3H), 2.30 (s, 3H), 2.19 (s, 3H), 2.17 methoxyacrylate (s, 3H); LCMS (M+1) : 425.10 1 methyl (Z)-2-(5-(5-((4- H-NMR (400 MHz, DMSO-d6) δ 7.66 (s, 1H), 7.57 (dd, J ethylphenoxy)methyl)-1,2,4- = 7.7, 1.6 Hz, 1H), 7.39 (d, J = 8.3 Hz, 1H), 7.24 (d, J = 1.5 259 oxadiazol-3-yl)-2- Hz, 1H), 7.16-7.13 (m, 2H), 6.97 (dt, J = 9.3, 2.6 Hz, 2H), methylphenoxy)-3- 5.52 (s, 2H), 3.86 (s, 3H), 3.64 (s, 3H), 2.54 (t, J = 7.6 Hz, methoxyacrylate 2H), 2.30 (s, 3H), 1.15-1.11 (m, 3H); LCMS (M+1) : 425.10 methyl (Z)-3-methoxy-2-(2-1H-NMR (400 MHz, DMSO-d6) δ 8.40 (dd, J = 5.0, 1.1 Hz, methyl-5-(5-(((3- 1H), 8.21 (dd, J = 7.6, 1.2 Hz, 1H), 7.64 (s, 1H), 7.53 (dd, 260 (trifluoromethyl)pyridin-2- J = 7.7, 1.6 Hz, 1H), 7.37 (d, J = 8.3 Hz, 1H), 7.27 (dd, J = yl)oxy)methyl)-1,2,4-oxadiazol-3- 7.0, 5.0 Hz, 1H), 7.22 (d, J = 1.7 Hz, 1H), 5.88 (s, 2H), 3.85 yl)phenoxy)acrylate (s, 3H), 3.64 (s, 3H), 2.29 (s, 3H); LCMS (M+1) : 466.10 1 methyl (Z)-3-methoxy-2-(2- H-NMR (400 MHz, DMSO-d6) δ 7.81 (d, J = 2.2 Hz, 1H), methyl-5-(5-((3-methyl-1 7.65 (s, 1H), 7.53 (dd, J = 7.7, 1.6 Hz, 1H), 7.37 (d, J = 8.1 261 H- pyrazol-1-yl)methyl)-1,2,4- Hz, 1H), 7.22 (d, J = 1.7 Hz, 1H), 6.11 (d, J = 2.2 Hz, 1H), oxadiazol-3-yl)phenoxy)acrylate 5.72 (s, 2H), 3.86 (s, 3H), 3.64 (s, 3H), 2.29 (s, 3H), 2.13 (s, 3H); LCMS (M+1) : 385.15 PI External 1H-NMR (400 MHz, DMSO-d6) δ 7.77 (d, J = 2.4 Hz, 1H), methyl (Z)-2-(5-(5-((3- 7.65 (s, 1H), 7.53 (dd, J = 7.7, 1.6 Hz, 1H), 7.38 (d, J = 8.3 cyclopropyl-1H-pyrazol-1- 262 Hz, 1H), 7.21 (d, J = 1.5 Hz, 1H), 6.01 (d, J = 2.2 Hz, 1H), yl)methyl)-1,2,4-oxadiazol-3-yl)- 5.71 (s, 2H), 3.86 (s, 3H), 3.64 (s, 3H), 2.29 (s, 3H), 1.87- 2-methylphenoxy)-3- 1.80 (m, 1H), 0.85-0.78 (m, 2H), 0.61-0.57 (m, 2H); LCMS methoxyacrylate (M+1) : 411.20 methyl (Z)-3-methoxy-2-(2-1H-NMR (400 MHz, DMSO-d6) δ 7.65 (s, 1H), 7.52 (dd, J methyl-5-(5-((5-methyl-3- = 7.6, 1.5 Hz, 1H), 7.38 (d, J = 7.8 Hz, 1H), 7.21 (d, J = 1.5 263 (trifluoromethyl)-1H-pyrazol-1- Hz, 1H), 6.64 (s, 1H), 5.94 (s, 2H), 3.86 (s, 3H), 3.64 (s, yl)methyl)-1,2,4-oxadiazol-3- 3H), 2.38 (s, 3H), 2.29 (s, 3H); LCMS (M-1) : 450.95 yl)phenoxy)acrylate methyl (Z)-2-(5-(5-((3,5-dichloro-1H-NMR (400 MHz, DMSO-d6) δ 8.47 (s, 2H), 7.63 (s, 4-oxopyridin-1(4H)-yl)methyl)- 1H), 7.51 (dd, J = 7.8, 1.4 Hz, 1H), 7.37 (d, J = 7.9 Hz, 1H), 264 1,2,4-oxadiazol-3-yl)-2- 7.20 (d, J = 1.2 Hz, 1H), 5.67 (s, 2H), 3.85 (s, 3H), 3.63 (s, methylphenoxy)-3- 3H), 2.29 (s, 3H); LCMS (M+1) : 465.95 methoxyacrylate 1 methyl (Z)-3-methoxy-2-(2- H-NMR (400 MHz, CHLOROFORM-D) δ 7.69 (qd, J = methyl-5-(5 4.3, 2.1 Hz, 1H), 7.56 (dd, J = 7.9, 2.1 Hz, 1H), 7.37 (s, 265 -(pyrrolidin-1- ylmethyl)-1,2,4-oxadiazol-3- 1H), 7.21 (dd, J = 10.5, 8.4 Hz, 1H), 3.89 (s, 3H), 3.73 (s, yl)phenoxy)acrylate 3H), 3.13 (d, J = 7.6 Hz, 2H), 2.90-2.79 (m, 2H), 2.76-2.69 (m, 1H), 2.48-2.36 (m, 2H) : LCMS (M+1) : 399.12 1 methyl (Z)-3-methoxy-2-(2- H-NMR (400 MHz, DMSO-d6) δ 7.66 (s, 1H), 7.56 (dd, J methyl-5-(5-(piperidin-1 = 7.6, 1.5 Hz, 1H), 7.38 (d, J = 7.9 Hz, 1H), 7.24 (d, J = 1.2 266 - ylmethyl)-1,2,4-oxadiazol-3- Hz, 1H), 3.87 (d, J = 2.8 Hz, 5H), 3.65 (s, 3H), 2.45 (t, J = yl)phenoxy)acrylate 5.2 Hz, 4H), 2.30 (s, 3H), 1.53-1.47 (m, 4H), 1.36 (d, J = 5.2 Hz, 2H); LCMS (M+1) : 388.15 methyl (Z)-2-(5-(5-((4-chloro-1H-1H-NMR (400 MHz, DMSO-d6) δ 8.21 (d, J = 5.8 Hz, 1H), pyrazol-1-yl)methyl)-1,2,4- 7.66-7.60 (m, 2H), 7.53 (dd, J = 7.6, 1.5 Hz, 1H), 7.37 (d, J 267 oxadiazol-3-yl)-2- = 7.9 Hz, 1H), 7.21 (d, J = 1.2 Hz, 1H), 5.83 (s, 2H), 3.86 methylphenoxy)-3- (s, 3H), 3.64 (s, 3H), 2.29 (s, 3H); LCMS (M+1) : 404.85 methoxyacrylate 1 methyl (Z)-3-methoxy-2-(2- H-NMR (400 MHz, DMSO-d6) δ 7.75 (d, J = 7.6 Hz, 1H), methyl-5-(5-((1-oxois 7.67-7.62 (m, 3H), 7.56-7.51 (m, 2H), 7.35 (d, J = 7.6 Hz, 268 oindolin-2- yl)methyl)-1,2,4-oxadiazol-3- 1H), 7.21 (d, J = 1.5 Hz, 1H), 5.15 (s, 2H), 4.64 (s, 2H), yl)phenoxy)acrylate 3.83 (s, 3H), 3.62 (s, 3H), 2.29 (s, 3H); LCMS (M+1) : 435.95 1 methyl (Z)-3-methoxy-2-(2- H-NMR (400 MHz, DMSO-d6) δ 7.64 (s, 1H), 7.51 (dd, J methyl-5-(5-(1- = 7.6, 1.5 Hz, 1H), 7.35 (d, J = 7.8 Hz, 1H), 7.18 (d, J = 1.5 269 methylcyclopropyl)-1,2,4- Hz, 1H), 3.87 (s, 3H), 3.64 (s, 3H), 2.29 (s, 3H), 1.53 (s, oxadiazol-3-yl)phenoxy)acrylate 3H), 1.35-1.33 (m, 2H), 1.12 (dd, J = 7.0, 4.3 Hz, 2H); LCMS (M+1) : 345.05 methyl (Z)-2-(5-(5-((2,2-1H-NMR (400 MHz, DMSO-d6) δ 7.66 (s, 1H), 7.56 (dd, J difluorocyclopropyl)methyl)- = 7.7, 1.6 Hz, 1H), 7.38 (d, J = 8.1 Hz, 1H), 7.24 (d, J = 1.5 270 1,2,4-oxadiazol-3-yl)-2- Hz, 1H), 3.87 (s, 3H), 3.65 (s, 3H), 3.20 (d, J = 7.6 Hz, 2H), methylphenoxy)-3- 2.31 (s, J = 8.3 Hz, 3H), 2.22-2.14 (m, 1H), 1.77-1.69 (m, methoxyacrylate 1H), 1.45 (dt, J = 13.4, 4.0 Hz, 1H); LCMS (M+1) : 380.90 1 methyl (Z)-3-methoxy-2-(2- H-NMR (400 MHz, DMSO-d6) δ 7.65 (s, 1H), 7.56 (dd, J me = 7.6, 1.5 Hz, 1H), 7.37 (d, J = 7.6 Hz, 1H), 7.23 (d, J = 1.5 271 thyl-5-(5-(1- methylcyclobutyl)-1,2,4- Hz, 1H), 3.87 (s, 3H), 3.65 (s, 3H), 2.60-2.56 (m, 2H), 2.30 oxadiazol-3-yl)phenoxy)acrylate (s, 3H), 2.14-2.07 (m, 3H), 1.99-1.94 (m, 2H), 1.61 (m, 2H); LCMS (M+1) : 359.00 methyl (Z)-2-(5-(5-(1-1H-NMR (400 MHz, DMSO-d6) δ 7.65 (s, 1H), 7.55 (dd, J 272 fluorocyclopropyl)-1,2,4- = 7.6, 1.5 Hz, 1H), 7.39 (d, J = 7.6 Hz, 1H), 7.22 (d, J = 1.5 oxadiazol-3-yl)-2- Hz, 1H), 3.87 (s, 3H), 3.65 (s, 3H), 2.31 (s, J = 5.5 Hz, 3H), PI External methylphenoxy)-3- 1.86-1.79 (m, 2H), 1.60-1.56 (m, 2H); LCMS (M+1) : methoxyacrylate 349.10 methyl (Z)-2-(5-(5-(2-1H-NMR (400 MHz, DMSO-d6) δ 7.66 (s, 1H), 7.58 (dd, J fluoropropan-2-yl)-1,2,4- = 7.8, 1.5 Hz, 1H), 7.40 (d, J = 7.8 Hz, 1H), 7.24 (d, J = 1.5 273 oxadiazol-3-yl)-2- Hz, 1H), 3.87 (s, 3H), 3.65 (s, 3H), 2.30 (s, 3H), 1.87 (s, methylphenoxy)-3- 3H), 1.83 (s, J = 11.0 Hz, 3H); LCMS (M+1) : 350.90 methoxyacrylate methyl (Z)-2-(2-chloro-5-(5-1H-NMR (400 MHz, DMSO-d6) δ 7.77-7.71 (m, 2H), 7.69 274 (2,2,2-trifluoroethyl)-1,2,4- (d, J = 8.3, 1.8 Hz, 1H), 7.38 (s, J = 1.5 Hz, 1H), 3.89 (s, J oxadiazol-3-yl)phenoxy)-3- = 5.2 Hz, 3H), 3.67 (s, 3H), 2.26-2.16 (m, 2H); LCMS methoxyacrylate (M+1) : 392.90 methyl (Z)-2-(2-chloro-5-(5-(3,5-1H-NMR (400 MHz, DMSO-d6) δ 7.89-7.85 (m, 2H), 7.75- 275 difluorophenyl)-1,2,4-oxadiazol- 7.70 (m, 4H), 7.45 (t, J = 1.0 Hz, 1H), 3.91 (s, 3H), 3.68 (s, 3-yl)phenoxy)-3-methoxyacrylate 3H); LCMS (M+1) : 422.85 1H-NMR (400 MHz, DMSO-d6) δ 8.16 (t, J = 1.7 Hz, 1H), methyl (Z)-2-(2-chloro-5-(5-(3- 8.13 (dt, J = 7.7, 1.3 Hz, 1H), 7.82 (dq, J = 8.1, 1.1 Hz, 1H), 276 chlorophenyl)-1,2,4-oxadiazol-3- 7.77-7.74 (m, 3H), 7.70 (t, J = 8.1 Hz, 1H), 7.45 (t, J = 1.1 yl)phenoxy)-3-methoxyacrylate Hz, 1H), 3.91 (s, 3H), 3.69 (s, 3H); LCMS (M+1) : 420.95 methyl (Z)-2-(2-chloro-5-(5-(3-1H-NMR (400 MHz, DMSO-d6) δ 8.36 (dd, J = 7.1, 2.2 Hz, 277 chloro-4-fluorophenyl)-1,2,4- 1H), 8.20 (qd, J = 4.5, 2.2 Hz, 1H), 7.75-7.70 (m, 4H), 7.44 oxadiazol-3-yl)phenoxy)-3- (s, 1H), 3.91 (s, 3H), 3.68 (s, 3H); LCMS (M+1) : 438.95 methoxyacrylate methyl (Z)-2-(2-chloro-5-(5-(4-1H-NMR (400 MHz, DMSO-d6) δ 8.18 (dd, J = 9.5, 1.8 Hz, 278 chloro-3-fluorophenyl)-1,2,4- 1H), 8.02 (dd, J = 8.4, 1.4 Hz, 1H), 7.91 (t, J = 7.9 Hz, 1H), oxadiazol-3-yl)phenoxy)-3- 7.76-7.72 (m, 3H), 7.45 (s, 1H), 3.88 (t, J = 10.2 Hz, 3H), methoxyacrylate 3.66 (t, J = 7.9 Hz, 3H); LCMS (M+18) : 455.85 1 methyl (Z)-2-(2-chloro-5-(5-(4- H-NMR (400 MHz, DMSO-d6) δ 8.21 (t, J = 8.1 Hz, 1H), chloro-2 7.84 (dd, J = 10.7, 1.8 Hz, 1H), 7.74 (d, J = 6.7 Hz, 3H), 279 -fluorophenyl)-1,2,4- oxadiazol-3-yl)phenoxy)-3- 7.59 (dd, J = 8.6, 1.8 Hz, 1H), 7.45 (s, 1H), 3.89 (s, J = 9.5 methoxyacrylate Hz, 3H), 3.67 (s, J = 6.7 Hz, 3H); LCMS (M+1) : 439.00 methyl (Z)-2-(2-chloro-5-(5-(2,6-1H-NMR (400 MHz, DMSO-d6) δ 7.63 (s, 1H), 7.60-7.58 280 dichlorophenyl)-1,2,4-oxadiazol- (m, 2H), 7.56-7.52 (m, 2H), 7.33 (d, J = 7.6 Hz, 1H), 6.99 3-yl)phenoxy)-3-methoxyacrylate (s, 1H), 3.87 (s, 3H), 3.67 (s, 3H); LCMS (M+1) : 455.95 methyl (Z)-2-(5-(5-((2,4-1H-NMR (400 MHz, DMSO-d6) δ 7.65 (s, 1H), 7.52 (dd, J dimethylthiazol-5-yl)methyl)- = 7.8, 1.7 Hz, 1H), 7.36 (d, J = 8.3 Hz, 1H), 7.21 (d, J = 1.5 281 1,2,4-oxadiazol-3-yl)-2- Hz, 1H), 4.58 (s, 2H), 3.86 (s, 3H), 3.64 (s, 3H), 2.55 (s, methylphenoxy)-3- 3H), 2.29 (s, 6H); LCMS (M+1): 416.05 methoxyacrylate 1 methyl (Z)-2-(2-chloro-5-(5-((4- H-NMR (400 MHz, DMSO-d6) δ 7.73 (s, 1H), 7.70 (d, J = fluoroph 8.3 Hz, 1H), 7.65 (dd, J = 8.3, 1.7 Hz, 1H), 7.37 (d, J = 1.7 282 enoxy)methyl)-1,2,4- oxadiazol-3-yl)phenoxy)-3- Hz, 1H), 7.17 (t, J = 8.9 Hz, 2H), 7.12-7.08 (m, 2H), 5.57 methoxyacrylate (s, 2H), 3.88 (s, 3H), 3.66 (s, 3H); LCMS (M+1): 434.85 1H-NMR (400 MHz, DMSO-d6) δ 7.73 (s, 1H), 7.70 (d, J = methyl (Z)-2-(2-chloro-5-(5- 8.3 Hz, 1H), 7.66 (dd, J = 8.3, 1.8 Hz, 1H), 7.37 (d, J = 1.8 283 (phenoxymethyl)-1,2,4-oxadiazol- Hz, 1H), 7.35-7.31 (m, 2H), 7.07 (d, J = 7.9 Hz, 2H), 7.01 3-yl)phenoxy)-3-methoxyacrylate (t, J = 7.3 Hz, 1H), 5.58 (s, 2H), 3.88 (s, 3H), 3.67 (s, 3H); LCMS (M+1): 416.90 1methyH-NMR (400 MHz, DMSO-d6) δ 7.73 (s, 1H), 7.69 (d, J =284l (Z)-2-(2-chloro-5-(5-((cyclohexyloxy)methyl)-1,2,4- 8.3 Hz, 1H), 7.65 (dd, J = 8.3, 1.7 Hz, 1H), 7.37 (d, J = 1.7 Hz, 1H), 4.87 (s, 2H), 3.89 (s, 3H), 3.67 (s, 3H), 3.45 (td, J PI External oxadiazol-3-yl)phenoxy)-3- = 8.6, 3.6 Hz, 1H), 1.87 (d, J = 9.8 Hz, 2H), 1.66 (d, J = 5.4 methoxyacrylate Hz, 2H), 1.47 (d, J = 6.4 Hz, 1H), 1.31-1.15 (m, 5H); LCMS (M+1): 422.85 methyl (Z)-2-(5-(5-(tert-1H-NMR (400 MHz, DMSO-d6) δ 7.73 (s, 1H), 7.69 (d, J = 285 butoxymethyl)-1,2,4-oxadiazol-3- 8.3 Hz, 1H), 7.65 (dd, J = 8.3, 1.5 Hz, 1H), 7.36 (d, J = 1.5 yl)-2-chlorophenoxy)-3- Hz, 1H), 4.78 (s, 2H), 3.89 (s, 3H), 3.67 (s, 3H), 1.21 (s, methoxyacrylate 9H); LCMS (M+1): 396.95 methyl (Z)-2-(2-chloro-5-(5-1H-NMR (400 MHz, DMSO-d6) δ 7.73 (s, 1H), 7.70 (d, J = 286 ((2,2,2-trifluoroethoxy)methyl)- 7.9 Hz, 1H), 7.67 (dd, J = 8.3, 1.8 Hz, 1H), 7.38 (d, J = 1.5 1,2,4-oxadiazol-3-yl)phenoxy)-3- Hz, 1H), 5.09 (s, 2H), 4.32 (q, J = 9.2 Hz, 2H), 3.89 (s, 3H), methoxyacrylate 3.67 (s, 3H); LCMS (M+1): 422.80 1 methyl (Z)-2-(2-fluoro-5-(5-((2- H-NMR (400 MHz, DMSO-d6) δ 7.72 (s, 1H), 7.67 (qd, J fluorophenoxy)methyl)- = 4.2, 2.0 Hz, 1H), 7.50 (dd, J = 11.0, 8.6 Hz, 1H), 7.42 (dd, 287 1,2,4- oxadiazol-3-yl)phenoxy)-3- J = 8.1, 2.0 Hz, 1H), 7.32-7.25 (m, 2H), 7.15 (t, J = 7.8 Hz, methoxyacrylate 1H), 7.06-7.01 (m, 1H), 5.66 (s, 2H), 3.88 (s, 3H), 3.67 (s, 3H); LCMS (M+1): 418.90 methyl (Z)-2-(2-fluoro-5-(5-((4-1H-NMR (400 MHz, DMSO-d6) δ 7.71 (s, 1H), 7.67 (qd, J 288 fluorophenoxy)methyl)-1,2,4- = 4.3, 2.0 Hz, 1H), 7.50 (dd, J = 10.9, 8.4 Hz, 1H), 7.41 (dd, oxadiazol-3-yl)phenoxy)-3- J = 8.1, 2.0 Hz, 1H), 7.19-7.08 (m, 4H), 5.56 (s, 2H), 3.88 methoxyacrylate (s, 3H), 3.67 (s, 3H); LCMS (M+1): 418.95 methyl (Z)-2-(5-(5-(tert-1H-NMR (400 MHz, DMSO-d6) δ 7.71 (d, J = 3.4 Hz, 1H), 289 butoxymethyl)-1,2,4-oxadiazol-3- 7.67 (qd, J = 4.3, 2.1 Hz, 1H), 7.49 (dd, J = 11.0, 8.6 Hz, yl)-2-fluorophenoxy)-3- 1H), 7.41 (dd, J = 8.1, 2.0 Hz, 1H), 4.77 (s, 2H), 3.89 (s, methoxyacrylate 3H), 3.67 (s, 3H), 1.22 (s, 9H); LCMS (M+1): 380.95 1 methyl (Z)-2-(2-fluoro-5-(5- H-NMR (400 MHz, DMSO-d6) δ 7.72 (s, 1H), 7.69 (qd, J ((2,2,2-trifluoroet = 4.3, 2.1 Hz, 1H), 7.50 (dd, J = 11.0, 8.6 Hz, 1H), 7.43 (dd, 290 hoxy)methyl)- 1,2,4-oxadiazol-3-yl)phenoxy)-3- J = 8.1, 2.0 Hz, 1H), 5.09 (s, 2H), 4.32 (q, J = 9.2 Hz, 2H), methoxyacrylate 3.89 (s, 3H), 3.67 (s, 3H); LCMS (M+1): 406.95 1 methyl (Z)-2-(2-chloro-5-(5-(1,1- H-NMR (400 MHz, DMSO-d6) δ 7.74 (s, 1H), 7.71 (d, J = 291 difluoroethyl)-1,2,4-oxadiazol-3- 8.3 Hz, 1H), 7.66 (dd, J = 8.3, 1.8 Hz, 1H), 7.37 (d, J = 1.8 yl)phenoxy)-3-methoxyacrylate Hz, 1H), 4.54 (q, J = 10.6 Hz, 3H), 3.89 (s, 3H), 3.67 (s, 3H); LCMS (M+1) : 369.05 1 methyl (Z)-2-(2-chloro-5-(5-(1- H-NMR (400 MHz, DMSO-d6) δ 7.72 (s, 1H), 7.69 (d, J = fluorocy 8.3 Hz, 1H), 7.64 (dd, J = 8.3, 1.8 Hz, 1H), 7.35 (d, J = 1.8 292 clopropyl)-1,2,4- oxadiazol-3-yl)phenoxy)-3- Hz, 1H), 3.89 (s, 3H), 3.68 (d, J = 6.7 Hz, 3H), 1.85 (qd, J methoxyacrylate = 9.2, 6.5 Hz, 2H), 1.62-1.56 (m, 2H); LCMS (M+1) : 368.95 1 methyl (Z)-2-(5-(5-benzyl-1,2,4- H-NMR (400 MHz, DMSO-d6) δ 7.72 (s, 1H), 7.67 (d, J = o 8.3 Hz, 1H), 7.62 (dd, J = 8.3, 1.8 Hz, 1H), 7.37-7.34 (m, 293 xadiazol-3-yl)-2- chlorophenoxy)-3- 4H), 7.33-7.28 (d, 1H), 7.24 (d, J = 7.3 Hz, 1H), 4.43 (s, methoxyacrylate 2H), 3.88 (s, 3H), 3.66 (s, 3H); LCMS (M+1) : 400.95 methyl (Z)-2-(5-(5-1H-NMR (400 MHz, DMSO-d6) δ 7.62 (s, 1H), 7.52 (dd, J (cyclopentylmethyl)-1,2,4- = 7.6, 1.5 Hz, 1H), 7.34 (d, J = 7.9 Hz, 1H), 7.20 (d, J = 1.2 294 oxadiazol-3-yl)-2- Hz, 1H), 3.84 (s, 3H), 3.62 (s, 3H), 2.95 (d, J = 7.3 Hz, 2H), methylphenoxy)-3- 2.30-2.23 (m, 4H), 1.76-1.71 (m, 2H), 1.60-1.47 (m, 4H), methoxyacrylate 1.25-1.18 (m, 2H); LCMS (M+1) : 372.42 1 methyl (Z)-2-(2-chloro-5-(5-(2- H-NMR (400 MHz, DMSO-d6) δ 7.73 (s, 1H), 7.71 (d, J = fl 8.3 Hz, 1H), 7.67 (dd, J = 8.3, 1.8 Hz, 1H), 7.37 (d, J = 1.8 295 uoropropan-2-yl)-1,2,4- oxadiazol-3-yl)phenoxy)-3- Hz, 1H), 3.89 (s, J = 4.9 Hz, 3H), 3.67 (s, 3H), 1.88 (s, 3H), methoxyacrylate 1.84 (s, J = 11.6 Hz, 3H); LCMS (M+1) : 307.70 PI External 1 methyl (Z)-2-(5-(5-(azetidin-1- H-NMR (400 MHz, DMSO-d6) δ 7.65 (s, 1H), 7.56 (dd, J ylmethyl)-1,2,4 = 7.6, 1.5 Hz, 1H), 7.37 (d, J = 7.6 Hz, 1H), 7.24 (d, J = 1.5 296 -oxadiazol-3-yl)- 2-methylphenoxy)-3- Hz, 1H), 4.03 (s, 2H), 3.87 (s, 3H), 3.72-3.67 (m, 2H), 3.64 methoxyacrylate (s, 3H), 2.69 (t, J = 6.7 Hz, 2H), 2.29 (s, 3H), 1.88-1.81 (m, 2H); LCMS (M+1): 360.2 methyl (Z)-2-(5-(5-((5-1H-NMR (400 MHz, DMSO-d6) δ 7.65 (s, 1H), 7.52 (dd, J (difluoromethyl)-3-methyl-1H- = 7.6, 1.5 Hz, 1H), 7.45-7.18 (m, 3H), 6.53 (s, 1H), 5.85 (s, 297 pyrazol-1-yl)methyl)-1,2,4- 2H), 3.86 (s, 3H), 3.64 (s, 3H), 2.29 (s, 3H), 2.18 (s, 3H); oxadiazol-3-yl)-2- LCMS (M+1) : 435.05 methylphenoxy)-3- methoxyacrylate 1H-NMR (400 MHz, DMSO-d6) δ 8.63 (d, J = 0.7 Hz, 1H), methyl (Z)-2-(5-(5-((2H-indazol- 7.76 (dt, J = 8.6, 1.0 Hz, 1H), 7.64 (s, 1H), 7.59 (dd, J = 8.8, 2 1.0 Hz, 1H), 7.52 (dd, J = 7.6, 1.5 Hz, 1H), 7.36 (d, J = 8.3 298 -yl)methyl)-1,2,4-oxadiazol-3- yl)-2-methylphenoxy)-3- Hz, 1H), 7.26 (ddd, J = 8.7, 6.6, 1.1 Hz, 1H), 7.21 (d, J = methoxyacrylate 1.7 Hz, 1H), 7.07 (ddd, J = 8.4, 6.6, 0.9 Hz, 1H), 6.19 (s, 2H), 3.84 (s, 3H), 3.62 (s, 3H), 2.29 (s, 3H); LCMS (M+1) : 421.05 methyl (Z)-3-methoxy-2-(2-1H-NMR (400 MHz, DMSO-d6) δ 7.62 (s, 1H), 7.57-7.53 methyl-5-(5-((2-methyl-1H- (m, 2H), 7.47 (dd, J = 7.6, 1.5 Hz, 1H), 7.34 (d, J = 8.1 Hz, 299 benzo[d]imidazol-1-yl)methyl)- 1H), 7.21-7.15 (m, 3H), 5.98 (s, 2H), 3.83 (s, 3H), 3.62 (s, 1,2,4-oxadiazol-3- 3H), 2.58 (s, 3H), 2.28 (s, 3H); LCMS (M+1) : 435.00 yl)phenoxy)acrylate methyl (Z)-2-(5-(5-((1H-indazol-1H-NMR (400 MHz, DMSO-d6) δ 8.19 (d, J = 1.0 Hz, 1H), 300 1-yl)methyl)-1,2,4-oxadiazol-3- 7.83-7.76 (m, 2H), 7.62 (s, 1H), 7.49-7.44 (m, 2H), 7.35 (d, yl)-2-methylphenoxy)-3- J = 8.1 Hz, 1H), 7.23-7.18 (m, 2H), 6.18 (s, 2H), 3.84 (s, methoxyacrylate 3H), 3.63 (s, 3H), 2.28 (s, 3H); LCMS (M+1) : 420.95 1H-NMR (400 MHz, DMSO-d6) δ 7.65 (s, 1H), 7.55 (dd, J methyl (Z)-3-methoxy-2-(2- = 7.6, 1.5 Hz, 1H), 7.37 (d, J = 7.6 Hz, 1H), 7.23 (d, J = 1.5 methyl-5-(5-(2-methyl-6- 301 Hz, 1H), 3.87 (s, 3H), 3.82 (dd, J = 11.6, 2.4 Hz, 2H), 3.65 (trifluoromethyl)pyridin-3-yl)- (s, 3H), 3.29-3.25 (m, 2H), 2.94 (d, J = 7.0 Hz, 2H), 2.32- 1,2,4-oxadiazol-3- 2.29 (m, 3H), 2.08-2.02 (m, 1H), 1.58 (dd, J = 12.8, 1.8 Hz, yl)phenoxy)acrylate 2H), 1.36-1.22 (m, 2H) : LCMS (M+1) : 389.17 methyl (Z)-3-methoxy-2-(2-1H-NMR (400 MHz, DMSO-d6) δ 9.48 (s, 1H), 8.81-8.79 methyl-5-(5-(6- (m, 1H), 8.19 (d, J = 8.1 Hz, 1H), 7.70-7.67 (m, 2H), 7.44 302 (trifluoromethyl)pyridin-3-yl)- (d, J = 7.8 Hz, 1H), 7.34 (d, J = 1.5 Hz, 1H), 3.89 (s, 3H), 1,2,4-oxadiazol-3- 3.66 (s, 3H), 2.33 (s, 3H); LCMS (M+1): 436.20 yl)phenoxy)acrylate methyl (Z)-2-(5-(5-(5-bromo-6-1H-NMR (400 MHz, DMSO-d6) δ 9.14 (d, J = 2.1 Hz, 1H), chloropyridin-3-yl)-1,2,4- 8.88 (d, J = 1.8 Hz, 1H), 7.68-7.66 (m, 2H), 7.43 (d, J = 8.3 303 oxadiazol-3-yl)-2- Hz, 1H), 7.32 (d, J = 1.5 Hz, 1H), 3.89 (s, 3H), 3.66 (s, 3H), methylphenoxy)-3- 2.32 (s, 3H); LCMS (M+1) : 482.00 methoxyacrylate 1 methyl (Z)-3-methoxy-2-(5-(5-(5- H-NMR (400 MHz, DMSO-d6) δ 8.91 (d, J = 1.5 Hz, 1H), methoxypyridin-3-yl) 8.61 (d, J = 3.1 Hz, 1H), 7.99 (q, J = 1.5 Hz, 1H), 7.69-7.66 304 -1,2,4- oxadiazol-3-yl)-2- (m, 2H), 7.43 (d, J = 8.3 Hz, 1H), 7.33 (d, J = 1.5 Hz, 1H), methylphenoxy)acrylate 3.97 (s, 3H), 3.89 (s, 3H), 3.66 (s, 3H), 2.32 (s, 3H); LCMS (M+1) : 397.95 methyl (Z)-3-methoxy-2-(2-1H-NMR (400 MHz, DMSO-d6) δ 9.38 (s, 1H), 9.18-9.17 methyl-5-(5-(4- (m, 1H), 8.10 (d, J = 5.2 Hz, 1H), 7.67-7.65 (m, 2H), 7.45- 305 (trifluoromethyl)pyridin-3-yl)- 7.43 (m, 1H), 7.34 (d, J = 1.5 Hz, 1H), 3.88 (s, 3H), 3.66 (s, 1,2,4-oxadiazol-3- 3H), 2.33 (s, 3H); LCMS (M+1) : 435.95 yl)phenoxy)acrylate PI External methyl (Z)-2-(5-(5-(6-1H-NMR (400 MHz, DMSO-d6) δ 9.15 (d, J = 1.8 Hz, 1H), chloropyridin-3-yl)-1,2,4- 8.55 (dd, J = 8.3, 2.4 Hz, 1H), 7.82 (dd, J = 8.3, 0.6 Hz, 306 oxadiazol-3-yl)-2- 1H), 7.68-7.65 (m, 2H), 7.43 (d, J = 7.9 Hz, 1H), 7.32 (d, J methylphenoxy)-3- = 1.5 Hz, 1H), 3.89 (s, 3H), 3.66 (s, 3H), 2.32 (s, 3H); methoxyacrylate LCMS (M+1) : 401.85 1 methyl (Z)-2-(2-fluoro-5-(5-(o- H-NMR (400 MHz, DMSO-d6) δ 8.08-8.06 (m, 1H), 7.76 307 tolyl)-1,2,4-oxadiazol-3- (qd, J = 4.3, 2.0 Hz, 1H), 7.73 (s, 1H), 7.59 (dd, J = 7.5, 1.3 yl)phenoxy)-3-methoxyacrylate Hz, 1H), 7.55-7.44 (m, 4H), 3.90 (s, 3H), 3.68 (s, 3H), 2.68 (s, 3H);LCMS (M+1) : 385.2 1 methyl (Z)-2-(5-(5-(3- H-NMR (400 MHz, DMSO-d6) δ 8.19-8.11 (m, 2H), 7.81 chlorophenyl)-1,2,4-o (dt, J = 7.1, 1.0 Hz, 1H), 7.76 (qd, J = 4.2, 2.0 Hz, 1H), 7.73 308 xadiazol-3- yl)-2-fluorophenoxy)-3- (s, 1H), 7.69 (t, J = 7.9 Hz, 1H), 7.55-7.49 (m, 2H), , 3.89 methoxyacrylate (d, J = 15.9 Hz, 3H), 3.70 (d, J = 14.2 Hz, 3H);LCMS (M+1) : 405.4 methyl (Z)-2-(5-(5-(4-1H-NMR (400 MHz, DMSO-d6) δ 8.09 (dd, J = 6.8, 2.0 Hz, 309 bromophenyl)-1,2,4-oxadiazol-3- 2H), 7.88 (dd, J = 6.8, 2.0 Hz, 2H), 7.77-7.73 (m, 2H), 7.55- yl)-2-fluorophenoxy)-3- 7.48 (m, 2H), 3.91 (s, 3H), 3.68 (s, 3H);LCMS (M+1) : methoxyacrylate 450.1 methyl (Z)-2-(5-(5-(2-(2,4-1H-NMR (400 MHz, DMSO-d6) δ 7.71 (d, J = 7.3 Hz, 1H), dichlorophenoxy)ethyl)-1,2,4- 7.67-7.63 (m, 2H), 7.49 (dd, J = 11.0, 8.6 Hz, 1H), 7.38 (dq, 310 oxadiazol-3-yl)-2- J = 8.5, 2.2 Hz, 2H), 7.32 (d, J = 9.0 Hz, 1H), 6.05 (q, J = fluorophenoxy)-3- 6.6 Hz, 1H), 3.89 (d, J = 9.8 Hz, 3H), 3.67 (d, J = 6.6 Hz, methoxyacrylate 3H), 2.06 (s, 1H), 1.82-1.78 (m, 3H);LCMS (M+1) : 484.1 methyl (Z)-2-(5-(5-1H-NMR (400 MHz, DMSO-d6) δ 8.32 (d, J = 8.1 Hz, 1H), (benzo[d]isoxazol-3-yl)-1,2,4- 8.02 (d, J = 8.6 Hz, 1H), 7.86 (t, J = 7.3 Hz, 1H), 7.77 (dd, 311 oxadiazol-3-yl)-2- J = 7.7, 1.3 Hz, 1H), 7.70 (s, 1H), 7.67 (t, J = 7.6 Hz, 1H), methylphenoxy)-3- 7.47 (d, J = 7.8 Hz, 1H), 7.40 (d, J = 1.2 Hz, 1H), 3.91 (s, methoxyacrylate 3H), 3.68 (s, 3H), 2.35 (s, 3H); LCMS (M+1): 407.95 1H-NMR (400 MHz, DMSO-d6) δ 7.71 (s, 1H), 7.68 (qd, J methyl (Z)-2-(2-fluoro-5-(5- = 4.2, 2.1 Hz, 1H), 7.50 (dd, J = 11.0, 8.6 Hz, 1H), 7.42 (dd, 312 (phenoxymethyl)-1,2,4-oxadiazol- J = 8.1, 2.0 Hz, 1H), 7.33 (dd, J = 8.6, 7.3 Hz, 2H), 7.07 (d, 3-yl)phenoxy)-3-methoxyacrylate J = 7.9 Hz, 2H), 7.01 (t, J = 7.3 Hz, 1H), 5.57 (s, 2H), 3.88 (s, 3H), 3.67 (s, 3H); LCMS (M+1): 400.95 1 methyl (Z)-3-methoxy-2-(2- H-NMR (400 MHz, DMSO-d6) δ 7.65 (s, 1H), 7.54 (dd, J methyl-5-( = 7.6, 1.5 Hz, 1H), 7.36 (d, J = 7.9 Hz, 1H), 7.22 (d, J = 1.5 313 5-(1- methylcyclopentyl)-1,2,4- Hz, 1H), 3.85 (d, J = 15.0 Hz, 3H), 3.65 (t, J = 15.1 Hz, oxadiazol-3-yl)phenoxy)acrylate 3H), 2.32-2.26 (m, 3H), 2.19-2.13 (m, 2H), 1.78-1.69 (m, 6H), 1.44 (s, 3H); LCMS (M+18) : 373.00 1H-NMR (400 MHz, DMSO-d6) δ 7.72 (s, 1H), 7.67 (qd, J methyl (Z)-2-(5-(5- = 4.3, 2.1 Hz, 1H), 7.49 (dd, J = 11.0, 8.6 Hz, 1H), 7.42 (dd, ((cyclohexyloxy)methyl)-1,2,4- 314 J = 8.3, 2.1 Hz, 1H), 4.86 (s, 2H), 3.89 (s, 3H), 3.67 (s, 3H), oxadiazol-3-yl)-2- 3.48-3.44 (m, 1H), 1.88-1.86 (m, 2H), 1.66 (d, J = 4.9 Hz, fluorophenoxy)-3- 2H), 1.47 (d, J = 7.0 Hz, 1H), 1.29-1.19 (m, 5H); LCMS methoxyacrylate (M+1): 407.20 methyl (Z)-2-(5-(5-(2,2-1H-NMR (400 MHz, DMSO-d6) δ 7.65 (s, 1H), 7.54 (dd, J difluorocyclopropyl)-1,2,4- = 7.6, 1.5 Hz, 1H), 7.38 (d, J = 7.9 Hz, 1H), 7.22 (d, J = 1.5 315 oxadiazol-3-yl)-2- Hz, 1H), 3.87 (s, 3H), 3.71-3.63 (m, 4H), 2.46-2.42 (m, methylphenoxy)-3- 1H), 2.37-2.32 (m, 1H), 2.31 (d, J = 7.9 Hz, 3H); LCMS methoxyacrylate (M+1) : 367.00 methyl (Z)-3-methoxy-2-(2-1H-NMR (400 MHz, DMSO-d6) δ 7.66 (s, 1H), 7.57 (dd, J 316 methyl-5-(5-(1,1,1-trifluoro-2- = 7.6, 1.5 Hz, 1H), 7.40 (d, J = 8.1 Hz, 1H), 7.24 (d, J = 1.5 methylpropan-2-yl)-1,2,4- Hz, 1H), 3.87 (s, 3H), 3.65 (s, 3H), 2.30 (s, 3H), 1.69 (s, oxadiazol-3-yl)phenoxy)acrylate 6H); LCMS (M+1) : 401.00 PI External 1 methyl (Z)-2-(2-chloro-5-(5-(2- H-NMR (400 MHz, DMSO-d6) δ 7.73 (s, 1H), 7.68 (d, J = 317 methoxyethyl)-1,2,4-oxadiazol-3- 8.3 Hz, 1H), 7.64 (dd, J = 8.3, 1.8 Hz, 1H), 7.36 (d, J = 1.8 yl)phenoxy)-3-methoxyacrylate Hz, 1H), 3.89 (s, 3H), 3.76 (s, J = 6.1 Hz, 3H), 3.67 (s, 3H), 3.25 (t, J = 6.1 Hz, 4H); LCMS (M+1) : 368.95 1 methyl (Z)-2-(2-chloro-5-(5-(2- H-NMR (400 MHz, DMSO-d6) δ 7.73 (s, 1H), 7.70 (d, J = methoxypropan-2-yl)-1,2 8.3 Hz, 1H), 7.66 (dd, J = 8.3, 1.8 Hz, 1H), 7.37 (d, J = 1.5 318 ,4- oxadiazol-3-yl)phenoxy)-3- Hz, 1H), 3.89 (s, 3H), 3.67 (s, 3H), 3.14 (s, 3H), 1.60 (d, J methoxyacrylate = 14.7 Hz, 3H), 1.29 (d, J = 7.3 Hz, 3H); LCMS (M+1) : 382.95 1 methyl (Z)-2-(2-fluoro-5-(5- H-NMR (400 MHz, DMSO-d6) δ 8.17-8.15 (m, 2H), 7.78- 319 phenyl-1,2,4-oxadiazol-3- 7.72 (m, 3H), 7.66 (t, J = 7.5 Hz, 2H), 7.55-7.49 (m, 2H), yl)phenoxy)-3-methoxyacrylate 3.91 (s, 3H), 3.69 (s, 3H); LCMS (M+1) : 371.00 methyl (Z)-2-(2-fluoro-5-(5-(5-1H-NMR (400 MHz, DMSO-d6) δ 7.86 (dd, J = 9.3, 2.9 Hz, 320 fluoro-2-methylphenyl)-1,2,4- 1H), 7.77 (qd, J = 4.2, 2.1 Hz, 1H), 7.73 (s, 1H), 7.57-7.45 oxadiazol-3-yl)phenoxy)-3- (m, 4H), 3.90 (s, 3H), 3.68 (s, 3H), 2.65 (s, 3H); LCMS methoxyacrylate (M+1) : 402.95 methyl (Z)-2-(5-(5-(2-chloro-6-1H-NMR (400 MHz, DMSO-d6) δ 7.82 (td, J = 8.3, 6.2 Hz, 321 fluorophenyl)-1,2,4-oxadiazol-3- 1H), 7.76 (qd, J = 4.3, 2.1 Hz, 1H), 7.72 (s, 1H), 7.67-7.65 yl)-2-fluorophenoxy)-3- (m, 1H), 7.60-7.49 (m, 3H), 3.90 (s, 3H), 3.68 (s, 3H); methoxyacrylate LCMS (M+1) : 422.90 methyl (Z)-2-(2-fluoro-5-(5-(4-1H-NMR (400 MHz, DMSO-d6) δ 8.29 (dt, J = 8.6, 2.0 Hz, 322 ((trifluoromethyl)thio)phenyl)- 2H), 8.00 (t, J = 8.3 Hz, 2H), 7.77 (qd, J = 4.2, 2.0 Hz, 1H), 1,2,4-oxadiazol-3-yl)phenoxy)-3- 7.73 (s, 1H), 7.56-7.49 (m, 2H), 3.91 (s, 3H), 3.69 (s, 3H); methoxyacrylate LCMS (M+1) : 470.90 methyl (Z)-2-(2-fluoro-5-(5-(2-1H-NMR (400 MHz, DMSO-d6) δ 8.17 (t, J = 4.2 Hz, 1H), 323 (trifluoromethyl)phenyl)-1,2,4- 8.07 (t, J = 4.4 Hz, 1H), 7.96 (t, J = 4.5 Hz, 2H), 7.77-7.73 oxadiazol-3-yl)phenoxy)-3- (m, 2H), 7.57-7.50 (m, 2H), 3.90 (s, 3H), 3.68 (s, 3H); methoxyacrylate LCMS (M+1) : 438.85 1 methyl (Z)-2-(2-fluoro-5-(5-(4- H-NMR (400 MHz, DMSO-d6) δ 8.25-8.22 (m, 2H), 7.76 324 fluorophenyl)-1,2,4-oxadiazol-3- (qd, J = 4.3, 2.1 Hz, 1H), 7.73 (s, 1H), 7.55-7.48 (m, 4H), yl)phenoxy)-3-methoxyacrylate 3.91 (s, 3H), 3.69 (s, 3H); LCMS (M+1) : 389.00 methyl (Z)-2-(5-(5-(tert-butyl)-1H-NMR (400 MHz, DMSO-d6) δ 7.71 (s, 1H), 7.65 (qd, J 325 1,2,4-oxadiazol-3-yl)-2- = 4.3, 2.1 Hz, 1H), 7.47 (dd, J = 11.0, 8.6 Hz, 1H), 7.39 (dd, fluorophenoxy)-3- J = 8.1, 2.0 Hz, 1H), 3.89 (s, 3H), 3.67 (s, 3H), 1.41 (s, 9H); methoxyacrylate LCMS (M+1) : 351.05 1 methyl (Z)-2-(5-(5-((1H-indol-1- H-NMR (400 MHz, DMSO-d6) δ 7.63 (s, 1H), 7.57 (t, J = yl)methyl)-1,2,4-o 7.8 Hz, 1H), 7.53-7.47 (m, 3H), 7.34 (t, J = 7.5 Hz, 1H), 326 xadiazol-3-yl)- 2-methylphenoxy)-3- 7.19-7.13 (m, 2H), 7.08-7.04 (m, 1H), 6.54-6.51 (m, 1H), methoxyacrylate 5.93 (s, 2H), 3.84 (s, 3H), 3.63 (s, 3H), 2.28 (s, 3H); LCMS (M+1) : 420.05 methyl (Z)-2-(5-(5-((3,4-1H-NMR (400 MHz, DMSO-d6) δ 7.65 (s, 1H), 7.58 (dd, J dihydroisoquinolin-2(1H)- = 7.7, 1.6 Hz, 1H), 7.38 (d, J = 7.8 Hz, 1H), 7.25 (d, J = 1.5 327 yl)methyl)-1,2,4-oxadiazol-3-yl)- Hz, 1H), 7.10-7.07 (m, 3H), 7.03 (d, J = 7.6 Hz, 1H), 4.13 2-methylphenoxy)-3- (s, 2H), 3.86 (s, 3H), 3.71 (s, 2H), 3.64 (s, 3H), 2.84 (s, 4H), methoxyacrylate 2.30 (s, 3H); LCMS (M+1) : 435.95 methyl (Z)-2-(5-(5-(1-(2,4-1H-NMR (400 MHz, DMSO-d6) δ 7.64-7.63 (m, 2H), 7.54 dichlorophenoxy)ethyl)-1,2,4- (dd, J = 7.6, 1.5 Hz, 1H), 7.39-7.36 (m, 2H), 7.31 (d, J = 328 oxadiazol-3-yl)-2- 8.8 Hz, 1H), 7.21 (d, J = 1.7 Hz, 1H), 6.04 (q, J = 6.6 Hz, methylphenoxy)-3- 1H), 3.86 (s, 3H), 3.64 (s, 3H), 2.29 (s, 2H), 1.78 (d, J = 6.6 methoxyacrylate Hz, 3H); LCMS (M+1) : 478.90329methyl (Z)-3-methoxy-2-(2- 1H-NMR (400 MHz, DMSO-d6) δ 7.66-7.64 (m, 1H), 7.50 methyl-5-(5-((4-oxo-2- (dd, J = 7.6, 1.5 Hz, 1H), 7.38-7.36 (m, 1H), 7.19 (d, J = PI External thioxothiazolidin-3-yl)methyl)- 1.5 Hz, 1H), 5.43 (s, 2H), 4.47 (s, 2H), 3.86 (s, 3H), 3.64 1,2,4-oxadiazol-3- (s, 3H), 2.29 (s, 3H); LCMS (M+1) : 436.10 yl)phenoxy)acrylate 1 methyl (Z)-3-methoxy-2-(2- H-NMR (400 MHz, DMSO-d6) δ 7.65 (s, 1H), 7.55 (dd, J methyl-5-(5-((4-oxothiazolidin-3- = 7.8, 1.4 Hz, 1H), 7.38 (d, J = 7.9 Hz, 1H), 7.23 (d, J = 1.2 330 yl)methyl)-1,2,4-oxadiazol-3- Hz, 1H), 4.89 (s, 2H), 4.54 (s, 2H), 3.87 (s, 3H), 3.64 (s, yl)phenoxy)acrylate 3H), 3.60 (s, 2H), 2.30 (s, 3H); LCMS (M+1) : 406.10 1 methyl (Z)-2-(2-fluoro-5-(5-(2- H-NMR (400 MHz, DMSO-d6) δ 7.71 (s, 1H), 7.66 (qd, J (methylthio)ethyl)-1, = 4.3, 2.1 Hz, 1H), 7.48 (dd, J = 11.0, 8.3 Hz, 1H), 7.40 (dd, 331 2,4- oxadiazol-3-yl)phenoxy)-3- J = 8.2, 2.1 Hz, 1H), 3.89 (s, 3H), 3.67 (s, 3H), 3.32 (s, 1H), methoxyacrylate 3.29 (s, 1H), 2.93 (t, J = 7.2 Hz, 2H), 2.10 (d, J = 3.7 Hz, 3H);LCMS (M+1) : 369.1 methyl (Z)-2-(5-(5-(2,3-1H-NMR (400 MHz, DMSO-d6) δ 8.10 (dd, J = 7.8, 1.5 Hz, 332 dichlorophenyl)-1,2,4-oxadiazol- 1H), 8.01 (dd, J = 8.2, 1.3 Hz, 1H), 7.78-7.74 (m, 1H), 7.72 3-yl)-2-fluorophenoxy)-3- (s, 1H), 7.64 (t, J = 7.9 Hz, 1H), 7.56-7.49 (m, 2H), 3.90 (s, methoxyacrylate 3H), 3.68 (s, 3H);LCMS (M+1) : 440.1 1H-NMR (400 MHz, DMSO-d6) δ 9.54 (d, J = 2.1 Hz, 1H), 9.27 (d, J = 1.8 Hz, 1H), 8.31-8.28 (m, 1H), 8.16 (d, J = 8.3 methyl (Z)-3-methoxy-2-(2- 333 Hz, 1H), 7.99-7.95 (m, 1H), 7.78 (t, J = 7.5 Hz, 1H), 7.72 methyl-5-(5-(quinolin-3-yl)-1,2,4- (dd, J = 7.8, 1.4 Hz, 1H), 7.69 (s, 1H), 7.48-7.44 (m, 1H), oxadiazol-3-yl)phenoxy)acrylate 7.37 (d, J = 1.5 Hz, 1H), 3.91 (s, 3H), 3.68 (s, 3H), 2.34 (s, 3H); LCMS (M+1) : 418.25 1 methyl (Z)-3-methoxy-2-(2- H-NMR (400 MHz, DMSO-d6) δ 7.65 (s, 1H), 7.56 (dd, J methyl-5-( = 7.8, 1.7 Hz, 1H), 7.40-7.38 (m, 1H), 7.27-7.22 (m, 3H), 334 5-(thiophen-3-yl)- 1,2,4-oxadiazol-3- 7.07-7.02 (m, 1H), 6.75-6.71 (m, 2H), 3.85 (d, J = 15.3 Hz, yl)phenoxy)acrylate 3H), 3.65 (s, 3H), 2.30 (s, 3H), 1.77 (d, J = 15.0 Hz, 6H) : LCMS (M+1) : 425.35 methyl (Z)-2-(5-(5-(5-1H-NMR (400 MHz, DMSO-d6) δ 8.42 (d, J = 1.5 Hz, 1H), ethylthiophen-3-yl)-1,2,4- 7.67 (s, 1H), 7.62 (dd, J = 7.6, 1.5 Hz, 1H), 7.45 (d, J = 1.2 335 oxadiazol-3-yl)-2- Hz, 1H), 7.40 (d, J = 7.6 Hz, 1H), 7.28 (d, J = 1.5 Hz, 1H), methylphenoxy)-3- 3.89 (s, 3H), 3.66 (s, 3H), 2.93-2.87 (m, 2H), 2.31 (s, 3H), methoxyacrylate 1.29 (t, J = 7.5 Hz, 3H); LCMS (M+1) : 401.05 methyl (Z)-2-(5-(5-(5-1H-NMR (400 MHz, DMSO-d6) δ 8.52 (d, J = 1.8 Hz, 1H), chlorothiophen-2-yl)-1,2,4- 7.76 (d, J = 1.8 Hz, 1H), 7.66 (s, 1H), 7.62 (dd, J = 7.6, 1.5 336 oxadiazol-3-yl)-2- Hz, 1H), 7.41 (d, J = 7.6 Hz, 1H), 7.28 (d, J = 1.5 Hz, 1H), methylphenoxy)-3- 3.88 (s, 3H), 3.66 (s, 3H), 2.31 (s, 3H); LCMS (M+1) : methoxyacrylate 407.10 methyl (Z)-2-(5-(5-((1H-1H-NMR (400 MHz, DMSO-d6) δ 8.14-8.11 (m, 1H), 7.94- benzo[d][1,2,3]triazol-1- 7.92 (m, 1H), 7.69 (s, 1H), 7.66-7.60 (m, 2H), 7.54 (dd, J = 337 yl)methyl)-1,2,4-oxadiazol-3-yl)- 8.3, 1.8 Hz, 1H), 7.49-7.45 (m, 1H), 7.29 (d, J = 1.8 Hz, 2-chlorophenoxy)-3- 1H), 6.59 (s, 2H), 3.83 (s, J = 15.0 Hz, 3H), 3.62 (s, J = 15.0 methoxyacrylate Hz, 3H); LCMS (M+1) : 442.15 methyl (Z)-2-(2-chloro-5-(5-((3,5-1H-NMR (400 MHz, DMSO-d6) δ 8.48 (s, 2H), 7.73 (s, 338 dichloro-4-oxopyridin-1(4H)- 1H), 7.70 (d, J = 8.3 Hz, 1H), 7.63 (dd, J = 8.2, 1.8 Hz, 1H), yl)methyl)-1,2,4-oxadiazol-3- 7.34 (d, J = 2.0 Hz, 1H), 5.71 (s, 2H), 3.89 (s, 3H), 3.67 (s, yl)phenoxy)-3-methoxyacrylate 3H); LCMS (M+1) : 486.00 methyl (Z)-2-(5-(5-((3,5-1H-NMR (400 MHz, DMSO-d6) δ 7.79 (s, 1H), 7.71-7.68 bis(trifluoromethyl)-1H-pyrazol- (m, 2H), 7.59 (dd, J = 8.3, 2.0 Hz, 1H), 7.33 (d, J = 2.0 Hz, 339 1-yl)methyl)-1,2,4-oxadiazol-3- 1H), 6.23 (s, 2H), 3.87 (s, 3H), 3.66 (s, 3H); LCMS (M+1) yl)-2-chlorophenoxy)-3- : 524.95 methoxyacrylate340methyl (Z)-2-(2-chloro-5-(5-(1-1H-NMR (400 MHz, DMSO-d6) δ 7.72 (s, 1H), 7.69 (d, J = (2,4-dichlorophenoxy)ethyl)- 8.3 Hz, 1H), 7.64-7.62 (m, 2H), 7.38 (dd, J = 8.9, 2.4 Hz, PI External 1,2,4-oxadiazol-3-yl)phenoxy)-3- 1H), 7.34-7.31 (m, 2H), 6.06 (q, J = 6.6 Hz, 1H), 3.88 (s, methoxyacrylate 3H), 3.66 (s, 3H), 1.79 (d, J = 6.4 Hz, 3H); LCMS (M+1) : 500.95 1 methyl (Z)-2-(2-chloro-5-(5-(2- H-NMR (400 MHz, DMSO-d6) δ 7.73 (s, 1H), 7.68 (d, J = (methy 7.9 Hz, 1H), 7.64 (dd, J = 8.3, 1.5 Hz, 1H), 7.36 (d, J = 1.5 341 lthio)ethyl)-1,2,4- oxadiazol-3-yl)phenoxy)-3- Hz, 1H), 3.87 (d, J = 14.7 Hz, 3H), 3.67 (s, 3H), 3.33 (s, methoxyacrylate 1H), 3.28 (d, J = 8.3 Hz, 1H), 2.94 (t, J = 7.2 Hz, 2H), 2.10 (s, 3H); LCMS (M+18) : 373.00 methyl (Z)-2-(2-chloro-5-(5-((4-1H-NMR (400 MHz, DMSO-d6) δ 7.72 (s, 1H), 7.68 (d, J = 342 oxo-2-thioxothiazolidin-3- 8.3 Hz, 1H), 7.59 (dd, J = 8.3, 1.8 Hz, 1H), 7.32 (d, J = 1.8 yl)methyl)-1,2,4-oxadiazol-3- Hz, 1H), 5.44 (s, 2H), 4.46 (s, 2H), 3.89 (s, 3H), 3.67 (s, yl)phenoxy)-3-methoxyacrylate 3H); LCMS (M+1) : 456.00 1H-NMR (400 MHz, DMSO-d6) δ 8.11 (dd, J = 7.8, 1.4 Hz, methyl (Z)-2-(2-chloro-5-(5-(2,3- 1H), 8.01 (dd, J = 8.3, 1.5 Hz, 1H), 7.74 (s, 2H), 7.64 (d, J 343 dichlorophenyl)-1,2,4-oxadiazol- = 8.1 Hz, 1H), 7.46 (s, 1H), 7.16 (d, J = 37.6 Hz, 1H), 3.91 3-yl)phenoxy)-3-methoxyacrylate (s, J = 10.4 Hz, 3H) , 3.69 (s, J = 6.7 Hz, 3H); LCMS (M+1) : 454.75 1H-NMR (400 MHz, CDCl3) δ 7.70 (qd, J = 4.3, 1.9 Hz, methyl (Z)-2-(2-fluoro-5-(5-(3- 1H), 7.57 (dd, J = 8.1, 2.0 Hz, 1H), 7.37 (d, J = 2.4 Hz, 1H), 344 phenylpropyl)-1,2,4-oxadiazol-3- 7.33-7.29 (m, 2H), 7.23-7.18 (m, 4H), 3.88 (s, 3H), 3.73 (s, yl)phenoxy)-3-methoxyacrylate 3H), 2.93 (t, J = 7.6 Hz, 2H), 2.76 (t, J = 7.5 Hz, 2H), 2.23- 2.16 (m, 2H); LCMS (M+1) : 413.15 1H-NMR (400 MHz, CDCl3) δ 7.71 (qd, J = 4.3, 1.9 Hz, methyl (Z)-2-(5-(5-(1-(2,4- 1H), 7.56 (dd, J = 7.9, 2.1 Hz, 1H), 7.40 (t, J = 2.1 Hz, 1H), dichlorophenoxy)ethyl)-1,2,4- 345 7.37 (s, 1H), 7.23-7.16 (m, 1H), 7.14 (dd, J = 8.9, 2.4 Hz, oxadiazol-3-yl)-2- 1H), 6.94 (d, J = 8.9 Hz, 1H), 5.54 (q, J = 6.7 Hz, 1H), 3.88 fluorophenoxy)-3- (s, 3H), 3.73 (s, 3H), 1.91 (d, J = 6.7 Hz, 3H); LCMS (M+1) methoxyacrylate : 483.00 methyl (Z)-2-(5-(5-(1,1-1H-NMR (400 MHz, CDCl3) δ 7.75 (qd, J = 4.3, 1.9 Hz, 346 difluoroethyl)-1,2,4-oxadiazol-3- 1H), 7.59 (dd, J = 7.9, 2.1 Hz, 1H), 7.38 (s, 1H), 7.24-7.21 yl)-2-fluorophenoxy)-3- (m, 1H), 3.90 (s, 3H), 3.74 (s, 3H), 2.21-2.12 (m, 3H); methoxyacrylate LCMS (M+1) : 359.05 methyl (Z)-2-(5-(5-((1H-1H-NMR (400 MHz, CDCl3) δ 8.14-8.12 (m, 1H), 7.67- benzo[d][1,2,3]triazol-1- 7.61 (m, 2H), 7.58-7.54 (m, 1H), 7.51 (dd, J = 7.9, 2.1 Hz, 347 yl)methyl)-1,2,4-oxadiazol-3-yl)- 1H), 7.46-7.41 (m, 1H), 7.34 (s, 1H), 7.19 (dd, J = 10.4, 8.6 2-fluorophenoxy)-3- Hz, 1H), 6.14 (s, 2H), 3.86 (s, 3H), 3.71 (s, 3H); LCMS methoxyacrylate (M+1) : 426.00 methyl (Z)-2-(2-fluoro-5-(5-1H-NMR (400 MHz, CDCl3) δ 7.73 (qd, J = 4.2, 2.0 Hz, 348 (2,2,2-trifluoroethyl)-1,2,4- 1H), 7.58 (dd, J = 7.9, 2.1 Hz, 1H), 7.38 (s, 1H), 7.23 (dd, oxadiazol-3-yl)phenoxy)-3- J = 10.4, 8.6 Hz, 1H), 3.90 (s, 3H), 3.84 (q, J = 9.5 Hz, 2H), methoxyacrylate 3.74 (s, 3H); LCMS (M-1) : 375.00 methyl (Z)-2-(5-(5-1H-NMR (400 MHz, CDCl3) δ 7.71 (qd, J = 4.3, 2.1 Hz, (cyclopropylmethyl)-1,2,4- 1H), 7.58 (dd, J = 8.1, 2.0 Hz, 1H), 7.36 (s, 1H), 7.21 (dd, 349 oxadiazol-3-yl)-2- J = 10.4, 8.6 Hz, 1H), 3.89 (s, 3H), 3.73 (s, 3H), 2.84 (d, J fluorophenoxy)-3- = 7.0 Hz, 2H), 1.25-1.20 (m, 1H), 0.67-0.62 (m, 2H), 0.34 methoxyacrylate (q, J = 5.2 Hz, 2H); LCMS (M+1) : 348.90 1 methyl (Z)-2-(5-(5-cyclopropyl- H-NMR (400 MHz, DMSO-d6) δ 7.70 (s, 1H), 7.61 (qd, J 1,2,4 = 4.3, 2.0 Hz, 1H), 7.46 (dd, J = 10.9, 8.4 Hz, 1H), 7.37 (dd, 350 -oxadiazol-3-yl)-2- fluorophenoxy)-3- J = 8.1, 2.0 Hz, 1H), 3.89 (s, 3H), 3.67 (s, 3H), 2.42-2.36 methoxyacrylate (m, 1H), 1.29-1.23 (m, 2H), 1.20-1.14 (m, 2H); LCMS (M+1) : 334.95 methyl (Z)-2-(5-(5-((3,5-dichloro-1H-NMR (400 MHz, DMSO-d6) δ 8.46 (s, 2H), 7.69 (s, 351 4-oxopyridin-1(4H)-yl)methyl)- 1H), 7.64-7.61 (m, 1H), 7.48 (dd, J = 10.9, 8.4 Hz, 1H), 1,2,4-oxadiazol-3-yl)-2- PI External fluorophenoxy)-3- 7.37 (dd, J = 8.1, 2.0 Hz, 1H), 5.68 (s, 2H), 4.02 (q, J = 7.1 methoxyacrylate Hz, 1H), 3.87 (s, 3H), 3.65 (s, 3H);LCMS (M+1) : 471.1 1H-NMR (400 MHz, DMSO-d6) δ 7.71 (s, 1H), 7.66 (qd, J methyl (Z)-2-(2-fluoro-5-(5-(2- = 4.2, 2.1 Hz, 1H), 7.48 (dd, J = 11.0, 8.6 Hz, 1H), 7.40 (dd, 352 methoxyethyl)-1,2,4-oxadiazol-3- J = 8.1, 2.0 Hz, 1H), 3.89 (s, 3H), 3.76 (t, J = 6.1 Hz, 2H), yl)phenoxy)-3-methoxyacrylate 3.67 (s, 3H), 3.26-3.23 (m, 5H);LCMS (M+1) : 353.1 methyl (Z)-2-(2-fluoro-5-(5-1H-NMR (400 MHz, DMSO-d6) δ 7.72 (s, 1H), 7.68 (qd, J 353 (methoxymethyl)-1,2,4- = 4.2, 2.1 Hz, 1H), 7.50 (dd, J = 10.9, 8.4 Hz, 1H), 7.42 (dd, oxadiazol-3-yl)phenoxy)-3- J = 8.2, 2.1 Hz, 1H), 4.80 (s, 2H), 3.89 (s, 3H), 3.67 (s, 3H), methoxyacrylate 3.42-3.38 (m, 3H) 1 methyl (Z)-2-(2-fluoro-5-(5-(1- H-NMR (400 MHz, DMSO-d6) δ 7.71 (s, 1H), 7.67 (qd, J = 4.3, 2.1 Hz, 1H), 7.48 (dd, J = 11.0, 8.6 Hz, 1H), 7.41 (dd, 354 methylcyclobutyl)-1,2,4- oxadiazol-3-yl)phenoxy)-3- J = 8.1, 2.0 Hz, 1H), 3.89 (s, 3H), 3.67 (s, 3H), 2.63-2.55 methoxyacrylate (m, 2H), 2.16-2.06 (m, 3H), 2.02-1.95 (m, 1H), 1.61 (s, 3H); LCMS (M+1): 363.00 1H-NMR (400 MHz, DMSO-d6) δ 7.65 (s, 1H), 7.55 (dd, J methyl (Z)-2-(5-(5-((4,4- = 7.6, 1.5 Hz, 1H), 7.37 (d, J = 7.9 Hz, 1H), 7.23 (d, J = 1.5 difluorocyclohexyl)methyl)-1,2,4- 355 Hz, 1H), 3.87 (s, 3H), 3.65 (s, 3H), 2.97 (d, J = 7.3 Hz, 2H), oxadiazol-3-yl)-2- 2.32-2.29 (s, 3H), 2.00-1.98 (m, 2H), 1.87 (t, J = 13.4 Hz, methylphenoxy)-3- 1H), 1.77 (q, J = 3.9 Hz, 3H), 1.36-1.30 (m, 2H), 1.22 (q, methoxyacrylate 1H); LCMS (M+1) : 423.25 1 methyl (Z)-3-methoxy-2-(2- H-NMR (400 MHz, DMSO-d6) δ 7.66 (s, 1H), 7.56 (dd, J methyl-5-(5-(4,4,4-t = 7.9, 1.5 Hz, 1H), 7.38 (d, J = 7.6 Hz, 1H), 7.23 (d, J = 1.5 356 rifluorobutan- 2-yl)-1,2,4-oxadiazol-3- Hz, 1H), 3.87 (s, 3H), 3.65-3.60 (s, 3H), 2.32-2.30 (s, 3H), yl)phenoxy)acrylate 1.98 (d, 1H), 1.44 (d, J = 7.0 Hz, 3H),1.23 (d,1H) 1.16 (t, J = 7.0 Hz, 1H); LCMS (M+1) : 401.10 1 methyl (Z)-3-methoxy-2-(2- H-NMR (400 MHz, DMSO-d6) δ 7.66 (s, 1H), 7.57 (dd, J me = 7.6, 1.5 Hz, 1H), 7.40 (d, J = 7.6 Hz, 1H), 7.24 (d, J = 1.5 357 thyl-5-(5-(1,1,1- trifluoropropan-2-yl)-1,2,4- Hz, 1H), 4.74-4.66 (m, 1H), 3.91-3.83 (m, 3H), 3.65 (t, J = oxadiazol-3-yl)phenoxy)acrylate 15.0 Hz, 3H), 2.29 (d, J = 14.4 Hz, 3H), 1.59 (d, J = 7.0 Hz, 3H); LCMS (M+1) : 386.85 1 methyl (Z)-3-methoxy-2-(2- H-NMR (400 MHz, DMSO-d6) δ 7.63 (s, 1H), 7.46 (dd, J methyl-5-(5-(1-(p- = 7.6, 1.5 Hz, 1H), 7.20-7.15 (m, 5H), 7.07 (d, J = 7.9 Hz, 358 tolyl)cyclopropyl)-1,2,4- 1H), 3.85 (s, 3H), 3.63 (s, 3H), 2.31 (s, 3H), 2.28 (s, 3H), oxadiazol-3-yl)phenoxy)acrylate 1.73 (dd, J = 7.2, 4.4 Hz, 2H), 1.54 (dd, J = 7.3, 4.6 Hz, 2H); LCMS (M+1) : 421.05 1 methyl (Z)-2-(5-(5-((1H-pyrazol- H-NMR (400 MHz, DMSO-d6) δ 7.96 (d, J = 1.8 Hz, 1H), 1-yl)methy 7.65 (s, 1H), 7.54-7.51 (m, 2H), 7.37 (d, J = 7.9 Hz, 1H), 359 l)-1,2,4-oxadiazol-3- yl)-2-methylphenoxy)-3- 7.21 (d, J = 1.5 Hz, 1H), 6.35 (s, J = 2.0 Hz, 1H), 5.84 (s, methoxyacrylate 2H), 3.86 (s, 3H), 3.64 (s, 3H), 2.32-2.29 (s, 3H); LCMS (M+1) : 371.00 1 methyl (Z)-2-(2-fluoro-5-(5-(m- H-NMR (400 MHz, DMSO-d6) δ 7.98-7.95 (m, 2H), 7.76 360 tolyl)-1,2,4-oxadiazol-3- (qd, J = 4.2, 2.0 Hz, 1H), 7.73 (s, 1H), 7.55-7.48 (m, 4H), yl)phenoxy)-3-methoxyacrylate 3.91 (s, 3H), 3.69 (s, 3H), 2.44 (s, 3H), 2.06 (s, 2H); LCMS (M+1) : 385.1 1 methyl (Z)-2-(5-(5-(4-chloro-3- H-NMR (400 MHz, DMSO-d6) δ 8.18 (dd, J = 9.3, 2.0 Hz, fluoro 1H), 8.03 (dd, J = 8.2, 1.6 Hz, 1H), 7.90 (t, J = 7.9 Hz, 1H), 361 phenyl)-1,2,4-oxadiazol-3- yl)-2-fluorophenoxy)-3- 7.76 (qd, J = 4.2, 2.1 Hz, 1H), 7.73 (s, 1H), 7.56-7.48 (m, methoxyacrylate 2H)3.91 (s, 3H), 3.68 (s, 3H); LCMS (M+1) : 423.6362methyl (Z)-2-(2-fluoro-5-(5-(2-1H-NMR (400 MHz, CDCl3) δ 7.75 (qd, J = 4.3, 1.9 Hz, methoxypropan-2-yl)-1,2,4- 1H), 7.60 (dd, J = 8.1, 2.0 Hz, 1H), 7.37 (s, 1H), 7.21 (dd, PI External oxadiazol-3-yl)phenoxy)-3- J = 10.4, 8.6 Hz, 1H), 3.90 (s, 3H), 3.74 (s, 3H), 3.35 (s, methoxyacrylate 3H), 1.46 (s, 6H); LCMS (M+1) : 367.00 methyl (Z)-2-(5-(5-((4,4-1H-NMR (400 MHz, DMSO-d6) δ 7.71 (s, 1H), 7.65 (qd, J difluorocyclohexyl)methyl)-1,2,4- = 4.3, 2.0 Hz, 1H), 7.48 (dd, J = 11.0, 8.6 Hz, 1H), 7.40 (dd, 363 oxadiazol-3-yl)-2- J = 8.3, 1.8 Hz, 1H), 3.89 (s, 3H), 3.67 (s, 3H), 2.98 (d, J = fluorophenoxy)-3- 7.0 Hz, 2H), 2.00-1.98 (m, 3H), 1.91-1.77 (m, 5H), 1.36- methoxyacrylate 1.27 (m, 2H); LCMS (M+1) : 427.10 1 methyl (Z)-2-(2-fluoro-5-(5- H-NMR (400 MHz, DMSO-d6) δ 7.72 (d, J = 7.0 Hz, 1H), (3,3,3-t 7.69-7.65 (m, 1H), 7.49 (dd, J = 11.0, 8.6 Hz, 1H), 7.41 (dd, 364 rifluoropropyl)-1,2,4- oxadiazol-3-yl)phenoxy)-3- J = 8.1, 2.0 Hz, 1H), 3.89 (s, 3H), 3.67 (s, 3H), 3.28 (d, J = methoxyacrylate 7.9 Hz, 2H), 2.95-2.81 (m, 2H); LCMS (M+1) : 391.05 methyl (Z)-2-(5-(5-((3,3-1H-NMR (400 MHz, CHLOROFORM-D) δ 7.70 (qd, J = difluorocyclobutyl)methyl)-1,2,4- 4.3, 2.0 Hz, 1H), 7.58-7.52 (m, 4H), 7.39-7.31 (m, 4H), 365 oxadiazol-3-yl)-2- 7.21 (dd, J = 10.5, 8.6 Hz, 1H), 3.89 (s, 3H), 3.74 (s, 3H), fluorophenoxy)-3- 3.26 (d, J = 3.4 Hz, 4H) : LCMS (M+1) : 467.45 methoxyacrylate methyl (Z)-2-(5-(5-((2,3-1H-NMR (400 MHz, DMSO-d6) δ 7.70 (td, J = 7.8, 1.1 Hz, dioxoindolin-1-yl)methyl)-1,2,4- 1H), 7.62 (d, J = 5.8 Hz, 2H), 7.52-7.48 (m, 1H), 7.37-7.34 366 oxadiazol-3-yl)-2- (m, 1H), 7.29 (d, J = 7.9 Hz, 1H), 7.19 (t, J = 7.3 Hz, 2H), methylphenoxy)-3- 5.37 (s, 2H), 3.84 (s, 3H), 3.63 (s, 3H), 2.28 (s, 3H), ; methoxyacrylate LCMS (M+1) : 450.3 methyl (Z)-3-methoxy-2-(2-1H-NMR (400 MHz, DMSO-d6) δ 7.65 (s, 1H), 7.54-7.52 methyl-5-(5-(1-(4-oxo-2- (m, 1H), 7.38 (d, J = 7.8 Hz, 1H), 7.20 (d, J = 1.2 Hz, 1H), 367 thioxothiazolidin-3-yl)ethyl)- 6.34 (q, J = 6.9 Hz, 1H), 4.36 (s, 2H), 3.87 (s, 3H), 3.65 (s, 1,2,4-oxadiazol-3- 3H), 2.30 (s, 3H), 1.78 (d, J = 7.1 Hz, 3H); LCMS (M+1) : yl)phenoxy)acrylate 450.05 1 methyl (Z)-2-(5-(5-(4- H-NMR (400 MHz, DMSO-d6) δ 7.65 (s, 1H), 7.54 (dd, J fluorophenethyl)-1,2,4-oxadiazol = 7.7, 1.3 Hz, 1H), 7.36 (d, J = 8.1 Hz, 1H), 7.32 (dd, J = 368 - 3-yl)-2-methylphenoxy)-3- 8.4, 5.7 Hz, 2H), 7.21 (d, J = 1.5 Hz, 1H), 7.10 (t, J = 8.9 methoxyacrylate Hz, 2H), 3.87 (s, 3H), 3.65 (s, 3H), 3.28 (d, J = 7.8 Hz, 2H), 3.09 (t, J = 7.6 Hz, 2H), 2.29 (s, 3H); LCMS (M+1) : 413.05 1 methyl (Z)-2-(5-(5-(3- H-NMR (400 MHz, DMSO-d6) δ 7.65 (s, 1H), 7.55 (dd, J cyanopro = 7.6, 1.5 Hz, 1H), 7.37 (d, J = 7.8 Hz, 1H), 7.23 (d, J = 1.5 369 pyl)-1,2,4-oxadiazol-3- yl)-2-methylphenoxy)-3- Hz, 1H), 3.86 (s, 3H), 3.65 (s, 3H), 3.07 (t, J = 7.5 Hz, 2H), methoxyacrylate 2.66 (t, J = 7.1 Hz, 2H), 2.29 (s, 3H), 2.11-2.04 (m, 2H); GCMS (M.) : 357.3 1H-NMR (400 MHz, DMSO-d6) δ 7.65 (s, 1H), 7.56 (dd, J methyl (Z)-2-(5-(5-((1,1- = 7.6, 1.5 Hz, 1H), 7.37 (d, J = 7.8 Hz, 1H), 7.23 (d, J = 1.5 dioxidotetrahydrothiophen-3- 370 Hz, 1H), 3.87 (s, 3H), 3.65 (s, 3H), 3.35 (q, J = 6.4 Hz, 1H), yl)methyl)-1,2,4-oxadiazol-3-yl)- 3.27-3.22 (m, 3H), 3.13-3.05 (m, 1H), 2.98-2.86 (m, 2H), 2-methylphenoxy)-3- 2.36-2.32 (m, 1H), 2.30 (s, 3H), 1.96-1.88 (m, 1H); LCMS methoxyacrylate (M-1) : 421.05 methyl (Z)-2-(5-(5-(2-1H-NMR (400 MHz, DMSO-d6) δ 9.15 (s, 1H), 7.67 (s, isopropyloxazol-4-yl)-1,2,4- 1H), 7.63-7.61 (m, 1H), 7.41 (d, J = 7.8 Hz, 1H), 7.28 (d, J 371 oxadiazol-3-yl)-2- = 1.2 Hz, 1H), 3.88 (s, 3H), 3.66 (s, 3H), 3.25-3.18 (m, 1H), methylphenoxy)-3- 2.31 (s, 3H), 1.34 (d, J = 7.1 Hz, 6H); LCMS (M+1) : methoxyacrylate 400.00 methyl (Z)-2-(5-(5-(1-(2,4-1H-NMR (400 MHz, DMSO-d6) δ 7.65 (s, 1H), 7.54 (dd, J dioxothiazolidin-3-yl)ethyl)- = 7.7, 1.6 Hz, 1H), 7.38 (d, J = 8.1 Hz, 1H), 7.20 (d, J = 1.5 372 1,2,4-oxadiazol-3-yl)-2- Hz, 1H), 5.77 (q, J = 7.0 Hz, 1H), 4.37 (d, J = 17.9 Hz, 1H), methylphenoxy)-3- 4.32-4.28 (m, 1H), 3.87 (s, 3H), 3.65 (s, 3H), 2.30 (s, 3H), methoxyacrylate 1.73 (d, J = 7.1 Hz, 3H); LCMS (M+1) : 433.95 PI External methyl (Z)-2-(5-(5-((2,4-1H-NMR (400 MHz, DMSO-d6) δ 7.65 (s, 1H), 7.52 (dd, J dioxothiazolidin-3-yl)methyl)- = 7.8, 1.5 Hz, 1H), 7.38 (d, J = 7.8 Hz, 1H), 7.20 (d, J = 1.2 373 1,2,4-oxadiazol-3-yl)-2- Hz, 1H), 5.09 (s, 2H), 4.36 (s, 2H), 3.87 (s, 3H), 3.65 (s, methylphenoxy)-3- 3H), 2.30 (s, 3H); LCMS (M+1) : 419.95 methoxyacrylate 1H-NMR (400 MHz, DMSO-d6) δ 8.51 (d, J = 2.0 Hz, 1H), methyl (Z)-3-methoxy-2-(2- 8.41 (dd, J = 4.8, 1.6 Hz, 1H), 7.72 (d, J = 7.8 Hz, 1H), 7.65 374 methyl-5-(5-(2-(pyridin-3- (s, 1H), 7.54 (dd, J = 7.6, 1.5 Hz, 1H), 7.37 (d, J = 7.8 Hz, yl)ethyl)-1,2,4-oxadiazol-3- 1H), 7.31 (dd, J = 7.6, 4.9 Hz, 1H), 7.21 (d, J = 1.5 Hz, 1H), yl)phenoxy)acrylate 3.87 (s, 3H), 3.65 (s, 3H), 3.34 (t, J = 7.6 Hz, 2H), 3.12 (t, J = 7.6 Hz, 2H), 2.29 (s, 3H); LCMS (M+1) : 396.00 1H-NMR (400 MHz, DMSO-d6) δ 7.65 (s, 1H), 7.54 (dd, J methyl (Z)-2-(5-(5-(4- = 7.8, 1.5 Hz, 1H), 7.36 (d, J = 7.8 Hz, 1H), 7.21 (d, J = 1.2 ethoxyphenethyl)-1,2,4- 375 Hz, 1H), 7.16 (d, J = 8.8 Hz, 2H), 6.81 (q, J = 4.2 Hz, 2H), oxadiazol-3-yl)-2- 3.96 (q, J = 6.9 Hz, 2H), 3.87 (s, 3H), 3.65 (s, 3H), 3.25 (t, methylphenoxy)-3- J = 7.6 Hz, 2H), 3.02 (t, J = 7.6 Hz, 2H), 2.29 (s, 3H), 1.28 methoxyacrylate (td, J = 6.9, 3.1 Hz, 3H); LCMS (M+1) : 439.05 1 methyl (Z)-2-(5-(5-(4- H-NMR (400 MHz, DMSO-d6) δ 7.65 (s, 1H), 7.53 (dd, J = 7.7, 1.3 Hz, 1H), 7.47 (d, J = 8.3 H 76 bromoph z, 2H), 7.36 (d, J = 8.1 3 enethyl)-1,2,4-oxadiazol- 3-yl)-2-methylphenoxy)-3- Hz, 1H), 7.25 (d, J = 8.3 Hz, 2H), 7.21 (d, J = 1.2 Hz, 1H), methoxyacrylate 3.87 (s, 3H), 3.65 (s, 3H), 3.29 (d, J = 7.8 Hz, 2H), 3.08 (t, J = 7.6 Hz, 2H), 2.29 (s, 3H); LCMS (M+1) : 474.90 methyl (Z)-2-(5-(5-(2,6-1H-NMR (400 MHz, DMSO-d6) δ 7.66 (s, 1H), 7.52 (dd, J dichlorophenethyl)-1,2,4- = 7.6, 1.5 Hz, 1H), 7.48-7.43 (m, 3H), 7.37-7.25 (m, 2H), 377 oxadiazol-3-yl)-2- 7.19 (d, J = 1.5 Hz, 1H), 3.86 (s, 3H), 3.65 (s, 3H), 3.36 (t, methylphenoxy)-3- J = 7.2 Hz, 2H), 3.24 (t, J = 7.3 Hz, 2H), 2.29 (s, 3H); methoxyacrylate LCMS (M+1) : 462.85 1 methyl (Z)-3-methoxy-2-(2- H-NMR (400 MHz, DMSO-d6) δ 7.65 (s, 1H), 7.56 (dd, J methyl-5-( = 7.8, 1.5 Hz, 1H), 7.38 (d, J = 8.1 Hz, 1H), 7.23 (d, J = 1.5 378 5-(3,3,3- trifluoropropyl)-1,2,4-oxadiazol- Hz, 1H), 3.87 (s, 3H), 3.65 (s, 3H), 3.27 (t, J = 7.7 Hz, 2H), 3-yl)phenoxy)acrylate 2.93-2.81 (m, 2H), 2.30 (s, 3H); LCMS (M+1) : 386.95 1 methyl (Z)-3-methoxy-2-(2- H-NMR (400 MHz, DMSO-d6) δ 7.65 (s, 1H), 7.54 (dd, J methyl-5 = 7.6, 1.2 Hz, 1H), 7.36 (d, J = 7.9 Hz, 1H), 7.22 (d, J = 1.5 379 -(5-(2-(1- methylcyclopropyl)ethyl)-1,2,4- Hz, 1H), 3.87 (s, 3H), 3.65 (s, 3H), 3.03 (t, J = 7.9 Hz, 2H), oxadiazol-3-yl)phenoxy)acrylate 2.29 (s, 3H), 1.70 (t, J = 7.9 Hz, 2H), 1.03 (s, 3H), 0.30- 0.19 (m, 4H); LCMS (M+1) : 373.20 methyl (Z)-2-(5-(5-1H-NMR (400 MHz, DMSO-d6) δ 7.66 (d, J = 5.2 Hz, 1H), 380 (cyanomethyl)-1,2,4-oxadiazol-3- 7.57 (dd, J = 7.6, 1.5 Hz, 1H), 7.40 (d, J = 7.9 Hz, 1H), 7.23 yl)-2-methylphenoxy)-3- (d, J = 1.5 Hz, 1H), 4.75 (s, 2H), 3.87 (s, 3H), 3.64 (s, 3H), methoxyacrylate 2.30 (s, 3H); LCMS (M-1) : 327.90 methyl (Z)-3-methoxy-2-(2-1H-NMR (400 MHz, DMSO-d6) δ 7.66 (s, 1H), 7.57 (dd, J 381 methyl-5-(5-(2,2,2-trifluoroethyl)- = 7.8, 1.5 Hz, 1H), 7.40 (d, J = 7.6 Hz, 1H), 7.24 (d, J = 1.5 1,2,4-oxadiazol-3- Hz, 1H), 4.51 (q, J = 10.7 Hz, 2H), 3.87 (s, 3H), 3.65 (s, yl)phenoxy)acrylate 3H), 2.30 (s, 3H); LCMS (M-1) : 370.95 1 methyl (Z)-2-(5-(5-(3,3- H-NMR (400 MHz, DMSO-d6) δ 7.65 (s, 1H), 7.55 (dd, J dimethylbutyl)-1,2,4 = 7.6, 1.5 Hz, 1H), 7.36 (d, J = 7.6 Hz, 1H), 7.22 (d, J = 1.5 382 -oxadiazol-3- yl)-2-methylphenoxy)-3- Hz, 1H), 3.87 (s, 3H), 3.65 (s, 3H), 2.95-2.91 (m, 2H), 2.29 methoxyacrylate (s, 3H), 1.70-1.65 (m, 2H), 0.92 (s,9H); LCMS (M+1) : 375.05 methyl (Z)-2-(5-(5-(2-1H-NMR (400 MHz, DMSO-d6) δ 7.65 (s, 1H), 7.54 (dd, J 383 cyclopentylethyl)-1,2,4- = 7.6, 1.2 Hz, 1H), 7.36 (d, J = 7.9 Hz, 1H), 7.22 (d, J = 1.2 oxadiazol-3-yl)-2- Hz, 1H), 3.87 (s, 3H), 3.65 (s, 3H), 2.97 (t, J = 7.3 Hz, 2H), PI External methylphenoxy)-3- 2.29 (s, 3H), 1.82-1.70 (m, 4H), 1.61-1.46 (m, 4H), 1.16- methoxyacrylate 1.04 (m, 3H); LCMS (M+1) : 387.05 1 methyl (Z)-2-(5-(5-(2- H-NMR (400 MHz, DMSO-d6) δ 7.65 (s, 1H), 7.55 (dd, J cyclopropylethyl)-1,2,4- = 7.8, 1.4 Hz, 1H), 7.36 (d, J = 7.9 Hz, 1H), 7.23 (d, J = 1.5 384 oxadiazol-3-yl)-2- Hz, 1H), 3.87 (s, 3H), 3.65 (s, 3H), 3.04 (t, J = 7.3 Hz, 2H), methylphenoxy)-3- 2.29 (s, 3H), 1.67 (q, J = 7.2 Hz, 2H), 0.80-0.73 (m, 1H), methoxyacrylate 0.41-0.35 (m, 2H), 0.08-0.01 (m, 2H); LCMS (M+1) : 359.00 methyl (Z)-3-methoxy-2-(2-1H-NMR (400 MHz, DMSO-d6) δ 7.66 (s, 1H), 7.59 (dd, J 385 methyl-5-(5- = 7.6, 1.5 Hz, 1H), 7.41 (d, J = 8.3 Hz, 1H), 7.25 (d, J = 1.5 ((methylsulfonyl)methyl)-1,2,4- Hz, 1H), 5.26 (s, 2H), 3.87 (s, 3H), 3.64 (s, 3H), 3.25 (s, oxadiazol-3-yl)phenoxy)acrylate 3H), 2.31 (s, 3H); LCMS (M+1) : 382.90 1 methyl (Z)-2-(5-(5-(2- H-NMR (400 MHz, DMSO-d6) δ 7.65 (s, 1H), 7.56 (dd, J cyanoeth = 7.6, 1.5 Hz, 1H), 7.39 (d, J = 7.6 Hz, 1H), 7.24 (d, J = 1.5 386 yl)-1,2,4-oxadiazol-3- yl)-2-methylphenoxy)-3- Hz, 1H), 3.87 (s, 3H), 3.65 (s, 3H), 3.37 (t, J = 7.0 Hz, 2H), methoxyacrylate 3.05 (t, J = 7.0 Hz, 2H), 2.30 (s, 3H); LCMS (M+1) : 344.1 methyl (Z)-2-(5-(5-(5-1H-NMR (400 MHz, DMSO-d6) δ 7.97 (d, J = 4.3 Hz, 1H), chlorothiophen-3-yl)-1,2,4- 7.67 (s, 1H), 7.60 (dd, J = 7.6, 1.5 Hz, 1H), 7.43-7.39 (m, 387 oxadiazol-3-yl)-2- 2H), 7.26 (d, J = 1.2 Hz, 1H), 3.88 (s, 3H), 3.65 (s, 3H), methylphenoxy)-3- 2.31 (s, 3H); LCMS (M+1) : 406.85 methoxyacrylate methyl (Z)-2-(2-chloro-5-(5-((3-1H-NMR (400 MHz, DMSO-d6) δ 8.21 (d, J = 1.5 Hz, 1H), 388 (trifluoromethyl)-1H-pyrazol-1- 7.70 (t, J = 8.3 Hz, 2H), 7.65-7.60 (m, 1H), 7.34 (d, J = 1.8 yl)methyl)-1,2,4-oxadiazol-3- Hz, 1H), 6.86 (d, J = 2.1 Hz, 1H), 6.02 (s, 2H), 3.88 (s, 3H), yl)phenoxy)-3-methoxyacrylate 3.66 (s, 3H); LCMS (M+1) : 459.00 methyl (Z)-2-(5-(5-(1-1H-NMR (400 MHz, DMSO-d6) δ 7.65 (s, 1H), 7.54-7.51 cyanocyclopropyl)-1,2,4- (m, 1H), 7.38 (d, J = 7.8 Hz, 1H), 7.19 (d, J = 1.5 Hz, 1H), 389 oxadiazol-3-yl)-2- 3.86 (s, 3H), 3.65 (s, 3H), 2.30 (s, 3H), 2.17 (dd, J = 8.7, methylphenoxy)-3- 5.0 Hz, 2H), 1.98 (dd, J = 8.7, 5.0 Hz, 2H); LCMS (M+1) : methoxyacrylate 356.05 1H-NMR (400 MHz, DMSO-d6) δ 7.71 (s, 1H), 7.68 (qd, J methyl (Z)-2-(5-(5- = 4.3, 2.1 Hz, 1H), 7.49 (dd, J = 11.0, 8.6 Hz, 1H), 7.42 (dd, (cyclobutoxymethyl)-1,2,4- 390 J = 8.1, 2.0 Hz, 1H), 4.76 (d, J = 10.5 Hz, 2H), 4.13-4.06 oxadiazol-3-yl)-2- (m, 1H), 3.89 (s, 3H), 3.67 (s, 3H), 2.18-2.11 (m, 2H), 2.06 fluorophenoxy)-3- (s, 1H), 1.93-1.83 (m, 2H), 1.63 (q, J = 10.0 Hz, 1H);LCMS methoxyacrylate (M+1) : 379.3 1 methyl (Z)-2-(2-fluoro-5-(5-((3- H-NMR (400 MHz, DMSO-d6) δ 8.21 (t, J = 1.1 Hz, 1H), (trifluoromethyl)-1 7.70 (s, 1H), 7.64 (qd, J = 4.3, 2.1 Hz, 1H), 7.49 (dd, J = 391 H-pyrazol-1- yl)methyl)-1,2,4-oxadiazol-3- 11.0, 8.6 Hz, 1H), 7.39 (dd, J = 8.3, 2.1 Hz, 1H), 6.86 (d, J yl)phenoxy)-3-methoxyacrylate = 2.1 Hz, 1H), 6.02 (s, 2H), 3.88 (s, 3H), 3.66 (s, 3H); LCMS (M+1) : 443.05 methyl (Z)-2-(5-(5-1H-NMR (400 MHz, CDCl3) δ 7.73 (qd, J = 4.3, 2.1 Hz, 392 (ethoxymethyl)-1,2,4-oxadiazol- 1H), 7.59 (dd, J = 7.9, 2.1 Hz, 1H), 7.36 (s, 1H), 7.21 (dd, 3-yl)-2-fluorophenoxy)-3- J = 10.5, 8.4 Hz, 1H), 4.76 (s, 2H), 3.89 (s, 3H), 3.73-3.63 methoxyacrylate (m, 5H), 1.33-1.28 (m, 3H); LCMS (M+1) : 353.00 1 methyl (Z)-2-(5-(5-(3- H-NMR (400 MHz, DMSO-d6) δ 7.72 (d, J = 10.1 Hz, 1H), chloropropyl)-1,2,4-ox 7.66 (qd, J = 4.3, 2.0 Hz, 1H), 7.51-7.46 (m, 1H), 7.40 (dd, 393 adiazol-3- yl)-2-fluorophenoxy)-3- J = 8.1, 2.0 Hz, 1H), 3.89 (s, 3H), 3.79-3.75 (m, 2H), 3.67 methoxyacrylate (s, 3H), 3.12 (t, J = 7.5 Hz, 2H), 2.26-2.19 (m, 2H); LCMS (M+1) : 370.80 1 meth H-NMR (400 MHz, DMSO-d6) δ 7.96 (d, J = 2.1 Hz, 1H),394yl (Z)-2-(5-(5-((1H-pyrazol- 1-yl)methyl)-1,2,4-oxadiazol-3- 7.72 (s, 1H), 7.68 (d, J = 8.6 Hz, 1H), 7.62 (dd, J = 8.3, 1.8 Hz, 1H), 7.53 (d, J = 0.8 Hz, 1H), 7.34 (d, J = 1.8 Hz, 1H), PI External yl)-2-chlorophenoxy)-3- 6.35 (t, J = 2.1 Hz, 1H), 5.86 (s, 2H), 3.88 (s, 3H), 3.66 (s, methoxyacrylate 3H); LCMS (M+1) : 390.85 1 methyl (Z)-2-(2-chloro-5-(5-(1-(4- H-NMR (400 MHz, DMSO-d6) δ 7.70 (s, 1H), 7.66-7.63 fluorophenyl)cyclopropyl) (m, 1H), 7.56-7.51 (m, 3H), 7.28 (d, J = 1.8 Hz, 1H), 7.25- 395 -1,2,4- oxadiazol-3-yl)phenoxy)-3- 7.19 (m, 2H), 4.02 (q, J = 7.1 Hz, 1H), 3.88 (s, J = 3.4 Hz, methoxyacrylate 3H), 3.66 (s, J = 4.0 Hz, 3H), 1.98 (s, 1H), 1.60 (dd, J = 7.5, 4.7 Hz, 2H); LCMS (M+1) : 444.90 1 methyl (Z)-2-(5-(5-(2-ethoxy-2- H-NMR (400 MHz, DMSO-d6) δ 7.64 (d, J = 12.2 Hz, 1H), oxoethyl)-1,2,4-oxadiazol-3 7.56 (dd, J = 7.6, 1.5 Hz, 1H), 7.39 (d, J = 7.9 Hz, 1H), 7.23 396 -yl)- 2-methylphenoxy)-3- (d, J = 1.5 Hz, 1H), 4.34 (s, 2H), 4.15 (qd, J = 7.0, 2.8 Hz, methoxyacrylate 2H), 3.87 (s, 3H), 3.65 (s, 3H), 2.30 (s, 3H), 1.22-1.15 (m, 3H); LCMS (M+1): 377.05 1 methyl (Z)-3-methoxy-2-(2- H-NMR (400 MHz, DMSO-d6) δ 7.66-7.62 (m, 1H), 7.57 methyl-5-(5-(3,3,3-t (dd, J = 7.6, 1.5 Hz, 1H), 7.39 (d, J = 8.3 Hz, 1H), 7.24 (d, 397 rifluoro-2- (trifluoromethyl)propyl)-1,2,4- J = 1.5 Hz, 1H), 4.92-4.80 (m, 1H), 3.87 (s, 3H), 3.75-3.69 oxadiazol-3-yl)phenoxy)acrylate (m, 2H), 3.65 (s, 3H), 2.30 (s, 3H); LCMS (M+1): 454.90 1 methyl (Z)-3-methoxy-2-(2- H-NMR (400 MHz, DMSO-d6) δ 7.63 (s, 1H), 7.49-7.44 methyl-5 (m, 3H), 7.36-7.33 (m, 1H), 7.19 (d, J = 1.5 Hz, 1H), 7.07 398 -(5-((2-methyl-1H-indol- 1-yl)methyl)-1,2,4-oxadiazol-3- (td, J = 7.6, 1.1 Hz, 1H), 7.01 (td, J = 7.4, 1.0 Hz, 1H), 6.31 yl)phenoxy)acrylate (d, J = 0.9 Hz, 1H), 5.86 (s, 2H), 3.84 (s, 3H), 3.63 (s, 3H), 2.44 (d, J = 0.9 Hz, 3H), 2.28 (s, 3H); LCMS (M+1): 434.05 1 methyl (Z)-3-methoxy-2-(2- H-NMR (400 MHz, DMSO-d6) δ 7.65 (s, 1H), 7.55 (dd, J methyl-5-(5 = 7.6, 1.5 Hz, 1H), 7.38 (d, J = 7.6 Hz, 1H), 7.24 (d, J = 1.5 399 -(3,4,4-trifluorobut-3- en-1-yl)-1,2,4-oxadiazol-3- Hz, 1H), 3.86 (s, 3H), 3.64 (s, 3H), 3.26 (t, J = 7.0 Hz, 2H), yl)phenoxy)acrylate 2.94-2.83 (m, 2H), 2.29 (s, 3H); LCMS (M+1): 398.95 1 methyl (Z)-2-(5-(5-(sec-butyl)- H-NMR (400 MHz, DMSO-d6) δ 7.65 (s, 1H), 7.55 (dd, J 1,2,4-oxa = 7.6, 1.5 Hz, 1H), 7.37 (d, J = 7.9 Hz, 1H), 7.23 (d, J = 1.5 400 diazol-3-yl)-2- methylphenoxy)-3- Hz, 1H), 3.87 (s, 3H), 3.65 (s, 3H), 3.16 (td, J = 13.9, 7.0 methoxyacrylate Hz, 1H), 2.29 (s, 3H), 1.82-1.66 (m, 2H), 1.36-1.30 (m, 3H), 0.87 (q, J = 7.4 Hz, 3H); LCMS (M+1): 347.05 methyl (Z)-2-(5-(5-((6-1H-NMR (400 MHz, DMSO-d6) δ 8.48 (dd, J = 2.4, 0.6 Hz, chloropyridin-3-yl)methyl)-1,2,4- 1H), 7.91 (dd, J = 8.3, 2.8 Hz, 1H), 7.64 (s, 1H), 7.54 (dd, 401 oxadiazol-3-yl)-2- J = 8.3, 0.6 Hz, 1H), 7.51 (dd, J = 7.9, 1.5 Hz, 1H), 7.37- methylphenoxy)-3- 7.35 (m, 1H), 7.20 (d, J = 1.5 Hz, 1H), 4.50 (s, 2H), 3.86 (s, methoxyacrylate 3H), 3.64 (s, 3H), 2.29 (s, 3H); LCMS (M+1): 416.00 methyl (Z)-2-(5-(5-((5-1H-NMR (400 MHz, DMSO-d6) δ 8.55 (d, J = 2.8 Hz, 1H), fluoropyridin-3-yl)methyl)-1,2,4- 8.53-8.52 (m, 1H), 7.85-7.81 (m, 1H), 7.64 (s, 1H), 7.52 402 oxadiazol-3-yl)-2- (dd, J = 7.6, 1.5 Hz, 1H), 7.36 (d, J = 8.3 Hz, 1H), 7.21 (d, methylphenoxy)-3- J = 1.5 Hz, 1H), 4.54 (s, 2H), 3.86 (s, 3H), 3.64 (s, 3H), methoxyacrylate 2.29 (s, 3H); LCMS (M+1): 400.00 methyl (Z)-2-(5-(5-(1,4-dimethyl-1H-NMR (400 MHz, DMSO-d6) δ 7.66 (dd, J = 7.9, 1.8 Hz, 403 1H-pyrazol-5-yl)-1,2,4-oxadiazol- 2H), 7.54 (d, J = 0.5 Hz, 1H), 7.42 (d, J = 8.3 Hz, 1H), 7.34 3-yl)-2-methylphenoxy)-3- (d, J = 1.5 Hz, 1H), 4.21 (s, 3H), 3.88 (s, 3H), 3.66 (s, 3H), methoxyacrylate 2.34 (s, 3H), 2.32 (s, 3H);LCMS (M+1) : 385.2 methyl (Z)-2-(5-(5-(3-1H-NMR (400 MHz, DMSO-d6) δ 7.70 (d, J = 2.0 Hz, 1H), (difluoromethyl)-1-methyl-1H- 7.67-7.65 (m, 2H), 7.43 (d, J = 8.3 Hz, 1H), 7.32 (d, J = 1.5 404 pyrazol-4-yl)-1,2,4-oxadiazol-3- Hz, 1H), 7.20 (d, J = 2.2 Hz, 1H), 4.27 (s, 3H), 3.88 (s, 3H), yl)-2-methylphenoxy)-3- 3.66 (s, 3H), 2.32 (s, 3H);LCMS (M+1) : 421.3 methoxyacrylate methyl (Z)-2-(2-fluoro-5-(5-(p- 1H-NMR (400 MHz, DMSO-d6) δ 8.05 (d, J = 8.3 Hz, 2H), 405 tolyl)-1,2,4-oxadiazol-3- 7.77-7.74 (m, 1H), 7.73 (s, 1H), 7.54-7.48 (m, 2H), 7.47 (d, yl)phenoxy)-3-methoxyacrylate PI External J = 8.6 Hz, 2H), 3.91 (s, 3H), 3.69 (s, 3H), 2.43 (s, 3H);LCMS (M+1) : 385.2 1 methyl (Z)-2-(5-(5- H-NMR (400 MHz, DMSO-d6) δ 7.66 (s, 1H), 7.57 (dd, J (ethoxymethyl)-1,2,4-o = 7.6, 1.5 Hz, 1H), 7.39-7.37 (m, 1H), 7.24 (d, J = 1.5 Hz, 406 xadiazol- 3-yl)-2-methylphenoxy)-3- 1H), 4.82 (s, 2H), 3.87 (s, 3H), 3.65 (s, 3H), 3.60 (q, J = 7.0 methoxyacrylate Hz, 2H), 2.30 (s, 3H), 1.18-1.14 (m, 3H); LCMS (M+1) : 349.00 methyl (Z)-2-(5-(5-1H-NMR (400 MHz, DMSO-d6) δ 7.66 (s, 1H), 7.57 (dd, J ((benzyloxy)methyl)-1,2,4- = 7.6, 1.5 Hz, 1H), 7.40-7.35 (m, 5H), 7.34-7.31 (m, 1H), 407 oxadiazol-3-yl)-2- 7.25 (d, J = 1.5 Hz, 1H), 4.90 (s, 2H), 4.65 (s, 2H), 3.87 (s, methylphenoxy)-3- 3H), 3.65 (s, 3H), 2.30 (s, 3H); LCMS (M+1) : 411.20 methoxyacrylate methyl (Z)-3-methoxy-2-(2-1H-NMR (400 MHz, DMSO-d6) δ 7.66 (s, 1H), 7.57 (s, methyl-5-(5-(4,5,6,7- 1H), 7.31 (dd, J = 8.1, 2.0 Hz, 1H), 7.17 (d, J = 1.8 Hz, 1H), 408 tetrahydrobenzo[b]thiophen-2-yl)- 7.08 (d, J = 8.3 Hz, 1H), 3.85 (s, 3H), 3.64 (s, 3H), 2.74 (t, 1,2,4-oxadiazol-3- J = 5.8 Hz, 2H), 2.60-2.57 (m, 2H), 2.17 (s, 3H), 1.78-1.72 yl)phenoxy)acrylate (m, 4H) methyl (Z)-2-(5-(5-(2-((4-1H-NMR (400 MHz, DMSO-d6) δ 7.66 (s, 1H), 7.52 (dd, J chlorophenyl)thio)propyl)-1,2,4- = 7.7, 1.6 Hz, 1H), 7.44-7.42 (m, 2H), 7.39-7.36 (m, 3H), 409 oxadiazol-3-yl)-2- 7.21 (d, J = 1.7 Hz, 1H), 3.87 (s, 3H), 3.87 (s, 1H), 3.65 (s, methylphenoxy)-3- 3H), 3.24 (dd, J = 12.3, 7.0 Hz, 2H), 2.30 (s, 3H), 1.36 (d, methoxyacrylate J = 6.6 Hz, 3H); LC...

Claims

PI External CLAIMS: 1) A compound of formula (I),5 wherein, A1is selected from NRA1or O; wherein RA1is selected from the group consisting of hydrogen, C1-C6- alkyl, C1-C6-haloalkyl, C1-C6-alkoxy, C3-C6-cycloalkyl and C3-C6-cycloalkyl-C1-C3-alkyl; R1is selected from the group consisting of hydrogen, halogen, C1-C3-alkyl, C1-C3-haloalkyl and C3-C6- cycloalkyl; 10 R2is selected from the group consisting of hydrogen, halogen, methyl and methoxy; R3is selected from the group consisting of hydrogen, halogen, C1-C3-alkyl and C1-C3-alkoxy; R4is selected from the group consisting of hydrogen, halogen, cyano, C1-C8-alkyl, C2-C6-alkenyl, C2- C6-alkynyl, C1-C6-haloalkyl, C2-C6-haloalkenyl, C2-C6-haloalkynyl, C3-C8-cycloalkyl, C3-C6- cycloalkenyl, C3-C6-cycloalkyloxy-C1-C3-alkyl, C3-C6-halocycloalkyl, C1-C6-alkoxy, C2-C6-15 alkenyloxy, C2-C6-alkynyloxy, C1-C6-haloalkoxy, C3-C6-cycloalkyloxy, C1-C6-alkylsulfanyl, C1-C6- haloalkylsulfanyl, cyano-C1-C6-alkyl-, C3-C6-cycloalkyl-C1-C6-alkyl-, C3-C6-cycloalkyl-C2-C6-alkenyl- ,C3-C6-cycloalkyl-C2-C4-alkynyl-, C1-C6-alkoxy-C1-C6-alkyl-, -(CHR3)0-2C(R6)=NOR11, -NR8R9, - NR8COR10, -NR8CONR8R9, -NR8SO2R10, -(CHR3)0-2COR9, -(CHR3)0-2COOR6, -(CHR3)0-2NHCOR6a, - (CHR3)0-2CONR8R9, -(CHR3)0-2NHCOOR6, -CON=SO(R12)-R13, -CONR8SO2R10, phenyl, phenyl-C1- 20 C6-alkyl-, phenoxy-C1-C3-alkyl-, naphthyl, C5-C12saturated or partially unsaturated bi- or tri- carbocyclyl rings, 5- or 6- membered heteroaryl rings, 8- to 10- membered bicyclic heteroaryl rings, 4- to 10- membered non-aromatic heterocyclyl rings, 4-10 membered non-aromatic heterocyclyl-C1-C3- alkyl, 4-10 membered non-aromatic heterocyclyloxy-C1-C3-alkyl, 5- or 6- membered heteroaryl-C1-C3- alkyl, 5- to 10- membered heteroaryloxy-C1-C3-alkyl and 9- or 10- membered bicyclic heteroaryl-C1- 25 C3-alkyl; wherein said 4- to 10- membered non-aromatic heterocyclyl ring, 5- or 6- membered heteroaryl ring and 8- to 10- membered bicyclic heteroaryl ring contain 1, 2 or 3 heteroatoms independently selected from N, O or S(O)0-2; wherein the aliphatic group of said R4is unsubstituted or substituted by one to four substituents independently selected from R7a, and the cyclic group of said R4is unsubstituted or substituted by one 30 to four substituents independently selected from R7b;PI External R5is selected from H or C1-C3-alkyl; or R5and RA1together with the N atom to which they are attached form a 5-6 membered non-aromatic heterocyclic ring which contain 1, 2 or 3 heteroatoms independently selected from N, O, S, S(O) or SO2, wherein one to two carbon atoms of the heterocyclic ring may be replaced with C=O or C=S; said 5 5-6 membered heterocyclic ring is unsubstituted or substituted with one to three substituents independently selected from halogen, C1-C6alkyl, C1-C6-haloalkyl, C1-C6-alkoxy or C1-C6-haloalkoxy; R6is selected from hydrogen or C1-C6-alkyl; R6ais selected from the group consisting of C1-C6-alkyl, C1-C6-haloalkyl, C1-C6-alkoxy, C1-C6- alkoxy-C1-C3-alkyl, C1-C6-alkylthio-C1-C3-alkyl, C3-C6-cycloalkyl and phenyl; wherein said 10 phenyl is unsubstituted or substituted with one to three identical or different substituents selected from chloro, fluoro, bromo, methyl, trifluoromethyl, methoxy or ethoxy; R7ais selected from the group consisting of halogen, cyano, NO2, -OH, -N(R8)2, C1-C6-alkyl, C2- C6-alkenyl, C2-C6-alkynyl, C1-C6-haloalkyl, C2-C6-haloalkenyl, C3-C6-cycloalkyl, C1-C6-alkoxy, C3-C6-cycloalkyloxy, C1-C6-haloalkoxy, C1-C6-alkylsulfanyl, -NH-S(O)2-C1-C6-alkyl, -S(O)2-C1-15 C6-alkyl, -SR9a, benzyloxy, pyrazolyl, pyridinyl, phenyl, naphthyl, indanyl, phenylthio, C1-C6- haloalkylsulfanyl and C1-C6-alkylcarbonyl; wherein said C3-C6-cycloalkyl, pyrazolyl, phenyl and phenylthio groups are unsubstituted or substituted with one to three identical or different substituents selected from chloro, fluoro, bromo, methyl, ethyl, amino, trifluoromethyl, methoxy or ethoxy; 20 R7bis selected from the group consisting of halogen, cyano, NO2, -OH, -N(R8)2, C1-C6-alkyl, C2- C6-alkenyl, C1-C6-cyanoalkyl, C1-C6-haloalkyl, C3-C6-cycloalkyl, C3-C6-cyanocycloalkyl C3-C6- cycloalkyl-C1-C3-alkyl, C1-C6-alkoxy, oxo, thioxo, C1-C6-haloalkoxy, C1-C6-alkylsulfanyl, C1-C6- haloalkylsulfanyl, phenyl, phenoxy, a 4-6 membered non-aromatic heterocyclyl ring which contain 1, 2 or 3 heteroatoms independently selected from N, O or S, C1-C6-alkylcarbonyl, -SCF3, -S(O)2-25 R9a, -(CHR3)0-2C(R6)=NOR11a, -NR8aR9a, -NR8aCOR10a, NR8aCONR8aR9a, -NR8aSO2R10a, -(CHR3)0- 2COR9a, -(CHR3)0-2COOR6, -(CHR3)0-2CONR8aR9a, -CON=SO(R12a)-R13aand -CONR8aSO2R10a; wherein said phenyl, phenoxy and heterocyclyl ring is unsubstituted or substituted with one to three identical or different substituents selected from chloro, fluoro, bromo, methyl, cyclopropyl, difluoromethyl, trifluoromethyl, methoxy, ethoxy or propoxy; 30 R8is independently selected from the group consisting of hydrogen, C1-C6-alkyl, C3-C6-cycloalkyl, phenyl and C1-C6-alkoxy; R9is selected from the group consisting of hydrogen, C1-C6-alkyl, C1-C6-haloalkyl, C3-C6-cycloalkyl, C3-C6-cycloalkyl-C1-C6-alkyl, phenyl and a 5-6 membered heteroaryl ring; wherein said phenyl isPI External unsubstituted or substituted with identical or different one to three groups selected from methyl, methoxy or halogen; R10is selected from the group consisting of halogen, -OH, -N(R8)2, C1-C6-alkyl, C1-C6-haloalkyl, C3- C6-cycloalkyl, C6-cycloalkyl-C1-C6-alkyl, phenyl and a 5-6 membered heteroaryl ring; 5 R11is selected from the group consisting of C1-C6-alkyl, C1-C6-haloalkyl, C3-C6-cycloalkyl, C3-C6- cycloalkyl-C1-C6-alkyl, benzyl and phenyl; R12is selected from the group consisting of C1-C6-alkyl, C1-C6-haloalkyl, C3-C6-cycloalkyl, C3-C6- cycloalkyl-C1-C6-alkyl, phenyl and a 5-6 membered heteroaryl ring; R13is selected from the group consisting of C1-C6-alkyl, C1-C6-haloalkyl, C3-C6-cycloalkyl, C3-C6- 10 cycloalkyl-C1-C6-alkyl, phenyl and a 5-6 membered heteroaryl ring; R8ais selected from the group consisting of hydrogen, C1-C6-alkyl, C3-C6-cycloalkyl and C1-C6- alkoxy; R9ais selected from the group consisting of hydrogen, C1-C6-alkyl, C1-C6-haloalkyl, C3-C6- cycloalkyl, C3-C6-cycloalkyl-C1-C6-alkyl, pyridinyl and phenyl; wherein said phenyl is 15 unsubstituted or substituted with identical or different one to three groups selected from methyl, methoxy or halogen; R10ais selected from the group consisting of halogen, OH, C1-C6-alkyl, C1-C6-haloalkyl, C3-C6- cycloalkyl and C6-cycloalkyl-C1-C6-alkyl; R11ais selected from the group consisting of C1-C6-alkyl, C1-C6-haloalkyl, C3-C6-cycloalkyl and 20 C3-C6-cycloalkyl-C1-C6-alkyl; R12ais selected from the group consisting of C1-C6-alkyl, C1-C6-haloalkyl, C3-C6-cycloalkyl and C3-C6-cycloalkyl-C1-C6-alkyl; R13ais selected from the group consisting of C1-C6-alkyl, C1-C6-haloalkyl, C3-C6-cycloalkyl and C3-C6-cycloalkyl-C1-C6-alkyl; 25 or salts, stereoisomers, polymorphs or N-oxides thereof. 2) The compound of formula (I) according to claim 1, wherein A1is O. 3) The compound of formula (I) according to claim 1 or 2, wherein R1is selected from the group consisting of hydrogen, halogen, methyl, ethyl and propyl. 4) The compound of formula (I) according to any one of the preceding claims wherein R2is selected 30 from the group consisting of hydrogen, halogen and methyl. 5) The compound of formula (I) according to any one of the preceding claims wherein R3is hydrogen.PI External 6) The compound of formula (I) according to any one of the preceding claims wherein R4is selected from the group consisting of hydrogen, halogen, cyano, C1-C8-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C1-C6-haloalkyl, C2-C6-haloalkenyl, C2-C6-haloalkynyl, C3-C8-cycloalkyl, C3-C6-cycloalkenyl, C3- C6-cycloalkyloxy-C1-C3-alkyl, C1-C6-alkoxy, C1-C6-haloalkoxy, C3-C6-cycloalkyloxy, C1-C6- 5 alkylsulfanyl, C3-C6-cycloalkyl-C1-C4-alkyl-, C1-C6-alkoxy-C1-C3-alkyl-, -(CHR3)0-2C(R6)=NOR11, -NR8R9, -NR8COR10, -(CHR3)0-2COR9, -(CHR3)0-2COOR6, -(CHR3)0-2NHCOR6a, - (CHR3)0-2CONR8R9, -(CHR3)0-2NHCOOR6, phenyl, phenyl-C1-C6-alkyl-, phenoxy-C1-C3-alkyl, naphthyl, a C5-C12saturated or partially unsaturated bi- or tri- carbocyclyl ring, a 5- or 6- membered heteroaryl ring, a 8 to 10 membered bicyclic heteroaryl ring, a 4- to 10- membered non-aromatic10 heterocyclyl ring, 4-10 membered non-aromatic heterocyclyl-C1-C3-alkyl, 4-10 membered non- aromatic heterocyclyloxy-C1-C3-alkyl, 5- or 6- membered heteroaryl-C1-C3-alkyl, 5- to 10- membered heteroaryloxy-C1-C3-alkyl and 9- or 10- membered bicyclic heteroaryl-C1-C3-alkyl; wherein said 4- to 10- membered non-aromatic heterocyclyl ring, 5- or 6- membered heteroaryl ring and 8 to 10 membered bicyclic heteroaryl ring contain 1, 2 or 3 heteroatoms independently selected 15 from N, O or S(O)0-2; wherein the aliphatic group of said R4is unsubstituted or substituted by one to four substituents independently selected from R7a, and the cyclic group of said R4is unsubstituted or substituted by one to four substituents independently selected from R7b; wherein R3, R6, R8, R9, R10, R11, R6a, R7aand R7bare as defined in claim 1. 20 7) A method for preparing a compound of formula (I) according to claim 1, wherein said method comprises the steps selected from a) to c) a) reacting a compound of formula (II) with a compound of formula (VIII) in the presence of a suitable solvent to obtain a compound of formula (I) as shown in below scheme:; 25 or reacting a compound of formula (II) with a compound of formula (IX) in the presence of a suitable coupling agent, a suitable base and a suitable solvent to obtain a compound of formula (I) as shown in below scheme:PI Externalor reacting a compound of formula (II) with a compound of formula (X) in the presence of a suitable base and a suitable solvent to obtain a compound of formula (I) as shown in below 5 scheme:; b) reacting a compound of formula (III) with aqueous hydroxylamine or hydroxylamine hydrochloride optionally in the presence of a suitable base and a suitable solvent to obtain a compound of formula (II) as shown in below scheme: 10c) reacting a compound of formula (IV) with cyanide salts via a metal catalysed reaction in the presence of a suitable base, a suitable metal catalyst and a suitable solvent to obtain a compound of formula (III) as shown in below scheme:15 wherein, LG is halogen, A1is oxygen and R1, R2, R3, R4and R5are as defined in claim 1. 8) A method for preparing a compound of formula (I) wherein A1is NRA1according to claim 1, wherein said method comprises the step of:PI External a) reacting a compound of formula (I) with a compound of formula (XI-A) in the presence of a suitable solvent and at a suitable temperature to obtain a compound of formula (I- B1):5 wherein, R1, R2, R3, R4, RA1and R5are as defined in claim 1. 9) A compound of formula (Z);, wherein, R1, R2, R3, A1and R5are as defined in claim 1. 10) A composition for controlling and / or preventing phytopathogenic microorganisms, comprising a 10 compound of formula (I), stereo-isomers, polymorphs, N-oxides or salts thereof, as claimed in claim 1 and one or more inert carriers. 11) The composition according to claim 10, wherein the concentration of the compound of formula (I) ranges from 1 to 99% by weight with respect to the total weight of the composition. 12) Use of the compounds of formula (I), stereo-isomers, polymorphs, N-oxides or salts according to 15 claim 1, composition thereof according to claim 10, for controlling or preventing agricultural crops and / or horticultural crops against phytopathogenic fungi. 13) A seed comprising a compound of formula (I), stereo-isomers, polymorphs, N-oxides or salts thereof according to claim 1, wherein the amount of the compound of formula (I), stereo-isomers, polymorphs or salts thereof is from 0.1 g to 1 kg per 100 kg of seed. 20 14) A method for controlling or preventing infestations of useful plants by phytopathogenic fungi in agricultural crops and / or horticultural crops, wherein said compound of formula (I), stereo-isomers, metal complexes, polymorphs, N-oxides or salts thereof according to claim 1, composition thereof according to claim 10, is applied to the plants, to parts thereof or to a locus thereof.

Images